<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/271475-5-6-dihydro-1h-pyridin-2-one-compounds by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:20:26 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 271475:5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS<br>
FIELD OF THE INVENTION<br>
[0001] The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and<br>
pharmaceutical compositions containing such compounds that are useful in treating<br>
infections by hepatitis C virus.<br>
BACKGROUND OF THE INVENTION<br>
[0002] Hepatitis C is a major health problem world-wide. The World Health<br>
Organization estimates that 170 million people are chronic carriers of the hepatitis C<br>
virus (HCV), with 4 million carriers in the United States alone. In the United States,<br>
HCV infection accounts for 40% of chronic liver disease and HCV disease is the most<br>
common cause for liver transplantation. HCV infection leads to a chronic infection<br>
and about 70% of persons infected will develop chronic histological changes in the<br>
liver (chronic hepatitis) with a 10-40% risk of cirrhosis and an estimated 4% lifetime<br>
risk of hepatocellular carcinoma. The CDC estimates that each year in the United<br>
States there are 35,000 new cases of HCV infection and approximately ten thousand<br>
deaths attributed to HCV disease.<br>
[0003] The current standard of care is a pegylated interferon/ribavirin<br>
combination at a cost of approximately S31,000/year. These drugs have difficult<br>
dosing problems and side-effects that preclude their use in almost half of diagnosed<br>
patients. Pegylated interferon treatment is associated with menacing flu-like<br>
symptoms, irritability, inability to concentrate, suicidal ideation, and leukocytopenia.<br>
Ribavirin is associated with hemolytic anemia and birth defects.<br>
[0004] The overall response to this standard therapy is low; approximately one<br>
third of patients do not respond. Of those who do respond, a large fraction relapses<br>
within six months of completing 6-12 months of therapy. As a consequence, the long-<br>
term response rate for all patients entering treatment is only about 50%. The<br>
relatively low response rate and the significant side-effects of current therapy anti-<br>
HCV drug treatments, coupled with the negative long term effects of chronic HCV<br>
infection, result in a continuing medical need for improved therapy. Antiviral<br>
pharmaceuticals to treat RNA virus diseases like HCV are few, and as described<br>
above are often associated with multiple adverse effects.<br>
[0005] A number of publications have described NS5B inhibitors useful in the<br>
treatment of hepatitis C infection. See, e.g., U.S. Patent Application Publication No.<br>
US 2008/0031852 (describing [1,2-6] pyridazinone compounds); U.S. Patent<br>
Application Publication No. US 2006/0189602 (disclosing certain pyridazinones);<br>
U.S. Patent Application Publication No. US 2006/0252785 (disclosing selected<br>
heterocyclics); and International Publication Nos. WO 03/059356, WO 2002/098424,<br>
and WO 01/85172 (each describing a particular class of substituted thiadiazines).<br>
[0006] While there are, in some cases, medicines available to reduce disease<br>
symptoms, there are few drugs to effectively inhibit replication of the underlying<br>
virus. The significance and prevalence of RNA virus diseases, including but not<br>
limited to chronic infection by the hepatitis C virus, and coupled with the limited<br>
availability and effectiveness of current antiviral pharmaceuticals, have created a<br>
compelling and continuing need for new pharmaceuticals to treat these diseases.<br>
SUMMARY OF THE INVENTION<br>
[0007] The present invention describes novel 5,6-dihydro-1H-pyridin-2-one<br>
compounds and pharmaceutically acceptable salts thereof, which are useful in treating<br>
or preventing a hepatitis C virus infection in a patient in need thereof comprising<br>
administering to the patient a therapeutically or prophylactically effective amount of a<br>
5,6-dihydro-1 H-pyridin-2-one compound.<br>
[0008] In a general aspect, the invention relates to compounds of Formula I<br><br>
wherein<br>
X is N or CR3,<br>
A is<br><br>
Ring B is 6-membered aryl or heterocyclyl, optionally substituted by 1 -3<br>
R1 moieties, wherein is R1 is H, halo, nitro, -CHR4-S(O)2R5, -C(S(O)2R5)=CHR4-,<br>
-NR5R6, -NR4S(O)2R5, or -NR4S(O)2NR5R6, wherein R4, R5, and R6 are independently<br>
H, C1-C6 alkyl, C3-C8 cycloalkyl, C(O)O-(C1-C6 alkyl), aryl, or heterocyclyl, or R4<br>
and R5 or R5 and R6 combine with the atom(s) to which they are attached to form a 5-<br>
or 6-membered heterocyclyl ring,<br>
R2 is H, C1-C6 alkyl, C3-C8 cycloalkyl, -C1-C6 alkylene(C3-C8 cycloalkyl), -C1-C6<br>
alkylene(aryl), -C1-C6 alkylene(heterocyclyl), aryl, or heterocyclyl,<br>
R3 is H, halo, or C1-C6 alkyl,<br>
Z is -(CR13R14)n-, or O,<br>
nis 1 or 2,<br>
R7 and R8 are independently H or C1-C6 alkyl,<br>
R9, R10, R11, R12, R13, R14, R15, and R16 are independently H, C1-C6 alkyl, hydroxy, or<br>
halo,<br>
wherein the above alkyl, alkylene, aryl, cycloalkyl, or heterocyclyl moieties<br>
provided in R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, and R16 are<br>
each optionally and independently substituted by 1-3 substituents selected from<br>
alkylamine,<br>
amino,<br>
aryl, cycloalkyl, heterocyclyl,<br>
C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6<br>
alkylamine, C1-C6 dialkylamine, C2-C6 alkenyl, or C2-C6 alkynyl, wherein<br>
each of which may be interrupted by one or more hetero atoms,<br>
carboxyl,<br>
cyano,<br>
halo,<br>
hydroxy,<br>
keto,<br>
nitro,<br>
-C(O)OH, -C(O)NH2, -C(O)(C1-C6 alkylamine), -C(O)(C1-C6 dialkylamine),<br>
-C(O)2-(C1-C5 alkyl), -C(O)2-(C3-C8 cycloalkyl), -C(O)2-(aryl), -C(O)2-<br>
(heterocyclyl), -C(O)2-(C1-C6 alkylene)aryl, -C(O)2-(C1-C6<br>
alkylene)heterocyclyl, -C(O)2-(C1-C6 alkylene)cycloalkyl, -C(O)(C1-C6 alkyl),<br>
-C(O)(C3-C8 cycloalkyl), -C(O)(aryl), -C(O)(heterocyclyl), -C(O)(C1-C6<br>
alkylene)aryl, -C(O)(C1-C6 alkylene)heterocyclyl, and -C(O)(C1-C6<br>
alkylene)cycloalkyl,<br>
wherein each of the above optional substituents can be further optionally<br>
substituted by 1-5 substituents selected from amino, cyano, halo, hydroxy, nitro, Ci-<br>
C6 alkylamine, C1-C6 dialkylamine, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkenyl, and C1-<br>
C6 hydroxyalkyl, wherein each alkyl is optionally substituted by one or more halo<br>
substituents,<br>
or a pharmaceutically acceptable salt, hydrate, solvate, tautomer or<br>
stereoisomer thereof.<br>
[0009] In one embodiment, the invention relates to compounds of Formula I<br>
wherein Ring B is selected from<br><br>
[0010] In another embodiment, Ring B is<br><br>
wherein R1 is H, halo, nitro, -CHR4-S(O)2R5, -C(S(O)2R5)=CHR4-, -NR5R6,<br>
-NR4S(O)2R5, or -NR4S(O)2NR5R6.<br>
[0011] In one embodiment, the invention relates to compounds of Formula I<br>
wherein R1 is -NR4S(O)2R5, wherein R4 and R5 are independently H, C1-C6 alkyl or<br>
C3-C8 cycloalkyl.<br>
[0012] In another embodiment, the invention relates to compounds of Formula I<br>
wherein R1 is selected from<br><br>
[0013] In one embodiment, the invention relates to compounds of Formula I<br>
wherein R2 is selected from<br><br>
[0014] In another embodiment, the invention relates to compounds of Formula I<br>
wherein R2 is selected from<br><br>
[0015] In yet another embodiment, the invention relates to compounds of Formula<br>
I wherein R2 is selected from<br><br>
[0016] In one embodiment, the invention relates to compounds of Formula I<br>
wherein R3 is selected from hydrogen or C1-C6 alkyl.<br>
[0017] In another embodiment, the invention relates to compounds of Formula I<br>
wherein R3 is selected from<br><br>
[0018] In one embodiment, the invention relates to compounds of Formula I<br>
wherein R7 and R8 are H.<br>
[0019] In one embodiment, the invention relates to compounds of Formula I<br>
wherein R9, R10, R11, R12, R13, R14, R15, and R16 are independently selected from<br><br>
[0020] In a further embodiment, the invention relates to compounds of Formula I<br>
wherein R9, R10, R11, R12, R13, R14, R15, and R16are independently selected from<br><br>
[0021] In another embodiment, the invention relates to compounds of Formula I<br>
wherein R9, R10, R11, R12, R13, R14, R15, and R16 are H or hydroxy.<br>
[0022] In yet another embodiment, the invention relates to compounds of Formula<br>
I wherein R9, R10, R11, R12, R13, R14, R15, and R16 are H.<br>
[0023] In one embodiment n is 1.<br>
[0024] In another embodiment, the invention relates to compounds selected from<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?.6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-endo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?.6-<br>
benzo[ 1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-endo)-N- {3 -[3 -(5-Fluoro-pyridin-2-ylmethyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-lA.6-<br>
benzo[1,2,4]tWadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1 ?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
AT-{3-[((1S,25,7R,8R))-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-l?u6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[((1S,25,7R,8R))-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-R6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
AT-{3-[((1S,25,7R,8R))-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?,6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N- {3 -[3 -(4-Fluoro-benzyl)-6-hydroxy-4-oxo-11 -oxa-3 -aza-<br>
tricyclot6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-encfo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-11-oxa-<br>
3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N- {3-[3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-l 1 -oxa-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5 -en-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N- {3 -[3 -(3,3 -Dimethyl-butyl)-6-hydroxy-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesuIfonamide,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-beiizyl)-6-hydroxy-4-oxo-ll-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo [ 1,2,4]thiadiazin-7 -yl} -methanesulfonamide,<br>
AT-{3-[(1S,25,7R,8R)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[(1S,25,7R,8R)-3-(3,4-Difluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
beiizo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[(1S,25,7R,8R)-3-(3,4-Difluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-l, 1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -TV-methyl-methanesulfonamide,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-Af-methyl-methanesulfonamide,<br>
(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
(1S,25,7R,8R)-5-[7-(l,l-Dioxo-4,5-dihydro-lH-1?6-thiophen-2-yl)-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-4-one,<br>
(1S,25,7R,8R)-5-[7-(1, 1 -Dioxo-tetrahydro-1 A.6-thiophen-2-yl)-1,1 -dioxo-1,4-<br>
dihydro-1 A.6-benzo [ 1,2,4]thiadiazin-3 -yl]-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
(1S,25,7R,8R)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N- {3 -[3 -(2-Cyclopropyl-ethyl)-6-hydroxy-4-oxo-l 1 -oxa-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(1S,25,7R,8R)-V-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide,<br>
(rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(1S,25,7R,8R)-5-[7-( 1,1 -Dioxo-1?6-isothiazolidin-2-yl)-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl]-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo [6.2.1.02'7]undec-5 -en-4-one,<br>
(1S,25,7R,8R)-N-[3-(6-Hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-<br>
yl)-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(1S,25,7R,8R)-5-(1,1-Dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-<br>
(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[ 1,4]thiazin-7-<br>
yl} -methanesulfonamide,<br>
(1S,25,7R,8R)-5-(7-Amino-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-<br>
3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
(rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo- 1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-e.ro)-7V-{3-[3-(3,3-Dimethyl-butyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(mc-di-exo)-6-Hydroxy-5-(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyl)-11-oxa-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
(1S,25,7R,8R)-6-Hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyl)-3-aza-tricyclo[6.2.1.02'7]undec-5-en-<br>
4-one,<br>
Cyclopropanesulfonic acid {3-[(1S,25,7R,8R)-3-(4-fluoro-benzyl)-6-hydroxy-<br>
4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(rac-di-exo)-N-{3-[3-(3,3-Dimethyl-butyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,4]thiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,4]thiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,4]thiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-N-methyl-methanesulfonamide,<br>
Cyclopropanesulfonic acid {3-(1S,25,7R,8R)-[6-hydroxy-3-(3-methyl-butyl)-<br>
4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(1S,25,7R,8R)-N- {3 -[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-benzenesulfonamide,<br>
(rac-di-ax0)-Cyclopropanesulfonic acid {3-[6-hydroxy-3-(3-methyl-butyl)-4-<br>
oxo-ll-oxa-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(rac-di-gxo)-Cyclopropanesulfonic acid {3-[3-(3,3-dimethyl-butyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-<br>
R6-benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
N-[3-(1S,25,7R,8R)-3-Cyclopentyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(rac-di-exo)-Cyclopropanesulfonicacid {3-[6-hydroxy-3-(3-methyl-butyl)-4-<br>
oxo-3-aza-tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo [ 1,2,4]thiadiazin-7 -yl} -am ide,<br>
(rac-di-exo)-CycIopropanesulfonicacid (3-[3-(4-fluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2. L02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-diIiydro- 1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
AT-t3-(1S,25,7R,8R)-(3-Cyclopentyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide-iV-isopropyl carbamate,<br>
(mc-di-exo)-N-[3-(3-Cyclopentyl-6-hydroxy-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]tliiadiazin-7-yl]-methanesulfonamide,<br>
N- {3 -[(2S,7R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.2.02'7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-<br>
7-yl} -methanesulfonamide,<br>
cis-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.2.02'7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(2R,7S)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02&gt;7.09,11]tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(2S,7R)-AT-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02'7.09,11]tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(1S,25,7R,8R)-5-(l, 1 -Dioxo-7-pyrrolidin-1 -yl-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-6-hydroxy-3-(3-methyl-butyl)-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
Pyridine-3-sulfonic acid {3-[(1S,25,7R,8R)-3-(4-fluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(1S,25,7R,8R)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamide,<br>
(1S,25,7R,8R)-N-[3-(3-Benzyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl)-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(1S,25,7R,8R)-iV-[3-(6-Hydroxy-3-isobutyl-4-oxo-3-a2a-<br>
tricyclo[6.2.l.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(1S,25,7R,8R)-N-{3-[3-(3-Chloro-4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricydo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro- 1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide,<br>
N- {3 -[(1S,25,7R,8R)-3-(3 -Fluoro-4-methyl-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(1S,25,7R,8R)-5-(7-Bromo-1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e][1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
N- {3 -[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e][1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(1S,25,7R,8R)-5-(l,l-Dioxo-1,4-dihydro-1?6-pyrido[2,3-e][1,2,4]thiadiazin-3-<br>
yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02'7]undec-5-en-4-one,<br>
(1S,25,7R,8R)-5-(1,1-Dioxo-1,4-dihydro-1?6-pyrido[4,3-e][1,2,4]thiadiazin-3-<br>
yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(1S,25,7R,8R)-5-(l,l-Dioxo-1,4-dihydro-1?6-pyrido[3,2-e][1,2,4]thiadiazin-3-<br>
yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
N-{3-[(1S,25,7R,8R)-3-(2-Cyclopropyl-ethyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6,9-dihydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N -{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, L-arginine salt,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, L-lysine salt,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, hemi magnesium salt,<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, sodium salt, and<br>
N-{3-[(1S,25,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, potassium salt.<br>
[0025] The invention is also directed to pharmaceutically acceptable salts and<br>
pharmaceutically acceptable solvates of the compounds of Formula I. Advantageous<br>
methods of making the compounds of Formula I are also described.<br>
[0026] In one aspect, the invention encompasses a method for treating or<br>
preventing hepatitis C virus infection in a mammal in need thereof, preferably in a<br>
human in need thereof, comprising administering to the patient a therapeutically or<br>
prophylactically effective amount of a Formula I compound. In one embodiment, the<br>
invention encompasses a method for treating or preventing hepatitis C virus infection<br>
by administering to a patient in need thereof a therapeutically or prophylactically<br>
effective amount of a Formula I compound that is an inhibitor of HCV NS5B<br>
polymerase.<br>
[0027] In another aspect, the invention encompasses a method for treating or<br>
preventing hepatitis C virus infection in a patient in need thereof, comprising<br>
administering to the patient a therapeutically or prophylactically effective amount of a<br>
compound of Formula I and a pharmaceutically acceptable excipient, carrier, or<br>
vehicle.<br>
[0028] In another aspect, the invention encompasses a method for treating or<br>
preventing hepatitis C virus infection in a patient in need thereof, comprising<br>
administering to the patient a therapeutically or prophylactically effective amount of a<br>
compound of Formula I and an additional therapeutic agent, preferably an additional<br>
antiviral agent or an immunomodulatory agent.<br>
DETAILED DESCRIPTION OF THE INVENTION<br>
[0029] Where the following terms are used in this specification, they are used<br>
as defined below:<br>
[0030] The terms "comprising," "having" and "including" are used herein in<br>
their open, non-limiting sense.<br>
[0031] The term "alkyl", as used herein, unless otherwise indicated, includes<br>
C1-C12 saturated monovalent hydrocarbon radicals having straight, branched, or cyclic<br>
moieties (including fused and bridged bicyclic and spirocyclic moieties), or a<br>
combination of the foregoing moieties. For an alkyl group to have cyclic moieties, the<br>
group must have at least three carbon atoms.<br>
[0032] The term "alkylene", as used herein, unless otherwise indicated,<br>
includes a C1-C12 divalent radical derived from alkyl, as exemplified by<br>
-CH2CH2CH2CH2-.<br>
[0033] The term "alkenyl", as used herein, unless otherwise indicated, includes<br>
C1-C12 alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as<br>
defined above and including E and Z isomers of said alkenyl moiety.<br>
[0034] The term "alkynyl", as used herein, unless otherwise indicated, includes<br>
C1-C12 alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as<br>
defined above.<br>
[0035] The term "alkoxy", as used herein, unless otherwise indicated, includes<br>
O-alkyl groups wherein alkyl is as defined above.<br>
[0036] The term "Me" means methyl, "Et" means ethyl, and "Ac" means<br>
acetyl.<br>
[0037] The term "cycloalkyl", as used herein, unless otherwise indicated refers<br>
to a non-aromatic, saturated or partially saturated, monocyclic or fused, spiro or<br>
unfused bicyclic or tricyclic hydrocarbon referred to herein containing a total of from<br>
3 to 10 carbon atoms, preferably 5-8 ring carbon atoms. Exemplary cycloalkyls<br>
include monocyclic rings having from 3-7, preferably 3-6, carbon atoms, such as<br>
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.<br>
Illustrative examples of cycloalkyl are derived from, but not limited to, the following:<br><br>
[0038] The term "aryl", as used herein, unless otherwise indicated, includes an<br>
organic radical derived from an aromatic hydrocarbon by removal of one hydrogen,<br>
such as phenyl or naphthyl, containing a total of from 6 to 10 carbon atoms.<br>
[0039] The term "heterocyclic" or "heterocyclyl", as used herein, unless<br>
otherwise indicated, includes aromatic (e.g., heteroaryls) and non-aromatic<br>
heterocyclic groups containing one to four heteroatoms each selected from O, S and<br>
N, wherein each heterocyclic group has from 4-10 atoms in its ring system, and with<br>
the proviso that the ring of said group does not contain two adjacent O atoms. Non-<br>
aromatic heterocyclic groups include groups having only 3 atoms in their ring system,<br>
but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The<br>
heterocyclic groups include benzo-fused ring systems. An example of a 4 membered<br>
heterocyclic group is azetidinyl (derived from azetidine). An example of a 5<br>
membered heterocyclic group is thiazolyl and an example of a 10 membered<br>
heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are<br>
pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl,<br>
dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino,<br>
thioxanyl, piperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl,<br>
thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-<br>
pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl,<br>
pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl,<br>
pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-<br>
azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinolizinyl. Examples of aromatic<br>
heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl,<br>
pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl,<br>
pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl,<br>
indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl,<br>
purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl,<br>
benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and<br>
furopyridinyl. The foregoing groups, as derived from the groups listed above, may be<br>
C-attached or N-attached where such is possible. For instance, a group derived from<br>
pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-2-yl (C-attached) or pyrrol-3-yl (C-<br>
attached). Further, a group derived from imidazole maybe imidazol-1 -yl (N-<br>
attached) or imidazol-2-yl (C-attached). The 4-10 membered heterocyclic may be<br>
optionally substituted on any ring carbon, sulfur, or nitrogen atom(s) by one to two<br>
oxo, per ring. An example of a heterocyclic group wherein 2 ring carbon atoms are<br>
substituted with oxo moieties is 1,1-dioxo-thiomorpholinyl. Other illustrative<br>
examples of 4-10 membered heterocyclic are derived from, but not limited to, the<br>
following:<br><br><br>
[0040] Unless defined otherwise, "alkyl," "alkylene," "alkenyl," "alkynyl,"<br>
"aryl," "cycloalkyl," or "heterocyclyl" are each optionally and independently<br>
substituted by 1 -3 substituents selected from alkylamine, amino, aryl, cycloalkyl,<br>
heterocyclyl, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6<br>
alkylamine, C1-C6 dialkylamine, C2-C6 alkenyl, or C2-C6 alkynyl, wherein each of<br>
which may be interrupted by one or more hetero atoms, carboxyl, cyano, halo,<br>
hydroxy, nitro, -C(O)OH, -C(O)2-(C1-C6 alkyl), -C(O)2-(C3-C8 cycloalkyl), -C(O)2-<br>
(aryl), -C(O)2-(heterocyclyl), -C(O)2-(C1-C6 alkylenc)aryl, -C(O)2-(C1-C6<br>
alkylene)heterocyclyl, -C(O)2-(C1-C6 alkylene)cycloalkyl, -C(O)(C1-C6 alkyl),<br>
-C(O)(C3-C8 cycloalkyl), -C(O)(aryl), -C(O)(heterocyclyl), -C(O)(C1-C6<br>
alkylene)aryl, -C(O)(C1-C6 alkylene)heterocyclyl, and -C(O)(C1-C6<br>
alkylene)cycloalkyl, wherein each of these optional substituents can be further<br>
optionally substituted by 1-5 substituents selected from amino, cyano, halo, hydroxy,<br>
nitro, C1-C6 alkylamine, C1-C6 dialkylamine, C1-C6 alkyl, C1-C6 alkoxy, C1-C6<br>
alkenyl, and C1-C6 hydroxyalkyl, wherein each alkyl is optionally substituted by one<br>
or more halo substituents, e.g., CF3.<br>
[0041] The term "immunomodulator" refers to natural or synthetic products<br>
capable of modifying the normal or aberrant immune system through stimulation or<br>
suppression.<br>
[0042] The term "preventing" refers to the ability of a compound or composition<br>
of the invention to prevent a disease identified herein in patients diagnosed as having<br>
the disease or who are at risk of developing such disease. The term also encompasses<br>
preventing further progression of the disease in patients who are already suffering<br>
from or have symptoms of such disease.<br>
[0043] The term "patient" or "subject" means an animal (e.g., cow, horse,<br>
sheep, pig, chicken, turkey, quail, cat, dog, mouse, rat, rabbit, guinea pig, etc.) or a<br>
mammal, including chimeric and transgenic animals and mammals. In the treatment<br>
or prevention of HCV infection, the term "patient" or "subject" preferably means a<br>
monkey or a human, most preferably a human. In a specific embodiment the patient<br>
or subject is infected by or exposed to the hepatitis C virus. In certain embodiments,<br>
the patient is a human infant (age 0-2), child (age 2-17), adolescent (age 12-17), adult<br>
(age 18 and up) or geriatric (age 70 and up) patient. In addition, the patient includes<br>
immunocompromised patients such as HIV positive patients, cancer patients, patients<br>
undergoing immunotherapy or chemotherapy. In a particular embodiment, the patient<br>
is a healthy individual, i.e., not displaying symptoms of other viral infections.<br>
[0044] The term a "therapeutically effective amount" refers to an amount of<br>
the compound of the invention sufficient to provide a benefit in the treatment or<br>
prevention of viral disease, to delay or minimize symptoms associated with viral<br>
infection or viral-induced disease, or to cure or ameliorate the disease or infection or<br>
cause thereof. In particular, a therapeutically effective amount means an amount<br>
sufficient to provide a therapeutic benefit in vivo. Used in connection with an amount<br>
of a compound of the invention, the term preferably encompasses a non-toxic amount<br>
that improves overall therapy, reduces or avoids symptoms or causes of disease, or<br>
enhances the therapeutic efficacy of or synergies with another therapeutic agent.<br>
[0045] The term a "prophylactically effective amount" refers to an amount of<br>
a compound of the invention or other active ingredient sufficient to result in the<br>
prevention of infection, recurrence or spread of viral infection. A prophylactically<br>
effective amount may refer to an amount sufficient to prevent initial infection or the<br>
recurrence or spread of the infection or a disease associated with the infection. Used<br>
in connection with an amount of a compound of the invention, the term preferably<br>
encompasses a non-toxic amount that improves overall prophylaxis or enhances the<br>
prophylactic efficacy of or synergies with another prophylactic or therapeutic agent.<br>
[0046] The term "in combination" refers to the use of more than one<br>
prophylactic and/or therapeutic agents simultaneously or sequentially and in a manner<br>
that their respective effects are additive or synergistic.<br>
[0047] The term "treating" refers to:<br>
(i) preventing a disease, disorder, or condition from occurring in an<br>
animal that may be predisposed to the disease, disorder and/or condition, but has not<br>
yet been diagnosed as having it;<br>
(ii) inhibiting the disease, disorder, or condition, i.e., arresting its<br>
development; and<br>
(iii) relieving the disease, disorder, or condition, i.e., causing regression of<br>
the disease, disorder, and/or condition.<br>
[0048] The terms "R" and "S" indicate the specific stereochemical<br>
configuration of a substituent at an asymmetric carbon atom in a chemical structure as<br>
drawn.<br>
[0049] The term "rac" indicates that a compound is a racemate, which is defined<br>
as an equimolar mixture of a pair of enantiomers. A "rac" compound does not exhibit<br>
optical activity. The chemical name or formula of a racemate is distinguished from<br>
those of the enantiomers by the prefix (Â±)- or rac- (or racem-) or by the symbols RS<br>
and SR.<br>
[0050] The terms "endo" and "exo" are descriptors of the relative orientation of<br>
substituents attached to non-bridgehead atoms in a bicyclo[xj.z]alkane (x= y&gt;z&gt; 0).<br>
[0051] The terms "syn" and "anti" are descriptors of the relative orientation of<br>
substituents attached to bridgehead atoms in a bicyclo[xj'.z]alkane (x = y &gt; z &gt; 0).<br><br>
[0052] The term "exo" is given to a substituent (e.g., Br attached to C-2 in the<br>
example below) that is orientated towards the highest numbered bridge (z bridge, e.g.,<br>
C-7 in example below); if the substituent is orientated away from the highest<br>
numbered bridge it is given the description "endo".<br>
[0053] The term "syn" is given to a substituent attached to the highest numbered<br>
bridge (z bridge, e.g., F attached to C-7 in the example below) and is orientated<br>
towards the lowest numbered bridge (x bridge, e.g., C-2 and C-3 in example below);<br>
if the substiuent is orientated away from the lowest numbered bridge it is given the<br>
description "anti."<br><br>
[0054] The terms "cis" and "trans" are descriptors which show the relationship<br>
between two ligands attached to separate atoms that are connected by a double bond<br>
or are contained in a ring. The two ligands are said to be located cis to each other if<br>
they lie on the same side of a plane. If they are on opposite sides, their relative<br>
position is described as trans. The appropriate reference plane of a double bond is<br>
perpendicular to that of the relevant o-bonds and passes through the double bond. For<br>
a ring it is the mean plane of the ring(s).<br>
[0055] The compounds of the invention may exhibit the phenomenon of<br>
tautomerism. While Formula I cannot expressly depict all possible tautomeric forms,<br>
it is to be understood that Formula I is intended to represent any tautomeric form of<br>
the depicted compound and is not to be limited merely to a specific compound form<br>
depicted by the formula drawings. For illustration, and in no way limiting the range<br>
of tautomers, the compounds of Formula I may exist as the following:<br>
WhenX = N:<br><br>
When X = CR3:<br><br>
Or, the compounds of Formula I may exist as the following:<br>
When X = N:<br><br>
When X = CR3:<br><br>
[0056] Some of the inventive compounds may exist as single stereoisomers (i.e.,<br>
essentially free of other stereoisomers), racemates, and/or mixtures of enantiomers<br>
and/or diastereomers. All such single stereoisomers, racemates and mixtures thereof<br>
are intended to be within the scope of the present invention. Preferably, the inventive<br>
compounds that are optically active are used in optically pure form.<br>
[0057] As generally understood by those skilled in the art, an optically pure<br>
compound having one chiral center (i.e., one asymmetric carbon atom) is one that<br>
consists essentially of one of the two possible enantiomers (i.e., is enantiomerically<br>
pure), and an optically pure compound having more than one chiral center is one that<br>
is both diastereomerically pure and enantiomerically pure. Preferably, the compounds<br>
of the present invention are used in a form that is at least 90% free of other<br>
enantiomers or diastereomers of the compounds, that is, a form that contains at least<br>
90% of a single isomer (80% enantiomeric excess ("e.e.") or diastereomeric excess<br>
("d.e.")), more preferably at least 95% (90% e.e. or d.e.), even more preferably at<br>
least 97.5% (95% e.e. or d.e.), and most preferably at least 99% (98% e.e. or d.e.).<br>
[0058] Additionally, the Formula I is intended to cover solvated as well as<br>
unsolvated forms of the identified structures. For example, Formula I includes<br>
compounds of the indicated structure in both hydrated and non-hydrsated forms.<br>
Other examples of solvates include the structures in combination with isopropanol,<br>
ethanol, methanol, DMSO, ethyl acetate, pentyl acetate, acetic acid, or ethanolamine.<br>
[0059] In addition to compounds of Formula I, the invention includes<br>
pharmaceutically acceptable prodrugs, pharmaceutically active metabolites, and<br>
pharmaceutically acceptable salts of such compounds and metabolites.<br>
[0060] "A pharmaceutically acceptable prodrug" is a compound that may be<br>
converted under physiological conditions or by solvolysis to the specified compound<br>
or to a pharmaceutically acceptable salt of such compound prior to exhibiting its<br>
pharmacological effect (s). Typically, the prodrug is formulated with the objective(s)<br>
of improved chemical stability, improved patient acceptance and compliance,<br>
improved bioavailability, prolonged duration of action, improved organ selectivity,<br>
improved formulation (e.g., increased hydrosolubility), and/or decreased side effects<br>
(e.g., toxicity). The prodrug can be readily prepared from the compounds of Formula<br>
I using methods known in the art, such as those described by Burger's Medicinal<br>
Chemistry and Drug Chemistry, 1, 172-178, 949-982 (1995). See also Bertolini et al,<br>
J. Med. Chem., 40,2011-2016 (1997); Shan, et al., J. Pharm. Sci, 86 (7), 765-767;<br>
Bagshawe, Drug Dev. Res., 34, 220-230 (1995); Bodor, Advances in Drug Res., 13,<br>
224-331 (1984); Bundgaard, Design of Prodrugs (Elsevier Press 1985); Larsen,<br>
Design and Application of Prodrugs, Drug Design and Development (Krogsgaard-<br>
Larsen et al., eds., Harwood Academic Publishers, 1991); Dear et al., J. Chromatogr.<br>
B, 748, 281-293 (2000); Spraul et al., J. Pharmaceutical &amp; Biomedical Analysis, 10,<br>
601-605 (1992); and Prox et al., Xenobiol, 3, 103-112 (1992).<br>
[0061] "A pharmaceutically active metabolite" is intended to mean a<br>
pharmacologically active product produced through metabolism in the body of a<br>
specified compound or salt thereof. After entry into the body, most drugs are<br>
substrates for chemical reactions that may change their physical properties and<br>
biologic effects. These metabolic conversions, which usually affect the polarity of the<br>
Formula I compounds, alter the way in which drugs are distributed in and excreted<br>
from the body. However, in some cases, metabolism of a drug is required for<br>
therapeutic effect. For example, anticancer drugs of the anti-metabolite class must be<br>
converted to their active forms after they have been transported into a cancer cell.<br>
[0062] Since most drugs undergo metabolic transformation of some kind, the<br>
biochemical reactions that play a role in drug metabolism may be numerous and<br>
diverse. The main site of drug metabolism is the liver, although other tissues may<br>
also participate.<br>
[0063] A feature characteristic of many of these transformations is that the<br>
metabolic products, or "metabolites," are more polar than the parent drugs, although a<br>
polar drug does sometime yield a less polar product. Substances with high lipid/water<br>
partition coefficients, which pass easily across membranes, also diffuse back readily<br>
from tubular urine through the renal tubular cells into the plasma. Thus, such<br>
substances tend to have a low renal clearance and a long persistence in the body. If a<br>
drug is metabolized to a more polar compound, one with a lower partition coefficient,<br>
its tubular reabsorption will be greatly reduced. Moreover, the specific secretory<br>
mechanisms for anions and cations in the proximal renal tubules and in the<br>
parenchymal liver cells operate upon highly polar substances.<br>
[0064] As a specific example, phenacetin (acetophenetidin) and acetanilide are<br>
both mild analgesic and antipyretic agents, but are transformed within the body to a<br>
more polar and more effective metabolite, p-hydroxyacetanilid (acetaminophen),<br>
which is widely used today. When a dose of acetanilide is given to a person, the<br>
successive metabolites peak and decay in the plasma sequentially. During the first<br>
hour, acetanilide is the principal plasma component. In the second hour, as the<br>
acetanilide level falls, the metabolite acetaminophen concentration reaches a peak.<br>
Finally, after a few hours, the principal plasma component is a further metabolite that<br>
is inert and can be excreted from the body. Thus, the plasma concentrations of one or<br>
more metabolites, as well as the drug itself, can be pharmacologically important.<br>
[0065] "A pharmaceutically acceptable salt" is intended to mean a salt that retains<br>
the biological effectiveness of the free acids and bases of the specified compound and<br>
that is not biologically or otherwise undesirable. A compound of the invention may<br>
possess a sufficiently acidic, a sufficiently basic, or both functional groups, and<br>
accordingly react with any of a number of inorganic or organic bases, and inorganic<br>
and organic acids, to form a pharmaceutically acceptable salt. Exemplary<br>
pharmaceutically acceptable salts include those salts prepared by reaction of the<br>
compounds of the present invention with a mineral or organic acid or an inorganic<br>
base, such as salts including sulfates, pyrosulfates, bisulfates, sulfites, bisulfites,<br>
phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates,<br>
pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates,<br>
caprylates, acrylates, formates, isobutyrates, caproates, heptanoates, propiolates,<br>
oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-<br>
dioates, hexyne-l,6-dioates, benzoates, chlorobenzoates, methylbenzoates,<br>
dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates,<br>
xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrates, citrates,<br>
lactates, y-hydroxybutyrates, glycolates, tartrates, methane-sulfonates,<br>
propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and<br>
mandelates.<br>
[0066] If the inventive compound is a base, the desired pharmaceutically<br>
acceptable salt may be prepared by any suitable method available in the art, for<br>
example, treatment of the free base with an inorganic acid, such as hydrochloric acid,<br>
hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, or with an<br>
organic acid , such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric<br>
acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a<br>
pyranosidyl acid, such as glucuronic acid or galacturonic acid, an a-hydroxy acid,<br>
such as citric acid or tartaric acid, an amino acid, such as aspartic acid or glutamic<br>
acid, an aromatic acid, such as benzoic acid or cinnamic acid, a sulfonic acid, such as<br>
p-toluenesulfonic acid or ethanesulfonic acid, or the like.<br>
[0067] If the inventive compound is an acid, the desired pharmaceutically<br>
acceptable salt may be prepared by any suitable method, for example, treatment of the<br>
free acid with an inorganic or organic base, such as an amine (primary, secondary or<br>
tertiary), an alkali metal hydroxide or alkaline earth metal hydroxide, or the like.<br>
Illustrative examples of suitable salts include organic salts derived from amino acids,<br>
such as glycine and arginine, ammonia, primary, secondary, and tertiary amines, and<br>
cyclic amines, such as piperidine, morpholine and piperazine, and inorganic salts<br>
derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc,<br>
aluminum and lithium.<br>
[0068] In the case of agents that are solids, it is understood by those skilled in the<br>
art that the inventive compounds and salts may exist in different crystal, co-crystal, or<br>
polymorphic forms, all of which are intended to be within the scope of the present<br>
invention and specified formulas.<br>
METHODS OF TREATMENT AND PREVENTION OF<br>
HEPATITIS C VIRAL INFECTIONS<br>
[0069] The present invention provides methods for treating or preventing a<br>
hepatitis C virus infection in a patient in need thereof.<br>
[0070] The present invention further provides methods for introducing a<br>
therapeutically effective amount of the Formula I compound or combination of such<br>
compounds into the blood stream of a patient in the treatment and/or prevention of<br>
hepatitis C viral infections.<br>
[0071] The magnitude of a prophylactic or therapeutic dose of a Formula I<br>
compound of the invention or a pharmaceutically acceptable salt, solvate, or hydrate,<br>
thereof in the acute or chronic treatment or prevention of an infection will vary,<br>
however, with the nature and severity of the infection, and the route by which the<br>
active ingredient is administered. The dose, and in some cases the dose frequency,<br>
will also vary according to the infection to be treated, the age, body weight, and<br>
response of the individual patient. Suitable dosing regimens can be readily selected<br>
by those skilled in the art with due consideration of such factors.<br>
[0072] The methods of the present invention are particularly well suited for<br>
human patients. In particular, the methods and doses of the present invention can be<br>
useful for immunocompromised patients including, but not limited to cancer patients,<br>
HTV infected patients, and patients with an immunodegenerative disease.<br>
Furthermore, the methods can be useful for immunocompromised patients currently in<br>
a state of remission. The methods and doses of the present invention are also useful<br>
for patients undergoing other antiviral treatments. The prevention methods of the<br>
present invention are particularly useful for patients at risk of viral infection. These<br>
patients include, but are not limited to health care workers, e.g., doctors, nurses,<br>
hospice care givers; military personnel; teachers; childcare workers; patients traveling<br>
to, or living in, foreign locales, in particular third world locales including social aid<br>
workers, missionaries, and foreign diplomats. Finally, the methods and compositions<br>
include the treatment of refractory patients or patients resistant to treatment such as<br>
resistance to reverse transcriptase inhibitors, protease inhibitors, etc.<br>
Doses<br>
[0073] Toxicity and efficacy of the compounds of the invention can be<br>
determined by standard pharmaceutical procedures in cell cultures or experimental<br>
animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and<br>
the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio<br>
between toxic and therapeutic effects is the therapeutic index and it can be expressed<br>
as the ratio LD50/ED50.<br>
[0074] The data obtained from the cell culture assays and animal studies can<br>
be used in formulating a range of dosage of the compounds for use in humans. The<br>
dosage of such compounds lies preferably within a range of circulating concentrations<br>
that include the ED50 with little or no toxicity. The dosage may vary within this range<br>
depending upon the dosage form employed and the route of administration utilized.<br>
For any compound used in the method of the invention, the therapeutically effective<br>
dose can be estimated initially from cell culture assays. A dose may be formulated in<br>
animal models to achieve a circulating plasma concentration range that includes the<br>
IC50 (i.e., the concentration of the test compound that achieves a half-maximal<br>
inhibition of symptoms) as determined in cell culture; alternatively, the dose of the<br>
Formula I compound may be formulated in animal models to achieve a circulating<br>
plasma concentration range of the compound that corresponds to the concentration<br>
required to achieve a fixed magnitude of response. Such information can be used to<br>
more accurately determine useful doses in humans. Levels in plasma may be<br>
measured, for example, by high performance liquid chromatography.<br>
[0075] The protocols and compositions of the invention are preferably tested<br>
in vitro, and then in vivo, for the desired therapeutic or prophylactic activity, prior to<br>
use in humans. For example, in vitro assays which can be used to determine whether<br>
administration of a specific therapeutic protocol is indicated, include in vitro cell<br>
culture assays in which cells that are responsive to the effects of the Formula I<br>
compounds are exposed to the ligand and the magnitude of response is measured by<br>
an appropriate technique. The assessment of the Formula I compound is then<br>
evaluated with respect to the Formula I compound potency, and the degree of<br>
conversion of the Formula I compound prodrug. Compounds for use in methods of<br>
the invention can be tested in suitable animal model systems prior to testing in<br>
humans, including but not limited to in rats, mice, chicken, cows, monkeys, rabbits,<br>
hamsters, etc. The compounds can then be used in the appropriate clinical trials.<br>
[0076] The magnitude of a prophylactic or therapeutic dose of a prodrug of a<br>
Formula I compound of the invention or a pharmaceutically acceptable salt, solvate,<br>
or hydrate thereof in the acute or chronic treatment or prevention of an infection or<br>
condition will vary with the nature and severity of the infection, and the route by<br>
which the active ingredient is administered. The dose, and perhaps the dose<br>
frequency, will also vary according to the infection to be treated, the age, body<br>
weight, and response of the individual patient. Suitable dosing regimens can be<br>
readily selected by those skilled in the art with due consideration of such factors. In<br>
one embodiment, the dose administered depends upon the specific compound to be<br>
used, and the weight and condition of the patient. Also, the dose may differ for<br>
various particular Formula I compounds; suitable doses can be predicted on the basis<br>
of the aforementioned in vitro measurements and on the basis of animal studies, such<br>
that smaller doses will be suitable for those Formula I compounds that show<br>
effectiveness at lower concentrations than other Formula I compounds when<br>
measured in the systems described or referenced herein. In general, the dose per day<br>
is in the range of from about 0.001 to 100 mg/kg, preferably about 1 to 25 mg/kg,<br>
more preferably about 5 to 15 mg/kg. For treatment of humans infected by hepatitis C<br>
viruses, about 0.1 mg to about 15 g per day is administered in about one to four<br>
divisions a day, preferably 100 mg to 12 g per day, more preferably from 100 mg to<br>
8000 mg per day.<br>
[0077] Additionally, the recommended daily dose ran can be administered in<br>
cycles as single agents or in combination with other therapeutic agents. In one<br>
embodiment, the daily dose is administered in a single dose or in equally divided<br>
doses. In a related embodiment, the recommended daily dose can be administered<br>
once time per week, two times per week, three times per week, four times per week or<br>
five times per week.<br>
[0078] In one embodiment, the compounds of the invention are administered<br>
to provide systemic distribution of the compound within the patient. In a related<br>
embodiment, the compounds of the invention are administered to produce a systemic<br>
effect in the body.<br>
[0079] In another embodiment the compounds of the invention are<br>
administered via oral, mucosal (including sublingual, buccal, rectal, nasal, or vaginal),<br>
parenteral (including subcutaneous, intramuscular, bolus injection, intraarterial, or<br>
intravenous), transdermal, or topical administration. In a specific embodiment the<br>
compounds of the invention are administered via mucosal (including sublingual,<br>
buccal, rectal, nasal, or vaginal), parenteral (including subcutaneous, intramuscular,<br>
bolus injection, intraarterial, or intravenous), transdermal, or topical administration.<br>
In a further specific embodiment, the compounds of the invention are administered<br>
via oral administration. In a further specific embodiment, the compounds of the<br>
invention are not administered via oral administration.<br>
[0080] Different therapeutically effective amounts may be applicable for<br>
different infections, as will be readily known by those of ordinary skill in the art.<br>
Similarly, amounts sufficient to treat or prevent such infections, but insufficient to<br>
cause, or sufficient to reduce, adverse effects associated with conventional therapies<br>
are also encompassed by the above described dosage amounts and dose frequency<br>
schedules.<br>
Combination Therapy<br>
[0081] Specific methods of the invention further comprise the administration<br>
of an additional therapeutic agent (i.e., a therapeutic agent other than a compound of<br>
the invention). In certain embodiments of the present invention, the compounds of<br>
the invention can be used in combination with at least one other therapeutic agent.<br>
Therapeutic agents include, but are not limited to antibiotics, antiemetic agents,<br>
antidepressants, and antifungal agents, anti-inflammatory agents, antiviral agents,<br>
anticancer agents, immunomodulatory agents, a-interferons, p-interferons, ribavirin,<br>
alkylating agents, hormones, cytokines, or toll receptor-like modulators. In one<br>
embodiment the invention encompasses the administration of an additional<br>
therapeutic agent that is HCV specific or demonstrates anti-HCV activity.<br>
[0082] The Formula I compounds of the invention can be administered or<br>
formulated in combination with antibiotics. For example, they can be formulated with<br>
a macrolide (e.g., tobramycin (TobiÂ®)), a cephalosporin (e.g., cephalexin (Keflex!),<br>
cephradine (VelosefÂ®), cefuroxime (CeftinÂ®), cefprozil (CefzilÂ®), cefaclor<br>
(CeclorÂ®), cefixime (SupraxÂ®) or cefadroxil (DuricefÂ®)), a clarithromycin (e.g.,<br>
clarithromycin (BiaxinÂ®)), an erythromycin (e.g., erythromycin (EMycinÂ®)), a<br>
penicillin (e.g., penicillin V (V-Cillin K.Â® or Pen Vee KÂ®)) or a quinolone (e.g.,<br>
ofloxacin (FloxinÂ®), ciprofloxacin (CiproÂ®) or norfloxacin<br>
(NoroxinÂ®)),aminoglycoside antibiotics (e.g., apramycin, arbekacin, bambermycins,<br>
butirosin, dibekacin, neomycin, neomycin, undecylenate, netilmicin, paromomycin,<br>
ribostamycin, sisomicin, and spectinomycin), amphenicol antibiotics (e.g.,<br>
azidamfenicol, chloramphenicol, florfenicol, and thiamphenicol), ansamycin<br>
antibiotics (e.g., rifamide and rifampin), carbacephems (e.g., loracarbef), carbapenems<br>
(e.g., biapenem and imipenem), cephalosporins (e.g., cefaclor, cefadroxil,<br>
cefamandole, cefatrizine, cefazedone, cefozopran, cefpimizole, cefpiramide, and<br>
cefpirome), cephamycins (e.g., cefbuperazone, cefmetazole, and cefminox),<br>
monobactams (e.g., aztreonam, carumonam, and tigemonam), oxacephems (e.g.,<br>
flomoxef, and moxalactam), penicillins (e.g., amdinocillin, amdinocillin pivoxil,<br>
amoxicillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, epicillin,<br>
fenbenicillin, floxacillin, penamccillin, penethamate hydriodide, penicillin o-<br>
benethamine, penicillin 0, penicillin V, penicillin V benzathine, penicillin V<br>
hydrabamine, penimepicycline, and phencihicillin potassium), lincosamides (e.g.,<br>
clindamycin, and lincomycin), amphomycin, bacitracin, capreomycin, colistin,<br>
enduracidin, enviomycin, tetracyclines (e.g., apicycline, chlortetracycline,<br>
clomocycline, and demeclocycline), 2,4-diaminopyrimidines (e.g., brodimoprim),<br>
nitrofurans (e.g., furaltadone, and furazolium chloride), quinolones and analogs<br>
thereof (e.g., cinoxacin, clinafloxacin, flumequine, and grepagloxacin), sulfonamides<br>
(e.g., acetyl sulfamethoxypyrazine, benzylsulfamide, noprylsulfamide,<br>
phthalylsulfacetamide, sulfachrysoidine, and sulfacytine), sulfones (e.g.,<br>
diathymosulfone, glucosulfone sodium, and solasulfone), cycloserine, mupirocin and<br>
tuberin.<br>
[0083] The Formula I compounds of the invention can also be administered or<br>
formulated in combination with an antiemetic agent. Suitable antiemetic agents<br>
include, but are not limited to, metoclopromide, domperidone, prochlorperazine,<br>
promethazine, chlorpromazine, trimethobenzamide, ondansetron, granisetron,<br>
hydroxyzine, acetylleucine monoethanolamine, alizapride, azasetron, benzquinamide,<br>
bietanautine, bromopride, buclizine, clebopride, cyclizine, dimenhydrinate,<br>
diphenidol, dolasetron, meclizine, methallatal, metopimazine, nabilone, oxyperndyl,<br>
pipamazine, scopolamine, sulpiride, tetrahydrocannabinols, thiethylperazine,<br>
thioproperazine, tropisetron, and mixtures thereof.<br>
[0084] The Formula I compounds of the invention can be administered or<br>
formulated in combination with an antidepressant. Suitable antidepressants include,<br>
but are not limited to, binedaline, caroxazone, citalopram, dimethazan, fencamine,<br>
indalpine, indeloxazine hydrochloride, nefopam, nomifensine, oxitriptan, oxypertine,<br>
paroxetine, sertraline, thiazesim, trazodone, benmoxine, iproclozide, iproniazid,<br>
isocarboxazid, nialamide, octamoxin, phenelzine, cotinine, rolicyprine, rolipram,<br>
maprotiline, metralindole, mianserin, mirtazepine, adinazolam, amitriptyline,<br>
amitriptylinoxide, amoxapine, butriptyline, clomipramine, demexiptiline,<br>
desipramine, dibenzepin, dimetacrine, dothiepin, doxepin, fluacizine, imipramine,<br>
imipramine N-oxide, iprindole, lofepramine, melitracen, metapramine, nortriptyline,<br>
noxiptilin, opipramol, pizotyline, propizepine, protriptyline, quinupramine, tianeptine,<br>
trimipramine, adrafinil, benactyzine, bupropion, butacetin, dioxadrol, duloxetine,<br>
etoperidone, febarbamate, femoxetine, fenpentadiol, fluoxetine, fluvoxamine,<br>
hematoporphyrin, hypericin, levophacetoperane, medifoxamine, milnacipran,<br>
minaprine, moclobemide, nefazodone, oxaflozane, piberaline, prolintane,<br>
pyrisuccideanol, ritanserin, roxindole, rubidium chloride, sulpiride, tandospirone,<br>
thozalinone, tofenacin, toloxatone, tranylcypromine, /.-tryptophan, venlafaxine,<br>
viloxazine, and zimeldine.<br>
[0085] The Formula I compounds of the invention can be administered or<br>
formulated in combination with an antifungal agent. Suitable antifungal agents<br>
include but are not limited to amphotericin B, itraconazole, ketoconazole, fluconazole,<br>
intrathecal, flucytosine, miconazole, butoconazole, clotrimazole, nystatin,<br>
terconazole, tioconazole, ciclopirox, econazole, haloprogrin, naftifine, terbinafine,<br>
undccylenate, and griseofulvin.<br>
[0086| The Formula I compounds of the invention can be administered or<br>
formulated in combination with an anti-inflammatory agent. Useful anti-<br>
inflammatory agents include, but are not limited to, non-steroidal anti-inflammatory<br>
drugs such as salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal,<br>
salsalate, olsalazine, sulfasalazine, acetaminophen, indomethacin, sulindac, etodolac,<br>
mefenamic acid, meclofenamate sodium, tolmetin, ketorolac, dichlofenac, ibuprofen,<br>
naproxen, naproxen sodium, fenoprofen, ketoprofen, flurbinprofen, oxaprozin,<br>
piroxicam, meloxicam, ampiroxicam, droxicam, pivoxicam, tenoxicam, nabumetome,<br>
phenylbutazone, oxyphenbutazone, antipyrine, aminopyrine, apazone and nimesulide;<br>
leukotriene antagonists including, but not limited to, zileuton, aurothioglucose, gold<br>
sodium thiomalate and auranofin; steroids including, but not limited to, alclometasone<br>
diproprionate, amcinonide, beclomethasone dipropionate, betametasone,<br>
betamethasone benzoate, betamethasone diproprionate, betamethasone sodium<br>
phosphate, betamethasone valerate, clobetasol proprionate, clocortolone pivalate,<br>
hydrocortisone, hydrocortisone derivatives, desonide, desoximatasone,<br>
dexamethasone, flunisolide, flucoxinolide, flurandrenolide, halcinocide, medrysone,<br>
methylprednisolone, methprednisolone acetate, methylprednisolone sodium succinate,<br>
mometasone furoate, paramethasone acetate, prednisolone, prednisolone acetate,<br>
prednisolone sodium phosphate, prednisolone tebuatate, prednisone, triamcinolone,<br>
triamcinolone acetonide, triamcinolone diacetate, and triamcinolone hexacetonide;<br>
and other anti-inflammatory agents including, but not limited to, methotrexate,<br>
colchicine, allopurinol, probenecid, sulfinpyrazone and benzbromarone.<br>
[0087] The Formula I compounds of the invention can be administered or<br>
formulated in combination with another antiviral agent. Useful antiviral agents<br>
include, but are not limited to, protease inhibitors, nucleoside reverse transcriptase<br>
inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleoside analogs.<br>
The antiviral agents include but are not limited to zidovudine, acyclovir,<br>
gangcyclovir, vidarabine, idoxuridine, trifluridine, levovirin, viramidine and ribavirin,<br>
as well as foscarnet, amantadine, rimantadine, saquinavir, indinavir, amprenavir,<br>
lopinavir, ritonavir, the a-interferons, Ã-interferons, adefovir, clevadine, entecavir,<br>
pleconaril.<br>
[0088] The Formula I compound of the invention can be administered or<br>
formulated in combination with an immunomodulatory agent. Immunomodulatory<br>
agents include, but are not limited to, methothrexate, leflunomide, cyclophosphamide,<br>
cyclosporine A, mycophenolate mofetil, rapamycin (sirolimus), mizoribine,<br>
deoxyspergualin, brequinar, malononitriloamindes (e.g., leflunamide), T cell receptor<br>
modulators, and cytokine receptor modulators, peptide mimetics, and antibodies (e.g.,<br>
human, humanized, chimeric, monoclonal, polyclonal, Fvs, ScFvs, Fab or F(ab)2<br>
fragments or epitope binding fragments), nucleic acid molecules (e.g., antisense<br>
nucleic acid molecules and triple helices), small molecules, organic compounds, and<br>
inorganic compounds. Examples of T cell receptor modulators include, but are not<br>
limited to, anti-T cell receptor antibodies (e.g., anti-CD4 antibodies (e.g., cM-T412<br>
(Boehringer), IDEC-CE9.1Â® (IDEC and SKB), mAB 4162W94, Orthoclone and<br>
OKTcdr4a (Janssen-Cilag)), anti-CD3 antibodies (e.g., Nuvion (Product Design<br>
Labs), OKT3 (Johnson &amp; Johnson), or Rituxan (IDEC)), anti-CD5 antibodies (e.g., an<br>
anti-CD5 ricin-linked immunoconjugate), anti-CD7 antibodies (e.g., CHH-380<br>
(Novartis)), anti-CD8 antibodies, anti-CD40 ligand monoclonal antibodies (e.g.,<br>
IDEC-131 (IDEC)), anti-CD52 antibodies (e.g., CAMPATH 1H (Ilex)), anti-CD2<br>
antibodies, anti-CD 1 la antibodies (e.g., Xanelim (Genentech)), anti-B7 antibodies<br>
(e.g., IDEC-114 (IDEC)), CTLA4-immunoglobulin, and toll receptor-like (TLR)<br>
modulators. Examples of cytokine receptor modulators include, but are not limited to,<br>
soluble cytokine receptors (e.g., the extracellular domain of a TNF-a receptor or a<br>
fragment thereof, the extracellular domain of an IL-ip receptor or a fragment thereof,<br>
and the extracellular domain of an IL-6 receptor or a fragment thereof), cytokines or<br>
fragments thereof (e.g., interleukin (IL)-2, IL-3, IL-4, DL-5, IL-6, DL-7, IL-8, IL-9, IL-<br>
10, IL-11, IL-12, IL-15, TNF-a, interferon (IFN)-a, IFN-Ã, IFN-?, and GM-CSF),<br>
anti-cytokine receptor antibodies (e.g., anti-IFN receptor antibodies, anti-IL-2<br>
receptor antibodies (e.g., Zenapax (Protein Design Labs)), anti-IL-4 receptor<br>
antibodies, anti-IL-6 receptor antibodies, anti-IL-10 receptor antibodies, and anti-IL-<br>
12 receptor antibodies), anti-cytokine antibodies (e.g., anti-IFN antibodies, anti-TNF-<br>
a antibodies, anti-IL-lp antibodies, anti-IL-6 antibodies, anti-IL-8 antibodies (e.g.,<br>
ABX-IL-8 (Abgenix)), and anti-IL-12 antibodies).<br>
[0089] The Formula I compounds of the invention can be administered or<br>
formulated in combination with an agent which inhibits viral enzymes, including but<br>
not limited to inhibitors of HCV protease, such as BILN 2061, SCH-503034, ITMN-<br>
191, or VX-950; and inhibitors of NS5B polymerase such as NM107 (and its prodrug<br>
NM283), R1626, R7078, BILN 1941, GSK625433, GILD9128 or HCV-796.<br>
[0090] The Formula I compounds of the invention can be administered or<br>
formulated in combination with an agent which inhibits HCV polymerase such as<br>
those described in Wu, Curr Drug Targets Infect Disord. 2003, 3(3), 207-19 or in<br>
combination with compounds that inhibit the helicase function of the virus such as<br>
those described in Bretner M, et al. Nucleosides Nucleotides Nucleic Acids. 2003,<br>
22(5-8), 1531, or with inhibitors of other HCV specific targets such as those described<br>
in Zhang X., IDrugs 2002, 5(2), 154-8.<br>
[0091] The Formula I compounds of the invention can be administered or<br>
formulated in combination with an agent which inhibits viral replication.<br>
[0092] The Formula I compounds of the invention can be administered or<br>
formulated in combination with cytokines. Examples of cytokines include, but are not<br>
limited to, interleukin-2 (IL-2), interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5<br>
(EL-5), interleukin-6 (IL-6), interleukin-7 (TL-7), interleukin-9 (IL-9), interleukin-10<br>
(EL-10), interleukin-12 (IL-12), interleukin 15 (IL-15), interleukin 18 (IL-18), platelet<br>
derived growth factor (PDGF), erythropoietin (Epo), epidermal growth factor (EGF),<br>
fibroblast growth factor (FGF), granulocyte macrophage stimulating factor (GM-<br>
CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating<br>
factor (M-CSF), prolactin, and interferon (IFN), e.g., IFN-a, and IFN-y).<br>
[0093] The Formula I compounds of the invention can be administered or<br>
formulated in combination with hormones. Examples of hormones include, but are<br>
not limited to, luteinizing hormone releasing hormone (LHRH), growth hormone<br>
(GH), growth hormone releasing hormone, ACTH, somatostatin, somatotropin,<br>
somatomedin, parathyroid hormone, hypothalamic releasing factors, insulin,<br>
glucagon, enkephalins, vasopressin, calcitonin, heparin, low molecular weight<br>
heparins, heparinoids, synthetic and natural opioids, insulin thyroid stimulating<br>
hormones, and endorphins.<br>
[0094] The Formula I compounds of the invention can be administered or<br>
formulated in combination with Ã-interferons which include, but are not limited to,<br>
interferon Ã-1a, interferon Ã-1b.<br>
[0095] The Formula I compounds of the invention can be administered or<br>
formulated in combination with a-interferons which include, but are not limited to,<br>
interferon a-1, interferon a-2a (roferon), interferon a-2b, intron, Peg-Intron, Pegasys,<br>
consensus interferon (infergen) and albuferon.<br>
[0096] The Formula I compounds of the invention can be administered or<br>
formulated in combination with an absorption enhancer, particularly those which<br>
target the lymphatic system, including, but not limited to sodium glycocholate;<br>
sodium caprate; N-lauryl-P-D-maltopyranoside; EDTA; mixed micelle; and those<br>
reported in Muranishi Crit. Rev. Ther. Drug Carrier Syst., 7, 1-33, which is hereby<br>
incorporated by reference in its entirety. Other known absorption enhancers can also<br>
be used. Thus, the invention also encompasses a pharmaceutical composition<br>
comprising one or more Formula I compounds of the invention and one or more<br>
absorption enhancers.<br>
[0097] The Formula I compounds of the invention can be administered or<br>
formulated in combination with a cytochrome P450 monooxygenase inhibitor, such<br>
as, but not limited to, ritonavir or a pharmaceutically acceptable salt, ester, and<br>
prodrug thereof to improve the pharmacokinetics (e.g., increased half-life, increased<br>
time to peak plasma concentration, increased blood levels) of a Formula 1 compound<br>
that is metabolized by cytochrome P450 monooxygenase. Thus, the invention also<br>
encompasses a pharmaceutical composition comprising Formula I compounds of the<br>
invention and one or more cytochrome P450 monooxygenase inhibitors.<br>
[0098] The Formula I compounds of the invention can be administered in<br>
combination with food to enhance absorption of the Formula I compounds in the<br>
gastrointestinal tract and to increase the bioavailability of the Formula I compounds.<br>
[0099] The Formula I compounds of the invention can be administered or<br>
formulated in combination with an alkylating agent. Examples of alkylating agents<br>
include, but are not limited to nitrogen mustards, ethylenimines, methylmelamines,<br>
alkyl sulfonates, nitrosoureas, triazenes, mechlorethamine, cyclophosphamide,<br>
ifosfamide, melphalan, chlorambucil, hexamethylmelaine, thiotepa, busulfan,<br>
carmustine, streptozocin, dacarbazine and temozolomide.<br>
[00100] The compounds of the invention and the other therapeutics agent can<br>
act additively or, more preferably, synergistically. In one embodiment, a composition<br>
comprising a compound of the invention is administered concurrently with the<br>
administration of another therapeutic agent, which can be part of the same<br>
composition or in a different composition from that comprising the compounds of the<br>
invention. In another embodiment, a compound of the invention is administered prior<br>
to or subsequent to administration of another therapeutic agent. In a separate<br>
embodiment, a compound of the invention is administered to a patient who has not<br>
previously undergone or is not currently undergoing treatment with another<br>
therapeutic agent, particularly an antiviral agent.<br>
[00101] In one embodiment, the methods of the invention comprise the<br>
administration of one or more Formula I compounds of the invention without an<br>
additional therapeutic agent.<br>
PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS<br>
[00102] Pharmaceutical compositions and single unit dosage forms comprising<br>
a Formula I compound of the invention, or a pharmaceutically acceptable salt, or<br>
hydrate thereof, are also encompassed by the invention. Individual dosage forms of<br>
the invention maybe suitable for oral, mucosal (including sublingual, buccal, rectal,<br>
nasal, or vaginal), parenteral (including subcutaneous, intramuscular, bolus injection,<br>
intraarterial, or intravenous), transdermal, or topical administratioa Pharmaceutical<br>
compositions and dosage forms of the invention typically also comprise one or more<br>
pharmaceutically acceptable excipients. Sterile dosage forms are also contemplated.<br>
[00103] In an alternative embodiment, pharmaceutical composition<br>
encompassed by this embodiment includes a Formula I compound of the invention, or<br>
a pharmaceutically acceptable salt, or hydrate thereof, and at least one additional<br>
therapeutic agent. Examples of additional therapeutic agents include, but are not<br>
limited to, those listed above.<br>
[00104] The composition, shape, and type of dosage forms of the invention will<br>
typically vary depending on their use. For example, a dosage form used in the acute<br>
treatment of a disease or a related disease may contain larger amounts of one or more<br>
of the active ingredients it comprises than a dosage form used in the chronic treatment<br>
of the same disease. Similarly, a parenteral dosage form may contain smaller<br>
amounts of one or more of the active ingredients it comprises than an oral dosage<br>
form used to treat the same disease or disorder. These and other ways in which<br>
specific dosage forms encompassed by this invention will vary from one another will<br>
be readily apparent to those skilled in the art. See, e.g., Remington 's Pharmaceutical<br>
Sciences, 18th ed., Mack Publishing, Easton PA (1990). Examples of dosage forms<br>
include, but are not limited to: tablets; caplets; capsules, such as soft elastic gelatin<br>
capsules; cachets; troches; lozenges; dispersions; suppositories; ointments; cataplasms<br>
(poultices); pastes; powders; dressings; creams; plasters; solutions; patches; aerosols<br>
(e.g., nasal sprays or inhalers); gels; liquid dosage forms suitable for oral or mucosal<br>
administration to a patient, including suspensions (e.g., aqueous or non-aqueous liquid<br>
suspensions, oil-in-water emulsions, or a water-in-oil liquid emulsions), solutions, and<br>
elixirs; liquid dosage forms suitable for parenteral administration to a patient; and<br>
sterile solids (e.g., crystalline or amorphous solids) that can be reconstituted to<br>
provide liquid dosage forms suitable for parenteral administration to a patient.<br>
[00105] Typical pharmaceutical compositions and dosage forms comprise one<br>
or more carriers, excipients or diluents. Suitable excipients are well known to those<br>
skilled in the art of pharmacy, and non-limiting examples of suitable excipients are<br>
provided herein. Whether a particular excipient is suitable for incorporation into a<br>
pharmaceutical composition or dosage form depends on a variety of factors well<br>
known in the art including, but not limited to, the way in which the dosage form will<br>
be administered to a patient. For example, oral dosage forms such as tablets may<br>
contain excipients not suited for use in parenteral dosage forms. The suitability of a<br>
particular excipient may also depend on the specific active ingredients in the dosage<br>
form.<br>
[00106] This invention further encompasses anhydrous pharmaceutical<br>
compositions and dosage forms comprising active ingredients, since water can<br>
facilitate the degradation of some compounds. For example, the addition of water<br>
(e.g., 5%) is widely accepted in the pharmaceutical arts as a means of simulating<br>
long-term storage in order to determine characteristics such as shelf-life or the<br>
stability of formulations over time. See, e.g., Carstensen, Drug Stability: Principles<br>
&amp; Practice, 2d. Ed., Marcel Dekker, NY, NY, 1995, pp. 379-80. In effect, water and<br>
heat accelerate the decomposition of some compounds. Thus, the effect of water on a<br>
formulation can be of great significance since moisture and/or humidity are<br>
commonly encountered during manufacture, handling, packaging, storage, shipment,<br>
and use of formulations.<br>
[00107] Anhydrous pharmaceutical compositions and dosage forms of the<br>
invention can be prepared using anhydrous or low moisture containing ingredients<br>
and low moisture or low humidity conditions.<br>
[00108] An anhydrous pharmaceutical composition should be prepared and<br>
stored such that its anhydrous nature is maintained. Accordingly, anhydrous<br>
compositions are preferably packaged using materials known to prevent exposure to<br>
water such that they can be included in suitable formulary kits. Examples of suitable<br>
packaging include, but are not limited to, hermetically sealed foils, plastics, unit dose<br>
containers (e.g., vials), blister packs, and strip packs.<br>
[00109] The invention further encompasses pharmaceutical compositions and<br>
dosage forms that comprise one or more compounds that reduce the rate by which an<br>
active ingredient will decompose. Such compounds, which are referred to herein as<br>
"stabilizers," include, but are not limited to, antioxidants such as ascorbic acid, pH<br>
buffers, or salt buffers.<br>
[00110] Like the amounts and types of excipients, the amounts and specific<br>
types of active ingredients in a dosage form may differ depending on factors such as,<br>
but not limited to, the route by which it is to be administered to patients. However,<br>
typical dosage forms of the invention comprise Formula I compounds of the<br>
invention, or a pharmaceutically acceptable salt or hydrate thereof comprise 0.1 mg to<br>
1500 mg per unit to provide doses of about 0.01 to 200 mg/kg per day.<br>
Oral Dosage Forms<br>
[00111] Pharmaceutical compositions of the invention that are suitable for oral<br>
administration can be presented as discrete dosage forms, such as, but are not limited<br>
to, tablets (e.g., chewable tablets), caplets, capsules, and liquids (e.g., flavored<br>
syrups). Such dosage forms contain predetermined amounts of active ingredients, and<br>
may be prepared by methods of pharmacy well known to those skilled in the art. See<br>
generally, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton<br>
PA (1990).<br>
[00112] Typical oral dosage forms of the invention are prepared by combining<br>
the active ingredient(s) in an intimate admixture with at least one excipient according<br>
to conventional pharmaceutical compounding techniques. Excipients can take a wide<br>
variety of forms depending on the form of preparation desired for administration. For<br>
example, excipients suitable for use in oral liquid or aerosol dosage forms include, but<br>
are not limited to, water, glycols, oils, alcohols, flavoring agents, preservatives, and<br>
coloring agents. Examples of excipients suitable for use in solid oral dosage forms<br>
(e.g., powders, tablets, capsules, and cap lets) include, but are not limited to, starches,<br>
sugars, micro-crystalline cellulose, diluents, granulating agents, lubricants, binders,<br>
and disintegrating agents.<br>
[00113] Because of their ease of administration, tablets and capsules represent<br>
the most advantageous oral dosage unit forms, in which case solid excipients are<br>
employed. If desired, tablets can be coated by standard aqueous or nonaqueous<br>
techniques. Such dosage forms can be prepared by any of the methods of pharmacy.<br>
In general, pharmaceutical compositions and dosage forms are prepared by uniformly<br>
and intimately admixing the active ingredients with liquid carriers, finely divided<br>
solid carriers, or both, and then shaping the product into the desired presentation if<br>
necessary.<br>
[00114] For example, a tablet can be prepared by compression or molding.<br>
Compressed tablets can be prepared by compressing in a suitable machine the active<br>
ingredients in a free-flowing form such as powder or granules, optionally mixed with<br>
an excipient. Molded tablets can be made by molding in a suitable machine a mixture<br>
of the powdered compound moistened with an inert liquid diluent.<br>
[00115] Examples of excipients that can be used in oral dosage forms of the<br>
invention include, but are not limited to, binders, fillers, disintegrants, and lubricants.<br>
Binders suitable for use in pharmaceutical compositions and dosage forms include,<br>
but are not limited to, corn starch, potato starch, or other starches, gelatin, natural and<br>
synthetic gums such as acacia, sodium alginate, alginic acid, other alginates,<br>
powdered tragacanth, guar gum, cellulose and its derivatives (e.g., ethyl cellulose,<br>
cellulose acetate, carboxymethyl cellulose calcium, sodium carboxymethyl cellulose),<br>
polyvinyl pyrrolidone, methyl cellulose, pre-gelatinized starch, hydroxypropyl methyl<br>
cellulose, (e.g., Nos. 2208, 2906, 2910), microcrystalline cellulose, and mixtures<br>
thereof.<br>
[00116] Examples of fillers suitable for use in the pharmaceutical compositions<br>
and dosage forms disclosed herein include, but are not limited to, talc, calcium<br>
carbonate (e.g., granules or powder), microcrystalline cellulose, powdered cellulose,<br>
dextrates, kaolin, mannitol, silicic acid, sorbitol, starch, pre-gelatinized starch, and<br>
mixtures thereof. The binder or filler in pharmaceutical compositions of the invention<br>
is typically present in from about 50 to about 99 weight percent of the pharmaceutical<br>
composition or dosage form.<br>
[00117] Suitable forms of microcrystalline cellulose include, but are not limited<br>
to, the materials sold as AVICEL-PH-101, AVICEL-PH-103 AV1CEL RC-581,<br>
AVICEL-PH-105 (available from FMC Corporation, American Viscose Division,<br>
Avicel Sales, Marcus Hook, PA), and mixtures thereof. A specific binder is a mixture<br>
of microcrystalline cellulose and sodium carboxymethyl cellulose sold as AVICEL<br>
RC-581. Suitable anhydrous or low moisture excipients or additives include<br>
AVICEL-PH-103â¢ and Starch 1500 LM.<br>
[00118] Disintegrants are used in the compositions of the invention to provide<br>
tablets that disintegrate when exposed to an aqueous environment. Tablets that<br>
contain too much disintegrant may disintegrate in storage, while those that contain too<br>
little may not disintegrate at a desired rate or under the desired conditions. Thus, a<br>
sufficient amount of disintegrant that is neither too much nor too little to detrimentally<br>
alter the release of the active ingredients should be used to form solid oral dosage<br>
forms of the invention. The amount of disintegrant used varies based upon the type of<br>
formulation, and is readily discernible to those of ordinary skill in the art. Typical<br>
pharmaceutical compositions comprise from about 0.5 to about 15 weight percent of<br>
disintegrant, specifically from about 1 to about 5 weight percent of disintegrant.<br>
[00119] Disintegrants that can be used in pharmaceutical compositions and<br>
dosage forms of the invention include, but are not limited to, agar-agar, alginic acid,<br>
calcium carbonate, microcrystalline cellulose, croscarmellose sodium, crospovidone,<br>
polacrilin potassium, sodium starch glycolate, potato or tapioca starch, pre-gelatinized<br>
starch, other starches, clays, other algins, other celluloses, gums, and mixtures thereof.<br>
[00120] Lubricants that can be used in pharmaceutical compositions and<br>
dosage forms of the invention include, but are not limited to, calcium stearate,<br>
magnesium stearate, mineral oil, light mineral oil, glycerin, sorbitol, mannitol,<br>
polyethylene glycol, other glycols, stearic acid, sodium lauryl sulfate, talc,<br>
hydrogenated vegetable oil (e.g., peanut oil, cottonseed oil, sunflower oil, sesame oil,<br>
olive oil, corn oil, and soybean oil), zinc stearate, ethyl oleate, ethyl laureate, agar,<br>
and mixtures thereof. Additional lubricants include, for example, a syloid silica gel<br>
(AEROSIL 200, manufactured by W.R. Grace Co. of Baltimore, MD), a coagulated<br>
aerosol of synthetic silica (marketed by Degussa Co. of Piano, TX), CAB-O-SIL (a<br>
pyrogenic silicon dioxide product sold by Cabot Co. of Boston, MA), and mixtures<br>
thereof. If used at all, lubricants are typically used in an amount of less than about 1<br>
weight percent of the pharmaceutical compositions or dosage forms into which they<br>
are incorporated.<br>
Delayed Release Dosage Forms<br>
[00121] Active ingredients of the invention can be administered by controlled<br>
release means or by delivery devices that are well known to those of ordinary skill in<br>
the art. Examples include, but are not limited to, those described in U.S. Patent Nos.:<br>
3,845,770; 3,916,899; 3,536,809; 3,598,123; and 4,008,719, 5,674,533, 5,059,595,<br>
5,591,767, 5,120,548, 5,073,543, 5,639,476, 5,354,556, and 5,733,566, each of which<br>
is incorporated herein by reference. Such dosage forms can be used to provide slow<br>
or controlled-release of one or more active ingredients using, for example,<br>
hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes,<br>
osmotic systems, multilayer coatings, microparticles, liposomes, microspheres, or a<br>
combination thereof to provide the desired release profile in varying proportions.<br>
Suitable controlled-release formulations known to those of ordinary skill in the art,<br>
including those described herein, can be readily selected for use with the active<br>
ingredients of the invention. The invention thus encompasses single unit dosage<br>
forms suitable for oral administration such as, but not limited to, tablets, capsules,<br>
gelcaps, and caplets that are adapted for controlled-release.<br>
[00122] All controlled-release pharmaceutical products have a common goal of<br>
improving drug therapy over that achieved by their non-controlled counterparts.<br>
Ideally, the use of an optimally designed controlled-release preparation in medical<br>
treatment is characterized by a minimum of drug substance being employed to cure or<br>
control the condition in a minimum amount of time. Advantages of controlled-release<br>
formulations include extended activity of the drug, reduced dosage frequency, and<br>
increased patient compliance. In addition, controlled-release formulations can be<br>
used to affect the time of onset of action or other characteristics, such as blood levels<br>
of the drug, and can thus affect the occurrence of side (e.g., adverse) effects.<br>
[00123] Most controlled-release formulations are designed to initially release<br>
an amount of drug (active ingredient) that promptly produces the desired therapeutic<br>
effect, and gradually and continually release of other amounts of drug to maintain this<br>
level of therapeutic or prophylactic effect over an extended period of time. In order to<br>
maintain this constant level of drug in the body, the drug must be released from the<br>
dosage form at a rate that will replace the amount of drug being metabolized and<br>
excreted from the body. Controlled-release of an active ingredient can be stimulated<br>
by various conditions including, but not limited to, pH, temperature, enzymes, water,<br>
or other physiological conditions or compounds.<br>
Parenteral Dosage Forms<br>
[00124] Parenteral dosage forms can be administered to patients by various<br>
routes including, but not limited to, subcutaneous, intravenous (including bolus<br>
injection), intramuscular, and intraarterial. Because their administration typically<br>
bypasses patients' natural defenses against contaminants, parenteral dosage forms are<br>
preferably sterile or capable of being sterilized prior to administration to a patient.<br>
Examples of parenteral dosage forms include, but are not limited to, solutions ready<br>
for injection, dry and/or lyophylized products ready to be dissolved or suspended in a<br>
pharmaceutically acceptable vehicle for injection (reconstitutable powders),<br>
suspensions ready for injection, and emulsions.<br>
[00125] Suitable vehicles that can be used to provide parenteral dosage forms<br>
of the invention are well known to those skilled in the art. Examples include, but are<br>
not limited to: Water for Injection USP; aqueous vehicles such as, but not limited to,<br>
Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and<br>
Sodium Chloride Injection, and Lactated Ringer's Injection; water-miscible vehicles<br>
such as, but not limited to, ethyl alcohol, polyethylene glycol, and polypropylene<br>
glycol; and non-aqueous vehicles such as, but not limited to, corn oil, cottonseed oil,<br>
peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.<br>
[001261 Compounds that increase the solubility of one or more of the active<br>
ingredients disclosed herein can also be incorporated into the parenteral dosage forms<br>
of the invention.<br>
Transdermal Dosage Forms<br>
[00127] Transdermal dosage forms include "reservoir type" or "matrix type"<br>
patches, which can be applied to the skin and worn for a specific period of time to<br>
permit the penetration of a desired amount of active ingredients.<br>
[00128] Suitable excipients (e.g., carriers and diluents) and other materials that<br>
can be used to provide transdermal and topical dosage forms encompassed by this<br>
invention are well known to those skilled in the pharmaceutical arts, and depend on<br>
the particular tissue to which a given pharmaceutical composition or dosage form will<br>
be applied. With that fact in mind, typical excipients include, but are not limited to,<br>
water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl<br>
myristate, isopropyl palmitate, mineral oil, and mixtures thereof.<br>
[00129] Depending on the specific tissue to be treated, additional components may<br>
be used prior to, in conjunction with, or subsequent to treatment with active<br>
ingredients of the invention. For example, penetration enhancers can be used to assist<br>
in delivering the active ingredients to the tissue. Suitable penetration enhancers<br>
include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and<br>
tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide;<br>
dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone;<br>
Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble<br>
sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).<br>
[00130] The pH of a pharmaceutical composition or dosage form, or of the<br>
tissue to which the pharmaceutical composition or dosage form is applied, may also<br>
be adjusted to improve delivery of one or more active ingredients. Similarly, the<br>
polarity of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve<br>
delivery. Compounds such as stearates can also be added to pharmaceutical<br>
compositions or dosage forms to advantageously alter the hydrophilicity or<br>
lipophilicity of one or more active ingredients so as to improve delivery. In this<br>
regard, stearates can serve as a lipid vehicle for the formulation, as an emulsifying<br>
agent or surfactant, and as a delivery-enhancing or penetration-enhancing agent.<br>
Different salts, hydrates or solvates of the active ingredients can be used to further<br>
adjust the properties of the resulting composition.<br>
Topical Dosage Forms<br>
[00131] Topical dosage forms of the invention include, but are not limited to,<br>
creams, lotions, ointments, gels, solutions, emulsions, suspensions, or other forms<br>
known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th<br>
eds., Mack Publishing, Easton PA (1990); and Introduction to Pharmaceutical<br>
Dosage Forms, 4th ed., Lea &amp; Febiger, Philadelphia (1985).<br>
[00132] Suitable excipients (e.g., carriers and diluents) and other materials that<br>
can be used to provide transdermal and topical dosage forms encompassed by this<br>
invention are well known to those skilled in the pharmaceutical arts, and depend on<br>
the particular tissue to which a given pharmaceutical composition or dosage form will<br>
be applied. With that fact in mind, typical excipients include, but are not limited to,<br>
water, acetone, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl<br>
myristate, isopropyl palmitate, mineral oil, and mixtures thereof.<br>
[00133] Depending on the specific tissue to be treated, additional components<br>
may be used prior to, in conjunction with, or subsequent to treatment with active<br>
ingredients of the invention. For example, penetration enhancers can be used to assist<br>
in delivering the active ingredients to the tissue. Suitable penetration enhancers<br>
include, but are not limited to: acetone; various alcohols such as ethanol, oleyl, and<br>
tetrahydrofuryl; alkyl sulfoxides such as dimethyl sulfoxide; dimethyl acetamide;<br>
dimethyl formamide; polyethylene glycol; pyrrolidones such as polyvinylpyrrolidone;<br>
Kollidon grades (Povidone, Polyvidone); urea; and various water-soluble or insoluble<br>
sugar esters such as Tween 80 (polysorbate 80) and Span 60 (sorbitan monostearate).<br>
Mucosal Dosage Forms<br>
[00134] Mucosal dosage forms of the invention include, but are not limited to,<br>
ophthalmic solutions, sprays and aerosols, or other forms known to one of skill in the<br>
art. See, e.g.. Remington's Pharmaceutical Sciences, 18th eds., Mack Publishing,<br>
Easton PA (1990); and Introduction to Pharmaceutical Dosage Forms, 4th ed., Lea &amp;<br>
Febiger, Philadelphia (1985). Dosage forms suitable for treating mucosal tissues<br>
within the oral cavity can be formulated as mouthwashes or as oral gels. In one<br>
embodiment, the aerosol comprises a carrier. In another embodiment, the aerosol is<br>
carrier free.<br>
[00135] The Formula I compounds of the invention may also be administered<br>
directly to the lung by inhalation. For administration by inhalation, a Formula I<br>
compound can be conveniently delivered to the lung by a number of different devices.<br>
For example, a Metered Dose Inhaler ("MDI") which utilizes canisters that contain a<br>
suitable low boiling propellant, e.g., dichlorodifluoromethane,<br>
trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable<br>
gas can be used to deliver a Formula I compound directly to the lung. MDI devices<br>
are available from a number of suppliers such as 3M Corporation, Aventis,<br>
Boehringer Ingelheim, Forest Laboratories, Glaxo-Wellcome, Schering Plough and<br>
Vectura.<br>
[00136] Alternatively, a Dry Powder Inhaler (DPI) device can be used to<br>
administer a Formula I compound to the lung (see, e.g., Raleigh et al., Proc. Amer.<br>
Assoc. Cancer Research Annual Meeting, 1999, 40, 397, which is herein incorporated<br>
by reference). DPI devices typically use a mechanism such as a burst of gas to create<br>
a cloud of dry powder inside a container, which can then be inhaled by the patient.<br>
DPI devices are also well known in the art and can be purchased from a number of<br>
vendors which include, for example, Fisons, Glaxo-Wellcome, Inhale Therapeutic<br>
Systems, ML Laboratories, Qdose and Vectura. A popular variation is the multiple<br>
dose DPI ("MDDPI") system, which allows for the delivery of more than one<br>
therapeutic dose. MDDPI devices are available from companies such as AstraZeneca,<br>
Glaxo Wellcome, IVAX, Schering Plough, SkyePharma and Vectura. For example,<br>
capsules and cartridges of gelatin for use in an inhaler or insufflator can be formulated<br>
containing a powder mix of the compound and a suitable powder base such as lactose<br>
or starch for these systems.<br>
[00137] Another type of device that can be used to deliver a Formula I<br>
compound to the lung is a liquid spray device supplied, for example, by Nadigm<br>
Corporation. Liquid spray systems use extremely small nozzle holes to aerosolize<br>
liquid drug formulations that can then be directly inhaled into the lung.<br>
[00138] In one embodiment, a nebulizer device is used to deliver a Formula I<br>
compound to the lung. Nebulizers create aerosols from liquid drug formulations by<br>
using, for example, ultrasonic energy to form fine particles that can be readily inhaled<br>
(See e.g., Verschoyle et al, British J. Cancer, 1999, 80, Suppl 2, 96, which is herein<br>
incorporated by reference). Examples of nebulizers include devices supplied by<br>
Sheffield/Systemic Pulmonary Delivery Ltd. (See, Nmer etai, U.S. Pat. No.<br>
5,954,047; van der Linden et al, U.S. Pat. No. 5,950,619; van der Linden et al, U.S.<br>
Pat. No. 5,970,974, which are herein incorporated by reference), Aventis and Batelle<br>
Pulmonary Therapeutics.<br>
[00139] In one embodiment, an electrohydrodynamic ("EHD") aerosol device<br>
is used to deliver Formula I compounds to the lung. EHD aerosol devices use<br>
electrical energy to aerosolize liquid drug solutions or suspensions (see, e.g., Noakes<br>
et al, U.S. Pat. No. 4,765,539; Coffee, U.S. Pat. No., 4,962,885; Coffee, PCT<br>
Application, WO 94/12285; Coffee, PCT Application, WO 94/14543; Coffee, PCT<br>
Application, WO 95/26234, Coffee, PCT Application, WO 95/26235, Coffee, PCT<br>
Application, WO 95/32807, which are herein incorporated by reference). The<br>
electrochemical properties of the Formula I compounds formulation may be important<br>
parameters to optimize when delivering this drug to the lung with an EHD aerosol<br>
device and such optimization is routinely performed by one of skill in the art. EHD<br>
aerosol devices may more efficiently delivery drugs to the lung than existing<br>
pulmonary delivery technologies. Other methods of intra-pulmonary delivery of<br>
Formula I compounds will be known to the skilled artisan and are within the scope of<br>
the invention.<br>
[00140] Liquid drug formulations suitable for use with nebulizers and liquid<br>
spray devices and EHD aerosol devices will typically include a Formula I compound<br>
with a pharmaceutically acceptable carrier. Preferably, the pharmaceutically<br>
acceptable carrier is a liquid such as alcohol, water, polyethylene glycol or a<br>
perfluorocarbon. Optionally, another material may be added to alter the aerosol<br>
properties of the solution or suspension of the Formula I compound. Preferably, this<br>
material is liquid such as an alcohol, glycol, polyglycol or a fatty acid. Other methods<br>
of formulating liquid drug solutions or suspension suitable for use in aerosol devices<br>
are known to those of skill in the art (see, e.g., Biesalski, U.S. Pat. Nos. 5,112,598;<br>
Biesalski, 5,556,611, which are herein incorporated by reference) A Formula I<br>
compound can also be formulated in rectal or vaginal compositions such as<br>
suppositories or retention enemas, e.g., containing conventional suppository bases<br>
such as cocoa butter or other glycerides.<br>
[00141] In addition to the formulations described previously, a Formula I<br>
compound can also be formulated as a depot preparation. Such long acting<br>
formulations can be administered by implantation (for example subcutaneously or<br>
intramuscularly) or by intramuscular injection. Thus, for example, the compounds<br>
can be formulated with suitable polymeric or hydrophobic materials (for example, as<br>
an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble<br>
derivatives, for example, as a sparingly soluble salt.<br>
[00142] Alternatively, other pharmaceutical delivery systems can be employed.<br>
Liposomes and emulsions are well known examples of delivery vehicles that can be<br>
used to deliver Formula I compounds. Certain organic solvents such as<br>
dimethylsulfoxide can also be employed, although usually at the cost of greater<br>
toxicity. A Formula I compound can also be delivered in a controlled release system.<br>
In one embodiment, a pump can be used (Sefton, CRC Crit. RefBiomed Eng., 1987,<br>
14, 201; Buchwald et al, Surgery, 1980, 88, 507; Saudekefa/., N. Engl. J. Med.,<br>
1989, 321, 574). In another embodiment, polymeric materials can be used (see<br>
Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres.,<br>
Boca Raton, Fla. (1974); Controlled Drug Bioavailability, Drug Product Design and<br>
Performance, Smolen and Ball (eds.), Wiley, New York (1984); Ranger and Peppas,<br>
J. Macromol. Sci. Rev. Macromol. Chem., 1983, 23, 61; see also Levy et ah, Science,<br>
1985, 228, 190; During et ah, Ann. Neurol., 1989,25,351; Howard et al, J.<br>
Neurosurg., 71, 105 (1989). In yet another embodiment, a controlled-release system<br>
can be placed in proximity of the target of the compounds of the invention, e.g., the<br>
lung, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, in<br>
Medical Applications of Controlled Release, supra, vol. 2, pp. 115 (1984)). Other<br>
controlled-release system can be used (see, e.g., Langer, Science, 1990, 249, 1527).<br>
[00143] Suitable excipients (e.g., carriers and diluents) and other materials that<br>
can be used to provide mucosal dosage forms encompassed by this invention are well<br>
known to those skilled in the pharmaceutical arts, and depend on the particular site or<br>
method which a given pharmaceutical composition or dosage form will be<br>
administered. With that fact in mind, typical excipients include, but are not limited to,<br>
water, ethanol, ethylene glycol, propylene glycol, butane-1,3-diol, isopropyl<br>
myristate, isopropyl palmitate, mineral oil, and mixtures thereof, which are non-toxic<br>
and pharmaceutically acceptable. Examples of such additional ingredients are well<br>
known in the art. See, e.g., Remington's Pharmaceutical Sciences, 18th eds., Mack<br>
Publishing, Easton PA (1990).<br>
[00144] The pH of a pharmaceutical composition or dosage form, or of the<br>
tissue to which the pharmaceutical composition or dosage form is applied, can also be<br>
adjusted to improve delivery of one or more active ingredients. Similarly, the polarity<br>
of a solvent carrier, its ionic strength, or tonicity can be adjusted to improve delivery.<br>
Compounds such as stearates can also be added to pharmaceutical compositions or<br>
dosage forms to advantageously alter the hydrophilicity or lipophilicity of one or<br>
more active ingredients so as to improve delivery. In this regard, stearates can serve<br>
as a lipid vehicle for the formulation, as an emulsifying agent or surfactant, and as a<br>
delivery-enhancing or penetration-enhancing agent. Different salts, hydrates or<br>
solvates of the active ingredients can be used to further adjust the properties of the<br>
resulting composition.<br>
KITS<br>
[00145] The invention provides a pharmaceutical pack or kit comprising one or<br>
more containers comprising a Formula I compound useful for the treatment or<br>
prevention of a Hepatitis C virus infection. In other embodiments, the invention<br>
provides a pharmaceutical pack or kit comprising one or more containers comprising<br>
a Formula I compound useful for the treatment or prevention of a Hepatitis C virus<br>
infection and one or more containers comprising an additional therapeutic agent,<br>
including but not limited to those listed above, in particular an antiviral agent, an<br>
interferon, an agent which inhibits viral enzymes, or an agent which inhibits viral<br>
replication, preferably the additional therapeutic agent is HCV specific or<br>
demonstrates anti-HCV activity.<br>
[00146] The invention also provides a pharmaceutical pack or kit comprising<br>
one or more containers comprising one or more of the ingredients of the<br>
pharmaceutical compositions of the invention. Optionally associated with such<br>
container(s) can be a notice in the form prescribed by a governmental agency<br>
regulating the manufacture, use or sale of pharmaceuticals or biological products,<br>
which notice reflects approval by the agency of manufacture, use or sale for human<br>
administration.<br>
[00147] The inventive agents may be prepared using the reaction routes and<br>
synthesis schemes as described below, employing the general techniques known in the<br>
art using starting materials that are readily available. The synthesis of non-<br>
exemplified compounds according to the invention may be successfully performed by<br>
modifications apparent to those skilled in the art, e.g., by appropriately protecting<br>
interfering groups, by changing to other suitable reagents known in the art, or by<br>
making routine modifications of reaction conditions. Alternatively, other reactions<br>
disclosed herein or generally known in the art will be recognized as having<br>
applicability for preparing other compounds of the invention.<br>
Preparation of Compounds<br>
[00148] In the synthetic schemes described below, unless otherwise indicated all<br>
temperatures are set forth in degrees Celsius and all parts and percentages are by<br>
weight.<br>
[00149] Reagents were purchased from commercial suppliers such as Aldrich<br>
Chemical Company or Lancaster Synthesis Ltd. and were used without further<br>
purification unless otherwise indicated. All solvents were purchased from<br>
commercial suppliers such as Aldrich, EMD Chemicals or Fisher and used as<br>
received.<br>
[00150] The reactions set forth below were done generally under a positive<br>
pressure of argon or nitrogen at an ambient temperature (unless otherwise stated) in<br>
anhydrous solvents, and the reaction flasks were fitted with rubber septa for the<br>
introduction of substrates and reagents via syringe. Glassware was oven dried and/or<br>
heat dried.<br>
[00151] The reactions were assayed by TLC and/or analyzed by LC-MS or HPLC<br>
and terminated as judged by the consumption of starting material. Analytical thin<br>
layer chromatography (TLC) was performed on glass-plates precoated with silica gel<br>
60 F254 0.25 mm plates (EMD Chemicals), and visualized with UV light (254 nm)<br>
and/or iodine on silica gel and/or heating with TLC stains such as ethanolic<br>
phosphomolybdic acid, ninhydrin solution, potassium permanganate solution or eerie<br>
sulfate solution. Preparative thin layer chromatography (prepTLC) was performed on<br>
glass-plates precoated with silica gel 60 F254 0.5 mm plates (20 Ã 20 cm, from<br>
Thomson Instrument Company) and visualized with UV light (254 nm).<br>
[00152] Work-ups were typically done by doubling the reaction volume with the<br>
reaction solvent or extraction solvent and then washing with the indicated aqueous<br>
solutions using 25% by volume of the extraction volume unless otherwise indicated.<br>
Product solutions were dried over anhydrous Na2SO4 and/or MgSO4 prior to filtration<br>
and evaporation of the solvents under reduced pressure on a rotary evaporator and<br>
noted as solvents removed in vacuo. Column chromatography was completed under<br>
positive pressure using Merck silica gel 60, 230-400 mesh or 50-200 mesh neutral<br>
alumina, ISCO Flash -chromatography using prepacked RediSep silica gel columns,<br>
or Analogix flash column chromatography using prepacked SuperFlash silica gel<br>
columns. Hydrogenolysis was done at the pressure indicated in the examples or at<br>
ambient pressure.<br>
[00153] 1H-NMR spectra and 13C-NMR were recorded on a Varian Mercury-<br>
VX400 instrument operating at 400 MHz. NMR spectra were obtained as CDCI3<br>
solutions (reported in ppm), using chloroform as the reference standard (7.27 ppm for<br>
the proton and 77.00 ppm for carbon), CD3OD (3.4 and 4.8 ppm for the protons and<br>
49.3 ppm for carbon), DMSO-d6 (2.49 ppm for proton), or internally tetramethylsilane<br>
(0.00 ppm) when appropriate. Other NMR solvents were used as needed. When peak<br>
multiplicities are reported, the following abbreviations are used: s (singlet), d<br>
(doublet), t (triplet), q (quartet), m (multiplet), br (broadened), bs (broad singlet), dd<br>
(doublet of doublets), dt (doublet of triplets). Coupling constants, when given, are<br>
reported in Hertz (Hz).<br>
[00154] Infrared (IR) spectra were recorded on an ATR FT-IR Spectrometer as<br>
neat oils or solids, and when given are reported in wave numbers (cm1). Mass<br>
spectra reported are (+)-ES or APCI (+) LC/MS conducted by the Analytical<br>
Chemistry Department of Anadys Pharmaceuticals, Inc. Elemental analyses were<br>
conducted by the Atlantic Microlab, Inc. in Norcross, GA. Melting points (mp) were<br>
determined on an open capillary apparatus, and are uncorrected.<br>
[00155] Enantiomeric excess (ee) values were determined by HPLC-analysis using<br>
the Chiralpak (Chiral Technologies Inc.) columns AS-RH, 2.1 x 150 mm, 5 micron, k<br>
= 312 nm or AS-RH, 4.6 Ã 250 mm, 5 micron, ?, = 310 nm.<br>
[00156] AS-RH, 2.1 Ã150 mm, 5 micron: Binary gradient HPLC separation.<br>
Solvent A: 0.1% Formic Acid in Water, Solvent B: 0.1% Formic Acid in<br>
Acetonitrile. Injected 10 ÂµL of sample dissolved in 50% methanol - 50% water [0.1<br>
mg/mL].<br><br>
[00157] AS-RH, 4.6 Ã 250 mm, 5 micron: Binary gradient HPLC separation.<br>
Solvent A: 0.05 % TFA in Water, Solvent B: 0.05 % TFA in Acetonitrile. Injected 3-<br>
5 Âµl of sample dissolved in acetonitrile [1 mg/mL].<br><br>
[00158] The described synthetic pathways and experimental procedures utilize<br>
many common chemical abbreviations, 2,2-DMP (2,2-dimethoxypropane), Ac<br>
(acetyl), ACN (acetonitrile), Bn (benzyl), BnOH (benzyl alcohol), Boc (tert-<br>
butoxycarbonyl), BoC2O (di-tert-butyl dicarbonate), Bz (benzoyl), CSI (chlorosulfonyl<br>
isocyanate), DBU (1,8-diazabicyclo[5.4.0]undec-7-ene), DCC (N,N'-<br>
dicyclohexylcarbodiimide), DCE (1,2-dichloroethane), DCM (dichloromethane),<br>
DEAD (diethylazodicarboxylate), DIE A (diisopropylethylamine), DMA (N,N-<br>
dimethylacetamide), DMAP (4-(N,N-dimethylamino)pyridine), DMF (N,N-<br>
dimethylformamide), DMSO (dimethyl sulfoxide), EDC (1-(3-dimethylaminopropyl)-<br>
3-ethylcarbodiimide hydrochloride), Et (ethyl), EtOAc (ethyl acetate), EtOH<br>
(ethanol), HATU (O-(7-azabenzotriazol- 1-yl)-1,1,3,3-tetramethyluronium<br>
hexafluorophosphate), HBTU (0-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium<br>
hexafluorophosphate), HF (hydrogen fluoride), HOAc (acetic acid), HOBT (1-<br>
hydroxybenzotriazole hydrate), HPLC (high pressure liquid chromatography), IPA<br>
(isopropyl alcohol), KHMDS (potassium bis(trimethylsilyl)amide), KN(TMS)2<br>
(potassium bis(trimethylsilyl)amide), KO'Bu (potassium rm-butoxide), LDA (lithium<br>
diisopropylamine), MCPBA (3-chloroperbenzoic acid), Me (methyl), MeCN<br>
(acetonitrile), MeOH (methanol), NaBH(OAc)3 (sodium triacetoxyborohydride),<br>
NaCNBH3 (sodium cyanoborohydride), NaH (sodium hydride), NaN(TMS)2 (sodium<br>
bis(trimethylsilyl)amide), NaOAc (sodium acetate), NaOEt (sodium ethoxide), Phe<br>
(phenylalanine), PPTS (pyridinium p-toluenesulfonate), PS (polymer supported), Py<br>
(pyridine), pyBOP (benzotriazol-l-yloxy)tripyrrolidinophosphonium<br>
hexafluorophosphate), TEA (triethylamine), TFA (trifluoroacetic acid), TFAA<br>
(trifluoroacetic anhydride), THF (tetrahydrofuran), TLC (thin layer chromatography),<br>
Tol (toluoyl), Val (valine), and the like.<br>
[00159] Scheme 1 provides a general procedure that can be used to prepare<br>
saturated 5,6-dihydro-lH-pyridin-2-one compounds of Formula I.<br><br>
[00160] The saturated cyclic N-substituted-Ã-amino acid ester intermediates, which<br>
can be obtained as described by one of the methods in schemes 3,4, 6, 7 or 8 can be<br>
condensed with a carboxylic acid intermediate (or a salt thereof, e.g., sodium salt)<br>
using standard peptide coupling conditions used for the formation of amide bonds,<br>
such as DCC, to yield the shown amide. This intermediate can be cyclized with or<br>
without isolation in the presence of abase (e.g., triethylamine) to give the desired<br>
saturated 5,6-dihydro-1H-pyridin-2-one compounds.<br>
[00161] Scheme 2 provides a general procedure that can be used to prepare<br>
unsaturated 5,6-dihydro-1H-pyridin-2-one compounds of Formula I.<br><br>
[00162] The unsaturated cyclic N-substituted-Ã-amino acid ester intermediates<br>
(with R as defined in scheme 1), which can be obtained as described by one of the<br>
methods in schemes 5 or 9, can be condensed with a carboxylic acid intermediate (or<br>
a salt thereof, e.g., sodium salt) using standard peptide coupling conditions used for<br>
the formation of amide bonds, such as DCC, to yield the shown amide. This<br>
intermediate can be cyclized with or without isolation in the presence of a base (e.g.,<br>
triethylamine) to give the desired unsaturated 5,6-dihydro-1H-pyridin-2-one<br>
compounds.<br>
[00163] Scheme 3 provides a general procedure that can be used to prepare<br>
saturated cyclic N-substituted-Ã-amino acid ester intermediates from saturated<br>
anhydrides.<br>
Scheme 3<br><br>
[00164] Commercially available saturated cyclic meso-anhydrides can be<br>
desymmetrized with the help of enzymes or chiral reagents, such as cinchona<br>
alkaloids (e.g., quinine or quinidine) as described in the literature to provide optically<br>
active saturated cyclic dicarboxylic acid monoesters (with R as defined in scheme 1).<br>
See J. Org. Chem., 65, 6984-6991 (2000); Synthesis, 11,1719-1730 (2001), and<br>
references cited therein.<br>
[00165] These intermediates can be further elaborated into protected optically<br>
active saturated cyclic P-amino acid esters (e.g., Cbz-protected) via a rearrangement<br>
reaction, such as the Curtius rearrangement (shown) or a Hofmann degradation.<br>
Hydrogenation of the protected saturated cyclic Ã-amino acid esters under standard<br>
conditions can be used to remove the protecting group and furnish the optically active<br>
saturated cyclic P-amino acid esters, which can be isolated (and used) as either the<br>
free bases or their corresponding salts. The optically active saturated cyclic Ã-amino<br>
acid esters (or their salts) can then be treated with aldehydes or ketones, where Rx and<br>
Rware independently C1-C5 alkyl, C3-C8 cycloalkyl, -C1-C5 alkylene(C3-C8<br>
cycloalkyl), -C1-C5 alkylene(aryl), -C1-C5 alkylene(heterocyclyl), aryl, or<br>
heterocyclyl, or Rw can combine with Rx to form a 3- to 8-membered ring, in the<br>
presence of a reducing agent (such as sodium cyanoborohydride) to afford the desired<br>
optically active saturated cyclic N-substituted-Ã-amino acid ester intermediates.<br>
Alternatively, the reaction sequence described above can be performed without<br>
enzymes or chiral reagents leading to the corresponding achiral intermediates and<br>
products.<br>
[00166] Scheme 4 provides a general procedure that can be used to prepare<br>
saturated cyclic N-substituted-Ã-amino acid ester intermediates from unsaturated<br>
anhydrides.<br><br>
[00167] Commercially available unsaturated cyclic meso-anhydrides can be<br>
desymmetrized as described above (scheme 3) to provide optically active unsaturated<br>
cyclic dicarboxylic acid monoesters (with R as defined in scheme 1). These<br>
intermediates can be further elaborated into protected optically active unsaturated<br>
cyclic Ã-amino acid esters (e.g., Cbz-protected) via a rearrangement reaction, such as<br>
the Curtius rearrangement (shown) or a Hofrnann degradation. Hydrogenation of the<br>
protected optically active unsaturated cyclic Ã-amino acid esters under standard<br>
conditions removes the protecting group and reduces the olefin to furnish the optically<br>
active saturated cyclic Ã-amino acid esters, which can be isolated (and used) as either<br>
the free bases or their corresponding salts.<br>
[00168] The optically active saturated cyclic Ã-amino acid esters (or their salts) can<br>
then be treated with aldehydes or ketones (with Rx and Rw as defined in scheme 3) in<br>
the presence of a reducing agent (such as sodium cyanoborohydride) to afford the<br>
desired optically active saturated cyclic N-substituted-Ã-amino acid ester<br>
intermediates. Alternatively, the reaction sequence described above can be performed<br>
without enzymes or chiral reagents leading to the corresponding achiral intermediates<br>
and products.<br>
[00169] Scheme 5 provides a general procedure that can be used to prepare<br>
unsaturated cyclic N-substiruted-Ã-amino acid ester intermediates from unsaturated<br>
anhydrides.<br><br>
[00170] Commercially available unsaturated cyclic meso-anhydrides can be<br>
desymmetrized as described above (scheme 4) to provide optically active unsaturated<br>
cyclic dicarboxylic acid monoesters (with R as defined in scheme 1). These<br>
intermediates can be further elaborated into protected optically active unsaturated<br>
cyclic Ã-amino acid esters (e.g., Boc-protected) via a rearrangement reaction, such as<br>
the Curtius rearrangement (shown) or a Hofmann degradation. The Boc protecting<br>
group can then be selectively removed in the presence of the olefin, thus leading to<br>
the optically active unsaturated cyclic Ã-amino acid ester intermediates, which can be<br>
isolated (and used) as either the salts or their corresponding free bases.<br>
[00171] The optically active unsaturated cyclic Ã-amino acid esters (or their salts)<br>
can then be treated with aldehydes or ketones (with Rx and Rw as defined in scheme 3)<br>
in the presence of a reducing agent (such as sodium cyanoborohydride) to afford the<br>
desired optically active unsaturated cyclic N-substituted-Ã-amino acid ester<br>
intermediates. Alternatively, the reaction sequence described above can be performed<br>
without enzymes or chiral reagents leading to the corresponding achiral intermediates<br>
and products.<br>
[00172] Scheme 6 provides an alternate general procedure that can be used to<br>
prepare saturated cyclic N-substituted-Ã-amino acid ester intermediates.<br>
Scheme 6<br><br>
[00173] Bicyclic olefins, such as norbornene, can be reacted with chlorosulfonyl<br>
isocyanate to yield the Ã-lactams shown. These intermediates can be hydrolyzed in<br>
the presence of a strong acid (such as hydrochloric acid) to afford the saturated cyclic<br>
Ã-amino acids (or their salts), which can then be further elaborated into the<br>
corresponding esters using standard conditions (with Ras defined in scheme 1). The<br>
saturated cyclic Ã-amino acid esters can then be treated with aldehydes or ketones<br>
(with Rx and Rw as defined in scheme 3) in the presence of a reducing agent, such as<br>
sodium cyanoborohydride, to afford the desired saturated cyclic N-substituted-Ã-<br>
amino acid ester intermediates.<br>
[00174] Scheme 7 provides a general scheme describing a method that can be used<br>
to resolve the di-exo enantiomers by diastereomeric crystallization<br><br>
[00175] The racemic di-exo-Ã-amino acid ester derivatives obtained from<br>
norbornene as described above, can be resolved by forming diastereomeric salts with<br>
an optically pure acid, such as (1S)-(+)-10-camphorsulfonic acid. The (1R,2R,3S,4S)-<br>
Ã-amino acid ester derivatives form a crystalline salt with (1S)-(+)-10-<br>
camphorsulfonic acid that can be selectively isolated by filtration from an appropriate<br>
solvent (e.g., ethyl acetate) and treated with a base, such as sodium carbonate, to<br>
afford the free enantiomerically pure cyclic (1R,2R,3S,4S)-Ã-amino acid esters. The<br>
optically pure cyclic (1R,2R,3S,4S)-Ã-amino acid esters (or their salts) can then be<br>
treated with aldehydes or ketones (with Rx and Rw as defined in scheme 3) in the<br>
presence of a reducing agent, such as sodium cyanoborohydride, to afford the desired<br>
optically pure saturated cyclic N-substituted- (1R,2R,3S,4S)-Ã-amino acid ester<br>
intermediates.<br>
[00176J Scheme 8 provides an alternative procedure that can be used to prepare<br>
enantiomerically pure saturated cyclic N-substituted-Ã-amino acid ester intermediates.<br><br>
[00177] The Ã-lactam (prepared as described in scheme 6) can be opened and<br>
resolved by forming diastereomeric salts with an optically pure acid, such as (1S)-(+)-<br>
10-camphorsulfonic acid (as described in scheme 7) in the presence of an alcohol<br>
(e.g., ethanol) to directly afford the diastereomerically pure (1R,2R,3S,4S)-Ã-amino<br>
acid ester as a salt with (1S)(+)-10-camphorsulfonic acid. Treatment with a base,<br>
such as potassium carbonate, followed by reductive alkylation with aldehydes or<br>
ketones (with Rx and Rw as defined in scheme 3) in the presence of a reducing agent,<br>
such as sodium cyanoborohydride, affords the desired enantiomerically pure saturated<br>
cyclic N-substituted- (1R,2R,3S,4S)-Ã-amino acid ester intermediates.<br>
[00178] Scheme 9 provides a general procedure that can be used to prepare<br>
saturated cyclic N-substituted-Ã-amino acid ester intermediates.<br>
Scheme 9<br><br>
[00179] The saturated cyclic Ã-amino acid esters (or their salts, with R as defined<br>
in scheme 1) can be purchased, prepared from the corresponding commercially<br>
available saturated cyclic Ã-amino acids, or can be prepared by methods described in<br>
schemes 3, 4, 6 or 7. The saturated cyclic Ã-amino acid esters can then be treated<br>
with aldehydes or ketones (with Rx and Rw as defined in scheme 3) in the presence of<br>
a reducing agent, such as sodium cyanoborohydride, to afford the desired saturated<br>
cyclic AA-substituted-Ã-amino acid ester intermediates. In each case the saturated<br>
cyclic Ã-amino acid esters or the desired saturated cyclic N-substituted-Ã-amino acid<br>
ester intermediates may be optically active.<br>
[00180] Scheme 10 provides an alternative general procedure that can be used to<br>
prepare saturated cyclic N-substituted-Ã-amino acid ester intermediates.<br><br>
[00181] The saturated cyclic Ã-amino acid esters (or their salts, with R as defined<br>
in scheme 1) can be purchased, prepared from the corresponding commercially<br>
available saturated cyclic Ã-amino acids, or can be prepared by the method described<br>
in schemes 3,4, 6 or 7. The saturated cyclic Ã-amino acid esters can then be treated<br>
with halides or pseudohalides Xa (e.g., bromides, iodides or inflates), where Rv is aryl<br>
or heterocyclyl, in the presence of metal catalyst such as copper (e.g., under Ullmann<br>
reaction conditions) or palladium (e.g., under Buchwald-Hartwig reaction conditions),<br>
to afford the desired saturated cyclic N-substituted-Ã-amino acid ester intermediates.<br>
In each case the saturated cyclic Ã-amino acid esters or the desired saturated cyclic N-<br>
substituted-Ã-amino acid ester intermediates may be optically active.<br>
[00182] Scheme 11 provides a general procedure that can be used to prepare<br>
unsaturated cyclic N-substituted-Ã-amino acid ester intermediates.<br><br>
[00183] The unsaturated cyclic Ã-amino acid esters (or their salts, with R as<br>
defined in scheme 1) can be purchased, prepared from the corresponding<br>
commercially available unsaturated cyclic Ã-amino acids, or can be prepared by the<br>
method described in scheme 5. The unsaturated cyclic Ã-amino acid esters can then<br>
be treated with aldehydes or ketones (with Rx and Rw as defined in scheme 3) in the<br>
presence of a reducing agent, such as sodium cyanoborohydride, to afford the desired<br>
unsaturated cyclic N-substituted-Ã-amino acid ester intermediates. In each case the<br>
unsaturated cyclic Ã-amino acid esters or the desired unsaturated cyclic N-substituted-<br>
Ã-amino acid ester intermediates may be optically active.<br>
[00184] Scheme 12 provides an alternative general procedure that can be used to<br>
prepare unsaturated cyclic N-substituted-Ã-amino acid ester intermediates.<br><br>
[00185] The unsaturated cyclic Ã-amino acid esters (or their salts, with R as<br>
defined in scheme 1) can be purchased, prepared from the corresponding<br>
commercially available unsaturated cyclic Ã-amino acids, or can be prepared by the<br>
method described in scheme 5. The unsaturated cyclic Ã-amino acid esters can then<br>
be treated with halides or pseudohalides Xa (e.g., bromides, iodides or triflates), where<br>
Rv is aryl or heterocyclyl, in the presence of metal catalyst such as copper (e.g., under<br>
Ullmann reaction conditions), to afford the desired unsaturated cyclic N-substituted-Ã-<br>
amino acid ester intermediates. In each case the unsaturated cyclic Ã-amino acid<br>
esters or the desired unsaturated cyclic N-substituted-Ã-amino acid ester intermediates<br>
may be optically active.<br>
[00186] Scheme 13 provides a general procedure that can be used to prepare 7-<br>
substituted-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,4]thiazin-3-yl-acetic acid<br>
intermediates.<br><br>
[00187] Commercially available 6-nitrobenzothiazole can be treated with<br>
hydrazine to obtain the 2-amino-5-nitro-benzenethiol, which can subsequently be<br>
reacted with chloroacetoacetate to give the (7-nitro-4H-benzo[1,4]thiazin-3-yl)-acetic<br>
acid ethyl ester. Reduction of the nitro group to the amino group can be accomplished<br>
by reaction with tin(II)chloride. Subsequent reaction with a sulfonyl chloride, such as<br>
methylsulfonyl chloride, can be used to obtain the corresponding sulfonamides.<br>
Protection of both nitrogens with a suitable protecting group such as a Boc group can<br>
be achieved by using standard methods for protecting amino groups. The sulfides can<br>
be oxidized using as suitable oxidizing reagent (e.g. MCPBA) to give the sulfones.<br>
Finally, deprotection of the amino groups using trifluoroacetic acid, followed by<br>
hydrolysis of the esters can be used to afford the desired acid intermediates.<br>
[00188] Scheme 14 provides a general procedure that can be used to prepare 7-<br>
substituted-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl-acetic acid<br>
intermediates.<br>
Scheme 14<br><br>
[00189] Commercially available 2-chloro-5-nitro-benzenesulfonic acid can be<br>
treated with thionyl chloride to give the sulfonylchloride, which can be further treated<br>
with ammonia to afford the sulfonamide intermediate. The chloride can be displaced<br>
with ammonia by treatment with ammonium hydroxide and ammonium carbonate in<br>
the presence of copper(II)sulfate. Reduction of the nitro group under standard<br>
hydrogenation conditions affords the aniline intermediate, which can be treated with a<br>
sulfonyl chloride, such as methylsulfonyl chloride, to yield the corresponding<br>
sulfonamide. Acylation of the 2-amino moiety with malonyl chlorides, e.g., ethyl 3-<br>
chloro-3-oxo-propionate, gives the corresponding amide, which can simultaneously<br>
be cyclized to the thiadiazine-dioxide and hydrolyzed to the desired acid intermediate.<br>
[00190] Scheme 15 provides an alternative procedure that can be used to prepare<br>
the 2-amino-5-nitro-benzenesulfonamide intermediate.<br><br>
[00191] Commercially available 2-amino-5-nitro-benzenesulfonic acid can be<br>
converted to the corresponding sulfonyl chloride with phosphoryl chloride in the<br>
presence of a suitable co-solvent, such as sulfolane. Treatment with ammonia, e.g.,<br>
aqueous ammonium hydroxide solution or ammonia gas, affords the desired 2-amino-<br>
5-nitro-benzenesulfonamide intermediate.<br>
[00192] Scheme 16 provides an alternative procedure that can be used to prepare<br>
the 2-amino-5-methanesulfonylamino-benzenesulfonamide intermediate.<br><br>
[00193] The 2-chloro-5-nitro-benzenesulfonamide intermediate (prepared as<br>
described in scheme 14) can be treated with a benzylic amine, such as benzylamine, to<br>
displace the chloro moiety. Hydrogenation under standard conditions in the presence<br>
of an acid (e.g., methanesulfonic acid) can be used to remove the benzylic group and<br>
to reduce the nitro group at the same time to afford the 2,5-diamino-<br>
benzenesulfonamide intermediate as a salt. Alternatively, the 2,5-diamino-<br>
benzenesulfonamide salt can be prepared by reduction of the 2-amino-5-nitro-<br>
benzenesulfonamide (prepared as described in schemes 14 and 15) under standard<br>
hydrogenation conditions in the presence of an acid (e.g., methanesulfonic acid).<br>
Subsequent reaction with methanesulfonyl chloride affords the desired 2-amino-5-<br>
methanesulfonylamino-benzenesulfonamide intermediate.<br>
[00194] Scheme 17 provides a procedure that was used to prepare the (7-iodo-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid intermediate.<br>
Scheme 17<br><br>
[00195] Commercially available 2-aminobenzenesulfonamide can be treated with<br>
iV-iodosuccinimide (NIS) to afford 2-amino-5-iodo-benzenesulfonamide. Acylation<br>
with a malonyl halide monoester, such as ethyl 3-chloro-3-oxo-propionate, or with a<br>
dialkyl malonate, such as diethyl malonate, affords the corresponding amide, which<br>
can simultaneously be cyclized to the thiadiazine-dioxide and hydrolyzed to the<br>
desired acid intermediate (or a salt thereof, e.g., sodium salt).<br>
[00196] Scheme 18 provides a procedure that was used to prepare the (1,1 -dioxo-<br>
1,4-dihydro-1?6-benzo[1 ,2,4]thiadiazin-3-yl)-acetic acid intermediate.<br><br>
[00197] Commercially available 2-aminobenzenesulfonamide can be acylated with<br>
a malonyl halide monoester, such as ethyl 3-chloro-3-oxo-propionate, or with a<br>
dialkyl malonate, such as diethyl malonate, to afford the corresponding amide, which<br>
can simultaneously be cyclized to the thiadiazine-dioxide and hydrolyzed to the<br>
desired acid intermediate (or a salt thereof, e.g., sodium salt).<br>
[00198] Scheme 19 provides a procedure that was used to prepare the 3-amino-<br>
pyridine-4-sulfonic acid amide intermediate.<br>
Scheme 19<br><br>
[00199] The 3-amino-pyridine-4-sulfonic acid amide intermediate can be prepared<br>
following procedures described in Tetrahedron 1998, 54, 13645-13654 (steps 2 - 4).<br>
Commercially available 4-chloro-3-nitro-pyridine can be treated with sodium sulfide<br>
hydrate to displace the chloro moiety. Treatment with chloramine followed by<br>
oxidation of the sulfur with an oxidizing agent, such as MCPBA, furnishes the nitro-<br>
sulfonamide intermediate. Reduction of the nitro group using standard conditions<br>
(e.g., tin(II)chloride) affords the desired 3-amino-pyridine-4-sulfonic acid amide<br>
intermediate.<br>
[00200] Scheme 20 provides a procedure that was used to prepare the 4-amino-<br>
pyridine-3-sulfonic acid amide intermediate.<br><br>
[00201] Commercially available pyridin-4-ylamine can be treated with<br>
chlorosulfonic acid in the presence of thionyl chloride to afford the sulfonyl chloride<br>
intermediate. Treatment with aqueous ammonium hydroxide solution affords the<br>
desired 4-amino-pyridine-3-sulfonic acid amide intermediate.<br>
[00202] Scheme 21 provides a procedure that was used to prepare the 3-amino-<br>
pyridine-2-sulfonic acid amide intermediate.<br>
Scheme 21<br><br>
[00203] Commercially available 2-chloro-3-nitro-pyridine can be treated with<br>
benzyl mercaptan in the presence of a base (e.g., potassium carbonate) to afford the<br>
sulfide intermediate. Oxidation with 1,3-dichloro-5,5-dimethyl-hydantoin furnishes<br>
the sulfonyl chloride, which can be treated with aqueous ammonium hydroxide<br>
solution to yield the sulfonamide intermediate. Reduction of the nitro group under<br>
standard hydrogenation conditions affords the desired 3-amino-pyridine-2-sulfonic<br>
acid amide intermediate.<br>
[00204] Scheme 22 provides a procedure that was used to prepare the 4-amino-<br>
pyridine-3-sulfonic acid amide intermediate.<br><br>
[00205] Commercially available 4-chloro-pyridine-3-sulfonic acid amide can be<br>
treated with sodium azide to furnish the azido intermediate, which can be reduced<br>
with a reducing agent (e.g., sodium borohydride) to afford the desired 4-amino-<br>
pyridine-3-sulfonic acid amide intermediate.<br>
[00206] Scheme 23 provides a procedure that was used to prepare the acid<br>
intermediates derived from aminopyridine sulfonic acid amide intermediates.<br><br>
[00207] The aminopyridine sulfonic acid amide intermediates described in schemes<br>
19-21 can be acylated with a malonyl halide monoester, such as ethyl 3-chloro-3-oxo-<br>
propionate, or with a dialkyl malonate, such as diethyl malonate, to afford the<br>
corresponding amide, which can simultaneously be cyclized to the thiadiazine-dioxide<br>
and hydrolyzed to the desired acid intermediate (or a salt thereof, e.g., sodium salt).<br>
[00208] Scheme 24 provides a general procedure that was used to prepare 5,6-<br>
dihydro-lH-pyridin-2-one compounds of Formula I from the corresponding iodo<br>
precursors.<br><br>
[00209] Optionally substituted 5,6-dihydro-lH-pyridin-2-ones can be treated with<br>
substituted sulfonamides in a copper-mediated displacement reaction to afford the<br>
desired 5,6-dihydro-lH-pyridin-2-one compounds of Formula I.<br>
[00210] Scheme 25 provides a general procedure that was used to prepare 5,6-<br>
dihydro-lH-pyridin-2-one compounds of Formula I bearing a sulfamide moiety from<br>
the corresponding iodo precursors.<br><br>
[00211] Optionally substituted 5,6-dihydro-1H-pyridin-2-ones can be treated with<br>
sodium azide to displace the iodo moiety. Reduction of the azido-intermediate using<br>
standard conditions, such as catalytic hydrogenation, affords the aniline intermediate.<br>
Further reaction with an optionally substituted sulfamoyl chloride in the presence of a<br>
base (e.g., triethylamine) affords the desired 5,6-dihydro-1H-pyridin-2-one<br>
compounds of Formula I.<br>
[00212] Scheme 26 provides a general procedure that was used to prepare N-<br>
substiruted 5,6-dihydro-1H-pyridin-2-one compounds of Formula I.<br><br>
[00213] The sulfonamide moiety of optionally substituted 5,6-dihydro-1H-pyridin-<br>
2-ones can be N-alkylated by treatment with an alkylating agent, such as alkyl halides<br>
or pseudohalides Xa (e.g., chlorides, bromides, iodides, mesylates, tosylates, triflates,<br>
or chloroformates), in the presence of a base (e.g., potassium carbonate) to afford the<br>
desired N-substituted 5,6-dihydro-1H-pyridin-2-one compounds of Formula I.<br>
[00214] Scheme 27 provides a procedure that was used to prepare the 5,6-dihydro-<br>
1H-pyridin-2-one compounds of Formula I from the corresponding iodo precursors.<br><br>
[00215] Optionally substituted 5,6-dihydro-1H-pyridin-2-ones can be treated with<br>
stannanes, such as the unsaturated cyclic sulfone shown above, in a Stille-type<br>
palladium-catalyzed reaction to afford the unsaturated intermediates shown.<br>
Reduction of the alkene using standard hydrogenation conditions affords the desired<br>
5,6-dihydro-1H-pyridin-2-one compounds of Formula I.<br>
[00216] Scheme 28 provides a general procedure that was used to prepare the 5,6-<br>
dihydro-1H-pyridin-2-one compounds of Formula I from the corresponding iodo<br>
precursors.<br><br>
[00217] Optionally substituted 5,6-dihydro-1H-pyridin-2-ones can be treated with<br>
amines in a copper-mediated displacement reaction to afford the desired 5,6-dihydro-<br>
lH-pyridin-2-one compounds of Formula I.<br>
[00218] Example 1: (rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1.4-dihydro-l?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) 2-Chloro-5-nitrobenzenesulfonamide<br><br>
[00219] To a solution of thionyl chloride (11 mL) and 2-chloro-5-nitro-<br>
benzenesulfonic acid (4.78 g, 20.1 mmol) was added N,N-dimethylformamide (0.92<br>
ÂµL) and the reaction mixture was heated at reflux for 4 h. The reaction mixture was<br>
then carefully quenched by pouring it into water and the product was isolated by<br>
vacuum filtration. The sulfonyl chloride was dissolved in a minimal amount of<br>
toluene and then added to a mixture of concentrated aqueous ammonium hydroxide<br>
solution (25 mL) and tetrahydrofuran (25 mL) at -10 Â°C. After stirring for 2 h the<br>
reaction was quenched by adding a 6.0 M aqueous hydrochloric acid solution until pH<br>
4 was reached. The layers were separated and the organic layer was concentrated in<br>
vacuo to a slurry. Pentane was added and the product was isolated by vacuum<br>
filtration to afford 2-chloro-5-nitrobenzenesulfonamide (2.0 g, 8.48 mmol, 42.4%), as<br>
a solid. 1H NMR (400 MHz, DMSO-d6) d: 7.94 (d, 1H, J= 8.8 Hz), 7.97 (bs, 2H),<br>
8.40 (dd, 1H, J1 = 8.6 Hz, J2 = 3.1 Hz), 8.64 (d, 1H, J= 3.1 Hz),<br>
b) 2-Amino-5 -nitrobenzenesulfonamide<br><br>
[00220] 2-Chloro-5-nitro-benzenesulfonamide (1.95 kg, 8.30 mol), ammonium<br>
carbonate (1.983 kg, 20.64 mol), and copper (II) sulfate (394 g, 2.47 mol) were<br>
charged to an autoclave and diluted with a 30% aqueous ammonium hydroxide<br>
solution (11.7 L, 330 mol). The mixture was heated at 118 Â°C for 3 days and was<br>
then cooled to 23 Â°C. The mixture was filtered and the solids were then washed with<br>
water (20 L). This solid was dissolved in hot methanol (20 mL/g), and the mixture<br>
was filtered to remove undissolved solids. The filtrate was stored at 4 Â°C overnight,<br>
and the resulting solid product was then filtered. The filtrate was partially<br>
concentrated by vacuum distillation and, when the concentrate was cooled to 23 Â°C,<br>
the solid product was then filtered off. The two crops of solid were combined and<br>
further dried in vacuo at 45 Â°C to afford the desired product, 2-amino-5-nitro-<br>
benzenesulfonamide (1.10 kg, 5.06 mol, 61%), as a solid. LH NMR (400 MHz,<br>
DMSO-ck) 8: 6.89 (d, J= 9.3 Hz, 1H), 7.12 (bs, 2H), 7.57 (bs, 2H), 8.07 (dd, J1 = 9.0<br>
Hz, J2 = 2.6 Hz, 1H), 8.43 (d, J= 3.0 Hz, 1H).<br>
[00221] Alternatively, 2-amino-5-nitrobenzenesulfonamide can be prepared as<br>
follows:<br>
[00222] 2-Amino-5-nitrobenzenesulfonic acid (200.00 g, 0.917 mol) was<br>
suspended in warm sulfolane (250 mL) and the suspension was heated to 80 Â°C.<br>
Phosphorous oxychloride (126 mL, 1.375 mol) was added and resulting mixture was<br>
heated to 110-120 Â°C and stirred for 4 h. The resulting solution was cooled to 60 Â°C<br>
and added dropwise into concentrated aqueous ammonium hydroxide solution (800<br>
mL, 11.9 mol) at 
wash was added into the above reaction mixture. The resulting suspension was stirred<br>
at 25 Â°C for 1 h, heated to 95 Â°C and stirred for 1 hour. The mixture was cooled to 80<br>
Â°C and the pH was adjusted to 6-8 with 3.0 M aqueous hydrochloric acid solution<br>
(-600 mL) and allowed to cool to 25 Â°C. The dark green suspension was filtered, and<br>
the wet filter cake was washed with water (300 mL) and dried at 60 Â°C overnight to<br>
give the crude product (140 g) as a green-yellow solid. The crude product was<br>
dissolved in 0.5 M aqueous sodium hydroxide solution (1.4 L, 0.7 mol). Charcoal (14<br>
g) was added and the mixture was heated to reflux and stirred for 15 min. The mixture<br>
was filtered through Celite and washed with 0.5 M aqueous sodium hydroxide<br>
solution (100 mL). The pH of the filtrate was adjusted to 6-8 with concentrated<br>
aqueous hydrochloric acid solution (~ 60 mL) and the yellow suspension was allowed<br>
to cool to 25 Â°C. The mixture was filtered and the wet filter cake was washed with<br>
water (200 mL) and dried at 60 Â°C overnight to afford the desired product, 2-amino-5-<br>
nitrobenzenesulfonamide (130 g, 0.599 mol, 65%) as a bright yellow powder.<br>
c) 2,5-Diaminobenzenesulfonamide<br><br>
[00223] 2-Amino-5-nitro-benzenesulfonamide (5.00 kg, 23.0 mol), methanol (65<br>
L), tetrahydrofuran (65 L), and 10% palladium on carbon (250 g) were charged to an<br>
autoclave. The mixture was cycled with nitrogen and hydrogen purges (3 Ã), and the<br>
mixture was then stirred under hydrogen (50 psi) at 23 Â°C overnight. The catalyst was<br>
removed by filtration and the filtrate was then concentrated in vacuo to give a brown<br>
solid. The solid was further dried in vacuo at 45 Â°C to afford the desired product, 2,5-<br>
diamino-benzenesulfonamide (4.21 kg, 22.4 mol, 98%), as a solid. 1H NMR (400<br>
MHz, DMSO-d6) d: 4.54 (2H, bs), 4.98 (2H, bs), 6.55 - 6.60 (2H, m), 6.87 (1H, d, J=<br>
2.2 Hz), 6.99 (2H, bs). LC-MS (ESI) calcd for C6H9N3O2S 187.04, found 188.3<br>
[M+H'].<br>
d) 2-Amino-5 -methanesulfonylamino-benzenesulfonamide<br><br>
[00224] 2,5-Diamino-benzenesulfonamide (4.20 kg, 22.4 mol) was dissolved in<br>
dichloromethane (120 L) and pyridine (8.00 kg, 89.9 mol), and the resulting solution<br>
was cooled to 0 Â°C. Methanesulfonyl chloride (2.80 kg, 24.4 mol) was added slowly,<br>
and the resulting mixture was allowed to warm to 23 Â°C and stirred for 2 days. The<br>
mixture was filtered and the resulting solid was washed with dichloromethane (2 Ã 20<br>
L). The solid was diluted with water (100 L) and 1.0 M aqueous hydrochloric acid<br>
solution (25 L), and was then stirred at 23 Â°C for 1 h. The mixture was filtered and<br>
the resulting solid was washed with water (20 L) and then with methyl-terr-butyl ether<br>
(2x10 L). The solid was further dried in vacuo at 45 Â°C to afford the desired<br>
product, 2-amino-5-methanesulfonylamino-benzenesulfonamide (4.39 kg, 16.5 mol,<br>
73%) as a pale pink solid. 1H NMR (400 MHz, CD3OD) d: 2.89 (3H, s), 6.82 (1H, d,<br>
J= 8.5 Hz), 7.20 (1H, dd, J1 = 8.5 Hz, J2 = 2.5 Hz), 7.58 (1H, d, J= 2.5 Hz). LC-MS<br>
(ESI) calcd for C7H11N3O4S2265.02, found 266.0 [M+H+].<br>
[00225] Alternatively, 2-amino-5-methanesulfonylamino-benzenesulfonamide can<br>
be prepared as follows:<br>
a')2-Benzylamino-5-nitro-benzenesulfonamide<br><br>
[00226] A mixture of 2-chloro-5-nitro-benzenesulfonamide (2.20 kg, 9.30 mol),<br>
benzylamine (1.5 L, 13.9 mol), triethylamine (2.5 L, 18.1 mol), and acetonitrile (22.0<br>
L) were heated at 92 Â°C for 20 h. The mixture was then cooled to 40 Â°C, and was<br>
then partially concentrated in vacuo. The residue was added to 0 Â°C water (22.0 L)<br>
and the resulting suspension was allowed to warm to 23 Â°C and stirred for 2 h. The<br>
suspension was filtered and the solid was then washed with water (5 L). The washed<br>
solid was suspended in absolute ethanol (11 L), and was then filtered and washed with<br>
absolute ethanol (5 L). The solid was further dried in vacuo at 45 Â°C to afford the<br>
desired product, 2-benzylamino-5-nitro-benzenesulfonamide (2.40 kg, 7.81 mol,<br>
84%), as a yellow solid. 1H NMR (400 MHz, DMSO-d6) d: 4.64 (2H, d, J= 4.6 Hz),<br>
6.81 (1H, d, J= 9.4 Hz), 7.23 - 7.44 (6H, m), 7.77 (2H, bs), 8.11 (1H, dd, J1 = 9.4 Hz,<br>
J2 = 2.3 Hz), 8.49 (1H, d, J= 3.1 Hz). LC-MS (ESI) calcd for C13H13N3O4S307.06,<br>
found 308.2 [M+H+] (100%), 615.2 [2M+H4] (81%).<br>
b') 2,5-Diamino-benzenesulfonamide methanesulfonate<br><br>
[00227] Methanesulfonic acid (465 mL, 7.16 mol) was added slowly to a<br>
solution of 2-benzylamino-5-nitro-benzenesulfonamide (2.20 kg, 7.16 mol) and<br>
tetrahydrofuran (11.0 L). The resulting solution was added to a mixture of 10%<br>
palladium on carbon (220 g of 50% water wet catalyst) and water (1.1 L) in a<br>
hydrogenation reactor. The mixture was further diluted with absolute ethanol (21.0 L)<br>
and was then hydrogenated with 55 psi hydrogen at 50 Â°C for 21 h. Additional 10%<br>
palladium on carbon (55 g of 50% water wet catalyst) was added, and hydrogenation<br>
at 55 psi and 50 Â°C was continued for 22 h. The resulting suspension was diluted with<br>
water (1.1 L) and the suspension was then filtered through a pad of Celite. The<br>
filtrate was partially concentrated in vacuo and was then diluted with acetonitrile<br>
(15.4 L). The solution was again partially concentrated in vacuo and diluted with<br>
acetonitrile (15.4 L). The resulting suspension was partially concentrated in vacuo<br>
and was allowed to stir at 23 Â°C for 2 h. The suspension was filtered and the solid<br>
was then washed with acetonitrile (3 L). The solid was further dried in vacuo at 45 Â°C<br>
to afford the desired product, 2,5-diamino-benzenesulfonamide methanesulfonate<br>
(1.88 kg, 6.64 mol, 93%), as a purple solid. 1HNMR (400 MHz, DMSO-d6) d: 2.34<br>
(3H, s), 6.05 (2H, b), 6.87 (1H, d, J= 8.6 Hz), 7.20 (1H, dd, J, = 8.6 Hz, J2 = 2.3 Hz),<br>
7.38 (2H, s), 7.53 (1H, d, J= 2.3 Hz), 9.62 (3H, b). LC-MS (ESI) calcd for<br>
C6H9NO2S 187.04, found 187.9 [M+H+].<br>
[00228] Alternatively, 2,5-diamino-benzenesulfonamide methanesulfonate can be<br>
prepared as follows:<br>
[00229] 2-Amino-5-nitrobenzenesulfonamide (prepared as described in Example<br>
1b, 100.00 g, 0.460 mol) and 5 % palladium on carbon (wet, 5.00 g) were suspended<br>
in ethanol (2 L) and water (100 mL). Methanesulfonic acid (33 mL, 0.51 mol) was<br>
added, and the resulting mixture was heated to 55 Â°C and stirred under atmospheric<br>
hydrogen for 8 h. The mixture was filtered and the filtrate was concentrated in vacuo<br>
to a volume of about 450 mL. To the concentrate was added acetonitrile (1 L) and<br>
resulting mixture was stirred at 25 Â°C overnight. The suspension was filtered to<br>
afford the desired product, 2,5-diamino-benzenesulfonamide methanesulfonate<br>
(122.36 g, 0.432 mol, 93.8%) as a purple solid.<br>
c')2-Amino-5-methanesulfonylamino-benzenesulfonamide<br><br>
[00230] 2,5-Diamino-benzenesulfonamide methanesulfonate (1.80 kg, 6.35 mol)<br>
was suspended in acetonitrile (24 L). Pyridine (1.55 L, 19.1 mol) was added,<br>
followed by the careful slow addition of methanesulfonyl chloride (517 mL, 6.68<br>
mol). After stirring at 23 Â°C for 20 h, the mixture was partially concentrated in vacuo<br>
at 55 Â°C. Water (18 L) was added to the concentrate, and the resulting suspension<br>
was stirred at 23 Â°C for 2 h. The solid was filtered and was then washed with water (4<br>
L) and air dried on the filter. The solid was suspended in absolute ethanol (9 L),<br>
stirred at 23 Â°C for 9 h, and was then filtered. The solid was washed with absolute<br>
ethanol (2Ã2 L), and was then further dried in vacuo at 50 Â°C to afford the desired<br>
product, 2-amino-5-methanesulfonylamino-benzenesulfonamide (1.45 kg, 5.48 mol,<br>
86%), as a purple solid.<br>
e) N-(4-Methanesulfonylamino-2-sulfamoyl-phenyl)-malonamic acid ethyl<br>
ester<br><br>
[00231] 2-Amino-5-methanesulfonylamino-benzenesulfonamide (23.27 g, 87.81<br>
mmol) was dissolved in N,N-dimethylacetamide (100 mL) and diethyl ether (100<br>
mL). Ethyl 3-chloro-3-oxo-propionate (13.88 g, 92.20 mmol) was added and the<br>
reaction mixture was stirred at 25 Â°C for 1 h. The reaction mixture was diluted with<br>
ethyl acetate (400 mL) and was extracted with water (400 mL). The aqueous layer<br>
was back-extracted with ethyl acetate (2 Ã 200 mL). The combined organic layers<br>
were dried over sodium sulfate, filtered, and most of the solvent was removed in<br>
vacuo to a volume of-100 mL.<br>
[00232] To the stirred solution was added hexanes (~100 mL) upon which a<br>
precipitate formed. The precipitate was collected by vacuum filtration, washed with<br>
hexanes and dried under high vacuum to afford the analytically pure product, N-(4-<br>
methanesulfonylamino-2-sulfamoyl-phenyl)-malonamic acid ethyl ester (31.22 g,<br>
85.53 mmol, 97.4%), as a light-brown solid. 1H NMR (400 MHz, CD3OD) d: 1.31<br>
(3H, t, J= 7.0 Hz), 3.00 (3H, s), 3.59 (2H, s), 4.25 (2H, quartet, J= 6.9 Hz), 7.42 -<br>
7.45 (1H, m), 7.86 (1H, m), 7.92 (1H, d, J= 8.8 Hz).<br>
f) N-(4-Methanesulfonylamino-2-sulfamoylphenyl)-malonamic acid methyl<br>
ester<br><br>
[00233] 2-Amino-5-methanesulfonylamino-benzenesulfonamide (prepared as<br>
described in Example 1d, 1.70 kg, 6.40 mol) was dissolved in tetrahydrofuran (35 L),<br>
and was then cooled to 0 Â°C. Methyl 3-chloro-3-oxopropionate (792 mL, 7.40 mol)<br>
was added slowly, and the resulting mixture was then allowed to warm to 23 Â°C and<br>
stirred for 2 days. The solvent was removed in vacuo, and the residue was then<br>
diluted with water (4 L) and saturated aqueous sodium bicarbonate solution (2 L).<br>
The resulting solid was filtered, and was then washed with water (5 L). The solid was<br>
suspended in hot methanol (15 mL/g), and was then cooled to 23 Â°C and filtered to<br>
afford the desired product, N-(4-methanesulfonylamino-2-sulfamoyl-phenyl)-<br>
malonamic acid methyl ester (1.68 kg, 4.61 mol, 72%), as a brown solid. 1H NMR<br>
(400 MHz, DMSO-d6) d: 3.02 (3H, s), 3.60 (2H, s), 3.66 (3H, s), 7.38 (1H, dd,.J, =<br>
2.3 Hz, J2 = 8.6 Hz), 7.53 (2H, bs), 7.73 (1H, d, J= 2.4 Hz), 7.83 (1H, d, J= 8.7 Hz),<br>
9.43 (1H, s), 9.99 (1H, s).<br>
g) (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid<br><br>
[00234] N-(4-Methanesulfonylamino-2-sulfamoyl-phenyl)-malonamic acid ethyl<br>
ester (prepared as described in Example le, 9.55 g, 26.16 mmol) was dissolved in 8%<br>
aqueous sodium hydroxide solution (262 mL) and heated at 100 Â°C for 1.5 h. The<br>
reaction mixture was cooled to 0 Â°C and the solution was acidified by slowly adding<br>
12.0 M aqueous hydrochloric acid solution until pH 1-2 was reached. A precipitate<br>
started to form and the suspension was allowed to stir for 30 min at 0 Â°C. The<br>
precipitate was collected by vacuum filtration, washed with cold water, and dried<br>
under high vacuum to afford the desired product, (7-methanesulfonylamino-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (7.20 g, 21.621 mmol,<br>
82.6%), as a pinkish solid. 1H NMR (400 MHz, DMSO-d6) d: 3.03 (3H, s), 3.56 (2H,<br>
s), 7.33 (1H, d, J=9A Hz), 7.52 - 7.54 (2H, m), 10.09 (1H, s), 12.24 (1H, s), 13.02<br>
(1H, bs). LC-MS (ESI) calcd for C10H11N3O6S2 333.01, found 334.1 [M+H+].<br>
[00235] Alternatively, (7-methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid can be prepared as follows:<br>
[00236] N-(4-methanesulfonylamino-2-sulfamoyl-phenyl)-malonamic acid methyl<br>
ester (prepared as described in Example lg, 1.35 kg, 3.69 mol) was added to 3.8 wt.<br>
% aqueous sodium hydroxide solution (14.0 kg). The resulting mixture was stirred at<br>
23 Â°C for 30 h, and was then cooled to 0 Â°C. A 2.0 M aqueous hydrochloric acid<br>
solution (9.72 L) was slowly added, stirring at 0 Â°C was continued for 30 min, and the<br>
mixture was then filtered. The solid was washed with water (1.4 L), and was then<br>
slurried in a mixture of methanol (1.4 L) and diethyl ether (2.7 L). After filtration, the<br>
solid was washed with diethyl ether (2 Ã 1.4 L) and was further dried in vacuo at 23<br>
Â°C to afford the desired product, (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (1.07 kg, 3.21 mol, 87%), as a light<br>
brown solid.<br>
h) (rac-di-exo)-3-(4-Fluoro-benzylamino)-bicyclo[2.2. 1]heptane-2-carboxylic acid<br>
ethyl ester<br><br>
[00237] (rac-di-e*o)-3-Amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br>
hydrochloride (1 g, 4.6 mmol) was suspended in methanol (23 mL). Sodium acetate<br>
(0.755 g, 9.2 mmol) was added followed by 4A powdered molecular sieves (1 g) and<br>
4-fluoro-benzaldehyde (0.571 g, 4.6 mmol). Sodium cyanoborohydride (0.578 g, 9.2<br>
mmol) was added and the mixture was stirred at 25 Â°C for 16 h. The mixture was<br>
poured into a 1:1 mixture of saturated aqueous sodium bicarbonate solution (200 mL)<br>
and ethyl acetate (200 mL). After shaking, both layers were passed through a plug of<br>
Celite. The organic layer was further washed with saturated aqueous brine solution<br>
(50 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford<br>
the crude product, (rac-di-exo)-3-(4-fluoro-benzylamino)-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (0.993 g, 3.41 mmol, 74%), as a clear oil. LC-MS (ESI)<br>
calcd for C17H22FNO2291.16, found 292.1 [M+H+].<br>
i) (rac-di-ero)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1, 1-dioxo-l ,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00238] (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.1 g,<br>
0.299 mmol) was dissolved in anhydrous N,N-dimethylformamide (1.5 mL). (rac-di-<br>
exo)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br>
(0.087 g, 0.3 mmol) was added followed by a 1.0 M solution of N,N-<br>
dicyclohexylcarbodiimide in dichloromethane (0.315 mL, 0.315 mmol). The mixture<br>
was stirred at 25 Â°C for 1.5 h. Triethylamine (0.124 mL, 0.9 mmol) was added and<br>
the mixture was stirred at 50 Â°C for 16 h. Upon cooling, the mixture was poured into<br>
1.0 M aqueous hydrochloric acid solution (100 mL). The product was extracted into<br>
ethyl acetate (100 mL). The organic layer was washed with 1.0 M aqueous<br>
hydrochloric acid solution (50 mL), saturated aqueous brine solution (25 mL) and<br>
dried over magnesium sulfate. Purification by flash column chromatography (Merck<br>
silica gel 60, 40-63 Âµm, 0 to 1% methanol in dichloromethane) followed by<br>
crystallization from methanol afforded the desired product, (rac-di-exo)-N-{3-[3-(4-<br>
fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1 -dioxo-<br>
1,4-dihydro-R6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.08 g, 0.141<br>
mmol, 47%), as a white powder. 1H NMR (400 MHz, DMSO-d6) d: 1.18 - 1.21 (2H,<br>
m), 1.39 - 1.59 (5H, m), 2.61 - 2.64 (1H, m), 3.03 (1H, d, J= 14.2 Hz), 3.05 (3H, s),<br>
3.53 (1H, d, J= 9.3 Hz), 4.41 (1H, d, J= 14.8 Hz), 4.96 (1H, d, J= 15.5 Hz), 7.14<br>
(2H, t, J= 9.0 Hz), 7.32 (2H, dd, J1 = 8.7 Hz, J2 = 6.2 Hz), 7.50 (1H, dd, J1 = 9.3 Hz,<br>
J2 = 2.4 Hz), 7.55 - 7.57 (2H, m), 10.17 (1H, s). LC-MS (ESI) calcd for<br>
C25H25FN4O6S2560.12, found 561.3 [M+H+]. HPLC-analysis: Chiralpak AS-RH4.6<br>
Ã 250 mm, 5 micron at r.t., Solvent A - Solvent B (see table for gradient), 0.8<br>
mL/min, 310 nm, t1 = 7.72 min, t2 = 9.00 min.<br>
[00239] Example 2: (rac-di-endo)-N- (3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?,6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-endo)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1 ]heptane-2-carboxylic<br>
acid ethyl ester<br><br>
[00240] (rac-di-endo)-3-Amino-bicyclo[2,2, 1]heptane-2-carboxylic acid ethyl ester<br>
hydrochloride (1 g, 4.6 mmol) was suspended in methanol (23 mL). Sodium acetate<br>
(0.755 g, 9.2 mmol) was added followed by 4A powdered molecular sieves (1 g) and<br>
4-fluoro-benzaldehyde (0.571 g, 4.6 mmol). Sodium cyanoborohydride (0.578 g, 9.2<br>
mmol) was added and the mixture was stirred at 25 Â°C for 16 h. The mixture was<br>
poured into a 1:1 mixture of saturated aqueous sodium bicarbonate solution (200 mL)<br>
and ethyl acetate (200 mL). After shaking, both layers were passed through a plug of<br>
Celite. The organic layer was further washed with saturated aqueous brine solution<br>
(50 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford<br>
the crude product, (di-encfo)-3-(4-fluoro-benzylamino)-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (1.096 g, 3.77 mmol, 82%), as a clear oil. LC-MS (ESI)<br>
calcd for C17H22FNO2 291.16, found 292.1 [M+H+].<br>
b) (rac-di-endo)-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00241] (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.1 g,<br>
0.299 mmol) was dissolved in anhydrous N,N-dimethylformamide (1.5 mL). (rac-di-<br>
eÂ«fi?o)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br>
(0.087 g, 0.3 mmol) was added followed by a 1.0 M solution of N.N-<br>
dicyclohexylcarbodiimide in dichloromethane (0.315 mL, 0.315 mmol). The mixture<br>
was stirred at 25 Â°C for 1.5 h. Triethylamine (0.124 mL, 0.9 mmol) was added and<br>
the mixture was stirred at 50 Â°C for 16 h. Upon cooling, the mixture was poured into<br>
1.0 M aqueous hydrochloric acid solution (100 mL). The product was extracted into<br>
ethyl acetate (100 mL). The organic layer was washed with 1.0 M aqueous<br>
hydrochloric acid solution (50 mL), saturated aqueous brine solution (25 mL) and<br>
dried over magnesium sulfate. Purification by flash column chromatography (Merck<br>
silica gel 60, 40-63 nm, 0 to 1% methanol in dichloromethane) followed by<br>
crystallization from methanol afforded the desired product, (rac-di-endo)-N- {3-[3-(4-<br>
fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-5 -en-5-yl]-1,1 -dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.092 g, 0.164<br>
mmol, 55%), as a white powder. 1H NMR (400 MHz, DMSO-d6) d: 1.25 -1.48 (6H,<br>
m), 2.64 - 2.73 (2H, m), 3.06 (3H, s), 3.24 (1H, d, J= 23.8 Hz), 3.72 (1H, d, J= 11.6<br>
Hz), 4.07 (1H, d, J= 14.8 Hz), 5.12 (1H, d, J= 15.3 Hz), 7.14 (2H, t, J= 8.6 Hz),<br>
7.39 (2H, dd, J, = 8.1 Hz, J2 = 5.7 Hz), 7.51 (1H, dd, J1 = 8.5 Hz, J2 = 2.4 Hz), 7.57 -<br>
7.60 (2H, m), 10.18 (1H, s). LC-MS (ESI) calcd for C25H25FN4O6S2560.12, found<br>
561.4 [M+H+]. HPLC-analysis: Chiralpak AS-RH 4.6 Ã 250 mm, 5 micron at r.t.,<br>
Solvent A - Solvent B (see table for gradient), 0.8 mL/min, 310 nm, t1 = 7.58 min, t2<br>
= 10.08 min.<br>
[00242] Example 3: frac-di-endo)-N-{3-[3-(5-Fluoro-pyridin-2-ylmethyr)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6,2,1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6 -<br>
benzol[1,2,4] thiadiazin-7-yl) -methanesulfonamide<br><br>
a) (rac-di-e,Â«c?o)-3-[(5-Fluoro-pyridin-2-ylmethyl)-amino]-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid ethyl ester<br><br>
[00243] (rac-di-endo)-3-Amino-bicyclo[2,2,1 ]heptane-2-carboxylic acid ethyl ester<br>
hydrochloride (1 g, 4.6 mmol) was suspended in methanol (23 mL). Sodium acetate<br>
(0.755 g, 9.2 mmol) was added followed by 4Ã powdered molecular sieves (1 g)<br>
followed by 5-fluoro-pyridine-2-carbaldehyde (0.576 g, 4.6 mmol). Sodium<br>
cyanoborohydride (0.578 g, 9.2 mmol) was added and the mixture was stirred at 25 Â°C<br>
for 16 h. The mixture was poured into a 1:1 mixture of saturated aqueous sodium<br>
bicarbonate solution (200 mL) and ethyl acetate (200 mL). After shaking, both layers<br>
were passed through a plug of Celite. The organic layer was further washed with<br>
saturated aqueous brine solution (50 mL), dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo to afford the crude product, (rac-di-entffo)-3-[(5-fluoro-pyridin-<br>
2-ylmethyl)-amino]-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (1.247 g, 4.27<br>
mmol, 93%), as a clear oil. LC-MS (ESI) calcd for C16H21FN2O2 292.16, found 293.1<br>
[M+H+].<br>
b)(rac-di-endo)-N-{3-[3-(5-Fluoro-pyridin-2-ylmethyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-lA.6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00244] (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.1 g,<br>
0.299 mmol) was dissolved in anhydrous N,N-dimethylformamide (1.5 mL). (rac-di-<br>
endo)-3-[(5-Fluoro-pyridin-2-ylmethyl)-amino]-bicyclo[2,2,1]heptane-2-carboxylic<br>
acid ethyl ester (0.088 g, 0.3 mmol) was added followed by a 1.0 M solution of N,N-<br>
dicyclohexylcarbodiimide in dichloromethane (0.315 mL, 0.315 mmol). The mixture<br>
was stirred at 25 Â°C for 1,5 h. Triethylamine (0.124 mL, 0.9 mmol) was added and<br>
the mixture was stirred at 50 Â°C for 16 h. Upon cooling, the mixture was poured into<br>
1.0 M aqueous hydrochloric acid solution (100 mL). The product was extracted into<br>
ethyl acetate (100 mL). The organic layer was washed with 1.0 M aqueous<br>
hydrochloric acid solution (50 mL), saturated aqueous brine solution (25 mL), dried<br>
over magnesium sulfate, and concentrated in vacuo. Crystallization from methanol<br>
afforded the desired product, (rac-di-endo)-N-{3-[3-(5-fluoro-pyridin-2-ylmethyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.087 g, 0.156 mmol, 52%), as a<br>
light yellow powder.<br>
lH NMR (400 MHz, DMSO-d6) d: 1.24 - 1.50 (6H, m), 2.64 - 2.73 (2H, m), 3.05 (3H,<br>
s), 3.28 (1H, d, J= 12.2 Hz), 3.89 (1H, d, J= 14.9 Hz), 4.25 (1H, d, J= 15.7 Hz),<br>
5.10 (1H, d, J= 15.5 Hz), 7.46 - 7.51 (2H, m), 7.55 - 7.57 (2H, m), 7.66 - 7.71 (1H,<br>
m), 8.49 (1H, d, J= 2.3 Hz), 10.17 (1H, s). LC-MS (ESI) calcd for C24H24FN5O6S2<br>
561.12, found 562.4 [M+H+].<br>
[00245] Example 4: N-{3-[(1S,2S,7R,8R-)3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihvdro-l?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (1R,2S,3R,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic acid<br><br>
[00246] The starting material (a) was prepared as described in J. Org. Chem. 2000,<br>
65, 6984-6991. cis-5-Norbornene-endo-2,3-dicarboxylic anhydride (4.104 g, 25<br>
mmol) was suspended in a 1:1 mixture of toluene and carbon tetrachloride (500 mL).<br>
The mixture was stirred for 20 min. Quinine (8.92 g, 27.5 mmol) was added and the<br>
flask was degassed and backfilled with nitrogen. The solution was cooled to -55 Â°C.<br>
While stirring, methanol (3.04 mL, 75 mmol) was added. The mixture was stirred at -<br>
55 Â°C for 20 h. Upon warming to 25 Â°C, the mixture was concentrated in vacuo to a<br>
thick oil. The oil was dissolved in ethyl acetate (400 mL), washed with 1.0 M<br>
aqueous hydrochloric acid solution (2 Ã 400 mL), saturated aqueous brine solution<br>
(100 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford<br>
the desired product, (1R,2S,3R,4S)-3-(methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid (4.8 g, 24.5 mmol, 98%), as a clear waxy solid. 1H NMR (400 MHz,<br>
DMSO-d6) d: 1.26 (1H, d, J= 8.5 Hz), 1.33 (1H, d, J= 8.8 Hz), 3.00 (1H, s), 3.03<br>
(1H, s), 3.21 - 3.30 (2H, m), 3.45 (3H, s), 6.02 - 6.04 (1H, m), 6.14 - 6.16 (1H, m),<br>
11.86(1H, s).<br>
b) Methyl (1R,2S,3R,4S)-3-{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1 ]hept-5-<br>
ene-2-carboxylate<br><br>
[00247] (1R,2S,3R,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic<br>
acid (4.61 g, 23.5 mmol) was dissolved in anhydrous tetrahydrofuran (40 mL). The<br>
flask was degassed and backfilled with nitrogen and the mixture was cooled to 0 Â°C.<br>
Triethylamine (9.9 mL, 70.5 mmol) was added followed by the dropwise addition of<br>
ethyl chloroformate (4.48 mL, 47 mmol) with vigorous stirring. Immediate<br>
precipitation was observed. Additional tetrahydrofuran (60 mL) was added. The<br>
mixture was stirred at 0 Â°C for 1 h. Sodium azide (4.58 g, 70.5 mmol) was dissolved<br>
in water (30 mL) and added to the reaction mixture at 0 Â°C. The mixture was stirred<br>
at 0 Â°C for 5 min. The ice bath was removed. The mixture was warmed to 25 Â°C and<br>
was stirred for 2 h. The mixture was poured into water (300 mL) and the product<br>
extracted into ethyl acetate (300 mL). The organic layer was further washed with<br>
half-saturated aqueous sodium bicarbonate solution (2 Ã 100 mL), saturated aqueous<br>
brine solution (100 mL), dried over magnesium sulfate, filtered, and concentrated in<br>
vacuo to afford a clear oil. The oil was dissolved in anhydrous benzene (50 mL) and<br>
refluxed while stirring under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was<br>
concentrated in vacuo to afford a slightly yellow oil. The oil was dissolved in<br>
dichloromethane (30 mL) and benzyl alcohol (2.68 mL, 25.9 mmol) was added<br>
followed by triethylamine (6.61 mL, 47 mmol). The mixture was refluxed under<br>
nitrogen for 16 h. Upon cooling to 25 Â°C the solution was concentrated in vacuo to<br>
afford a golden oil. Purification by flash column chromatography (Merck silica gel<br>
60, 40-63 |im, 15% ethyl acetate in hexanes) afforded the desired product, methyl<br>
(lS,2/?,35',4i?)-3-{[(benzyloxy)carbonyl]amino} bicyclo[2,2,1 ]hept-5-ene-2-<br>
carboxylate (5.51 g, 18.31 mmol, 78%), as a clear oil. 1H NMR (400 MHz, CDCl3) d:<br>
1.38 (1H, d, J= 9.1 Hz), 1.50 (1H, d, J= 9.4 Hz), 3.10 (2H, s), 3.21 (1H, dd, J, = 9.2<br>
Hz, J2 = 2.3 Hz), 3.53 (3H, s), 4.62 (1H, dt, J1 = 9.4 Hz, J2 = 2.9 Hz), 5.07 (2H, q, J=<br>
13.0 Hz), 5.29 (1H, d, J= 8.6 Hz), 6.15 - 6.17 (1H, m), 6.37 - 6.38 (1H, m), 7.29 -<br>
7.35 (5H, m). LC-MS (ESI) calcd for C17H19NO4301.13, found 258.1 (100%), 302.2<br>
[M+H'] (70%), 603.5 [2M+H+] (20%).<br>
c) Methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1]heptane-2-carboxylate<br>
hydrochloride<br><br>
[00248] Methyl (1R,2S,3R,4S)-3-{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1]hept-<br>
5-ene-2-carboxylate (5.5 g, 18.27 mmol) was dissolved in ethyl acetate (75 mL). 5%<br>
Palladium on carbon (650 mg) was added. The flask was degassed and backfilled<br>
with hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The<br>
mixture was passed through a plug of Celite and the filtrate was concentrated in vacuo<br>
to afford a thick clear oil. The oil was dissolved in ethyl acetate (15 mL) and added<br>
dropwise, with vigorous stirring, to a mixture of a 4.0 M solution of hydrochloric acid<br>
in 1,4-dioxane (10 mL, 40 mmol) in diethyl ether (90 mL). The desired product<br>
began to precipitate as a white solid. The mixture was stirred for 20 min. The<br>
precipitate was collected by vacuum filtration, and was washed with additional diethyl<br>
ether (15 mL). The solid was further dried in vacuo for 1 h to afford the desired<br>
product, methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1]heptane-2-carboxylate<br>
hydrochloride (2.61 g, 12.69 mmol, 69%), as a white powder. 'H NMR (400 MHz,<br>
DMSO-d6)d: 1.34- 1.43 (4H,m), 1.54 (1H, d, J=9.5 Hz), 1.68 (1H, d, J= 11.4 Hz),<br>
2.47 - 2.48 (2H, m), 3.03 (1H, dd, J1 = 11.0 Hz, J2 = 4.0 Hz), 3.49 - 3.53 (1H, m),<br>
3.62 (3H, s), 8.07 (3H, bs). LC-MS (ESI) calcd for C9H15NO2 (free amine) 169.11,<br>
found 170.1 [M+H+] (100%), 339.2 [2M+H+] (50%).<br>
d) Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1 ]heptane-2-<br>
carboxylate<br><br>
[00249] Methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1]heptane-2-carboxylate<br>
hydrochloride (1 g, 4.86 mmol) was dissolved in methanol (23 mL). Sodium acetate<br>
(0.755 g, 9.2 mmol) was added followed by 4A powdered molecular sieves (1 g) and<br>
4-fluoro-benzaldehyde (0.571 g, 4.6 mmol). Sodium cyanoborohydride (0.578 g, 9.2<br>
mmol) was added and the mixture was stirred at 25 Â°C for 16 h. The mixture was<br>
poured into a mixture of saturated aqueous sodium bicarbonate solution (200 mL) and<br>
ethyl acetate (300 mL). After shaking, both layers were passed through a plug of<br>
Celite. The organic layer was further washed with saturated aqueous sodium<br>
bicarbonate solution (100 mL), saturated aqueous brine solution (100 mL), dried over<br>
magnesium sulfate, filtered, and concentrated in vacuo to afford the crude product,<br>
methyl ((1R,2S,3R,4S))-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1 ]heptane-2-carboxylate<br>
(1.172 g, 4.23 mmol, 92%), as a clear oil. LC-MS (ESI) calcd for C16H20FNO2<br>
277.15, found 278.2 [M+H+].<br>
e) N-{3-[(1S,2S,7R,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-l?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
[00250] Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2, 1]heptane-2-<br>
carboxylate (0.087 g, 0.3 mmol) was dissolved in anhydrous A^iV-dimethylformamide<br>
(2.8 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-lA.6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.1 g,<br>
0.3 mmol) was added followed by N-methylmorpholine (0.07 mL, 0.63 mmol). The<br>
mixture was stirred until everything dissolved, approximately 5 min. l-(3-<br>
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.061 g, 0.315 mmol) was<br>
added and the mixture was stirred at 25 Â°C for 4 h. Triethylamine (0.126 mL, 0.9<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h. Upon cooling to 25<br>
Â°C, the solution was diluted with ethyl acetate (25 mL) and washed with 1.0 M<br>
aqueous hydrochloric acid solution (2 Ã 25 mL), saturated aqueous brine solution (10<br>
mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
golden oil. The oil was dissolved in methanol (4 mL) and the product was<br>
precipitated by the addition of 1.0 M aqueous hydrochloric acid solution (4 mL) while<br>
stirring. The solid was collected by vacuum filtration and further dried in vacuo to<br>
afford the desired product, N-{3-[(1R,2S,3R,4S)-3(4-fluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-l?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.0805 g, 0.144 mmol, 48%), as a<br>
white powder. 1H NMR (400 MHz, DMSO-d6) d: 1.23 - 1.48 (6H, m), 2.67 - 2.68<br>
(2H, m), 3.06 (3H, s), 3.24 (1H, d, J= 15.0 Hz), 3.72 (1H, d, J= 11.9 Hz), 4.07 (1H,<br>
d, J= 15.6 Hz), 5.12 (1H, d, J= 15.7 Hz), 7.14 (2H, t, J= 8.4 Hz), 7.39 (2H, dd, J1 =<br>
8.2 Hz, J2 = 5.8 Hz), 7.51 (1H, dd, J1 = 8.4 Hz, J2 = 2.3 Hz), 7.57 - 7.60 (2H, m),<br>
10.18 (1H, s). LC-MS (ESI) calcd for C25H25FN4O6S2 560.12, found 561.3 [M+H+].<br>
ee = 99% [HPLC-analysis: Chiralpak AS-RH 4.6 Ã 250 mm, 5 micron at r.t., Solvent<br>
A - Solvent B (see table for gradient), 0.8 mL/min, 310 nm, t1 = 7.58 min (major), t2<br>
= 10.08 min].<br>
[00251] Example 5: N-{3-[(1R,2R,7S,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-l?6-<br>
berizo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (1R,2S,3R,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic acid<br><br>
[00252] The starting material (a) was prepared as described in J. Org. Chem. 2000,<br>
65, 6984-6991. m-5-Norbornene-endo-2,3-dicarboxylic anhydride (8.21 g, 50 mmol)<br>
was suspended in a 1:1 mixture of toluene and carbon tetrachloride (250 mL). The<br>
mixture was stirred for 10 min. Quinidine (17.84 g, 55 mmol) was added and the<br>
flask was degassed and backfilled with nitrogen. The solution was cooled to -55 Â°C.<br>
While stirring, methanol (6.08 mL, 150 mmol) was added. The mixture was stirred at<br>
-55 Â°C for 18 h. Upon warming to 25 Â°C, the mixture was concentrated in vacuo to a<br>
thick oil. The oil was dissolved in a mixture of ethyl acetate (400 mL) and 1.0 M<br>
aqueous hydrochloric acid solution (300 mL). After shaking, the layers were<br>
separated and the organic layer was further washed with 1.0 M aqueous hydrochloric<br>
acid solution (2 Ã 100 mL), saturated aqueous brine solution (100 mL), dried over<br>
magnesium sulfate, filtered, and concentrated in vacuo to afford the desired product,<br>
(1R,2S,3R,4S)-3-(methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic acid (9.15<br>
g, 46.6 mmol, 94%), as a clear oil. 1H NMR (400 MHz, DMSO-d6) d: 1.26 (1H, d, J<br>
= 8.4 Hz), 1.33 (1H, d, J= 8.4 Hz), 3.00 (1H, s), 3.03 (1H, s), 3.21 - 3.29 (2H, m),<br>
3.45 (3H, s), 6.02 - 6.04 (1H, m), 6.14 - 6.16 (1H, m), 11.86 (1H, s).<br>
b) Methyl (1R,2S,3R,4S)-3-{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1]hept-5-<br>
ene-2-carboxylate<br><br>
[00253] The intermediate (b) was prepared as described in Synthesis 2001, 11,<br>
1719-1730. (1R,2S,3R,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1 ]hept-5-ene-2-<br>
carboxylic acid (8.94 g, 45.57 mmol) was dissolved in anhydrous tetrahydrofuran<br>
(200 mL). The flask was degassed and backfilled with nitrogen and the mixture was<br>
cooled to 0 Â°C. Triethylamine (19.2 mL, 136.7 mmol) was added followed by the<br>
dropwise addition of ethyl chloroformate (8.69 mL, 91.1 mmol) with vigorous<br>
stirring. Immediate precipitation was observed. The mixture was stirred at 0 Â°C for 1<br>
h. Sodium azide (8.89 g, 136.7 mmol) was dissolved in water (60 mL) and added to<br>
the reaction mixture at 0 Â°C. The mixture was stirred at 0 Â°C for 1 h. The ice bath<br>
was removed. The mixture was warmed to 25 Â°C and continued to stir for 2 h. The<br>
mixture was poured into water (400 mL) and the product extracted into ethyl acetate<br>
(400 mL). The organic layer was further washed with half-saturated aqueous sodium<br>
bicarbonate solution (2 x 200 mL), saturated aqueous brine solution (2 x 200 mL),<br>
dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a slightly<br>
brown oil. The oil was dissolved in anhydrous benzene (100 mL) and refluxed while<br>
stirring under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was concentrated<br>
in vacuo to afford a slightly brown oil. The oil was dissolved in dichloromethane (60<br>
mL) and benzyl alcohol (5.19 mL, 50.13 mmol) was added followed by triethylamine<br>
(12.81 mL, 91.14 mmol). The mixture was refluxed under nitrogen for 16 h. Upon<br>
cooling to 25 Â°C the solution was concentrated in vacuo to afford a golden oil.<br>
Purification by flash column chromatography (Merck silica gel 60, 40-63 urn, 10%<br>
ethyl acetate in hexanes) afforded the desired product, methyl (1R,2S,3R,4S)-3-<br>
{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1]hept-5-ene-2-carboxylate (10.1 g, 33.55<br>
mmol, 74%), as a clear oil. 1H NMR (400 MHz, CDCl3) d: 1.38 (1H, d, J= 8.7 Hz),<br>
1.50 (1H, d, J= 8.4 Hz), 3.10 (2H, s), 3.21 (1H, d, J= 8.8 Hz), 3.53 (3H, s), 4.59 -<br>
4.64 (1H, m), 5.07 (2H, q, J= 13.0 Hz), 5.29 (1H, d, J= 8.3 Hz), 6.15 - 6.17 (1H, m),<br>
6.37 - 6.38 (1H, m), 7.27 - 7.36 (5H, m). LC-MS (ESI) calcd for C17H19NO4 301.13,<br>
found 258.1 (100%), 302.2 [M+H+] (70%), 603.5 [2M+H+] (20%).<br>
c) Methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1 ]heptane-2-carboxylate<br>
hydrochloride<br><br>
[00254] Methyl (1R,2S,3R,4S)-3-{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1]hept-<br>
5-ene-2-carboxylate (10 g, 33.22 mmol) was dissolved in ethyl acetate (150 mL). 5%<br>
Palladium on carbon (1.5 mg) was added. The flask was degassed and backfilled with<br>
hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 2 h. The mixture was<br>
passed through a plug of Celite and the filtrate was concentrated in vacuo to a volume<br>
of 50 mL. The solution was added dropwise, with vigorous stirring, to a mixture of<br>
4.0 M hydrochloric acid solution in 1,4-dioxane (20 mL) in diethyl ether (200 mL).<br>
The desired product began to precipitate as a white solid. The mixture was stirred for<br>
10 min. The precipitate was collected by vacuum filtration, washed with additional<br>
diethyl ether (15 mL). The solid was further dried in vacuo for 1 h to afford the<br>
desired product, methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1]heptane-2-carboxylate<br>
hydrochloride (5.21 g, 25.33 mmol, 76.3%), as a white powder. 1H NMR (400 MHz,<br>
DMSO-d6) d: 1.33 - 1.42 (4H, m), 1.54 (1H, d, J= 10.3 Hz), 1.69 (1H, d, J= 11.5<br>
Hz), 2.46 - 2.48 (2H, m), 3.03 (1H, dd, J1 = 10.8 Hz, J2 = 4.1 Hz), 3.46 - 3.55 (1H,<br>
m), 3.62 (3H, s), 8.09 (3H, bs). LC-MS (ESI) calcd for C9H15NO2 (free amine)<br>
169.11, found 170.1 [M+H+] (100%), 339.2 [2M+H+] (50%).<br>
d) Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1]heptane-2-<br>
carboxylate<br><br>
[00255] Methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1 ]heptane-2-carboxylate<br>
hydrochloride (1 g, 4.86 mmol) was dissolved in methanol (23 mL). Sodium acetate<br>
(0.755 g, 9.2 mmol) was added followed by 4A powdered molecular sieves (1 g) and<br>
4-fluoro-benzaldehyde (0.571 g, 4.6 mmol). Sodium cyanoborohydride (0.578 g, 9.2<br>
mmol) was added and the mixture was stirred at 25 Â°C for 16 h. The mixture was<br>
poured into a mixture of saturated aqueous sodium bicarbonate solution (200 mL) and<br>
ethyl acetate (300 mL). After shaking, both layers were passed through a plug of<br>
Celite. The organic layer was further washed with saturated aqueous sodium<br>
bicarbonate solution (100 mL), saturated aqueous brine solution (100 mL), dried over<br>
magnesium sulfate, filtered, and concentrated in vacuo to afford the crude product,<br>
methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1 ]heptane-2-carboxylate<br>
(1.11 g, 4.0 mmol, 87%), as aclear oil. LC-MS (ESI) calcd for C16H20FNO2 277.15,<br>
found 278.2 [M+H+].<br>
e) N- {3-[(1R,2R,7S,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1, 1-dioxo-l ,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00256] Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1 ]heptane-2-<br>
carboxylate (0.087 g, 0.3 mmol) was dissolved in anhydrous N,N-dimethylformamide<br>
(2.8 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-l?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.1 g,<br>
0.3 mmol) was added followed by N-methylmorpholine (0.07 mL, 0.63 mmol). The<br>
mixture was stirred until everything dissolved, approximately 5 min. l-(3-<br>
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.061 g, 0.315 mmol) was<br>
added and the mixture was stirred at 25 Â°C for 4 h. Triethylamine (0.126 mL, 0.9<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h. Upon cooling to 25<br>
Â°C, the solution was diluted with ethyl acetate (25 mL) and washed with 1.0 M<br>
aqueous hydrochloric acid solution (2 x 25 mL), saturated aqueous brine solution (10<br>
mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
golden oil. The oil was dissolved in methanol (4 mL) and the product was<br>
precipitated by the addition of 1.0 M aqueous hydrochloric acid solution (4 mL) while<br>
stirring. The solid was collected by vacuum filtration and further dried in vacuo to<br>
afford the desired product, N-{3-[(1R,2R,7S,8S)-3-(4-fIuoro-benzyl)-6-hydroxy-4-<br>
oxo-3 -aza-tricyclo[6.2.1.027]undec-5 -en-5 -yl]-l, 1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.0781 g, 0.139 mmol, 46%), as a<br>
white powder. 1H NMR (400 MHz, DMSO-d6) d: 1.23 - 1.48 (6H, m), 2.67 - 2.68<br>
(2H, m), 3.06 (3H, s), 3.24 (1H, d, J= 15.0 Hz), 3.72 (1H, d, J= 11.9 Hz), 4.07 (1H,<br>
d, J= 15.6 Hz), 5.12 (1H, d, J= 15.7 Hz), 7.14 (2H, t, J= 8.4 Hz), 7.39 (2H, dd, J, =<br>
8.2 Hz, J2 = 5.8 Hz), 7.51 (1H, dd, J1 = 8.4 Hz, J2 = 2.3 Hz), 7.57 - 7.60 (2H, m),<br>
10.18 (1H, s). LC-MS (ESI) calcd for C25H25FN4O6S2 560.12, found 561.3 [M+H+].<br>
ee = 99% [HPLC-analysis: Chiralpak AS-RH 4.6 Ã 250 mm, 5 micron at r.t., Solvent<br>
A - Solvent B (see table for gradient), 0.8 mL/min, 310 nm, t1 = 7.58 min, t2 = 10.08<br>
min (major)].<br>
[00257] Example 6: N- {3-[((1R,2R,7S,8S)-3-(4-Fluoro-benzvl)-6-hydroxy-4-oxo-3-<br>
aza-tricvclo[6.2.1.02'7]undec-5 -en-5-yl]-1.1 -dioxo-1.4-dihvdro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (1R,2S,3R,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic acid<br><br>
[00258] The starting material (a) was prepared as described in J. Org. Chetn. 2000,<br>
65, 6984-6991. m-5-Norbornene-eto-2,3-dicarboxylic anhydride (5 g, 30.45 mmol)<br>
was suspended in a 1:1 mixture of toluene and carbon tetrachloride (610 mL). The<br>
mixture was stirred for 10 min. Quinine (10.87 g, 33.5 mmol) was added and the<br>
flask was degassed and backfilled with nitrogen. The solution was cooled to -55 Â°C.<br>
While stirring, methanol (3.7 mL, 91.35 mmol) was added. The mixture was stirred<br>
at -55 Â°C for 16 h. Upon wanning to 25 Â°C, the mixture was concentrated in vacuo to<br>
a foam. The foam was dissolved in a mixture of ethyl acetate (400 mL) and 1.0 M<br>
aqueous hydrochloric acid solution (400 mL). The layers were separated and the<br>
organic layer was further washed with 1.0 M aqueous hydrochloric acid solution (2 x<br>
200 mL), saturated aqueous brine solution (100 mL) and dried over magnesium<br>
sulfate, filtered, and concentrated in vacuo to afford the desired product,<br>
(15,2S,3i?,4/?)-3-(methoxycarbonyl)bicyclo[2,2,1 ]hept-5-ene-2-carboxylic acid (5.95<br>
g, 30.3 mmol, 99%), as a clear oil. 1H NMR (400 MHz, DMSO-d6) d: 1.31 (1H, d, J<br>
= 8.5 Hz), 1.98 (1H, d, J= 8.6 Hz), 2.51 (2H, d, J= 1.6 Hz), 2.95 (2H, bs), 3.52 (3H,<br>
s), 6.17-6.21 (2H, m), 12.16 (1H,s).<br>
b) Methyl (1R,2S,3R,4S)3-{[(benzyloxy)arbonyl]aminolbicyclo[2,2,1]hept-5-<br>
ene-2-carboxylate<br><br>
[00259] (1R,2S,3R,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic<br>
acid (5.9 g, 30 mmol) was dissolved in anhydrous tetrahydrofuran (133 mL). The<br>
flask was degassed and backfilled with nitrogen and the mixture was cooled to 0 Â°C.<br>
Triethylamine (12.64 ml, 90 mmol) was added followed by the dropwise addition of<br>
ethyl chloroformate (5.72 mL, 60 mmol) with vigorous stirring. Immediate<br>
precipitation was observed. The mixture was stirred at 0 Â°C for 1 h. Sodium azide<br>
(5.86 g, 90 mmol) was dissolved in water (40 mL) and added to the reaction mixture<br>
at 0 Â°C. The mixture was stirred at 0 Â°C for 5 min. The ice bath was removed. The<br>
mixture was warmed to 25 Â°C and continued to stir for 2 h. The mixture was poured<br>
into water (300 mL) and the product extracted into ethyl acetate (300 mL). The<br>
organic layer was further washed with half-saturated aqueous sodium bicarbonate<br>
solution (2 x 100 mL), saturated aqueous brine solution (100 mL), dried over<br>
magnesium sulfate, filtered, and concentrated in vacuo to afford a light brown oil.<br>
The oil was dissolved in anhydrous benzene (66 mL) and refluxed while stirring<br>
under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was concentrated in vacuo<br>
to afford a light brown oil. The oil was dissolved in dichloromethane (40 mL) and<br>
benzyl alcohol (3.41 mL, 33 mmol) was added followed by triethylamine (8.44 mL,<br>
60 mmol). The mixture was refluxed under nitrogen for 16 h. Upon cooling to 25 Â°C<br>
the solution was concentrated in vacuo to afford a thick oil. Purification by flash<br>
column chromatography (Merck silica gel 60, 40-63 Âµm; 1st column: 3:1<br>
hexanes/ethyl acetate; 2nd column: 2:4:1 dichloromethane/pentane/diethyl ether)<br>
afforded the desired product, methyl (1R,2S,3R,4S)-3-<br>
{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1]hept-5-ene-2-carboxylate (6.95 g, 23.09<br>
mmol, 77%), as a pale yellow oil. 1H NMR (400 MHz, CDCl3) 8: 1.59 (1H, d, J= 9.3<br>
Hz), 1.96 (1H, d, J= 9.3 Hz), 2.66 (1H, d, J= 7.9 Hz), 2.75 (1H, s), 2.96 (1H, s), 3.59<br>
(3H, s), 4.01 (1H, t, /= 8.5 Hz), 5.09 (2H, q, J= 10.4 Hz), 5.46 (1H, d, J= 9.4 Hz),<br>
6.17 - 6.22 (2H, m), 7.29 - 7.36 (5H, m). LC-MS (ESI) calcd for C17H19NO4 301.13,<br>
found 258.1 (100%), 302.2 [M+H+] (70%), 603.5 [2M+H+] (20%).<br>
c) Methyl (15,2i?,35,4J?)-3-aminobicyclo[2,2,1 ]heptane-2-carboxylate<br>
hydrochloride<br><br>
[00260] Methyl (1R,2S,3R,4S)-3-{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1]hept-<br>
5-ene-2-carboxylate (1 g, 3.32 mmol) was dissolved in ethyl acetate (15 mL). 5%<br>
Palladium on carbon (120 mg) was added. The flask was degassed and backfilled<br>
with hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The<br>
mixture was passed through a plug of Celite and the filtrate was concentrated in vacuo<br>
to afford a thick clear oil. The oil was dissolved in diethyl ether (10 mL) and added<br>
dropwise, with vigorous stirring, to a mixture of 4.0 M hydrochloric acid solution in<br>
1,4-dioxane (1.8 mL) in diethyl ether (18 mL). The desired product began to<br>
precipitate as a white solid. Additional diethyl ether (10 mL) was added and the<br>
mixture was stirred for 10 min. The precipitate was collected by vacuum filtration,<br>
washed with additional diethyl ether (2Ã8 mL). The solid was further dried in vacuo<br>
for 1 h to afford the desired product, methyl (1R,2S,3R,4S)-3-<br>
aminobicyclo[2,2,1]heptane-2-carboxylate hydrochloride (0.64 g, 3.11 mmol, 94%),<br>
as a white powder. 1H NMR (400 MHz, DMSO-d6) d: 1.17 - 1.27 (3H, m), 1.40 -<br>
1.61 (2H, m), 1.91 (1H, d, J= 10.7 Hz), 2.36 (1H, d, J= 4.1 Hz), 2.44 (1H, d, J= 3.1<br>
Hz), 2.75 (1H, d, J= 7.8 Hz), 3.30 - 3.38 (1H, m), 3.61 (3H, s), 8.05 (3H, bs). LC-<br>
MS (ESI) calcd for C9H15NO2 (free amine) 169.11, found 170.3 [M+H+] (100%),<br>
339.3 [2M+H+] (50%).<br>
d) Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1 ]heptane-2-<br>
carboxylate<br><br>
[00261] Methyl (1S,2R,3S,4R)-3-aminobicyclo[2,2,1 ]heptane-2-carboxylate<br>
hydrochloride (prepared as described in Example 6c, 0.5 g, 2.43 mmol) was dissolved<br>
in methanol (12 mL). Sodium acetate (0.4 g, 4.86 mmol) was added followed by 4Ã<br>
powdered molecular sieves (0.5 g) and 4-fluoro-benzaldehyde (0.302 g, 2.43 mmol).<br>
Sodium cyanoborohydride (0.305 g, 4.86 mmol) was added and the mixture was<br>
stirred at 25 Â°C for 16 h. The mixture was poured into a mixture of saturated aqueous<br>
sodium bicarbonate solution (200 mL) and ethyl acetate (300 mL). After shaking,<br>
both layers were passed through a plug of Celite. The organic layer was further<br>
washed with saturated aqueous sodium bicarbonate solution (100 mL), saturated<br>
aqueous brine solution (100 mL), dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo to afford the crude product, methyl (1S,2R,3S,4R)-3-[(4-<br>
fluorobenzyl)amino]bicyclo[2,2,1]heptane-2-carboxylate (0.663 g, 2.39 mmol, 98%),<br>
as a clear oil. LC-MS (ESI) calcd for C16H20FNO2 277.15, found 278.2 [M+H+].<br>
e) N- {3-[(1R,2S,7R,8S)-3-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-S-en-S-yl]-1,1-dioxo-M-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00262] Methyl (1S,2R,3S,4R)-3-[(4-fluorobenzyl)amino]bicyclo[2,2, 1]heptane-2-<br>
carboxylate (0.6 g, 2.16 mmol) was dissolved in anhydrous N,N-dimethylformamide<br>
(20 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-l?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.72 g,<br>
2.16 mmol) was added followed by Af-methylmorpholine (0.5 mL, 4.54 mmol). The<br>
mixture was stirred until everything dissolved, approximately 5 min. l-(3-<br>
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.435 g, 2.27 mmol) was<br>
added and the mixture was stirred at 25 Â°C for 45 min. Triethylamine (0.91 mL, 6.48<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h.<br>
[00263] Upon cooling to 25 Â°C, the solution was diluted with ethyl acetate (300<br>
mL) and washed with 1.0 M aqueous hydrochloric acid solution (3 x 300 mL),<br>
saturated aqueous brine solution (100 mL), dried over magnesium sulfate, filtered,<br>
and concentrated in vacuo to afford a golden oil. Purification by flash column<br>
chromatography (Merck silica gel 60, 40-63 Âµm, 0 to 0.75% methanol in<br>
dichloromethane) afforded the product as white foam. The foam was dissolved in<br>
methanol (10 mL) and the product was precipitated by the addition of a 1.0 M<br>
aqueous hydrochloric acid solution (20 mL) while stirring. The solid was collected by<br>
vacuum filtration and further dried in vacuo to afford the desired product, N-{3-<br>
[(1R,2S, 7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-<br>
5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-<br>
methanesulfonamide (0.573 g, 1.02 mmol, 47%), as a white powder. 1H. NMR (400<br>
MHz, DMSO-d6) d: 1.16 - 1.22 (2H, m), 1.37 - 1.65 (4H, m), 2.49 - 2.53 (1H, m),<br>
2.63 (1H, d, J= 2.3 Hz), 3.02 (1H, d, J= 8.5 Hz), 3.05 (3H, s), 3.52 (1H, d, J= 9.4<br>
Hz), 4.41 (1H, d, J= 15.6 Hz), 4.95 (1H, d, J= 15.6 Hz), 7.14 (2H, t, J= 9.0 Hz),<br>
7.32 (2H, dd, J1 = 8.1 Hz, J2 = 5.7 Hz), 7.50 (1H, dd, J1 = 9.5 Hz, J2 = 2.3 Hz), 7.55 -<br>
7.57 (2H, m), 10.17 (1H, s). LC-MS (ESI) calcd for C25H25FN4O6S2 560.12, found<br>
561.3 [M+H+]. ee = 90% [HPLC-analysis: Chiralpak AS-RH 2.1 Ã 150 mm, 5 micron<br>
at r.t., Solvent A - Solvent B (see table for gradient), 0.3 mL/min, 312 nra, t\ = A3<br>
min (major), t1 = 6.0 min].<br>
[00264] Alternatively, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3 -aza-tricyclo [6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide can be prepared as follows:<br>
f) (rac-di-ero)-3-Aza-tricyclo[4.2.1.02,5]nonan-4-one<br><br>
[00265] Bicyclo[2,2,1]hept-2-ene (1000 g, 10.6 mol) was dissolved in ethyl acetate<br>
(1.7 L) and the resulting solution was cooled to 0 Â°C. Chlorosulfonyl isocyanate (969<br>
mL, 11.1 mol) was added at 0-20 Â°C over 30 min. The mixture was allowed to warm<br>
to 25 Â°C and stirred for 4 h, then cooled to 0 Â°C. A mixture of sodium sulfite (1500 g,<br>
11.9 mol) in water (6 L) was added at 0-20 Â°C. The milky suspension was stirred at<br>
25 Â°C for 30 min and cooled to 0 Â°C. A 50% queous sodium hydroxide solution (1.6<br>
L, 30.3 mol) was added at 0-15 Â°C to adjust to pH 7. A saturated aqueous sodium<br>
carbonate solution (300 mL) was added to adjust the pH to 7.5-8.0. The mixture was<br>
filtered and the solid was washed with ethyl acetate (3 Ã 2 L) and the solid was<br>
discarded. The combined ethyl acetate extracts were washed with saturated aqueous<br>
brine solution (2 L), dried over magnesium sulfate and filtered. The solution was<br>
concentrated in vacuo to dryness to afford the desired product, (rac-di-exo)-3-aza-<br>
tricyclo[4.2.1.02'5]nonan-4-one (1220 g, 8.9 mol, 84%), as a white glassy solid. 1H<br>
NMR (400 MHz, CDCl3) d 1.02 - 1.11 (2H, m), 1.24 (1H, dt, J1 = 10.9 Hz, J2 = 1.6<br>
Hz), 1.51 - 1.72 (3H, m), 2.37 - 2.37 (1H, m), 2.43-2.44 (1H, m), 2.99-3.00 (1H, m),<br>
3.40 (1H, d, J= 3.4 Hz), 5.73 (1H, bs).<br>
g) (rac-di-exo)-3-Amino-bicyclo[2,2,1]heptane-2-carboxylic acid hydrochloride<br><br>
[00266] To (rac-di-exo)-3-aza-tricyclo[4.2.1.02'3]nonan-4-one (23.37 g, 170.4<br>
mmol) was added a 12.0 M aqueous hydrochloric acid solution (150 mL). The<br>
mixture was stirred at 25 Â°C for 12 h. The solvent was evaporated in vacuo and the<br>
crude compound was dried under high vacuum for 0.5 h. The crude compound was<br>
triturated with acetone and filtered to afford (rac-di-exo)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid hydrochloride (28.43 g, 148.3 mmol, 87%),<br>
as a white solid. 1H NMR (400 MHz, DMSO-d6) d 1.15 - 1.26 (3H, m), 1.42 - 1.59<br>
(2H, m), 1.87 (1H, d, J= 10.3 Hz), 2.33 (1H, d, J= 3.4 Hz), 2.45 (1H, d, J= 2.3 Hz),<br>
2.67 (1H, d, J= 7.6 Hz), 3.23 - 3.26 (1H, m), 7.93 (3H, bs), 12.73 (1H, bs).<br>
[00267] h) (rac-di-exo)-3-Amino-bicyclo[2,2,1 ]heptane-2-carboxylic acid ethyl<br>
ester hydrochloride<br><br>
[00268] To absolute ethanol (75 mL) at -10 Â°C was added thionyl chloride (4.1 mL,<br>
54.5 mmol) dropwise followed by (rac-di-exo)-3-amino-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid hydrochloride (9.60 g, 50.1 mmol). The mixture was stirred at 0 Â°C<br>
for 1 h, at 25 Â°C for 4 h, and heated at reflux for 0.5 h. The solution was concentrated<br>
in vacuo and dried under high vacuum to afford the crude (rac-di-exo)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester hydrochloride (11.01 g, 50.1<br>
mmol, 100%), as an off-white solid. 1H NMR (400 MHz, DMSO-d6) d 1.17-1.27<br>
(3H, m), 1.21(3H,t, J=7.0 Hz), 1.43 - 1.57 (2H, m), 1.91 (1H, d, J= 10.0 Hz), 2.36<br>
(1H, d, J= 3.9 Hz), 2.42 (1H, d, J= 3.0 Hz), 2.72 (1H, d, J= 7.6 Hz), 3.28 (1H, d, J=<br>
8.3 Hz), 4.00 - 4.13 (2H, m), 8.06 (3H, bs).<br>
[00269] i) (rac-di-exo)-3-Amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl<br>
ester<br><br>
[00270] To (rac-di-exo)-3-amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl<br>
ester hydrochloride (11.01 g, 50.1 mmol) was added saturated aqueous sodium<br>
bicarbonate solution (50 mL) and the mixture was stirred at 25 Â°C for 0.5 h. The<br>
crude product was extracted with ethyl acetate (3 Ã 100 mL). The solution was dried<br>
over magnesium sulfate, filtered, and concentrated in vacuo and dried under high<br>
vacuum for 2 h to afford the crude (rac-di-exo)-3-amino-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (8.17 g, 44.6 mmol, 89%), as a brown oil. 1H NMR (400<br>
MHz, CDCl3) d 1.10 - 1.26 (3H, m), 1.29 (3H, t, J= 7.0 Hz), 1.45 - 1.62 (2H, m),<br>
1.86 (2H, bs), 1.95 (1H, dt, J; = 10.3 Hz, J2=l.9 Hz), 2.09 (1H, d, J= 4.5 Hz), 2.49<br>
(1H, d, J= 4.2 Hz), 2.56 (1H, d, J= 9.0 Hz), 3.24 (1H, d, J= 7.7 Hz), 4.09 - 4.21 (2H,<br>
m).<br>
j)(1R,2S,3R,4S)-3-Ethoxycarbonyl-bicyclo[2,2,1]hept-2-yl-aminium(1'5)-(+)-10-<br>
camphorsulfonate<br><br>
[00271] To a solution of (rac-di-exo)-3-amino-bicyclo[2,2,1 ]heptane-2-carboxylic<br>
acid ethyl ester (408.47 g, 2.98 mol) in ethyl acetate (500 mL) was added a solution of<br>
(1S)-(+)-10-camphorsulfonic acid (691.70 g, 2.98 mol) in ethanol (800 mL) at 50-75<br>
Â°C over 30 min. The resulting solution was stirred at 70 Â°C for 1 h. More ethyl<br>
acetate (2.7 L) was added at &gt;55 Â°C. The solution was allowed to cool to 50 Â°C and<br>
seeded with (1R,2S,3R,4S)-3-ethoxycarbonyl-bicyclo[2,2,1]hept-2-yl-aminium (1'S)-<br>
(+)-10-camphorsulfonate (ca. 20 mg). The mixture was allowed to cool to 25 Â°C and<br>
stirred for 16 h. The suspension was filtered and the wet filter cake was washed with<br>
ethyl acetate (2 Ã 500 mL). The crude salt was recrystallized from ethanol (600 mL)<br>
and ethyl acetate (3 L) to afford the desired product, (1R,2S,3R,4S)3-ethoxycarbonyl-<br>
bicyclo[2,2,1]hept-2-yl-aminium (1'S)-(+)-10-camphorsulfonate (334.84 g, 0.806<br>
mol, 27%, &gt;99.5% de), as a white solid. 1H NMR (400 MHz, CDCl3) d 0.84 (3H, s),<br>
1.08 (3H,s), 1.30 (3H, t,J=6.9 Hz), 1.32-1.43 (4H, m), 1.58-1.75 (3H, m), 1.89 (1H,<br>
d, J= 17.7 Hz), 1.95-2.07 (3H, m), 2.33 (1H, dt, J1 = 18.4 Hz, J2 = 3.9 Hz), 2.53 (1H,<br>
s), 2.58-2.65 (1H, m), 2.69 (1H, d, J= 2.9 Hz), 2.76-2.79 (2H, m), 3.26 (1H, d, J=<br>
14.1 Hz), 3.60 (1H, d, J= 7.4 Hz), 4.14-4.27 (2H, m), 7.80 (3H, bs).<br>
[00272] Alternatively, (1R,2S,3R,4S)-3-ethoxycarbonyl-bicyclo[2,2,1]hept-2-yl-<br>
aminium (1 'S)-(+)-10-camphorsulfonate can be prepared as follows:<br>
(rac-di-exo)-3-Aza-tricyclo[4.2.1.02'5]nonan-4-one (prepared as described in<br>
Example 6f, 1220 g, 8.9 mol) was dissolved in ethyl acetate (1.7 L). The solution was<br>
heated to 50 Â°C and a solution of (15)-(+)-10-camphorsulfonic acid (2066 g, 8.9 mol)<br>
in ethanol (2.5 L) at 50-75 Â°C over 30 min. The resulting solution was stirred at 70<br>
Â°C for 2 h. More ethyl acetate (8 L) was added causing the temperature to drop to<br>
&gt;55 Â°C and the solution was seeded with (1R,2S,3R,4S)-3-ethoxycarbonyl-<br>
bicyclo[2,2,1]hept-2-yl-aminium (1'S)-(+)-10-camphorsulfonate (ca. 100 mg). The<br>
mixture was allowed to cool to 25 Â°C and stirred for 16 h. The precipitate was<br>
collected by filtration and the wet filter cake was washed with ethyl acetate (2Ã2 L).<br>
The crude salt was dried at 25 Â°C for 48 h and then was recrystallized from ethanol (2<br>
L) and ethyl acetate (2.5 L) to afford the desired product, (1R,2S,3R,4S)-3-<br>
ethoxycarbonyl-bicyclo[2,2,1]hept-2-yl-aminium (1'S)-(+)-10-camphorsulfonate (920<br>
g, 2.21 mol, 25%, &gt;99.9% de), as a white solid.<br>
k) (1S,2R,3S,4R)-3-Amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br><br>
[00273] To (1R,2S,3R,4S)-3-ethoxycarbonyl-bicyclo[2,2,1 ]hept-2-yl-aminium<br>
(1'S)-(+)-10-camphorsulfonate (2.76 g, 6.64 mmol) was added ethyl acetate (28 mL)<br>
and saturated aqueous sodium carbonate solution (28 mL) and the mixture was stirred<br>
at 25 Â°C for 0.5 h. The organic layer was separated and the aqueous layer was<br>
extracted with ethyl acetate (2 Ã 50 mL). The solution was dried over magnesium<br>
sulfate, filtered, and concentrated in vacuo and dried under high vacuum for 1 h to<br>
afford (1S,2R,3S,4R)-3-amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br>
(1.15 g, 6.28 mmol, 95%), as a colorless oil. 1HNMR(400 MHz, CDCl3) d 1.10 -<br>
1.26 (3H, m), 1.29 (3H, t, J= 7.0 Hz), 1.45 - 1.62 (2H, m), 1.86 (2H, bs), 1.95 (1H, dt,<br>
J1 = 10.3 Hz, J2 = 1.9 Hz), 2.09 (1H, d, J= 4.5 Hz), 2.49 (1H, d, J = 4.2 Hz), 2.56<br>
(1H, d, J= 9.0 Hz), 3.24 (1H, d, J= 7.7 Hz), 4.09 - 4.21 (2H, m).<br>
[00274] In order to determine the enantiomeric excess, (1S,2R,3S,4R)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester was derivatized to the (S)-<br>
mandelate salt as follows: To a solution of (1S,2R,3S,4R)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (34.2 mg, 0.187 mmol) in ethyl<br>
acetate (1 mL) was added (S)-a-hydroxyphenylacetic acid (28.7 mg, 0.187 mmol) and<br>
the mixture was stirred at 25 Â°C for 0.5 h. The solid was filtered and dried under high<br>
vacuum to afford (1S,2R,3S,4R)-3-ethoxycarbonyl-bicyclo[2,2,1]hept-2-yl-aminium<br>
(S)-a-hydroxyphenylacetate (11.4 mg, 0.034 mmol, 18%, de = 97%), as a white solid.<br>
1HNMR(400MHz, CDCl3) d 1.08- 1.20 (3H,m), 1.28 (3H, t, J= 7.1 Hz), 1.50-<br>
1.59 (2H, m), 1.79 (1H, d, J= 10.9 Hz), 2.23 (1H, s), 2.46 - 2.48 (2H, m), 3.04 (1H, d,<br>
J= 7.8 Hz), 4.05 - 4.18 (2H, m), 4.89 (1H, s), 5.49 (3H, bs), 7.22 - 7.31 (3H, m), 7.43<br>
(2H, d,J=6.9Hz).<br>
1) (1S,2R,3S,4R)-3-(4-Fluorobenzylamino)-bicyclo[2,2,1 ]heptane-2-carboxylic<br>
acid ethyl ester<br><br>
[00275] To a solution of (1S,2R,3S,4R)-3-amino-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (1.15 g, 6.28 mmol) in ethanol (30 mL) was added 4-<br>
fluorobenzaldehyde (0.68 mL, 6.31 mmol), glacial acetic acid (0.4 mL, 6.99 mmol),<br>
and sodium cyanoborohydride (1.04 g, 15.7 mmol) at 25 Â°C. After stirring for 3 h, the<br>
mixture was diluted with ethyl acetate (50 mL) and quenched with saturated aqueous<br>
sodium bicarbonate solution (50 mL) for 0.5 h. The mixture was filtered through<br>
Celite. The organic layer was separated and the aqueous layer was extracted with<br>
ethyl acetate (2 Ã 50 mL). When all solvent was removed, a solid was formed. The<br>
solid was filtered, washed with water, and dried in vacuo to afford the desired<br>
product, (1S,2R,3S,4R)-3-(4-fluorobenzylamino)-bicyclo[2,2,1]heptane-2-carboxylic<br>
acid ethyl ester (1.74 g, 5.97 mmol, 95%), as a white solid. 1H NMR (400 MHz,<br>
CDCl3)d 1.05- 1.16 (2H,m), 1.21 (1H, dt, J, = 8.0 Hz, J2 = 1.6 Hz), 1.27 (3H, t,J=<br>
7.4 Hz), 1.45 - 1.61 (2H, m), 1.94 (1H, dt, J1 = 10.1 Hz, J2=1.9 Hz), 2.28 (1H, d, J=<br>
3.9 Hz), 2.43 (1H, d, J= 3.3 Hz), 2.60 (1H, dd, J1 = 8.8 Hz, J2 = 1.5 Hz), 2.94 (1H, d,<br>
J= 7.8 Hz), 3.66 (1H, d,J= 13.2 Hz), 3.80 (1H, d, J= 13.5 Hz), 4.13 (2H, q, J= 7.0<br>
Hz), 6.97 (2H, t, J= 8.5 Hz), 7.26 (2H, t, J= 7.1 Hz).<br>
[00276] Alternatively, (1S,2R,3S,4R)-3-(4-Fluorobenzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester can be prepared as follows:<br>
[00277] (1S,2R,3S,4R)-3-ethoxycarbonyl-bicyclo[2,2,1]hept-2-yl-aminium(1'S)-<br>
(+)-10-camphorsulfonate (prepared as described in Example 6j, 2000 g, 4.81 mol) and<br>
powdered potassium carbonate (1320 g, 9.62 mol) were suspended in ethyl acetate (20<br>
L). The suspension was stirred at 25 Â°C for 16 h and filtered. The ethyl acetate filtrate<br>
was concentrated in vacuo to afford the free amine (1050 g) as a liquid. The liquid<br>
was dissolved in ethanol (10 L), and 4-fluorobenzaldehyde (558 mL, 5.3 mol) and<br>
acetic acid (362 mL, 6.3 mol) were added, causing the temperature to rise to 28-30 Â°C.<br>
The solution was allowed to cool to 25 Â°C and stirred for 30 min. A cloudy solution of<br>
sodium cyanoborohydride (756 g, 12.03 mol) in ethanol (5 L) was added in 20 min,<br>
causing the temperature to rise to 45-50 Â°C. The mixture was allowed to cool to 25 Â°C<br>
and stirred for 16 h. The mixture was concentrated in vacuo to a volume of about 13-<br>
14 L. Water (1-2 L) was added, and the resulting mixture was further concentrated in<br>
vacuo. A saturated aqueous sodium bicarbonate solution (4 L) and water (4 L) were<br>
added with stirring. The pH was adjusted to 8.0-8.5 by adding additional saturated<br>
aqueous sodium bicarbonate solution (~500 mL). The mixture was stirred for 1 h<br>
before the solids were collected by filtration and the the wet filter cake was washed<br>
with water (2 L). The solid was dried in vacuo at 35 Â°C for 64 h to afford the desired<br>
product, (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-bicyclo[2,2,1]heptane-2-carboxylic<br>
acid ethyl ester (1350 g, 4.63 mol, 96%), as a white solid.<br>
m) (1S,2R,3S,4R)-3-{(4-Fluorobenzyl)-[2-(7-methanesulfonylamino-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-3-yl)-acetyl]-amino}-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br><br>
[00278] To a solution of (1S,2R,3S,4R)-3-(4-fluorobenzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (100.6 mg, 0.345 mmol) in N,N-<br>
dimethylformamide (3.0 mL) was added (7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-l?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in<br>
Example lg, 120.8 mg, 0.362 mmol), 4-dimethylaminopyridine (10.6 mg, 0.086<br>
mmol), and l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (70.9<br>
mg, 0.362 mmol). After stirring at 25 Â°C for 12 h, the mixture was diluted with ethyl<br>
acetate and acidified with 1.0 M aqueous hydrochloric acid solution to pH 1. The<br>
organic layer was separated and the aqueous layer was extracted with ethyl acetate (2<br>
x 20 mL). The combined organic layer was dried over magnesium sulfate, filtered,<br>
and concentrated in vacuo, and dried under high vacuum to afford the crude product,<br>
(1S,2R,3S,4R)-3-{(4-fluorobenzyl)-[2-(7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetyl]-amino} -bicyclo[2,2,1 ]heptane-2-<br>
carboxylic acid ethyl ester, as a faintly yellow oil. The crude product was used in the<br>
next step without further purification. LC-MS (ESI) calcd for C27H31FN4O7S2 606.16,<br>
found 607.2 [M+H+].<br>
n)N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-l?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00279] To a solution of the crude (1S,2R,3S,4R)-3- {(4-fluorobenzyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?,6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester in absolute ethanol<br>
(3 mL) was added a 21 wt. % solution of sodium ethoxide in ethanol (0.51 mL, 1.37<br>
mmol). After stirring at 60 Â°C for 2 h, the mixture was diluted with ethyl acetate and<br>
acidified with 1.0 M aqueous hydrochloric acid solution to pH 1. The organic layer<br>
was separated and the aqueous layer was extracted with ethyl acetate (2 Ã 20 mL).<br>
The combined organic layer was dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo. The crude mixture was purified by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 100% ethyl acetate in hexanes)<br>
to afford the desired product, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (131.5 mg, 0.235 mmol, 68% over<br>
two steps), as an off-white solid. 1H NMR (400 MHz, CD3OD) d 1.28 (2H, d, J =<br>
11.0 Hz), 1.47 (1H, t, J= 10.8 Hz), 1.57 - 1.74 (3H, m), 2.56 (1H, d, J= 3.2 Hz), 2.75<br>
(1H, d, J= 2.3 Hz), 2.96 (1H, d, J= 9.2 Hz), 3.02 (3H, s), 3.58 (1H, d, J= 9.2 Hz),<br>
4.42 (1H, d, J= 15.5 Hz), 5.03 (1H, d, J= 15.7 Hz), 7.04 (2H, t, J= 8.5 Hz), 7.31<br>
(2H, dd, J1 = 7.9 Hz, J2 = 5.5 Hz), 7.37 (1H, d, J= 8.8 Hz), 7.54 (1H, dd, J1 = 8.3 Hz,<br>
J2 = 2.3 Hz), 7.69 (1H, d, J= 2.3 Hz). LC-MS (ESI) calcd for C25H25FN4O6S2<br>
560.12, found 561.4 [M+H+]. ee = 98.5% [HPLC-analysis: Chiralpak AS-RH 2.1 Ã<br>
150 mm, 5 micron at r.t, Solvent A - Solvent B (see table for gradient), 0.3 mL/min,<br>
312 nm, t1 = 7.58 min (major), t2 = 8.95 min].<br>
[00280] Alternatively, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3 -aza-tricyclo [6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzof l,2,4]thiadiazin-7-yl}-methanesulfonamide can be prepared as follows:<br>
[00281] (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzofl,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 1.88<br>
kg, 5.63 mol) and (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (prepared as described in Example 61, 1.72 kg, 5.91 mol)<br>
were dissolved in acetonitrile (18.8 L) at 23 Â°C. N-Methylmorpholine (1.25 kg, 12.4<br>
mol) was added and the resulting suspension was stirred at 23 Â°C for 1 h. The<br>
suspension was cooled to 0 Â°C and l-[3-(dimethylamino)propyl]-3-ethylcarbodiimide<br>
hydrochloride (1.19 kg, 6.20 mol) was added in one portion. The mixture was stirred<br>
at 0 Â°C for 3 h, and was then allowed to warm to 23 Â°C and stirred overnight.<br>
Triethylamine (1.88 kg, 18.6 mol) was added and the mixture was then heated at 50<br>
Â°C for 3 h. The mixture was partially concentrated in vacuo at 45 Â°C, and was then<br>
diluted with ethyl acetate (22.5 L) and washed with 2.0 M aqueous hydrochloric acid<br>
solution (22.6 L). The resulting aqueous fraction was extracted with ethyl acetate (2 x<br>
9.4 L). The combined organic extracts were washed with 1.0 M aqueous hydrochloric<br>
acid solution (10.4 L) and then with water (18.8 L). The resulting organic<br>
fraction was filtered through Celite (600 g), and the filtrate was then partially<br>
concentrated in vacuo at 45 Â°C. Absolute ethanol (5.6 L) was added to the residue,<br>
and the mixture was then heated at 50 Â°C with stirring. Dichloromethane (400 mi.)<br>
was added in portions until crystallization initiated. Absolute ethanol (20.7 L) was<br>
added in portions over 1 h, and the resulting mixture was stirred at 23 Â°C overnight.<br>
The mixture was filtered and the solid was then washed with absolute ethanol (1.9 L).<br>
The solid was further dried in vacuo at 45 Â°C to afford the desired product, N-{3-<br>
[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-<br>
5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-<br>
methanesulfonamide (2.46 kg, 4.39 mol, 78%), as an off-white crystalline solid.<br>
[00282] X-ray data - Graph 1 shows a x-ray diffraction of N-{3-[(1R,2S,7R,8S)-3-<br>
(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza- tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (asprepared<br>
in Example 6 on a kg scale). In the x-ray graph, the angle of diffraction 2 theta is<br>
plotted on the x-axis and the peak intensity is plotted on the y-axis. The strongest<br>
lines in the x-ray diffraction graph are observed at angles of 6.2Â°, 17.9Â°, 19.7Â°, 20.5Â°,<br>
22.6Â°, and 24.8Â° Â± 0.3Â°, with lesser intensity lines at 12.4Â°, 16.5Â°, 18.7Â°, 21.6Â°, 23.2Â°,<br>
24.1Â°, 25.6Â°, 26.6Â°, 27.1Â°, 28.5Â°, and 29.3Â°.<br>
Graph 1. Powder X-Ray Diffraction<br><br>
[00283] IR data- Graph 2 shows a FT-Raman spectrum of N-{3-[(1R,2S,7R,8S)-3-<br>
(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (as prepared<br>
in Example 6 on a kg scale), which is characterized by the following major IR bands<br>
at 1617, 1524, 1321, 1260, 1229, 1217, and 1163 cm-1, with minor bands at 1498,<br>
1465, 1147, 836, 727, and 406 cm"1.<br>
Graph 2. FT-Raman Spectrum.<br><br>
[00284] Example 7: N-(3-[(1S,2R,7S,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a)(1R,2R,3S,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic acid<br><br>
[00285] The starting material (a) was prepared as described in J. Org. Chem. 2000,<br>
65, 6984-6991. cis-5-Norbornene-exo-2,3-dicarboxylic anhydride (5 g, 30.45 mmol)<br>
was suspended in a 1:1 mixture of toluene and carbon tetrachloride (150 mL). The<br>
mixture was stirred for 10 min. Quinidine (10.9 g, 33.5 mmol) was added and the<br>
flask was degassed and backfilled with nitrogen. The solution was cooled to -55 Â°C.<br>
While stirring, methanol (3.7 mL, 91.35 mmol) was added. The mixture was stirred<br>
at -55 Â°C for 16 h. Upon warming to 25 Â°C, the mixture was concentrated in vacuo to<br>
a foam. The foam was dissolved in a mixture of ethyl acetate (400 mL) and 1.0 M<br>
aqueous hydrochloric acid solution (400 mL). The layers were separated and the<br>
organic layer was further washed with 1.0 M aqueous hydrochloric acid solution (2 *<br>
100 mL), saturated aqueous brine solution (100 mL) and dried over magnesium<br>
sulfate, filtered, and concentrated in vacuo to afford the desired product,<br>
(1R,2S,3S,4S)-3-(methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-carboxylic acid (5.92<br>
g, 30.2 mmol, 99%), as a clear oil. 1H NMR (400 MHz, DMSO-d6) d: 1.29 (1H, d, J<br>
= 10.2 Hz), 1.96 (1H, d, J= 8.6 Hz), 2.47 - 2.49 (2H, m), 2.93 - 2.94 (2H, m), 3.51<br>
(3H, s), 6.15 - 6.20 (2H, m), 12.15 (1H, s).<br>
b) Methyl (1S,2S,3R,4R)-3-{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1 ]hept-5-<br>
ene-2-carboxylate<br><br>
[00286] The intermediate (b) was prepared as described in Synthesis 2001, 11,<br>
1719-1730. (1R,2R,3S,4S)-3-(Methoxycarbonyl)bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid (5.9 g, 30 mmol) was dissolved in anhydrous tetrahydrofuran (133<br>
mL). The flask was degassed and backfilled with nitrogen and the mixture was<br>
cooled to 0 Â°C. Triethylamine (12.64 mL, 90 mmol) was added followed by the<br>
dropwise addition of ethyl chloroformate (5.72 mL, 60 mmol) with vigorous stirring.<br>
Immediate precipitation was observed. The mixture was stirred at 0 Â°C for 1 h.<br>
Sodium azide (5.86 g, 90 mmol) was dissolved in water (40 mL) and added to the<br>
reaction mixture at 0 Â°C. The mixture was stirred at 0 Â°C for 5 min. The ice bath was<br>
removed. The mixture was warmed to 25 Â°C and continued to stir for 2 h. The<br>
mixture was poured into water (300 mL) and the product extracted into ethyl acetate<br>
(350 mL). The organic layer was further washed with half-saturated aqueous sodium<br>
bicarbonate solution (2 Ã 100 mL), saturated aqueous brine solution (100 mL), dried<br>
over magnesium sulfate, filtered, and concentrated in vacuo to afford a light brown<br>
oil.<br>
[00287] The oil was dissolved in anhydrous benzene (66 mL) and refluxed while<br>
stirring under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was concentrated<br>
in vacuo to afford a light yellow oil. The oil was dissolved in dichloromethane (40<br>
mL) and benzyl alcohol (3.41 mL, 33 mmol) was added followed by triethylamine<br>
(8.44 mL, 60 mmol). The mixture was refluxed under nitrogen for 16 h. Upon<br>
cooling to 25 Â°C the solution was concentrated in vacuo to afford a thick oil.<br>
Purification by flash column chromatography (Merck silica gel 60, 40-63 Âµm; 1st<br>
column: 3:1 hexanes/ethyl acetate; 2nd column: 2:4:1 dichloromethane/pentane/diethyl<br>
ether) afforded the desired product, methyl (1S,2S,3R,4R)-3-<br>
{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1]hept-5-ene-2-carboxylate (6.195 g, 20.58<br>
mmol, 69%), as a faintly yellow oil. 1H NMR (400 MHz, CDCl3) d: 1.60 (1H, d, J=<br>
9.4 Hz), 1.97 (1H, d, J= 9.3 Hz), 2.66 (1H, d, J= 7.5 Hz), 2.75 (1H, s), 2.96 (1H, s),<br>
3.60 (3H, s), 4.02 (1H, t, J= 8.9 Hz), 5.09 (2H, q, J= 10.5 Hz), 5.47 (1H, d, J= 8.8<br>
Hz), 6.18 - 6.23 (2H, m), 7.29 - 7.37 (5H, m). LC-MS (ESI) calcd for C17H19NO4<br>
301.13, found 258.1 (100%), 302.2 [M+H+] (70%), 603.4 [2M+H+] (20%).<br>
c) Methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1 ]heptane-2-carboxylate<br>
hydrochloride<br><br>
[00288] Methyl (1S,2S,3R,4R)-3-{[(benzyloxy)carbonyl]amino}bicyclo[2,2,1 ]hept-<br>
5-ene-2-carboxylate (1 g, 3.32 mmol) was dissolved in ethyl acetate (15 mL). 5%<br>
Palladium on carbon (120 mg) was added. The flask was degassed and backfilled<br>
with hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The<br>
mixture was passed through a plug of Celite and the filtrate was concentrated in vacuo<br>
to afford a thick clear oil. The oil was dissolved in diethyl ether (10 mL) and added<br>
dropwise, with vigorous stirring, to a mixture of 4.0 M hydrochloric acid solution in<br>
1,4-dioxane (1.8 mL, 7.2 mmol) in diethyl ether (18 mL). The desired product began<br>
to precipitate as a white solid. Additional diethyl ether (10 mL) was added and the<br>
mixture was stirred for 10 min. The precipitate was collected by vacuum filtration<br>
and washed with additional diethyl ether (2Ã8 mL). The solid was further dried in<br>
vacuo for 1 h to afford the desired product, methyl (1R,2S,3R,4S)-3-<br>
aminobicyclo[2,2,1]heptane-2-carboxylate hydrochloride (0.554 g, 2.7 mmol, 81%),<br>
as a white powder. 1HMR (400 MHz, DMSO-d6)d: 1.18 -1.27 (3H, m), 1.37 -<br>
1.61 (2H, m), 1.90 (1H, d, J= 11.0 Hz), 2.35 (1H, d, J= 3.8 Hz), 2.44 (1H, d, J= 3.1<br>
Hz), 2.75 (1H, d, J= 8.7 Hz), 3.29 - 3.34 (1H, m), 3.61 (3H, s), 8.03 (3H, bs). LC-<br>
MS (ESI) calcd for C9H15NO2 (free amine) 169.11, found 170.3 [M+H+] (100%),<br>
339.3 [2M+H+] (50%).<br>
d) Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1]heptane-2-<br>
carboxylate<br><br>
[00289] Methyl (1R,2S,3R,4S)-3-aminobicyclo[2,2,1 ]heptane-2-carboxylate<br>
hydrochloride (0.5 g, 2.43 mmol) was dissolved in methanol (12 mL). Sodium<br>
acetate (0.4 g, 4.86 mmol) was added followed by 4A powdered molecular sieves (0.5<br>
g) and 4-fluoro-benzaldehyde (0.302 g, 2.43 mmol). Sodium cyanoborohydride<br>
(0.305 g, 4.86 mmol) was added and the mixture was stirred at 25 Â°C for 3 h. The<br>
mixture was poured into ethyl acetate (300 mL) and shaken with saturated aqueous<br>
sodium bicarbonate solution (200 mL). Both layers were passed through a plug of<br>
Celite. The organic layer was further washed with saturated aqueous sodium<br>
bicarbonate solution (100 mL), saturated aqueous brine solution (100 mL), dried over<br>
magnesium sulfate, filtered, and concentrated in vacuo to afford the crude product,<br>
methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1 ]heptane-2-carboxylate<br>
(0.675 g, 2.43 mmol, 99%), as a clear oil. LC-MS (ESI) calcd for C16H20FNO2<br>
277.15, found 278.2 [M+H+].<br>
e) N- {3-[(1S,2R,7S,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00290] Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]bicyclo[2,2, 1]heptane-2-<br>
carboxylate (0.6 g, 2.16 mmol) was dissolved in anhydrous N,N-dimethylformamide<br>
(20 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-l?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example 1g, 0.72 g,<br>
2.16 mmol) was added followed by N-methylmorpholine (0.5 mL, 4.54 mmol). The<br>
mixture was stirred until everything dissolved, approximately 5 min. l-(3-<br>
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.435 g, 2.27 mmol) was<br>
added and the mixture was stirred at 25 Â°C for 45 min. Triethylamine (0.91 mL, 6.48<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h. Upon cooling to 25<br>
Â°C, the solution was diluted with ethyl acetate (300 mL) and washed with 1.0 M<br>
aqueous hydrochloric acid solution (3 Ã 300 mL), saturated aqueous brine solution<br>
(100 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford<br>
a golden oil. Purification by flash column chromatography (Merck silica gel 60,40-<br>
63 Âµm, 0 to 0.75% methanol in dichloromethane) afforded the product as white foam.<br>
The foam was dissolved in methanol (10 mL) and the product was precipitated by the<br>
addition of 1.0 M aqueous hydrochloric acid solution (20 mL) while stirring. The<br>
solid was collected by vacuum filtration and further dried in vacuo to afford the<br>
desired product, N- {3-[(1S,2R,7S,8R)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.592 g, 1.06 mmol, 49%), as a<br>
white powder. 1HNMR(400 MHz, DMSO-d6)d: 1.15 - 1.22 (2H, m), 1.39 - 1.61<br>
(4H, m), 2.49 - 2.55 (1H, m), 2.62 - 2.63 (1H, m), 3.02 (1H, d, J= 9.8 Hz), 3.05 (3H,<br>
s), 3.52 (1H, d, J= 9.3 Hz), 4.41 (1H, d, J= 15.5 Hz), 4.95 (1H, d, J= 15.5 Hz), 7.14<br>
(2H, t, J= 8.7 Hz), 7.32 (2H, dd, J1 = 8.2 Hz, J2 = 5.7 Hz), 7.50 (1H, dd, J, = 8.4 Hz,<br>
J2 = 2.4 Hz), 7.55 - 7.57 (2H, m), 10.17 (1H, s). LC-MS (ESI) calcd for<br>
C25H25FN4O6S2 560.12, found 561.3 [M+H+]. ee = 96% [HPLC-analysis: Chiralpak<br>
AS-RH 2.1 Ã 150 mm, 5 micron at r.t, Solvent A - Solvent B (see table for gradient),<br>
0.3 mL/min, 312 nm, t1 = 4.3 min, t2 = 6.0 min (major)].<br>
[00291] Example 8: (rac-di-exo)-N-{3-r3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-11-<br>
oxa-3-aza-tricvclo[6.2.1.02,7lundec-5-en-5-yl]-1,1-dioxo-1.4-dihydro-l?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-3-Amino-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl<br>
ester<br><br>
[00292] To a stirred solution of (rac-di-exo)-3-amino-7-oxa-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid (1.0 g, 6.37 mmol) in anhydrous methanol and benzene (1:1, 20<br>
mL), a 2.0 M solution of (trimethylsilyl)diazomethane in diethyl ether (6.37 mL, 12.7<br>
mmol) was added dropwise. The resulting mixture was stirred for 1 h, and<br>
concentrated in vacuo to afford the desired product, (rac-di-exo)-3-amino-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (1.02 g, 5.85 mmol, 94%), as a<br>
colorless oil. 1H NMR (400 MHz, CDCl3)d: 1.53 (2H, m), 1.62 (2H, m), 2.68 (1H, d,<br>
J= 7.6 Hz), 3.27 (1H, d, J= 7.6 Hz), 3.59 (3H, s), 4.14 (1H, d, J= 6.0 Hz), 4.67 (1H,<br>
d,J=4.8Hz).<br>
b) (rac-di-exo)-3 -(4-Fluoro-benzylamino)-7-oxa-bicyclo[2,2,1 ]heptane-2-<br>
carboxylic acid methyl ester<br><br>
[00293] 4-Fluoro-benzaldehyde (0.62 mL, 5.85 mmol) was added to a solution of<br>
(rac-di-exo)-3-amino-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br>
(1.02 g, 5.85 mmol) in anhydrous methanol (20 mL) at 25 Â°C under a nitrogen<br>
atmosphere. After stirring for 10 min, glacial acetic acid (0.8 mL) and sodium<br>
cyanoborohydride (920 mg, 14.6 mmol) were added sequentially, and the resulting<br>
mixture was stirred at 25 Â°C for 18 h. The reaction mixture was poured into saturated<br>
aqueous sodium bicarbonate solution and extracted with ethyl acetate. The combined<br>
organic layers were washed with saturated aqueous brine solution, dried over sodium<br>
sulfate, filtered, and concentrated in vacuo. The residue was dried under high vacuum<br>
to afford the desired product, (rac-di-exo)-3-(4-fluoro-benzylamino)-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (1.40 g, 5.02 mmol, 86%), as a<br>
colorless oil. 1H NMR (400 MHz, CDCl3) d: 1.73 (4H, m), 2.86 (1H, d, J= 8.0 Hz),<br>
3.15 (1H, d, J= 8.0 Hz), 3.68 (1H, d, J= 13.6 Hz), 3.73 (3H, s), 3.84 (1H, d, J= 13.6<br>
Hz), 4.46 (1H, d, J= 5.2 Hz), 4.73 (1H, d, J= 4.8 Hz), 6.99 (2H, m), 7.26 (2H, m).<br>
c) (rac-di-exo)-3- {(4-Fluoro-benzyl)-[2-(7-methanesulfonylamino-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-amino}-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br><br>
[00294] To a stirred solution of (rac-di-exo)-3-(4-fiuoro-benzylamino)-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (190 mg, 0.68 mmol) in<br>
anhydrous N,N-dimethylformamide (4 mL) under a nitrogen atmosphere, (7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetic<br>
acid (prepared as described in Example 1g, 185 mg, 0.55 mmol), N-methylmorpholine<br>
(149 ÂµL, 1.36 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide<br>
hydrochloride (130 mg, 0.68 mmol) were added sequentially. After stirring at 25 Â°C<br>
for 3 h, the reaction mixture was poured into 1.0 M aqueous hydrochloric acid<br>
solution, and extracted with ethyl acetate. The combined organic layers were washed<br>
with saturated aqueous brine solution, dried over sodium sulfate, filtered, and<br>
concentrated in vacuo. The crude product, (rac-di-exo)-3-{(4-fluoro-benzyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester, was used<br>
in the next step without further purification. LC-MS (ESI) calcd for C25H27FN4O8S2<br>
594.13, found 595.2 [M+H+].<br>
d) (rac-di-exo)-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-l 1 -oxa-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00295] To a stirred solution of the crude (rac-di-exo)-3- {(4-fiuoro-benzyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester in<br>
absolute ethanol (8 mL) under a nitrogen atmosphere, a 21 wt% solution of sodium<br>
ethoxide in ethanol (0.81 mL, 1.10 mmol) was added. The mixture was stirred at 60<br>
Â°C for 30 min, and then cooled to 25 Â°C. 1.0 M aqueous hydrochloric acid solution (4<br>
mL, 4 mmol) was added slowly to the mixture, upon which a white solid precipitated.<br>
The suspension was stirred for 15 min, filtered through a filter funnel, and washed<br>
with water. The solid was collected, dried under high vacuum to afford analytically<br>
pure(rac-di-exo)-N-{3-[3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (165 mg, 0.29 mmol, 53% over<br>
two steps), as an off-white solid. 1H NMR (400 MHz, DMSO-d6)d: 1.67 (4H, m),<br>
3.05 (3H, s), 3.32 (1H, m), 3.79 (1H, d, J= 9.2 Hz), 4.39 (1H, d, J= 15.6 Hz), 4.69<br>
(1H, d, J= 4.4 Hz), 4.76 (1H, d, J= 3.6 Hz), 5.04 (1H, d, J= 15.6 Hz), 7.16 (2H, m),<br>
7.33 (2H, m), 7.49 (1H, dd, J= 9.2 Hz), 7.56 (2H, m), 10.17 (1H, s), 13.89 (1H, s).<br>
LC-MS (ESI) calcd for C24H23FN4O7S2 562.10, found 563.4 [M+H+].<br>
[00296] Example 9: (rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yll-1,1-dioxo-1.4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-3-Amino-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester<br>
hydrochloride<br><br>
[00297] (rac-di-exo)-3-Amino-bicyclo[2,2,1 ]hept-5-ene-2-carboxylic acid<br>
hydrochloride (1 g, 5.27 mmol) was dissolved in methanol (7 mL). Benzene (10 mL)<br>
was added followed by the dropwise addition of a 2.0 M solution of<br>
(trimethylsilyl)diazomethane in dichloromethane (5 mL, 10 mmol). The yellow<br>
solution was stirred at 25 Â°C for 10 min. Additional 2.0 M solution of<br>
(trimethylsilyl)diazomethane in dichloromethane (2 mL, 4 mmol) was added. The<br>
yellow solution was stirred at 25 Â°C for 10 min. The solution was concentrated in<br>
vacuo to afford a yellow oil. The oil was dissolved in methanol (15 mL) and<br>
concentrated in vacuo to afford the desired product, (rac-di-exo)-3-amino-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester hydrochloride (1.07 g, 5.25<br>
mmol, 99%), as a yellow oil. LC-MS (ESI) calcd for C9H13NO2 (free amine) 167.09,<br>
found 168.2 [M+H+] (100%), 335.4 [2M+ H+] (25%).<br>
b) (rac-di-exo)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1]hept-5-ene-2-carboxylic<br>
acid methyl ester<br><br>
[00298] (rac-di-exo)-3-Amino-bicyclo[2,2,1 ]hept-5-ene-2-carboxylic acid methyl<br>
ester hydrochloride (1.07 g, 5.25 mmol) was suspended in methanol (23 mL).<br>
Sodium acetate (0.865 g, 10.54 mmol) was added followed by 4A powdered<br>
molecular sieves (1 g) and 4-fluoro-benzaldehyde (0.621 g, 5 mmol). Sodium<br>
cyanoborohydride (0.662 g, 10.54 mmol) was added and the mixture was stirred at 25<br>
Â°C for 16 h. The mixture was poured into a 1:1 mixture of saturated aqueous sodium<br>
bicarbonate solution (200 mL) and ethyl acetate (200 mL). The mixture was shaken<br>
and the layers separated. The organic layer was further washed with saturated<br>
aqueous brine solution (50 mL), dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo to afford the crude product, (rac-di-exo)-3 -(4-fluoro-<br>
benzylamino)-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (1.044 g, 3.79<br>
mmol, 76%), as a clear oil. LC-MS (ESI) calcd for C16H18FNO2 275.13, found 276.2<br>
[M+H+].<br>
c) (rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
[00299] (rac-di-exo)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid methyl ester (0.083 g, 0.3 mmol) was dissolved in anhydrous N,N-<br>
dimethylformamide (2.8 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-lA.6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example 1g, 0.1 g,<br>
0.3 mmol) was added followed by N-methylmorpholine (0.07 mL, 0.63 mmol). The<br>
mixture was stirred until everything dissolved, approximately 5 min. l-(3-<br>
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.061 g, 0.315 mmol) was<br>
added and the mixture was stirred at 25 Â°C for 45 min. Triethylamine (0.126 mL, 0.9<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h. After cooling to 25<br>
Â°C, the solution was diluted with a 1.0 M aqueous hydrochloric acid solution (8 mL).<br>
The resulting precipitate was collected by vacuum filtration, dissolved in methanol<br>
and concentrated in vacuo to afford the crude product as a beige powder. Purification<br>
by flash column chromatography (Merck silica gel 60, 40-63 Âµm, 0 to 0.75%<br>
methanol in dichloromethane) afforded the product as a white foam. The foam was<br>
triturated with a 1:1 mixture of diethyl ether and hexanes (6 mL) and the resulting<br>
solid was collected by vacuum filtration. The solid was dried in vacuo for 16 h to<br>
afford the desired product, (rac-di-exo)-N-{3-[3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3 -aza-tricyclo [6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (40.3 mg, 0.072 mmol, 24%), as a<br>
white powder. 1H NMR (400 MHz, DMSO-d6)d: 1.37 (1H, d, J= 9.5 Hz), 1.62 (1H,<br>
d, J= 9.4 Hz), 2.81 - 2.89 (1H, m), 3.05 (3H, s), 3.19 - 3.40 (4H, m), 4.52 (1H, d, J=<br>
15.5 Hz), 5.04 (1H, d, J= 14.8 Hz), 6.13 (1H, dd, J1 = 5.5 Hz, J2 = 3.1 Hz), 6.35 (1H,<br>
dd, J1 = 5.9 Hz, J2 = 2.5 Hz), 7.14 (2H, t, J= 9.1 Hz), 7.34 (2H, dd, J1 = 7.8 Hz, J2 =<br>
5.6 Hz), 7.49 (1H, dd, J1 = 8.8 Hz, J2 = 2.0 Hz), 7.54 - 7.59 (2H, m), 10.16 (1H, s).<br>
LC-MS (ESI) calcd for C25H23FN4O6S2 558.10, found 559.1 [M+H+].<br>
[003001 Example 10: (rac-di-endo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02'7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonarnide<br><br>
a) (rac-di-endo)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1]hept-5-ene-2-carboxylic<br>
acid ethyl ester<br><br>
[00301] (rac-di-endo)-3-Amino-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid ethyl<br>
ester hydrochloride (1 g, 4.6 mmol) was suspended in methanol (23 mL). Sodium<br>
acetate (0.753 g, 9.18 mmol) was added followed by 4Ã powdered molecular sieves<br>
(1 g) and 4-fluoro-benzaldehyde (0.57 g, 4.59 mmol). Sodium cyanoborohydride<br>
(0.577 g, 9.18 mmol) was added and the mixture was stirred at 25 Â°C for 16 h. The<br>
mixture was poured into a 1:1 mixture of saturated aqueous sodium bicarbonate<br>
solution (200 mL) and ethyl acetate (200 mL). The mixture was shaken and the layers<br>
separated. The organic layer was further washed with saturated aqueous brine<br>
solution (50 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to<br>
afford the crude product, (rac-di-endo)-3-(4-fluoro-benzylamino)-bicyclo[2,2,1]hept-<br>
5-ene-2-carboxylic acid methyl ester (1.18 g, 4.08 mmol, 88%), as a clear oil. LC-MS<br>
(ESI) calcd for C17H20FNO2 289.15, found 290.2 [M+H+].<br>
b) (rac-di-endo)-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo [6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00302] (rac-di-endo)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1 ]hept-5-ene-2-<br>
carboxylic acid methyl ester (0.087 g, 0.3 mmol) was dissolved in anhydrous N,N-<br>
dimethylformamide (2.8 mL). (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example 1g, 0.1 g,<br>
0.3 mmol) was added followed by N-methylmorpholine (0.07 mL, 0.63 mmol). The<br>
mixture was stirred until everything dissolved, approximately 5 min. l-(3-<br>
Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.061 g, 0.315 mmol) was<br>
added and the mixture was stirred at 25 Â°C for 45 min. Triethylamine (0.126 mL, 0.9<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h. After cooling to 25<br>
Â°C, the solution was diluted with a 1.0 M aqueous hydrochloric acid solution (8 mL, 8<br>
mmol). The resulting precipitate was collected by vacuum filtration, dissolved in<br>
methanol and concentrated in vacuo to afford the crude product as a beige powder.<br>
Purification by flash column chromatography (Merck silica gel 60, 40-63 Âµm, 0 to<br>
0.75% methanol in dichloromethane) afforded the product as white foam. The foam<br>
was triturated with a 1:1 mixture of diethyl ether and hexanes (6 mL) and the resulting<br>
solid was collected by vacuum filtration. The solid was dried in vacuo for 16 h to<br>
afford the desired product, (rac-di-endo)-N-{3-[3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (69.3 mg, 0.124 mmol, 41%), as a<br>
white powder. 1H NMR (400 MHz, DMSO-d6)d: 1.28 - 1.28 (2H, m), 3.33 - 3.41<br>
(3H, m), 3.92 - 4.00 (1H, m), 4.33 (1H, d, J= 14.7 Hz), 4.96 (1H, d, J= 15.6 Hz),<br>
5.89 - 5.92 (1H, m), 6.11-6.13 (1H, m), 7.10 (2H, t, J= 9.1 Hz), 7.35 (2H, dd, J1 =<br>
8.2 Hz, J2 = 5.9 Hz), 7.43 (1H, dd, J1 = 8.4 Hz, J2 = 2.4 Hz), 7.48 - 7.50 (2H, m),<br>
10.10 (1H, s). LC-MS (ESI) calcd for C25H23FN4O6S2 558.10, found 559.0 [M+H+].<br>
[00303] Example 11: N-(3-[1S,2R,7S,8R)-3-(4-Fluoro-3-methyl-benzyl)-6-<br>
hydroxy-4-oxo-11 -oxa-3 -aza-tricyclo[6.2.1.02'7]undec-5 -en-5 -yl]-1,1 -dioxo-1,4-<br>
dihvdro-1?6-benzo[ 1.2.4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a) (1S,2R,3S,4R)-3-(Methoxycarbonyl)-7-oxabicyclo[2,2,1]heptane-2-carboxylic<br>
acid<br><br>
[00304] exo-4,10-Dioxa-tricyclo[5.2.1.02'6]decane-3,5-dione (5.10 g, 30.3 mmol)<br>
was dissolved in a 1:1 mixture of toluene and carbon tetrachloride (600 mL). The<br>
mixture was cooled to -55 Â°C under a nitrogen atmosphere, and then quinine (10.54 g,<br>
32.5 mmol) was added. Methanol (3.59 mL, 90 mmol) in a 1:1 mixture of toluene<br>
and carbon tetrachloride (30 mL) was slowly added via an addition funnel. The<br>
suspension was stirred at -55 Â°C for 60 h, and then allowed to warm to 25 Â°C. The<br>
mixture was concentrated in vacuo and the residue was dissolved in ethyl acetate (400<br>
mL), washed with a 1.0 M aqueous hydrochloric acid solution (2 Ã 300 mL) and<br>
saturated aqueous brine solution, dried over magnesium sulfate and filtered. The<br>
filtrate was concentrated in vacuo to afford the desired product, (1S,2R,3S,4R)-3-<br>
(methoxycarbonyl)-7-oxabicyclo[2,2,1]heptane-2-carboxylic acid (2.46 g, 12.3 mmol,<br>
41%), as a clear oil. 1H NMR (400 MHz, DMSO-d6)d: 1.49-1.53 (4H, m), 2.99<br>
(2H, s), 3.50 (3H, s), 4.66 (2H, m), 12.15 (1H, s).<br>
b) Methyl (1R,2S,3R,4S)-3-{[(benzyloxy)carbonyl]amino}-7-<br>
oxabicyclo[2,2,1 ]heptane-2-carboxylate<br><br>
[00305] (1S,2R,3S,4R)-3-(Methoxycarbonyl)-7-oxabicyclo[2,2,1 ]heptane-2-<br>
carboxylic acid (2.46 g, 12.3 mmol) was dissolved in anhydrous tetrahydrofuran (35<br>
mL) and cooled to -10 Â°C under a nitrogen atmosphere. Triethylamine (5.13 mL, 36.9<br>
mmol) was added followed by the dropwise addition of ethyl chloroformate (2.35 mL,<br>
24.6 mmol) with vigorous stirring. Immediate precipitation was observed. The<br>
mixture was stirred at -10 Â°C for 1 h. Sodium azide (2.40 g, 36.9 mmol) was<br>
dissolved in water (17 mL) and added to the reaction mixture at -10 Â°C. The mixture<br>
was stirred at -10 Â°C for 15 min, and then was allowed to warm to 25 Â°C and stirred<br>
for 2 h. The mixture was poured into water (100 mL) and extracted with ethyl<br>
acetate. The combined organic layers were washed with saturated aqueous sodium<br>
bicarbonate solution and saturated aqueous brine solution, dried over magnesium<br>
sulfate and filtered. The filtrate was concentrated in vacuo to afford the acyl azide<br>
intermediate as a clear oil. The oil was dissolved in anhydrous benzene (80 mL) and<br>
refluxed for 2 h under a nitrogen atmosphere. The solution was allowed to cool to 25<br>
Â°C, and concentrated in vacuo to afford a yellow oil. The oil was dissolved in<br>
dichloromethane (45 mL), triethylamine (3.46 mL, 24.6 mmol) and benzyl alcohol<br>
(1.27 mL, 12.3 mmol) were added sequentially. The resulting mixture was refluxed<br>
for 16 h under a nitrogen atmosphere. The mixture was allowed to cool to 25 Â°C,<br>
concentrated in vacuo and the residue was purified by flash column chromatography<br>
(Teledyne Isco RediSep column; 0 to 50% ethyl acetate in hexanes) to afford the<br>
desired product, methyl (1R,2S,3R,4S)-3-{[(benzyloxy)carbonyl]amino}-7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (2.23 g, 7.30 mmol, 59%), as a clear oil. 1H<br>
NMR(400 MHz, CDCl3) d: 1.51 (2H, m), 1.72 (1H, m), 1.79 (1H, m), 2.97 (1H, d, J<br>
= 8.4 Hz), 3.56 (3H, s), 4.33 (1H, m), 4.37 (d, 1H, J= 5.6 Hz), 4.78 (1H, d, J= 4.4<br>
Hz), 5.10 (2H, m), 5.42 (1H, d, J= 10.0 Hz), 7.35 (5H, m). LC-MS (ESI) calcd for<br>
C16H19NO5 305.1, found 306.5 [M+H+].<br>
c) Methyl (1R,2S,3R,4S)3-amino-7-oxabicyclo[2,2,1 ]heptane-2-carboxylate<br><br>
[00306] To a solution of methyl (1 R,2S,3R,4S)-3 - {[(benzyloxy)carbonyl]amino} -7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (2.23 g, 7.30 mmol) in ethyl acetate (60 mL),<br>
5% palladium on carbon (0.5 g, 22% by weight) was added. The flask was degassed<br>
and backfilled with hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16<br>
h, passed through a plug of Celite and rinsed with ethyl acetate. The filtrate was<br>
concentrated in vacuo to afford the desired product, methyl (1R,2S,3R,4S)-3-amino-7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (1.0 g, 5.84 mmol, 80%), as a clear oil. 1H<br>
NMR (400 MHz, CDCl3) d: 1.43 (2H, m), 1.67 (1H, m), 1.76 (1H, m), 2.82 (1H, d, J<br>
= 7.6 Hz), 3.41 (1H, d, J= 7.6 Hz), 3.73 (3H, s), 4.28 (1H, d, J= 6.0 Hz), 4.81 (1H, d,<br>
J=4.8 Hz).<br>
d) Methyl (1R,2S,3R,4S)-3-[(4-fluoro-3-methylbenzyl)amino]-7-<br>
oxabicyclo[2,2,1 ]heptane-2-carboxylate<br><br>
1<br>
[00307] To a stirred solution of methyl (1R,2S,3R,4S)-3-amino-7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (400 mg, 2.34 mmol) in methanol (8 mL)<br>
under a nitrogen atmosphere, 4-fluoro-3-methyl-benzaldehyde (0.29 mL, 2.34 mmol)<br>
was added. The mixture was stirred for 10 min, and then acetic acid (0.4 mL) was<br>
added followed by sodium cyanoborohydride (368 mg, 5.85 mmol). The resulting<br>
mixture was stirred at 25 Â°C for 16 h, and then poured into a mixture of saturated<br>
aqueous sodium bicarbonate solution (50 mL) and ethyl acetate (100 mL). The layers<br>
were separated and the aqueous layer was extracted with ethyl acetate. The combined<br>
organic layers were washed with saturated aqueous brine solution, dried over<br>
magnesium sulfate and filtered. The filtrate was concentrated in vacuo to afford the<br>
desired product, methyl (1R,2S,3R,4S)-3-[(4-fluoro-3-methylbenzyl)amino]-7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (610 mg, 2.08 mmol, 80%), as a clear oil. 1H<br>
NMR (400 MHz, CDCl3)d: 1.40 (2H, m), 1.76 (2H, m), 2.27 (3H, d, J= 2.0 Hz), 2.86<br>
(1H, d, J= 7.6 Hz), 3.16 (1H, d, J= 8.4 Hz), 3.64 (1H, d, J= 13.2 Hz), 3.74 (3H, s),<br>
3.79 (1H, d, J= 13.6 Hz), 4.46 (1H, d, J= 5.2 Hz), 4.73 (1H, d, J= 4.8 Hz), 6.92 (2H,<br>
m), 7.07 (2H, m).<br>
e) N- {3 -[(1S,2R,7S,8R)-3 -(4-Fluoro-3 -methyl-benzyl)-6-hydroxy-4-oxo-11 -oxa-3 -<br>
aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1, 1-dioxo-l ,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00308] To a stirred solution of methyl (1R,2S,3R,4S)-3-[(4-fluoro-3-<br>
methylbenzyl)amino]-7-oxabicyclo[2,2,1]heptane-2-carboxylate (100 mg, 0.34 mmol)<br>
and(7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-<br>
yl)-acetic acid (prepared as described in Example 1g, 114 mg, 0.34 mmol) in<br>
anhydrous N,N-dimethylformamide (4 mL) under a nitrogen atmosphere, N-<br>
methylmorpholine (0.075 mL, 0.68 mmol) and l-(3-dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (72 mg, 0.37 mmol) were added sequentially. The<br>
mixture was stirred at 25 Â°C for 2.5 h, poured into 1.0 M aqueous hydrochloric acid<br>
solution, and then was extracted with ethyl acetate. The combined organic layers<br>
were washed with saturated aqueous brine solution, dried over magnesium sulfate and<br>
filtered. The filtrate was concentrated in vacuo to afford the amide intermediate<br>
which was used in the next step without further purification.<br>
[00309] The above intermediate was dissolved in ethanol (5 mL), a 21 wt. %<br>
solution of sodium ethoxide in ethanol (0.5 mL, 1.36 mmol) was added and the<br>
mixture was stirred at 60 Â°C for 30 min. The reaction mixture was cooled to 0 Â°C,<br>
and then 0.3 M aqueous hydrochloric acid solution (10 mL) was slowly added. The<br>
product precipitated upon stirring. The solid was collected by filtration, rinsed with<br>
water, and further purified by prep-HPLC [Column Luna 5Âµ C18 (2) 100A AXIA 150<br>
Ã 21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min flow rate, 0.05%<br>
trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic acid in water] to afford the<br>
desired product, N- {3-[(1S,2R,7S,8R)-3-(4-fluoro-3 -methyl-benzyl)-6-hydroxy-4-oxo-<br>
11-oxa-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (60 mg, 0.10 mmol, 31%), as an<br>
off-white solid. 1HNMR(400 MHz, DMSO-d6)d: 1.50-1.71 (4H, m), 2.21 (3H, d,<br>
J= 2.0 Hz), 3.05 (3H, s), 3.40 (1H, m), 3.78 (1H, d, J= 9.2 Hz), 4.34 (1H, d, J= 15.2<br>
Hz), 4.71 (1H, d, J= 4.8 Hz), 4.76 (1H, d, J= 3.6 Hz), 5.02 (1H, d, J= 15.6 Hz), 7.06<br>
- 7.21 (3H, m), 7.49 (1H, dd, J = 8.4, 2.4 Hz), 7.56 (2H, m). LC-MS (ESI) calcd for<br>
C25H25FN4O7S2 576.1, found 577.5 [M+H+]. Anal, calcd for C25H25FN4O7S2: C,<br>
52.07; H, 4.37; N, 9.72; found: C, 51.75; H, 4.63; N, 9.77.<br>
[00310] Example 12: (rac-di-exo)-N-(3-[3-(4-Fluoro-3-methyl-benzyl)-6-hydroxv-<br>
4-oxo-11-oxa-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1.1 -dioxo-1,4-dihydro-1?6-<br>
benzor[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-3-(4-Fluoro-3-methyl-benzylamino)-7-oxa-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid methyl ester<br><br>
[00311] 4-Fluoro-3-methyl-benzaldehyde (0.14 mL, 1.10 mmol) was added to a<br>
solution of (rac-di-exo)-3-amino-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid<br>
methyl ester (prepared as described in Example 8a, 200 mg, 1.17 mmol) in anhydrous<br>
methanol (10 mL) at 25 Â°C under a nitrogen atmosphere. After stirring for 20 min,<br>
glacial acetic acid (0.3 mL) and sodium cyanoborohydride (184 mg, 2.93 mmol) were<br>
added sequentially, and the resulting mixture was stirred at 25 Â°C for 18 h. The<br>
reaction mixture was poured into saturated aqueous sodium bicarbonate solution and<br>
extracted with ethyl acetate. The combined organic layers were washed with<br>
saturated aqueous brine solution, dried over sodium sulfate and filtered. The filtrate<br>
was concentrated in vacuo to afford the desired product, (rac-di-exo)-3-(4-fluoro-3-<br>
methyl-benzylamino)-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br>
(167 mg, 0.57 mmol, 49%), as a yellow oil. 1H NMR (400 MHz, CDCl3) d: 1.38 -<br>
1.48 (2H, m), 1.65 - 1.82 (2H, m), 2.27 (3H, s), 2.89 (1H, d, J= 7.6 Hz), 3.26 (1H, d,<br>
J= 8.0 Hz), 3.67 (1H, d, J= 13.2 Hz), 3.75 (3H, s), 3.86 (1H, d, J= 13.2 Hz), 4.66<br>
(1H, d, J= 5.2 Hz), 4.71 (1H, d, J= 4.4 Hz), 6.93 (1H, t, J= 9.6 Hz), 7.13 (1H, m),<br>
7.19 (1H, m). LC-MS (ESI) calcd for C16H20FNO3 293.14, found 294.3 [M+H+].<br>
b) (rac-di-exo)-N-{3-[3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-11-oxa-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00312] To a stirred solution of (rac-di-exo)-3-(4-fluoro-3-methyl-benzylamino)-7-<br>
oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (26 mg, 0.08 mmol) in<br>
anhydrous N,N-dimethylformamide (2 mL) under a nitrogen atmosphere, (7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3-yl)-acetic<br>
acid (prepared as described in Example lg, 30 mg, 0.09 mmol), N-methylmorpholine<br>
(22 ÂµL, 0.2 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide<br>
hydrochloride (19 mg, 0.10 mmol) were added sequentially. After stirring at 25 Â°C<br>
for 1.5 h, the reaction mixture was diluted with ethyl acetate, washed with 1.0 M<br>
aqueous hydrochloric acid solution and saturated aqueous brine solution, dried over<br>
sodium sulfate and filtered. The filtrate was concentrated in vacuo to afford the crude<br>
intermediate. The crude amide intermediate was dissolved in absolute ethanol (5<br>
mL), and a 21 wt. % solution of sodium ethoxide in ethanol (0.13 mL, 0.35 mmol)<br>
was added. The mixture was stirred at 60 Â°C for 1 h, and then was allowed to cool to<br>
25 Â°C. A 1.0 M aqueous hydrochloric acid solution (4 mL) was added slowly to the<br>
mixture, and a white solid precipitated upon stirring. The solid was collected by<br>
filtration, rinsed with water and dried in vacuo to afford the desired product, (rac-di-<br>
exo)-N- {3-[3 -(4-fluoro-3 -methyl-benzyl)-6-hydroxy-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02'7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (20 mg, 0.034 mmol, 43%), as an<br>
off-white solid. 1H NMR (400 MHz, DMSO-d6) d: 1.50 -1.70 (4H, m), 2.21 (3H, s),<br>
3.05 (3H, s), 3.78 (1H, d, J= 8.8 Hz), 4.33 (1H, d, J= 15.2 Hz), 4.70 (1H, d, J= 4.4<br>
Hz), 4.76 (1H, d, J= 4.0 Hz), 5.03 (1H, d, J= 14.8 Hz), 7.04 - 7.20 (3H, m), 7.49<br>
(1H, m), 7.56 (2H, m), 10.17 (1H, s). LC-MS (ESI) calcd for C25H251FN4O7S2 576.11,<br>
found 577.3 [M+H+].<br>
[00313] Example 13: (rac-di-exo)-N-{3-[3-(3,3-Dimethyl-butyl)-6-hydroxy-4-oxo-<br>
11 -oxa-3 -aza-tricyclo[6.2.1 .02,7]undec-5-en-5-yl]-1,1 -dioxo-1.4-dihvdro- 1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-3-(3,3-Dimethyl-butylamino)-7-oxa-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid methyl ester<br><br>
[00314] 3,3-Dimethyl-butyraldehyde (120 mg, 1.20 mmol) was added to a solution<br>
of (rac-di-exo)-3-amino-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br>
(prepared as described in Example 8a, 200 mg, 1.17 mmol) in anhydrous methanol<br>
(10 mL) at 25 Â°C under a nitrogen atmosphere. After stirring for 20 min, glacial<br>
acetic acid (0.3 mL) and sodium cyanoborohydride (150 mg, 2.38 mmol) were added<br>
sequentially, and the resulting mixture was stirred at 25 Â°C for 18 h. The reaction<br>
mixture was poured into saturated aqueous sodium bicarbonate solution and was<br>
extracted with ethyl acetate. The combined organic layers were washed with<br>
saturated aqueous brine solution, dried over sodium sulfate and filtered. The filtrate<br>
was concentrated in vacuo to afford the desired product, (rac-di-exo)-3-(3,3-dimethyl-<br>
butylamino)-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (300 mg,<br>
1.17 mmol, 100%), as a yellow oil. 1HNMR (400 MHz, CDCl3)d: 0.91 (9H, s), 1.42<br>
(4H, m), 1.70 - 1.80 (2H, m), 2.46 (1H, m), 2.74 (1H, m), 2.89 (1H, d, J= 8.4 Hz),<br>
3.26 (1H, d, J= 8.0 Hz), 3.71 (3H, s), 4.61 (1H, s), 4.70 (1H, m). LC-MS (ESI) calcd<br>
for C14H25NO3255.18, found 256.2 [M+H+].<br>
b) (rac-di-exo)-3-(3,3-Dimethyl-butyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-11-oxa-3-aza-tricyclo[6.2.1.02,7]undec-<br>
5-en-4-one<br><br>
[00315] To a stirred solution of (rac-di-exo)-3-(3,3-dimethyl-butylamino)-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (200 mg, 0.78 mmol) in<br>
anhydrous N,N-dimethylformamide (4 mL) under a nitrogen atmosphere, (7-iodo-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described<br>
in US patent application US 2008/0031852,287 mg, 0.78 mmol), N-<br>
methylmorpholine (0.2 mL, 1.72 mmol) and l-(3-dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (165 mg, 0.86 mmol) were added sequentially.<br>
After stirring at 25 Â°C for 2.5 h, the reaction mixture was diluted with ethyl acetate,<br>
washed with 1.0 M aqueous hydrochloric acid solution and saturated aqueous brine<br>
solution, dried over sodium sulfate and filtered. The filtrate was concentrated in<br>
vacuo to afford the crude amide intermediate. The above intermediate was dissolved<br>
in absolute ethanol (10 mL), and a 21 wt. % solution of sodium ethoxide in ethanol<br>
(1.17 mL, 3.16 mmol) was added. The mixture was stirred at 60 Â°C for 1 h, and then<br>
was allowed to cool to 25 Â°C. A 1.0 M aqueous hydrochloric acid solution (4 mL)<br>
was added slowly to the mixture, and white solid precipitated upon stirring. The solid<br>
was collected by filtration, rinsed with water and dried in vacuo to afford the desired<br>
product, (rac-di-exo)-3-(3,3-dimethyl-butyl)-6-hydroxy-5-(7-iodo-l,l-dioxo-l,4-<br>
dihydro-1?6-benzo[l ,2,4]thiadiazin-3 -yl)-11 -oxa-3-aza-tricyclo[6.2.1.02'7]undec-5 -en-<br>
4-one (200 mg, 0.35 mmol, 45%), as a yellow solid. 1H NMR (400 MHz, DMSO-d6)<br>
8: 0.93 (9H, s), 1.45 (2H, m), 1.63 (2H, m), 1.71 (2H, m), 1.95 (1H, m), 3.30 (1H, m),<br>
3.84 (1H, m), 3.89 (1H, m), 4.74 (2H, bs), 7.35 (1H, d, J= 8.4 Hz), 7.98 (1H, dd, J=<br>
8.4, 1.6 Hz), 8.07 (1H, d, J= 1.6 Hz). LC-MS (ESI) calcd for C22H26IN3O5S 571.06,<br>
found 572.3 [M+H+].<br>
c) (rac-di-exo)-N- {3-[3-(3,3-Dimethyl-butyl)-6-hydroxy-4-oxo-l l-oxa-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-l,l-dioxo-l,4-dihydro-1?6-<br>
benzo[l,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00316] A reaction flask was charged with copper (I) iodide (20 mg, 0.11 mmol),<br>
sarcosine (N-methyl glycine) (10 mg, 0.11 mmol), methanesulfonamide (83 mg, 0.87<br>
mmol), (rac-di-exo)-3-(3,3-dimethyl-butyl)-6-hydroxy-5-(7-iodo-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-11 -oxa-3-aza-tricyclo[6.2.1.02,7]undec-5 -en-<br>
4-one (100 mg, 0.17 mmol) and potassium phosphate (111 mg, 0.52 mmol). The<br>
flask was degassed and backfilled with nitrogen, and then anhydrous N,N-<br>
dimethylformamide (3 mL) was added. The resulting suspension was vigorously<br>
stirred at 100 Â°C for 16 h, and then allowed to cool to 25 Â°C. The mixture was passed<br>
through a plug of Celite and rinsed with 10% methanol/dichloromethane. The filtrate<br>
was concentrated in vacuo, and the residue was purified by prep-HPLC [Column<br>
Luna 5Âµ C18 (2) 100A AXIA 150 Ã 21.2 mm, 5 micron, 30%-95% in 7 min @ 30<br>
mL/min flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic<br>
acid in water] to afford the desired product, (rac-di-exo)-N-{3-[3-(3,3-dimethyl-<br>
butyl)-6-hydroxy-4-oxo-l 1 -oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (25 mg, 0.046<br>
mmol, 27%), as an off-white solid. 1HMR (400 MHz, DMSO-d6)d: 0.94 (9H, s),<br>
1.48 (2H, m), 1.63 (2H, m), 1.70 (2H, m), 2.97 (1H, m), 3.30 (1H, m), 3.80 - 3.90<br>
(2H, m), 4.75 (2H, s), 7.49 (1H, dd, J= 8.4, 2.4 Hz), 7.56 (2H, m), 10.17 (1H, s). LC-<br>
MS (ESI) calcd for C23H30N4O7S2538.16, found 539.4 [M+H+].<br>
[00317] Example 14: N-(3-[(1S,2R,7S,8R)-3-(4-Fluoro-benzyl)6-hydroxy-4-oxo-<br>
H-oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1.4-dihvdro-1?6-<br>
bereo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-Methyl 3-amino-7-oxabicycIo[2,2,1]heptane-2-carboxylate<br><br>
[00318] To a stirred solution of (rac-di-exo)-3-amino-7-oxa-bicyclo[2,2,1 ]heptane-<br>
2-carboxylic acid (1.0 g, 6.37 mmol) in a 1:1 mixture of anhydrous methanol and<br>
benzene (20 mL), a 2.0 M solution of (trimethylsilyl)diazomethane in hexanes (6.37<br>
mL, 12.7 mmol) was added dropwise. The resulting mixture was stirred for 1 h, and<br>
concentrated in vacuo to afford the desired product, (rac-di-exo)-methyl 3-amino-7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (1.02 g, 5.96 mmol, 94%), as a colorless oil.<br>
1HNMR (400 MHz, CDC3)d: 1.53 (2H, m), 1.62 (2H, m), 2.68 (1H, d, J= 7.6 Hz),<br>
3.27 (1H, d, J = 7.6 Hz), 3.59 (3H, s), 4.14 (1H, d, J= 6.0 Hz), 4.67 (1H, d, J= 4.8<br>
Hz).<br>
b) (rac-di-exo)-Methyl 3-[(4-fluorobenzyl)amino]-7-oxabicyclo[2,2, 1]heptane-2-<br>
carboxylate<br><br>
[00319] 4-Fluoro-benzaldehyde (0.62 mL, 5.85 mmol) was added to a solution of<br>
(rac-di-exo)-methyl 3-amino-7-oxabicyclo[2,2,1]heptane-2-carboxylate (1.02 g, 5.85<br>
mmol) in anhydrous methanol (20 mL) at 25 Â°C under a nitrogen atmosphere. After<br>
stirring for 10 min, glacial acetic acid (0.8 mL) and sodium cyanoborohydride (920<br>
mg, 14.6 mmol) were added sequentially, and the resulting mixture was stirred at 25<br>
Â°C for 18 h. The reaction mixture was poured into saturated sodium bicarbonate<br>
solution and extracted with ethyl acetate. The combined organic layers were washed<br>
with saturated aqueous brine solution, dried over sodium sulfate and filtered. The<br>
filtrate was concentrated in vacuo, and the residue was dried under high vacuum to<br>
afford the desired product, (rac-di-exo)-methyl 3-[(4-fluorobenzyl)amino]-7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (1.40 g, 5.01 mmol, 86%), as a colorless oil.<br>
1HNMR (400 MHz, CDCl3)d: 1.30 - 1.42 (2H, m), 1.73 (2H, m), 2.86 (1H, d, J= 8.0<br>
Hz), 3.15 (1H, d, J= 8.0 Hz), 3.68 (1H, d, J= 13.6 Hz), 3.73 (3H, s), 3.84 (1H, d, J=<br>
13.6 Hz), 4.46 (1H, d, J= 5.2 Hz), 4.73 (1H, d, J= 4.8 Hz), 6.99 (2H, m), 7.26 (2H,<br>
m).<br>
c) Methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]-7-oxabicyclo[2,2,1]heptane-<br>
2-carboxylate<br><br>
[00320] To a stirred solution of (rac-di-exo)-methyl 3 -[(4-fluorobenzyl)amino]-7-<br>
oxabicyclo[2,2,1]heptane-2-carboxylate (210 mg, 0.75 mmol) in ethyl acetate (6 mL),<br>
a solution of (S)-(+)-mandelic acid (57.2 mg, 0.38 mmol) in ethyl acetate (3 mL) was<br>
added dropwise. The clear solution became cloudy and turned into a suspension upon<br>
stirring for 15 min, and stirring was continued for 20 min. The solid was collected by<br>
filtration, rinsed with ethyl acetate and dried in vacuo to afford the desired product in<br>
a mandelic acid salt form (90 mg, 0.21 mmol, 56%) (&gt;96% de, based on 1H NMR<br>
analysis), as a white solid. 1H NMR (400 MHz, CDCl3) d: 1.37 - 1.49 (2H, m), 1.75<br>
(2H, m), 2.88 (1H, d, J= 8.0 Hz), 3.78 (1H, d, J= 7.6 Hz), 3.65 (1H, d, J= 12.8 Hz),<br>
3.72 (3H, s), 3.91 (1H, d, J= 13.2 Hz), 4.62 (1H, d, J= 5.2 Hz), 4.70 (1H, d, J = 4.8<br>
Hz), 5.12 (1H, s), 6.94 (2H, m), 7.19 (2H, m), 7.34 (3H, m), 7.46 (2H, m).<br>
[00321] The above obtained intermediate (90 mg, 0.21 mmol) was suspended in a<br>
1:1 mixture of saturated aqueous sodium bicarbonate solution (5 mL) and ethyl<br>
acetate (5 mL), and stirred for 30 min at 25 Â°C. The layers were separated and the<br>
aqueous layer was extracted with ethyl acetate. The combined organic layers were<br>
washed with saturated aqueous brine solution, dried over magnesium sulfate and<br>
filtered. The filtrate was concentrated in vacuo to afford the free amine, methyl<br>
(1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]-7-oxabicyclo[2,2,1]heptane-2-carboxylate<br>
(56 mg, 0.21 mmol, 95%), as a clear oil. 1H NMR (400 MHz, CDCl3) d: 1.25 - 1.44<br>
(2H, m), 1.64 - 1.82 (2H, m), 2.86 (1H, d, J= 8.0 Hz), 3.15 (1H, d, J= 8.0 Hz), 3.67<br>
(1H, d, J= 13.6 Hz), 3.73 (3H, s), 3.84 (1H, d, J= 13.6 Hz), 4.46 (1H, d, J =5.2 Hz),<br>
4.72 (1H, d, J= 4.8 Hz), 6.99 (2H, m), 7.26 (2H, m).<br>
d) N- {3-[(1S,2R,7S,8R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-l l-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-d1Hydro-1?6-<br>
benzo [ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
[00322] To a stirred solution of methyl (1R,2S,3R,4S)-3-[(4-fluorobenzyl)amino]-<br>
7-oxabicyclo[2,2,1]heptane-2-carboxylate (0.056 g, 0.21 mmol) in anhydrous N,N-<br>
dimethylformamide (3 mL) under a nitrogen atmosphere, (7-methanesulfonylamino-<br>
1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as<br>
described in Example lg, 0.070 g, 0.21 mmol) was added followed by N-<br>
methylmorpholine (0.046 mL, 0.42 mmol) and 1-(3-dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (40 mg, 0.21 mmol). The mixture was stirred at 25<br>
Â°C for 1 h, triethylamine (0.88 mL, 0.63 mmol) was added and the resulting mixture<br>
was stirred at 50 Â°C for 16 h. The reaction mixture was allowed to cool to 25 Â°C,<br>
diluted with ethyl acetate, washed with 1.0M aqueous hydrochloric acid solution and<br>
saturated aqueous brine solution, dried over magnesium sulfate and filtered. The<br>
filtrate was concentrated in vacuo and the residue was purified by prep-HPLC<br>
[Column Luna 5Âµ C18 (2) 100Ã AXIA 150 Ã 21.2 mm, 5 micron, 30%-95% in 7 min<br>
@ 30 mL/min flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05%<br>
trifluoroacetic acid in water] to afford the desired product, N-{3-[(1S,2R,7S,8R)-3-(4-<br>
fluoro-benzyl)-6-hydroxy-4-oxo-11-oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-<br>
1,1-dioxo-1,4-d1Hydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (48 mg,<br>
0.085 mmol, 41%), as an off-white solid. 1H NMR (400 MHz, DMSO-d6) d: 1.51 -<br>
1.71 (4H, m), 3.05 (3H, s), 3.30 (1H, m), 3.79 (1H, d, J= 8.4 Hz), 4.40 (1H, d, J=<br>
15.6 Hz), 4.70 (1H, d, J= 4.8 Hz), 4.76 (1H, d, J= 4.8 Hz), 5.04 (1H, d, J= 14.8 Hz),<br>
7.15 (2H, t, J= 8.4 Hz), 7.33 (2H, m), 7.49 (1H, dd, J= 8.4, 2.4 Hz), 7.55 (2H, m).<br>
LC-MS (ESI) calcd for C24H23FN4O7S2 562.1, found 563.5 [M+H-]. Anal, calcd for<br>
C24H23FN4O7S2: C, 51.24; H, 4.12; N, 9.96; found: C, 51.10; H, 4.51; N, 9.98. ee &gt;<br>
98% [HPLC-analysis: Chiralpak AS-RH 4.6 Ã 250 mm, 5 micron, 0.8 mL/min, 310<br>
nm].<br>
[00323] Example 15: N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-3-methyl-benzyl,-6-<br>
hvdroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) Methyl (1S,2R,3S,4R)-3-(4-fluoro-3-methyl-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylate<br><br>
[00324] Methyl (1S,2R,3S,4R)-3-aminobicyclo[2,2,1 ]heptane-2-carboxylate<br>
hydrochloride (prepared as described in Example 6c, 0.32 g, 1.56 mmol) was<br>
dissolved in methanol (8 mL). Sodium acetate (0.26 g, 3.12 mmol) was added<br>
followed by 4A powdered molecular sieves (0.32 g) and 4-fluoro-3-methyl<br>
benzaldehyde (0.19 mL, 1.56 mmol). Sodium cyanoborohydride (0.24 g, 3.12 mmol)<br>
was added and the mixture was stirred at 25 Â°C for 16 h. The mixture was poured into<br>
a mixture of saturated aqueous sodium bicarbonate solution (20 mL) and ethyl acetate<br>
(30 mL). After shaking, both layers were passed through a plug of Celite. The<br>
organic layer was further washed with saturated aqueous sodium bicarbonate solution<br>
(10 mL), saturated aqueous brine solution (10 mL), dried over magnesium sulfate,<br>
filtered, and concentrated in vacuo to afford the crude product, methyl (1S,2R,3S,4R)-<br>
3-(4-fluoro-3-methyl-benzylamino)-bicyclo[2,2,1]heptane-2-carboxylate (0.35 g, 1.20<br>
mmol, 77%), as a clear oil. LC-MS (ESI) calcd for C17H22FNO2 291.36, found 292.5<br>
[M+H+],<br>
b)7V-{3-[(1R,2S,7R,85)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-d1Hydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
[00325] Methyl (1S,2R,3S,4R)-3-(4-fluoro-3-methyl-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylate (0.090 g, 0.31 mmol) was dissolved in anhydrous<br>
N,N-dimethylformamide (3 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg,<br>
0.10 g, 0.31 mmol) was added followed by N-methylmorpholine (0.071 mL, 0.65<br>
mmol). The mixture was stirred until everything dissolved, approximately 5 min. 1-<br>
(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.062 g, 0.32 mmol)<br>
was added and the mixture was stirred at 25 Â°C for 4 h. Triethylamine (0.13 mL, 0.92<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h. Upon cooling to 25<br>
Â°C, the solution was diluted with ethyl acetate (50 mL) and washed with 1.0 M<br>
aqueous hydrochloric acid solution (2 Ã 50 mL), saturated aqueous brine solution (20<br>
mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
golden oil. Purification by flash column chromatography (Teledyne Isco RediSep<br>
column; 50 to 100% ethyl acetate in hexanes) afforded the desired product, N-{3-<br>
[(1R,2S,7R,8S)-3-(4-fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.12 g, 0.21 mmol, 68%), as a<br>
white powder. 1H NMR (400 MHz, CDCl3) d: 1.43 - 2.85 (9H, m), 2.29 (3H, s), 3.07<br>
(3H, s), 3.45 - 3.47 (1H, m), 5.17 - 5.21 (2H, m), 6.95 - 7.05 (3H, m), 7.59 - 7.66 (3H,<br>
m). LC-MS (ESI) calcd for C26H27FN4O6S2 574.64, found 575.3 [M+H+].<br>
[00326] Example 16: N-{3-[(1R,2S,7R,8S)-3-(3,4-Difluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1.4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) Methyl (1S,2R,3S,4R)-3-(3,4-difluoro-benzylamino)-bicyclo[2,2,1]heptane-2-<br>
carboxylate<br><br>
[00327] Methyl (1S,2R,3S,4R)-3-aminobicyclo[2,2,1]heptane-2-carboxylate<br>
hydrochloride (prepared as described in Example 6c, 0.32 g, 1.58 mmol) was<br>
dissolved in methanol (8 mL). Sodium acetate (0.26 g, 3.16 mmol) was added<br>
followed by 4A powdered molecular sieves (0.33 g) and 3,4-difluoro benzaldehyde<br>
(0.17 mL, 1.58 mmol). Sodium cyanoborohydride (0.22 g, 3.16 mmol) was added<br>
and the mixture was stirred at 25 Â°C for 16 h. The mixture was poured into a mixture<br>
of saturated aqueous sodium bicarbonate solution (20 mL) and ethyl acetate (30 mL).<br>
After shaking, both layers were passed through a plug of Celite. The organic layer<br>
was further washed with saturated aqueous sodium bicarbonate solution (10 mL),<br>
saturated aqueous brine solution (10 mL), dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo to afford the crude product, methyl (1S,2R,3S,4R)-3-(3,4-<br>
difluoro-benzylamino)-bicyclo[2,2,1]heptane-2-carboxylate (0.36 g, 1.22 mmol,<br>
78%), as a clear oil. LC-MS (ESI) calcd for C16H19F2NO2 295.32, found 296.3<br>
[M+rT].<br>
b)N-{3-[(1S,2S,7S,8S))-3-(3,4-Difluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00328] Methyl 1S,2R,3S,4R)-3-(4-fluoro-3-methyl-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylate (0.088 g, 0.30 mmol) was dissolved in anhydrous<br>
N,N-dimethylformamide (3 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg,<br>
0.10 g, 0.30 mmol) was added followed by N-methylmorpholine (0.069 mL, 0.63<br>
mmol). The mixture was stirred until everything dissolved, approximately 5 min. 1 -<br>
(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.060 g, 0.32 mmol)<br>
was added and the mixture was stirred at 25 Â°C for 4 h. Triethylamine (0.12 mL, 0.90<br>
mmol) was added and the mixture was stirred at 50 Â°C for 16 h. Upon cooling to 25<br>
Â°C, the solution was diluted with ethyl acetate (40 mL) and washed with 1.0 M<br>
aqueous hydrochloric acid solution (2 Ã 20 mL), saturated aqueous brine solution (20<br>
mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
golden oil. Purification by flash column chromatography (Teledyne Isco RediSep<br>
column; 50 to 100% ethyl acetate in hexanes) afforded the desired product, N- {3-<br>
[(1R,2S,7R,8S)-3-(3,4-difluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.082 g, 0.14 mmol, 47%), as a<br>
white powder. 1H NMR (400 MHz, CDCl3)d: 1.42 - 1.79 (6H, m), 2.51 - 2.54 (1H,<br>
m), 2.84 - 2.88 (2H, m), 3.07 (3H, s), 3.47 - 3.49 (1H, m), 5.06 - 5.10 (2H, m), 6.95 -<br>
7.18 (3H, m), 7.60 - 7.66 (3H, m). LC-MS (ESI) calcd for C25H24F2N4O6S2 578.61,<br>
found 579.2 [M+H+].<br>
[00329] Example 17: N-(3-[(1R,2S,7R,8S)-3-(3,4-Difluoro-benzyn-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1.4-dihydro-1?6-<br>
benzon[1,2,4]thiadiazin-7-yl}-N-methyl-methanesulfonamide<br><br>
[00330] N-{3-[(1R,2S,7R,8S)-3-(3,4-Difluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
16, 114 mg, 0.20 mmol) was dissolved in N,N-dimethylformamide (7 mL). Potassium<br>
carbonate (55 mg, 0.40 mmol) and iodomethane (0.014 mL, 0.22 mmol) were added<br>
sequentially. The reaction was stirred at 25 Â°C for 18 h. The reaction was quenched<br>
via the addition of 1.0 M aqueous hydrochloric acid solution (20 mL). The mixture<br>
was extracted with ethyl acetate (3 Ã 30 mL). The combined organic layers were<br>
washed with saturated aqueous brine solution (20 mL), dried over magnesium sulfate,<br>
filtered, and concentrated in vacuo to afford a golden oil. Purification by flash<br>
column chromatography (Teledyne Isco RediSep column; 0 to 20% ethyl acetate in<br>
dichloromethane) afforded the desired product, N-{3-[(1R,2S,7R,8S)-3-(3,4-difiuoro-<br>
benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1,02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-<br>
dihydro-l?6-benzo[1,2,4]thiadiazin-7-yl}-N-methyl-methanesulfonamide (94 mg,<br>
0.06 mmol, 77%) as a white powder. 1HNMR (400 MHz, CDCl3)d: 1.42 - 1.76 (6H,<br>
m), 2.51 - 2.54 (1H, m), 2.84 - 2.88 (2H, m), 3.07 (3H, s), 3.38 (3H, s), 3.47 - 3.49<br>
(1H, m), 5.07 - 5.10 (2H, m), 6.96 - 7.16 (3H, m), 7.72 - 8.01 (3H, m). LC-MS (ESI)<br>
calcd for C26H26F2N4O6S2 592.63, found 593.4 [M+H+].<br>
[00331] Example 18: N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-3-methyl-benzyn-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1.1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-N-methyl-methanesulfonamide<br><br>
[00332] N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
15, 92 mg, 0.16 mmol) was dissolved in N,N-dimethylformamide (6 mL). Potassium<br>
carbonate (44 mg, 0.32 mmol) and iodomethane (0.011 mL, 0.18 mmol) were added<br>
sequentially. The reaction was stirred at 25 Â°C for 18 h. The reaction was quenched<br>
via the addition of 1.0 M aqueous hydrochloric acid solution (20 mL). The mixture<br>
was extracted with ethyl acetate (3 Ã 30 mL). The combined organic layers were<br>
washed with saturated aqueous brine solution (20 mL), dried over magnesium sulfate,<br>
filtered, and concentrated in vacuo to afford a golden oil. Purification by flash<br>
column chromatography (Teledyne Isco RediSep column; 0 to 20% ethyl acetate in<br>
dichloromethane) afforded the desired product, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-3-<br>
methyl-benzyl)-6-hydroxy-4-oxo-3 -aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -<br>
dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide<br>
(91 mg, 0.15 mmol, 96%), as a white powder. 1H NMR (400 MHz, CDCl3) d: 1.18 -<br>
2.85 (9H, m), 2.90 (3H, s), 2.97 (3H, s), 3.38 (3H, s), 3.45 - 3.47 (1H, m), 5.17 - 5.21<br>
(2H, m), 6.96 - 7.08 (3H, m), 7.72 - 8.02 (3H, m). LC-MS (ESI) calcd for<br>
C27H29FN4O6S2 588.67, found 589.2 [M+H+].<br>
[00333] Example 19: (1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-5-(7-iodo-1.1-<br>
dioxo-1.4-dihydro-l?6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undec-5-<br>
en-4-one<br><br>
[00334] N,N-diisopropylethylamine (1.79 mL, 10.3 mmol) and (benzotriazol-<br>
lyloxy)-tris(dimethylamino)-phosphoniumhexafluorophosphate (1.52 g, 3.44 mmol)<br>
were added sequentially to a solution of (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (prepared as described in Example<br>
61, 1.0 g, 3.43 mmol) and (7-iodo-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-<br>
3-yl)-acetic acid (prepared as described in US patent application US 2008/0031852,<br>
1.26 g, 3.44 mmol) in N,N-dimethylformamide (25 mL) at 25 Â°C. The resulting<br>
solution was stirred at 25 Â°C for 19 h, and then was concentrated in vacuo. The<br>
residue was partitioned between 1.0 M aqueous hydrochloric acid solution (150 mL)<br>
and ethyl acetate (2 Ã 150 mL). The organic layers were dried over sodium sulfate,<br>
filtered and concentrated in vacuo. The resulting orange oil was dissolved in ethanol<br>
(50 mL) at 25 Â°C. A 21 wt. % solution of sodium ethoxide in ethanol (3.33 mL, 10.3<br>
mmol) was added and the reaction mixture was heated at 60 Â°C for 3 h. After cooling<br>
to 25 Â°C, the reaction mixture was concentrated in vacuo to approximately 5 mL<br>
volume and was then partitioned between 1.0 M aqueous hydrochloric acid solution<br>
(150 mL) and ethyl acetate (2 Ã 150 mL). The organic layers were dried over sodium<br>
sulfate, filtered and concentrated in vacuo. The residue was purified by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 60% ethyl acetate in hexanes)<br>
to afford the desired product, (1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-<br>
1,1-dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-3-yl)-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (1.0 g, 1.69 mmol, 49%), as apale yellow foam.<br>
1HNMR(400 MHz, DMSO-d6) d: 1.15 - 1.21 (3H, m), 1.38 - 1.41 (1H, m), 1.46 -<br>
1.61 (3H, m), 2.62 (1H, d, J= 2.4 Hz), 2.98 (1H, d, J= 9.4 Hz), 3.52 (1H, d, J= 9.3<br>
Hz), 4.40 (1H, d, J= 15.7 Hz), 4.95 (1H, d, J= 15.6 Hz), 7.14 (2H, d, J= 17.9 Hz),<br>
7.11 - 7.16 (2H, m), 7.30 - 7.34 (3H, m), 7.97 (1H, dd, J1 = 2.3 Hz, J2 = 8.6 Hz), 8.07<br>
(1H, d, J= 1.5 Hz). LC-MS (ESI) calcd for C24H21FIN3O4S 593.03, found 594.2<br>
[M+H+].<br>
[00335] Example 20: (1R,2S,7R,8S)-5-[7-(1,1-Dioxo-4,5-dihydro-1H-1?6-<br>
thiophen-2-vl)- 1.1 -dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3 -yl]-3-(4-fluoro-<br>
benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02'7]undec-5-en-4-one<br><br>
[00336] To a solution of (1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-<br>
1,1 -dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-3-yl)-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (prepared as described in Example 19, 200 mg,<br>
0.34 mmol) and tributyl-(l,l-dioxo-4,5-dihydro-lH-l?6-thiophen-2-yl)-stannane<br>
(prepared as described in US patent application US 2008/0031852, 180 mg, 0.44<br>
mmol) in anhydrous N,N-dimethylformamide (7 mL) under a nitrogen atmosphere,<br>
Pd(PPh3)4 (20 mg, 0.017 mmol) was added. The resulting mixture was stirred at 90<br>
Â°C for 22 h, and then allowed to cool to 25 Â°C. The reaction mixture was<br>
concentrated in vacuo and the residue was purified by prep-HPLC [Column Luna 5Âµ<br>
C18 (2) 100Ã AXIA 150 Ã 21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min<br>
flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic acid in<br>
water] to afford the desired product, (1R,2S,7R,8S)-5-[7-(l,l-dioxo-4,5-dihydro-1H-<br>
1?6-thiophen-2-yl)-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-<br>
fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one (38 mg, 0.065<br>
mmol, 20%), as an off-white solid. 1HNMR (400 MHz, DMSO-d6)d: 1.19 (2H, m),<br>
1.42 - 1.61 (4H, m), 2.50 (1H, m), 2.65 (1H, m), 2.97 (2H, m), 3.05 (1H, m), 3.53<br>
(3H, m), 4.43 (1H, d, J= 14.4 Hz), 4.96 (1H, d, J= 15.6 Hz), 7.15 (2H, m), 7.33 (2H,<br>
m), 7.41 (1H, t, J= 3.6 Hz), 7.66 (1H, d, J= 9.2 Hz), 7.96 (1H, dd, J= 8.8, 2.4 Hz),<br>
8.10 (1H, d, J=2.4 Hz). LC-MS (ESI) calcd for C28H26FN3O6S2 583.12, found 584.2<br>
[M+H+].<br>
[00337] Example 21: (1R,2S,7R,8S)-5-[7-(1,1-Dioxo-tetrahydro-1?6-thiophen-2-<br>
yl)- 1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl]-3 -(4-fluoro-benzyl)-6-<br>
hydroxy-3-aza-tricyclo[6.2.1.02'7]undec-5-en-4-one<br><br>
[00338] (1R,2S,7R,8S)-5-[7-(l,l-Dioxo-4,5-dihydro-1H-1?6-thiophen-2-yl)-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluoro-benzyl)-6-hydroxy-3-<br>
aza-tricyclo[6.2.1.02'7]undec-5-en-4-one (prepared as described in Example 20, 30<br>
mg, 0.05 mmol) was dissolved in methanol (15 mL) and 5% palladium on charcoal<br>
(100 mg) was added. The flask was degassed and backfilled with hydrogen gas via<br>
balloon. The mixture was stirred at 25 Â°C for 16 h. The mixture was passed through a<br>
plug of Celite, rinsed with 10% methanol/dichloromethane, and the filtrate was<br>
concentrated in vacuo. The residue was purified by prep-HPLC [Column Luna 5Âµ<br>
C18 (2) 100A AXIA 150 Ã 21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min<br>
flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic acid in<br>
water] to afford the desired product, (1R,2S,7R,8S)-5-[7-(l,l-dioxo-tetrahydro-1?6-<br>
thiophen-2-yl)-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl]-3-(4-fluoro-<br>
benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one (26 mg, 0.044 mmol,<br>
86%), as a white powder. 1H NMR (400 MHz, DMSO-d6) d: 1.19 (2H, m), 1.40 -<br>
1.60 (4H, m), 2.12 (1H, m), 2.67 (1H, m), 2.36 (1H, m), 2.50 (1H, m), 2.65 (1H, m),<br>
3.03 (1H, m), 3.23 (1H, m), 3.32 (1H, m), 3.53 (1H, d, J= 10.0 Hz), 4.42 (1H, d, J=<br>
15.2 Hz), 4.56 (1H, dd, J= 11.6, 6.8 Hz), 4.97 (1H, d, J= 15.6 Hz), 7.14 (2H, m),<br>
7.33 (2H, m), 7.58 (1H, d, J= 8.8 Hz), 7.69 (1H, dd, J= 8.8, 2.4 Hz), 7.82 (1H, d, J=<br>
2.4 Hz); LC-MS (ESI) calcd for C28H28FN3O6S2 585.14, found 586.3 [M+H+].<br>
[00339] Example 22: (1R,2S,7R,8S)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7lundec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a)(1S,2R,3S,4R)-3-(3-Methyl-butylamino)-bicyclo[2,2,1]heptane-2-carboxylic<br>
acid ethyl ester<br><br>
[00340] (1S,2R,3S,4R)-3-Amino-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl<br>
ester (prepared as described in Example 6k, 0.5 g, 2.7 mmol) was dissolved in<br>
methanol (25 mL). Isovaleraldehyde (0.233 g, 2.7 mmol) was added followed by<br>
acetic acid (1 mL). The solution continued to stir at 25 Â°C for 10 min. Sodium<br>
cyanoborohydride (0.424 g, 6.75 mmol) was added and the mixture was stirred at 25<br>
Â°C for 5 h. The mixture was poured into aqueous half-saturated aqueous sodium<br>
bicarbonate solution (100 mL). The aqueous layer was extracted with ethyl acetate (2<br>
Ã 100 mL). The organic layer was dried over sodium sulfate, filtered, and<br>
concentrated in vacuo to afford the crude product, (1S,2R,3S,4R)-3-(3-methyl-<br>
butylamino)-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (0.43 g, 1.7 mmol,<br>
63%), as a light yellow oil, which was used in the next step without any further<br>
purification. LC-MS (ESI) calcd for C15H27NO2 253.2, found 254.1 [M+H+].<br>
b) (1S,2R,3S,4R)-3-[[2-(7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid ethyl ester<br><br>
[00341] (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.216<br>
g, 0.649 mmol) was dissolved in anhydrous N,N-dimethylformamide (5 mL).<br>
((1S,2R,3S,4R)-3-(3-Methyl-butylamino)-bicyclo[2,2,1]heptane-2-carboxylic acid<br>
ethyl ester (0.164 g, 0.649 mmol) was added followed by l-(3-dimethylaminopropyl)-<br>
3-ethylcarbodiimide hydrochloride (0.13 g, 0.681 mmol). Then N-methylmorpholine<br>
(0.138 g, 1.36 mmol) was added into the above reaction mixture. The mixture was<br>
stirred at 25 Â°C for 4 h. The solution was poured into 1.0 M aqueous hydrochloric<br>
acid solution (100 mL). The aqueous layer was extracted with ethyl acetate (2 Ã 100<br>
mL). The organic layer was dried over magnisium sulfate, filtered, and concentrated<br>
in vacuo to afford the crude product, (1S,2R,3S,4R)-3-[[2-(7-methanesulfonylamino-<br>
1,1 -dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-3-yl)-acetyl]-(3 -methyl-butyl)-<br>
amino]-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester, as a light yellow oil,<br>
which was used in the next step without any further purification. LC-MS (ESI) calcd<br>
for C25H36N4O7S2 568.2, found 569.5 [M+H+].<br>
c) (1R,2S,7R,8S)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00342] The crude (1S,2R,3S,4R)-3-[[2-(7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetyl]-(3 -methyl-butyl)-amino]-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester was dissolved in ethanol (7 mL)<br>
and a 21 wt. % solution of sodium ethoxide in ethanol (1.15 mL, 3.25 mmol) was<br>
added into the above solution. The mixture was stirred at 60 Â°C for 4 h and cooled<br>
down to 25 Â°C. The mixture was poured into 0.5 M aqueous hydrochloric acid<br>
solution (100 mL). The aqueous layer was extracted with ethyl acetate (2 Ã 100 mL).<br>
The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo<br>
to afford the crude product, which was purified by flash column chromatography<br>
(Teledyne Isco RediSep column; 100% ethyl acetate) to afford the desired product,<br>
(1R,2S,7R,8S)-N-{3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[l,2,4]thiadiazin-7-yl}-methanesulfonamide (0.19 g, 0.364 mmol, 56.1% over<br>
two steps), as an off-white solid. 1H NMR (400 MHz, DMSO-d6) d: 0.89 - 0.93 (6H,<br>
m), 1.16 - 1.23 (2H, m), 1.28 -1.32 (1H, m), 1.35 -1.62 (7H, m), 1.99 - 1.99 (1H, m),<br>
2.52 - 2.54 (1H, m), 2.63 (1H, bs), 3.06 (3H, s), 3.62 - 3.72 (2H, m), 7.50 (1H, dd, J1<br>
= 8.9 Hz, J2 = 2.2 Hz), 7.57 - 7.59 (2H, m), 10.17 (1H, s). LC-MS (ESI) calcd for<br>
C23H30N4O6S2 522.16, found 523.6 [M+H+].<br>
[00343] Example 23: (rac-di-exo)-N-{3-[3-(2-Cyclopropyl-ethyl)-6-hydroxy-4-<br>
oxo-1 l-oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1.4-dihydro-l?6-<br>
benzo [ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a) Cyclopropylacetaldehyde<br><br>
[00344] To a 2.0 M solution of oxalyl chloride in dichloromethane (9.8 mL, 19.6<br>
mmol) at -78 Â°C was added dimethyl sulfoxide dropwise. After stirring for 15 min at<br>
-78 Â°C, a solution of cyclopropylethyl alcohol (1.5 g, 17.4 mmol) in dichloromethane<br>
(3.5 mL) was added. After stirring for an additional 1 h, triethylamine (13.8 mL, 98.3<br>
mmol) was added. The reaction mixture was allowed to warm to 25 Â°C and diluted<br>
with water. The organic layer was separated and the aqueous layer was extracted with<br>
dichloromethane (3 Ã 50 mL). The combined organic layers were dried over<br>
anhydrous magnesium sulfate and concentrated in vacuo at 0 Â°C to afford the crude<br>
cyclopropylacetaldehyde, which was used in the next step without further purification.<br>
1HNMR (400 MHz, CDCl3) d 0.19 (2H, dd, J1 = 10.3 Hz, J2 = 5.2 Hz), 0.62 (2H, dd,<br>
J1 = 13.2 Hz, J2 = 5.3 Hz), 1.03 - 0.97 (1H, m), 2.30 (2H, d, J= 5.1 Hz), 9.79 (1H, d,<br>
J=1.7Hz).<br>
b) (rac-di-exo)-3-(2-Cyclopropyl-ethylamino)-7-oxa-bicyclo[2.2.1 ]heptane-2-<br>
carboxylic acid methyl ester<br><br>
[00345] Cyclopropylacetaldehyde (148 mg, 1.75 mmol) was added to a solution of<br>
(rac-di-exo)-3-amino-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br>
(prepared as described in Example 8a, 300 mg, 1.75 mmol) in anhydrous methanol<br>
(10 mL) at 25 Â°C under a nitrogen atmosphere. After stirring for 20 min, glacial<br>
acetic acid (0.3 mL) and sodium cyanoborohydride (150 mg, 2.38 mmol) were added<br>
sequentially, and the resulting mixture was stirred at 25 Â°C for 18 h. The reaction<br>
mixture was poured into saturated aqueous sodium bicarbonate solution and was<br>
extracted with ethyl acetate. The combined organic layers were washed with<br>
saturated aqueous brine solution, dried over sodium sulfate and filtered. The filtrate<br>
was concentrated in vacuo to afford the desired product, (rac-di-exo)-3-(2-<br>
cyclopropyl-ethylamino)-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br>
(220 mg, 0.92 mmol, 53%), as a yellow oil. 1HNMR (400 MHz, CDCl3) d: 0.19 (2H,<br>
m), 0.52 (2H, m), 0.70 (1H, m), 1.65 - 2.00 (6H, m), 3.10 (1H, d, J= 8.4 Hz), 3.23<br>
(2H, m), 3.82 (3H, s), 3.93 (1H, m), 4.90 (1H, d, J= 4.8 Hz), 5.17 (1H, d, J= 5.2 Hz).<br>
c) (rac-di-exo)-N-{3-[3-(2-Cyclopropyl-ethyl)-6-hydroxy-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00346] To a stirred solution of (rac-di-exo)-3-(2-cyclopropyl-ethylamino)-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (120 mg, 0.50 mmol) in<br>
anhydrous N, N-dimethylformamide (2 mL) under a nitrogen atmosphere, (7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetic<br>
acid (prepared as described in Example lg, 107 mg, 0.32 mmol), N-methylmorpholine<br>
(0.12 mL, 1.09 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide<br>
hydrochloride (105 mg, 0.55 mmol) were added sequentially. After stirring at 25 Â°C<br>
for 2 h, the reaction mixture was diluted with ethyl acetate, washed with 1.0 M<br>
aqueous hydrochloric acid solution and saturated aqueous brine solution, dried over<br>
sodium sulfate and filtered. The filtrate was concentrated in vacuo to afford the crude<br>
intermediate. The crude amide intermediate was dissolved in absolute ethanol (5<br>
mL), and a 21 wt. % solution of sodium ethoxide in ethanol (0.8 mL, 2.16 mmol) was<br>
added. The mixture was stirred at 60 Â°C for 2 h, and then was allowed to cool to 25<br>
Â°C. A 0.5 M aqueous hydrochloric acid solution (10 mL) was added, and then the<br>
mixture was extracted with ethyl acetate, washed with saturated aqueous brine<br>
solution, dried over sodium sulfate and filtered. The filtrate was concentrated in<br>
vacuo and the residue was purified by prep-HPLC [Column Luna 5Âµ C18 (2) 100A<br>
AXIA 150 Ã 21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min flow rate, 0.05%<br>
trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic acid in water] to afford the<br>
desired product, (rac-di-exo)-N-{3-[3-(2-cyclopropyl-ethyl)-6-hydroxy-4-oxo-11-oxa-<br>
3 -aza-tricyclo [6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (25 mg, 0.048 mmol, 15%), as a<br>
yellow solid. 1H NMR (400 MHz, DMSO-d6) d: 0.07 (2H, m), 0.41 (2H, m), 0.70<br>
(1H, m), 1.37 - 1.72 (6H, m), 3.05 (3H, s), 3.07 (1H, m), 3.30 (m, 1H), 3.92 (2H, m),<br>
4.74 (2H, m), 7.49 (1H, m), 7.55 (2H, m), 10.16 (1H, s). LC-MS (ESI) calcd for<br>
C22H26N4O7S2522.12, found 523.4 [M+H+].<br>
[00347] Example 24: (1R,2S,7R,8S)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-<br>
aza-tricvclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide<br><br>
(1R,2S,7R,8S)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
22, 90 mg, 0.172 mmol) was dissolved in anhydrous N,N-dirnethylformamide (2 mL).<br>
Potassium carbonate (0.04 g, 0.344 mmol) was added followed by iodomethane<br>
(0.027 g, 0.189 mmol). The mixture was stirred at 25 Â°C for 5 h. The reaction<br>
mixture was extracted with ethyl acetate (2 Ã 100 mL) and water (100 mL). The<br>
organic layer was washed with saturated aqueous brine solution (50 mL), dried over<br>
sodium sulfate and filtered. The filtrate was concentrated in vacuo to afford the crude<br>
product, which was purified by flash column chromatography (Teledyne Isco RediSep<br>
column; 40% ethyl acetate in hexanes) to afford the desired product, (1R,2S,7R,8S)-N-<br>
{3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-<br>
1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-7-yl} -N-methyl-<br>
methanesulfonamide (0.052 g, 0.097 mmol, 56.4%), as a white solid. 1H NMR (400<br>
MHz, DMSO-d6) d: 0.92 (6H, d, J= 6.4 Hz), 1.21 - 1.26 (1H, m), 1.28 - 1.33 (1H, m),<br>
1.39 - 1.63 (7H, m), 2.54 (1H, bs), 2.63 - 2.67 (1H, m), 3.00 (3H, s), 3.06 - 3.17 (1H,<br>
m), 3.29 (3H, s), 3.63 - 3.72 (2H, m), 7.62 (1H, d, J= 8.5 Hz), 7.70 - 7.73 (1H, m),<br>
7.85 (1H, s). LC-MS (ESI) calcd for C24H32N4O6S2 536.18, found 537.6.6 [M+H+].<br>
[00348] Example 25: (rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-11-<br>
oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yll-1,1-dioxo-1.4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a) (rac-di-exo)-3-(3-Methyl-butylamino)-7-oxa-bicyclo[2,2,1 ]heptane-2-<br>
carboxylic acid methyl ester<br><br>
[00349] (rac-di-exo)-3-amino-7-oxa-bicyclo[2,2,1 ]heptane-2-carboxylic acid<br>
methyl ester (prepared as described in Example 8a, 0.4 g, 2.34 mmol) was dissolved<br>
in methanol (20 mL). Isovaleraldehyde (0.202 g, 2.34 mmol) was added followed by<br>
acetic acid (1 mL). The solution continued to stir at 25 Â°C for 10 min. Sodium<br>
cyanoborohydride (0.37 g, 5.85 mmol) was added and the mixture was stirred at 25 Â°C<br>
for 16 h. The mixture was poured into a half-saturated aqueous sodium bicarbonate<br>
solution (150 mL). The aqueous layer was extracted with ethyl acetate (2 Ã 150 mL).<br>
The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo<br>
to afford the crude product, (rac-di-ero)-3-(3-methyl-butylamino)-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (0.3 g, 2.34 mmol, 53.1%), as a<br>
clear oil. LC-MS (ESI) calcd for C13H23NO3 241.17, found 242.4 [M+H+].<br>
b) (rac-di-exo)-3 -[[2 -(7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br><br>
[00350] (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.211<br>
g, 0.696 mmol) was dissolved in anhydrous N,N-dimethylformamide (6 mL). (rac-di-<br>
exo)-3-(3-Methyl-butylamino)-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl<br>
ester (0.168 g, 0.696 mmol) was added followed by l-(3-dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (0.14 g, 0.731 mmol). Then N-methylmorpholine<br>
(0.148 g, 1.46 mmol) was added into the above reaction mixture. The mixture was<br>
stirred at 25 Â°C for 5 h. The solution was poured into 1.0 M aqueous hydrochloric<br>
acid solution (100 mL). The aqueous layer was extracted with ethyl acetate (2 Ã 100<br>
mL). The organic layer was dried over sodium sulfate, filtered, and concentrated in<br>
vacuo to afford the crude product, (rac-di-exo)-3-[[2-(7-methanesulfonylamino-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-<br>
7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester, as a light yellow oil,<br>
which was used in the next step without any further purification. LC-MS (ESI) calcd<br>
for C23H32N4O8S2 556.17, found 557.4 [M+H+].<br>
c) (rac-di-exo)-N- {3 - [6-Hydroxy-3 -(3 -methyl-butyl)-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo [ 1,2,4]thiadiazin-7 -yl} -methanesulfonamide<br><br>
[00351] The crude (rac-di-exo)-3-[[2-(7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetyl]-(3 -methyl-butyl)-amino]-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester was dissolved in ethanol (7 mL),<br>
and a 21 wt. % solution of sodium ethoxide in ethanol (1.3 mL, 3.48 mmol) was<br>
added into the above solution. The mixture was stirred at 60 Â°C for 4 h and cooled<br>
down to 25 Â°C. The mixture was poured into 0.5 M aqueous hydrochloric acid<br>
solution (100 mL). The aqueous layer was extracted with ethyl acetate (2 Ã 100 mL).<br>
The organic layer was dried over sodium sulfate, filtered, and concentrated in vacuo<br>
to afford the crude product, which was purified by flash column chromatography<br>
(Teledyne Isco RediSep column; 100% ethyl acetate) to afford the desired product,<br>
(rac-di-exo)-N-{3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6 benzo[1,2,4]thiadiazin-<br>
7-yl}-methanesulfonamide (0.07 g, 0.133 mmol, 19.2% over two steps), as a light<br>
yellow solid. 1H NMR (400 MHz, DMSO-d6)d: 0.92 (6H, d, J= 5.5 Hz), 1.06 - 1.31<br>
(2H, m), 1.40 - 1.72 (6H, m), 3.05 (3H, s), 3.17 - 3.22 (1H, m), 3.80 - 3.87 (2H, m),<br>
4.72 - 4.73 (2H, m), 7.47 - 7.55 (3H, m), 10.12 (1H, bs). LC-MS (ESI) calcd for<br>
C22H28N4O7S2 524.14, found 525.4 [M+H+].<br>
[00352] Example 26: (1R,2S,7R,8S)-5-[7-(1,1-Dioxo-1?6-isothiazohdin-2-yl)-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluoro-benzyn-6-hydroxy-3-<br>
aza-tricyclo[6.2.1.02,71undec-5-en-4-one<br><br>
[00353] A reaction flask was charged with copper (I) iodide (8 mg, 0.042<br>
mmol), sarcosine (N-methyl glycine) (9 mg, 0.1 mmol), isothiazolidine 1,1-dioxide<br>
(204 mg, 1.685 mmol), (1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undec-5-<br>
en-4-one (prepared as described in Example 19, 100 mg, 0.168 mmol) and potassium<br>
phosphate (179 mg, 0.842 mmol). The flask was degassed and backfilled with<br>
nitrogen, and then anhydrous N,N-dimethylformamide (3 mL) was added. The<br>
resulting suspension was vigorously stirred at 100 Â°C for 17 h, and then allowed to<br>
cool to 25 Â°C. The mixture was diluted with ethyl acetate (30 mL) and washed with<br>
1.0 M aqueous hydrochloric acid solution (2 Ã 20 mL) and saturated aqueous brine<br>
solution (40 mL). The organic layer was dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo. Purification by flash column chromatography (Teledyne Isco<br>
RediSep column; 1st column: 100% dichloromethane, 2nd column: 5% hexanes in<br>
dichloromethane) to afford the desired product. The crude product was triturated with<br>
absolute ethanol (3 Ã) and dried in vacuo at 60 Â°C to afford the desired product,<br>
(1R,2S,7R,8S)-5-[7-(1, 1 -dioxo-1?6-isothiazolidin-2-yl)-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (70 mg, 0.119 mmol, 71%), as a solid. 1H NMR<br>
(400 MHz, DMSO-d6) d: 1.17 -1.24 (2H, m), 1.40 - 1.61 (4H, m), 2.39 - 2.46 (2H,<br>
m), 2.51 - 2.54 (1H, m), 2.64 - 2.65 (1H, m), 3.03 - 3.05 (1H, m), 3.53 - 3.60 (3H, m),<br>
3.83 (2H, t, J= 6.3 Hz), 4.43 (1H, d, J= 15.4 Hz), 4.97 (1H, d, J= 15.6 Hz), 7.15<br>
(2H, t, J= 9.0 Hz), 7.32 - 7.35 (2H, m), 7.51 - 7.54 (2H, m), 7.62 (1H, d, J= 8.5 Hz).<br>
LC-MS (ESI) calcd for C27H27FN4O6S2 586.14, found 587.4 [M+H+].<br>
[00354] Example 27: (1R,2S,7R,8S)-N-[3-(6-Hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7lundec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzon[1,2,4]thiadiazin-7-yll-methanesulfonamide<br><br>
[00355] A suspension of (1S,2R,3S,4R)-3-ethoxycarbonyl-bicyclo[2,2,1 ]hept-2-yl-<br>
aminium (1 'S)-(+)-10-camphorsulfonate (prepared as described in Example 6j, 5.00 g,<br>
12.0 mmol) and potassium carbonate (4.16 g, 30.1 mmol) in ethyl acetate (80 mL)<br>
was stirred at 25 Â°C for 5 h, then was filtered through a medium frit. The filtrate was<br>
concentrated in vacuo to afford the crude (1S,2R,3S,4R)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (2.14 g). A portion of this<br>
material (1.00 g, 5.52 mmol) and (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg,<br>
1.84 g, 5.52 mmol) were dissolved in N,N-dimethylformamide at 25 Â°C and l-(3-<br>
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.11 g, 5.79 mmol) and N-<br>
methylmorpholine (1.27 mL, 11.6 mmol) were added sequentially. The resulting<br>
solution was stirred at 25 Â°C for 22 h, and then was concentrated in vacuo. The<br>
residue was partitioned between 1.0 M aqueous hydrochloric acid solution (200 mL)<br>
and ethyl acetate (2 Ã 150 mL). The organic layers were dried over sodium sulfate,<br>
filtered and concentrated in vacuo. The resulting orange oil was dissolved in ethanol<br>
(70 mL) at 25 Â°C. A 21 wt. % solution of sodium ethoxide in ethanol (10.7 mL, 33.0<br>
mmol) was added and the reaction mixture was heated at 90 Â°C for 3 d. After cooling<br>
to 25 Â°C, the reaction mixture was concentrated in vacuo to a volume of<br>
approximately 5 mL and was then partitioned between 1.0 M aqueous hydrochloric<br>
acid solution (200 mL) and ethyl acetate (2 Ã 150 mL). The organic layers were dried<br>
over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by<br>
flash column chromatography (Teledyne Isco RediSep column; 0 to 7% methanol in<br>
dichloromethane) to afford the desired product, (1R,2S,7R,8S)-N-[3-(6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide (0.25 g, 0.552 mmol, 10%), as a<br>
white solid. 1HNMR(400 MHz, DMSO-d6)d: 1.17 - 1.22 (2H, m), 1.39 -1.58 (3H,<br>
m), 2.24 (1H, bs), 2.32 (1H, bs), 2.64 - 2.66 (1H, m), 2.84 - 2.87 (1H, m), 3.04 (3H,<br>
s), 3.54 (1H, bs), 3.63 (1H, bs), 7.49 (2H, bs), 7.55 (1H, bs), 8.11 (1H, bs), 9.52 (1H,<br>
bs), 10.12 (1H, bs). LC-MS (ESI) calcd for C18H20N4O6S2 452.08, found 453.2<br>
[M+H+].<br>
[00356] Example 28: (1R,2S,7R,8S)-5-(1,1-Dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.027]undec-5-en-4-one<br><br>
a) N-(2-Sulfamoyl-phenyl)-malonamic acid ethyl ester<br><br>
[00357] 2-Amino-benzenesulfonamide (5 g, 29 mmol) was dissolved in N,N-<br>
dimethylacetamide (25 mL) and diethyl ether (25 mL). Ethyl-3-chloro-3-oxo-<br>
propionate (4.6 g, 30.45 mmol) was added into the above reaction solution. The<br>
reaction mixture was stirred at 25 Â°C for 3 h. The product started to precipitate and<br>
was collected by vacuum filtration. The solid was dissolved in ethyl acetate (200 mL)<br>
and extracted with water (200 mL). The aqueous layer was back-extracted with ethyl<br>
acetate (200 mL). The combined organic layers were dried over sodium sulfate,<br>
filtered, and concentrated in vacuo to afford the crude product, iV-(2-sulfamoyl-<br>
phenyl)-malonamic acid ethyl ester, as a white solid, which was used in the next step<br>
without further purification. 1H NMR (400 MHz, DMSO-d6)d: 1.23 (3H, t, J= 7.0<br>
Hz), 3.61 (2H, s), 4.14 (2H, quartet, J= 7.0 Hz), 7.29 - 7.33 (1H, m), 7.53 (2H, bs),<br>
7.56 - 7.60 (1H, m), 7.84 - 7.86 (1H, m), 7.97 - 7.99 (1H, m), 9.54 (1H, bs). LC-MS<br>
(ESI) calcd for C11H14N2O5S 286.06, found 287.1 [M+H+]<br>
b)(1,1-Dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid<br><br>
[00358] Solid sodium hydroxide (3.48 g, 87 mmol) was dissolved in water to make<br>
a saturated solution. The crude N-(2-sulfamoyl-phenyl)-malonamic acid ethyl ester<br>
was added into the sodium hydroxide solutioa The reaction mixture was heated at<br>
110 Â°C for 2.5 h, and then was cooled down to 25 Â°C. The reaction mixture was<br>
acidified by slowly adding a 12.0 M aqueous hydrochloric acid solution (9.67 g, 116<br>
mmol) while cooling in an ice- water bath. The product precipitated and was<br>
collected by vacuum filtration. The solid was washed with cold water and dried under<br>
high vacuum to afford the crude product, (1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (5 g, 20.8 mmol, 71.7% over two steps), as a<br>
white solid. 1H NMR (400 MHz, DMSO-d6)d: 3.58 (2H, s), 7.31 (1H, d, J= 8.0 Hz),<br>
7.44 (1H, dd, J1 = 7.8 Hz, J2 = 7.8 Hz), 7.67 (1H, dd, J1= 7.8 Hz, J2 = 7.8 Hz), 7.79<br>
(1H, d, J= 7.9 Hz), 12.18 (1H, bs), 13.03 (1H, bs). LC-MS (ESI) calcd for<br>
C9H8N2O4S 240.02, found 241.1 [M+H+].<br>
c)(1S,2R,3S,4R)-3-[[2-(1,1-Dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-<br>
yl)-acetyl]-(4-fluoro-benzyl)-amino]-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl<br>
ester<br><br>
(1,1-Dioxo-1,4-dihydro-l 6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (0.2 g,<br>
0.833 mmol) was dissolved in anhydrous N,N-dimethylformamide (8 mL).<br>
(1 S,2R,3 S,4R)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1 ]heptane-2-carboxylic acid<br>
ethyl ester (prepared as described in Example 61, 0.244 g, 0.833 mmol) was added<br>
followed by l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.168 g,<br>
0.875 mmol). Then N-methylmorpholine (0.177 g, 1.75 mmol) was added into the<br>
above reaction mixture. The mixture was stirred at 25 oC for 16 h. The solution was<br>
poured into 1.0 M aqueous hydrochloric acid solution (100 mL). The aqueous layer<br>
was extracted with ethyl acetate (2 Ã 100 mL). The organic layer was dried over<br>
sodium sulfate, filtered, and concentrated in vacuo to afford the crude product,<br>
(1S,2R,3S,4R)-3-[[2-(1,1-dioxo-1,4-dihydro-l 6-benzo[1,2,4]thiadiazin-3-yl)-<br>
acetyl]-(4-fluoro-benzyl)-amino]-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester,<br>
as an orange oil, which was used in the next step without any further purification.<br>
LC-MS (ESI) calcd for C26H28FN3O5S 513.58, found 514.4 [M+H+].<br>
d) (1R,2S,7R,8S)-5-( 1,1 -Dioxo-1, 2-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3-yl)-<br>
3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00359] The crude (1S,2R,3S,4R)-3-[[2-(1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(4-fluoro-benzyl)-amino]-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid ethyl ester was dissolved in ethanol (8 mL), and a 21 wt. % solution<br>
of sodium ethoxide in ethanol (1.6 mL, 4.2 mmol) was added into the above solution.<br>
The mixture was stirred at 60 Â°C for 4 h and allowed to cool down to 25 Â°C. The<br>
mixture was poured into 0.5 M aqueous hydrochloric acid solution (100 mL). The<br>
product started to precipitate and was collected by vacuum filtration. The precipitate<br>
was purified by flash column chromatography (Teledyne Isco RediSep column; 100%<br>
ethyl acetate) to afford the desired product, (1R,2S,7R,8S)-5-(1,1-dioxo-1, 2-dihydro-<br>
1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (0.242 g, 0.517 mmol, 62.1% over two steps), as<br>
a white solid. 1H NMR (400 MHz, DMSO-d6)d: 1.16 - 1.22 (2H, m), 1.40 - 1.60<br>
(4H, m), 2.51 (1H, bs), 2.64 (1H, d, J= 2.1 Hz), 3.03 (1H, d, J= 8.0 Hz), 3.54 (1H, d,<br>
J= 9.3 Hz), 4.42 (1H, d, J= 15.6 Hz), 4.97 (1H, d, J= 15.7 Hz), 7.15 (2H, t, J= 8.8<br>
Hz), 7.33 (2H, dd, J1 = 8.0 Hz, J2 = 5.9 Hz), 7.45 - 7.53 (2H, m), 7.67 - 7.71 (1H, m),<br>
7.85 (1H, d, J= 7.9 Hz). LC-MS (ESI) calcd for C24H22FN3O4S 467.13, found 468.2<br>
[M+H+]. Anal, calcd for C24H22FN3O4S: C, 61.66; H, 4.74; N, 8.99; found C, 61.96;<br>
H, 4.88; N, 8.99.<br>
[00360] Example 29: N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl} -methanesulfonamide<br><br>
a) (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[1,4]thiazin-3-<br>
yl)-acetic acid<br><br>
[00361] A solution of (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-3-yl)-acetic acid ethyl ester (prepared as described in US patent<br>
application US 2008/0031852, 600 mg, 1.666 mmol) in methanol (30 mL) was cooled<br>
to 0 Â°C in an ice-water bath and treated with 2.0 M aqueous lithium hydroxide<br>
solution (4.17 mL, 8.332 mmol). The reaction mixture was allowed to warm to 25 Â°C<br>
and stirred for 1 h. The methanol was removed in vacuo and the reaction mixture was<br>
poured into 0.5 M aqueous hydrochloric acid solution (20 mL) on ice, extracted with<br>
ethyl acetate (3 Ã 50 mL), dried over sodium sulfate, filtered, and concentrated in<br>
vacuo to afford an orange solid. The crude solid was triturated with diethyl ether to<br>
afford the desired product, (7-methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-3-yl)-acetic acid (409 mg, 1.232 mmol, 73.9%), as a yellow solid.<br>
LC-MS calcd for C11H12N2O6S2 332.4, found 333.0 [M+H+].<br>
b) N- {3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1 ,4]thiazin-7-<br>
yl} -methanesulfonamide<br><br>
[00362] Methyl (1S,2R,3S,4R)-3-[(4-fluorobenzyl)amino]bicyclo[2,2,1 ]heptane-2-<br>
carboxylate (prepared as described in Example 6d, 0.20 g, 0.69 mmol) was dissolved<br>
in anhydrous N,N-dimethylformamide (7 mL). (7-Methanesulfonylamino-1, 1 -dioxo-<br>
1,4-dihydro-1?6-benzo[1,4]thiazin-3-yl)-acetic acid (0.23 g, 0.69 mmol) was added<br>
followed by N-methylmorpholine (0.17 mL, 1.52 mmol). The mixture was stirred<br>
until everything dissolved, approximately 5 min. l-(3-Dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (0.15 g, 0.76 mmol) was added and the mixture was<br>
stirred at 25 Â°C for 16 h. The reaction was quenched via addition of saturated aqueous<br>
sodium bicarbonate solution (20 mL). The mixture was extracted with ethyl acetate<br>
(3 Ã 30 mL). The organic layers were combined and washed with saturated aqueous<br>
brine solution (20 mL). The resulting solution was dried over magnesium sulfate,<br>
filtered, and concentrated in vacuo to afford a golden oil. The oil was dissolved in<br>
ethanol (10 mL). A 21 wt. % solution of sodium ethoxide in ethanol (0.65 mL, 1.74<br>
mmol) was added. The reaction was stirred at 60 Â°C for 16 h. The reaction was<br>
quenched via the addition of 1.0 M aqueous hydrochloric acid solution (10 mL). The<br>
mixture was extracted with ethyl acetate (3 Ã 20 mL). The organic layer was further<br>
washed with saturated aqueous sodium bicarbonate solution (2 Ã 20 mL), saturated<br>
aqueous brine solution (20 mL), dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo to afford a clear oil. Purification by flash column<br>
chromatography (Teledyne Isco RediSep column; 22 to 75% ethyl acetate in hexanes)<br>
afforded the desired product, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide (0.020 g, 0.04 mmol, 5.3%), as a yellow<br>
powder. lH NMR (400 MHz, CDCl3)d: 1.21 - 1.64 (6H, m), 2.52 - 2.71 (3H, m),<br>
3.07 (3H, s), 3.39 - 3.52 (1H, m), 5.15 - 5.28 (2H, m), 6.60 (1H, s), 7.02 - 7.06 (2H,<br>
m), 7.22 - 7.26 (2H, m), 7.54 - 7.66 (3H, m). LC-MS (ESI) calcd for C26H26FN3O6S2<br>
559.63, found 560.5 [M+H+].<br>
[00363] Example 30: (1R,2S,7R,8S)-5-(7-Amino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thoadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
a) (1R,2S,7R,8S)-5-(7-Azido-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00364] (1R,2S,7R,8S)-3 -(4-Fluoro-benzyl)-6-hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-<br>
dihydro- 1?6-benzo [ 1,2,4]thiadiazin-3 -yl)-3 -aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br>
(prepared as described in Example 19, 0.513 g, 0.864 mmol), sodium azide (1.12 g,<br>
17.2 mmol), sodium ascorbate (0.086 g, 0.43 mmol), copper (I) iodide (0.16 g, 0.84<br>
mmol), and trans-N,N'-dimethylcyclohexane-1,2-diamine (0.20 mL, 1.27 mmol) were<br>
dissolved in a 5:1 mixture of dimethyl sulfoxide and water (10 mL) at 25 Â°C. The<br>
reaction flask was degassed and backfilled with nitrogen (5 Ã). After stirring at 25 Â°C<br>
for 14 h, the reaction mixture was partitioned between water (150 mL) and ethyl<br>
acetate (2 x 150 mL). The organic layer was dried over sodium sulfate, filtered and<br>
concentrated in vacuo. The residue was purified by flash column chromatography<br>
(Teledyne Isco RediSep column; 0 to 60% ethyl acetate in hexanes) to afford the<br>
desired product, (1R,2S,7R,8S)-5-(7-azido-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-3 -yl)-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (0.348 g, 0.684 mmol, 79%), as a dark brown<br>
foam, which was used in the next step without any further purification.<br>
b) (1R,2S,7R,8S)-5-(7-Amino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-3 -yl)-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00365] (1R,2S,7R,8S)-5 -(7-Azido-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (0.348 g, 0.684 mmol) was dissolved in a 1:1<br>
mixture if methanol and ethyl acetate (15 mL) at 25 Â°C. Palladium on carbon (0.40 g,<br>
5%, "wet") was added, resulting in a black suspension. The reaction was maintained<br>
under a hydrogen atmosphere (balloon) at 25 Â°C for 6 h, and then was filtered through<br>
Celite. The Celite was washed with ethyl acetate (2Ã30 mL) and the filtrate was<br>
concentrated in vacuo. The residue was purified by flash column chromatography<br>
(Teledyne Isco RediSep column; 50 to 100% ethyl acetate in hexanes) to afford the<br>
desired product, (1R,2S,7R,8S)-5-(7-amino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (0.159 g, 0.330 mmol, 48%), as a pale yellow<br>
solid. 1H NMR (400 MHz, CDCl3)d: 1.08 - 1.19 (3H, m), 1.40 - 1.57 (3H, m), 2.99<br>
(1H, d, J= 7.2 Hz), 3.31 (3H, s), 3.36 - 3.37 (1H, m), 3.50 (1H, d, J= 7.8 Hz), 4.39<br>
(1H, d, J= 14.6 Hz), 4.93 (1H, d, J= 14.5 Hz), 6.86 - 6.91 (3H, m), 7.13 - 7.15 (2H,<br>
m), 7.21 (1H, d, J= 8.8 Hz), 7.30 (2H, bs), 13.79 (1H, s). LC-MS (ESI) calcd for<br>
C24H23FN4O4S 482.14, found 483.4 [M+H+].<br>
[00366] Example 31: (rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1.4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a) (rac-di-exo)-3-Amino-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl<br>
ester hydrochloride<br><br>
[00367] (rac-di-exo)-3-Amino-bicyclo[2,2,1 ]hept-5-ene-2-carboxylic acid<br>
hydrochloride (1.0 g, 5.27 mmol) was dissolved in methanol (7 mL). Benzene (10<br>
mL) was added followed by the dropwise addition of a 2.0 M solution of<br>
(trimethylsilyl)diazomethane in diethyl ether (5 mL, 10 mmol). After stirring for 10<br>
min, additional 2.0 M solution of (trimethylsilyl)diazomethane in diethyl ether (3 mL,<br>
6 mmol) was added and the reaction mixture was stirred for an additional 20 min after<br>
which time the solution remained yellow in color. The solvents were removed in<br>
vacuo, the residue was taken up in methanol (15 mL) and the solvent was removed in<br>
vacuo to afford the crude product, (rac-di-exo)-3-amino-bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid methyl ester hydrochloride (0.98 g, 4.83 mmol, 91.6%), as a yellow<br>
oil, which was used in the next step without any further purification.<br>
b) (rac-di-exo)-3-(3-Methyl-butylamino)-bicyclo[2,2,1 ]hept-5-ene-2-<br>
carboxylic acid methyl ester<br><br>
[00368] (rac-di-exo)-3-Amino-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl<br>
ester hydrochloride (0.955 g, 4.703 mmol) was suspended in methanol (10 mL).<br>
Sodium acetate (0.791 g, 9.652 mmol) was added followed by 4Ã powdered<br>
molecular sieves (1.0 g) and 3-methyl-butyraldehyde (0.385 g, 4.468 mmol). Sodium<br>
cyanoborohydride (0.593 g, 9.406 mmol) was added and the mixture was stirred at 25<br>
Â°C for 18 h. The mixture was poured into a saturated aqueous sodium bicarbonate<br>
solution (100 mL) and extracted with ethyl acetate (100 mL). The layers were<br>
separated and the organic layer was washed with saturated aqueous brine solution,<br>
dried over sodium sulfate, filtered, and concentrated in vacuo. Further purification by<br>
flash column chromatography (Teledyne Isco RediSep column; 0 to 10% methanol in<br>
dichloromethane) afforded the desired product, (rac-di-exo)-3-(3-methyl-butylamino)-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (0.774 g, 3.14 mmol, 66.7%),<br>
as a yellow oil. 1H NMR (400 MHz, CDCl3) 6: 0.89 (3H, d, J= 1.6 Hz), 0.90 (3H, d,<br>
J= 2.1 Hz), 1.27 - 1.39 (2H, m), 1.54 - 1.64 (2H, m), 2.07 (1H, d, J= 9.4 Hz), 2.42 -<br>
2.56 (2H, m), 2.66 - 2.73 (1H, m), 2.84 (1H, bs), 2.92 (1H, bs), 2.98 (1H, d, J= 7.7<br>
Hz), 3.69 (3H, s), 6.14 (2H, s). LC-MS calcd forC14H23NO2 237.17, found 238.2<br>
[M+H+].<br>
c) (rac-di-exo)-3-[[2-(7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-bicyclo[2,2, 1]hept-5-<br>
ene-2-carboxylic acid methyl ester<br><br>
[00369] To a solution of (rac-di-exo)-3-(3-methyl-butylamino)-bicyclo[2,2,1]hept-<br>
5-ene-2-carboxylic acid methyl ester (208.7 mg, 0.880 mmol) in N,N-<br>
dimethylformamide (3 mL) was added (7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in<br>
Example lg, 351.7 mg, 1.056 mmol) and the mixture was vortexed until all material<br>
had completely dissolved. A 1.0 M solution of N,N-dicyclohexylcarbodiimide in<br>
dichloromethane (1.144 mL, 1.144 mmol) was added to the above solution and the<br>
mixture was stirred at 25 Â°C for 18 h under a nitrogen atmosphere. The precipitated<br>
N,N-dicyclohexylurea was removed by filtration over Celite, the filter cake was<br>
washed with dichloromethane (3 Ã 5 mL), and the solvent was removed in vacuo.<br>
The residue was dissolved in a 1:1 mixture of ethyl acetate and hexanes (20 mL),<br>
washed with saturated aqueous brine solution, saturated aqueous sodium bicarbonate<br>
solution and water. The layers were separated and the aqueous layers were back-<br>
extracted with a 1:1 mixture of ethyl acetate and hexanes (20 mL). The combined<br>
organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to<br>
afford the crude product, (rac-di-exo)-3-[[2-(7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetyl]-(3 -methyl-butyl)-amino]-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester, as a yellow oil, which was<br>
used in the next step without any further purification. LC-MS calcd for C24H32N4O7S2<br>
552.17, found 553.3 [M+H+].<br>
d) (rac-di-exo)-N- {3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00370] The crude (rac-di-exo)-3-[[2-(7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetyl]-(3 -methyl-butyl)-amino]-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester was dissolved in ethanol (20<br>
mL). To this solution was added a 21 wt. % solution of sodium ethoxide in ethanol<br>
(1.141 g, 3.52 mmol) and the reaction mixture was stirred at 25 Â°C for 2 h. Upon<br>
addition of a 1.0 M aqueous hydrochloric acid solution the product precipitated and<br>
was collected by vacuum filtration. Further purification by trituration with<br>
dichloromethane and ethyl acetate gave a tan solid, which was further washed with<br>
ethyl acetate, and then dried in vacuo, to afford the desired product, (rac-di-exo)-N-<br>
{3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-<br>
yl]-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br>
(116.6 mg, 0.224 mmol, 25.5%), as an off-white solid. 1H NMR (400 MHz, DMSO-<br>
d6) d: 0.93 (6H, d, J= 5.3 Hz), 1.35 - 1.70 (5H, m), 2.85 (1H, d, J= 8.7 Hz), 3.06 (3H,<br>
s), 3.13 - 3.31 (5H m), 3.49 (1H, d, J= 8.6 Hz), 3.75 - 3.83 (1H, m), 6.23 (1H, s),<br>
6.39 (1H, s), 7.50 - 7.58 (3H, m), 10.18 (1H, s). LC-MS calcd for C23H28N4O6S2<br>
520.15, found 521.4 [M+H+].<br>
[00371] Example 32: (rac-di-exo)-N-{3-[3-(3,3-Dimethvl-butyl)-6-hydroxv-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a) (rac-di-exo)-3-(3,3-Dimethyl-butylamino)-bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid methyl ester<br><br>
[00372] (rac-di-exo)-3-Amino-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl<br>
ester hydrochloride (0.984 g, 4.846 mmol) was suspended in methanol (10 mL).<br>
Sodium acetate (0.795 g, 9.692 mmol) was added followed by 4A powdered<br>
molecular sieves (1.0 g) and 3,3-dimethylbutyraldehyde (0.461 g, 4.604 mmol).<br>
Sodium cyanoborohydride (0.610 g, 9.692 mmol) was added and the mixture was<br>
stirred at 25 Â°C for 18 h. The mixture was poured into a saturated aqueous sodium<br>
bicarbonate solution (100 mL) and extracted with ethyl acetate (100 mL). The layers<br>
were separated and the organic layer was washed with saturated aqueous brine<br>
solution, dried over sodium sulfate, filtered, and concentrated in vacuo. Further<br>
purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
10% methanol in dichloromethane) afforded the desired product, (rac-di-exo)-3-(3,3-<br>
dimethyl-butylamino)-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (0.773<br>
g, 3.08 mmol, 63.5%), as a yellow oil. 1H NMR (400 MHz, CDCl3)d: 0.91 (9H, s),<br>
1.31 - 1.40 (2H,m), 1.55 (1H, d, J= 9.5 Hz), 2.08 (1H, d, J= 8.8 Hz), 2.43 - 2.49<br>
(1H, m), 2.55 (1H, d, J= 7.8 Hz), 2.64 - 2.74 (1H, m), 2.85 (1H, bs), 2.93 (1H, bs),<br>
2.99 (1H, d, J= 7.7 Hz), 3.69 (3H, s), 6.15 (2H, s). LC-MS calcd for C15H25NO2<br>
251.19, found 252.2 [M+H+].<br>
b) (rac-di-exo)-3- {(3,3-Dimethyl-butyl)-[2-(7-methanesulfonylamino-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-amino}-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester<br><br>
[00373] To a solution of (rac-di-exo)-3-(3,3-dimethyl-butylamino)-<br>
bicyelo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (233.3 mg, 0.929 mmol) in<br>
N,N-dimethylformamide (3 mL) was added (7-methanesulfonylamino-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in<br>
Example 1 g, 371.2 mg, 1.115 mmol) and the mixture was vortexed until all material<br>
had completely dissolved. A 1.0 M solution of N,N-dicyclohexylcarbodiimide in<br>
dichloromethane (1.208 mL, 1.208 mmol) was added to the above solution and the<br>
mixture was stirred at 25 Â°C for 18 h under a nitrogen atmosphere. The precipitated<br>
N,N-dicyclohexylurea was removed by filtration over Celite, the filter cake was<br>
washed with dichloromethane (3Ã5 mL), and the solvent was removed in vacuo.<br>
The residue was dissolved in a 1:1 mixture of ethyl acetate and hexanes (20 mL),<br>
washed with saturated aqueous brine solution, saturated aqueous sodium bicarbonate<br>
solution and water. The layers were separated and the aqueous layers were back-<br>
extracted with a 1:1 mixture of ethyl acetate and hexanes (20 mL). The combined<br>
organic layers were dried over sodium sulfate, filtered, and concentrated in vacuo to<br>
afford the crude product, (rac-di-exo)-3-{(3,3-dimethyl-butyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester, as a yellow<br>
oil, which was used in the next step without any further purification. LC-MS calcd<br>
for C25H34N4O7S2 566.19, found 567.4 [M+H+].<br>
c) (rac-di-exo)-N-{3-[3-(3,3-Dimethyl-butyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo [1,2,4]thiadiazin- 7 -yl} -methanesulfonamide<br><br>
[00374] The crude (rac-di-exo)-3- {(3,3-dimethyl-butyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (710.8 mg,<br>
0.929 mmol) was dissolved in ethanol. To this solution was added a 21 wt. %<br>
solution of sodium ethoxide in ethanol (1.204 g, 3.716 mmol) and the reaction<br>
mixture was stirred at 25 Â°C for 2 h. Upon addition of a 1.0 M aqueous hydrochloric<br>
acid solution the product precipitated and was collected by vacuum filtration. Further<br>
purification by trituration with dichloromethane and ethyl acetate gave a tan solid,<br>
which was further washed with ethyl acetate, and then dried in vacuo, to afford the<br>
desired product, (rac-di-exo)-N- {3-[3-(3,3-dimethyl-butyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-lA.6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (210.7 mg, 0.394 mmol, 42.5%<br>
over two steps), as an off-white solid. 1H NMR (400 MHz, DMSO-d6)d: 0.96 (9H,<br>
s), 1.39 - 1.56 (4H, m), 2.85 (1H, d, J= 9.3 Hz), 3.06 (3H, s), 3.12 - 3.30 (5H, m),<br>
3.49 (1H, d, J= 9.1 Hz), 3.74 - 3.81 (1H, m), 6.23 (1H, s), 6.40 (1H, s), 7.50 - 7.60<br>
(3H, m), 10.18 (1H, s). LC-MS calcd for C24H30N4O6S2 534.16, found 535.4 [M+H+].<br>
[00375] Example 33: (rac-di-exo)-6-Hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1.2.41thiadiazin-3-yl)-3-(3-methyl-butyl)-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7lundec-5-en-4-one<br><br>
a) (rac-di-exo)-3-[[2-(7-Iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br><br>
[00376] (7-Iodo-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetic<br>
acid (prepared as described in US patent application US 2008/0031852, 0.2 g, 0.546<br>
mmol) was dissolved in anhydrous N,N-dimethylformamide (5 mL). (rac-di-exo)-3 -<br>
(3-Methyl-butylamino)-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester<br>
(prepared as described in Example 25a, 0.132 g, 0.546 mmol) was added followed by<br>
l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.11 g, 0.573 mmol).<br>
Then N-methylmorpholine (0.116 g, 1.15 mmol) was added into the above reaction<br>
mixture. The mixture was stirred at 25 Â°C for 16 h. The solution was poured into 1.0<br>
M aqueous hydrochloric acid solution (100 mL). The aqueous layer was extracted<br>
with ethyl acetate (2 Ã 100 mL). The organic layer was dried over sodium sulfate,<br>
filtered, and concentrated in vacuo to afford the crude product, (rac-di-exo)-3-[[2-(7-<br>
iodo-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetyl]-(3 -methyl-<br>
butyl)-amino]-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester, as a light<br>
yellow oil, which was used in the next step without any further purification. LC-MS<br>
(ESI) calcd for C22H28IN3O6S 589.07, found 590.5 [M+H+].<br>
b) (rac-di-exo)-6-Hydroxy-5-(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-3 -yl)-3 -(3 -methyl-butyl)-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00377] The crude (rac-di-exo)-3-[[2-(7-iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester was dissolved in ethanol (5 mL),<br>
and a 21 wt. % solution of sodium ethoxide in ethanol (1 mL, 2.73 mmol) was added<br>
into the above solution. The mixture was stirred at 60 Â°C for 6 h and allowed to cool<br>
to 25 Â°C. The mixture was poured into 0.5 M aqueous hydrochloric acid solution (100<br>
mL). The product started to precipitate and was collected by vacuum filtration. The<br>
precipitate was purified by flash column chromatography (Teledyne Isco RediSep<br>
column; 100% ethyl acetate) to afford the desired product, (rac-di-exo)-6-hydroxy-5-<br>
(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-3 -yl)-3 -(3 -methyl-butyl)-<br>
1 l-oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one (0.066 g, 0.118 mmol, 21.7% over<br>
two steps), as a white solid. 1H NMR (400 MHz, DMSO-d6) d: 0.92 (6H, d, J= 6.2<br>
Hz), 1.41 - 1.73 (7H, m), 2.52-2.52 (1H, m), 2.94 - 3.07 (1H, m), 3.81 - 3.92 (2H,<br>
m), 4.75 (2H, d, J= 2.2 Hz), 7.37 (1H, d, J= 8.5 Hz), 8.00 (1H, dd, J, = 8.6 Hz, J2 =<br>
2.2 Hz), 8.08 (1H, s). LC-MS (ESI) calcd for C21H24IN3O5S 557.05, found 558.2<br>
[M+H+]. Anal, calcd for C21H24IN3O5S â¢ 0.5 H2O: C, 44.53; H, 4.45; N, 7.45; found<br>
C, 44.69; H, 4.15; N, 7.45.<br>
[00378] Example 34: (1R,2S,7R,8S)-6-Hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyn-3-aza-tricyclo[6.2.1.02,71undec-5-<br>
en-4-one<br><br>
a) (1S,2R,3S,4R)-3-[[2-(7-Iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid ethyl ester<br><br>
[00379] (7-Iodo-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3-yl)-acetic<br>
acid (prepared as described in US patent application US 2008/0031852, 0.2 g, 0.546<br>
mmol) was dissolved in anhydrous N,N-dimethylformamide (5 mL). (1S,2R,3S,4R)-<br>
3-(3-Methyl-butylamino)-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br>
(prepared as described in Example 22a, 0.138 g, 0.546 mmol) was added followed by<br>
1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.11 g, 0.573 mmol).<br>
Then N-methylmorpholine (0.116 g, 1.15 mmol) was added into the above reaction<br>
mixture. The mixture was stirred at 25 Â°C for 16 h. The solution was poured into 1.0<br>
M aqueous hydrochloric acid solution (100 mL). The aqueous layer was extracted<br>
with ethyl acetate (2 Ã 100 mL). The organic layer was dried over sodium sulfate,<br>
filtered, and concentrated in vacuo to afford the crude product, (lS,2R,3S,4R)-3-[[2-<br>
(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-3 -yl)-acetyl]-(3 -methyl-<br>
butyl)-amino]-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester, as a light yellow<br>
oil, which was used in the next step without any further purification. LC-MS (ESI)<br>
calcd for C24H32IN3O5S 601.11, found 602.6 [M+H+].<br>
b)(1R,2S,7R,8S)-6-Hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-3 -yl)-3 -(3 -methyl-butyl)-3 -aza-tricyclo [6.2.1.02,7]undec-5-en-<br>
4-one<br><br>
[00380] The crude (1S,2R,3S,4R)-3-[[2-(7-iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid ethyl ester (0.546 mmol) was dissolved in ethanol (5 mL), and a 21<br>
wt. % solution of sodium ethoxide in ethanol (1 mL, 2.73 mmol) was added into the<br>
above solution. The mixture was stirred at 60 Â°C for 6 h and allowed to cool to 25 Â°C.<br>
The mixture was poured into 0.5 M aqueous hydrochloric acid solution (100 mL).<br>
The product started to precipitate and was collected by vacuum filtration. The<br>
precipitate was purified by flash column chromatography (Teledyne Isco RediSep<br>
column; 40% ethyl acetate in hexanes) to afford the desired product, (1R,2S,7R,8S)-6-<br>
hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-(3-<br>
methyl-butyl)-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one (0.122 g, 0.2 mmol, 40.3%<br>
over two steps), as a light yellow solid. 1H NMR (400 MHz, DMSO-d6)d: 0.92 (6H,<br>
d, J= 5.4 Hz), 1.16 - 1.63 (9H, m), 2.99 - 3.12 (2H, m), 3.62 - 3.71 (2H, m), 7.37 (1H,<br>
d, J= 8.3 Hz), 7.99 (1H, dd, J1 = 8.6 Hz, J2 = 1.6 Hz), 8.08 (1H, s). LC-MS (ESI)<br>
calcd for C22H26IN3O4S 555.07, found 556.3 [M+H+].<br>
[00381] Example 35: Cyclopropane sulfonic acid (3-[(1R,2S,7R,8S)-3-(4-fluoro-<br>
benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo [1.2.4]thiadiazin-7-yl} -amide<br><br>
[00382] (1R,2S,7R,8S)-3 -(4-Fluoro-benzyl)-6-hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3-yl)-3 -aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br>
(prepared as described in Example 19, 81 mg, 0.14 mmol), cyclopropane sulfonic acid<br>
amide (132 mg, 1.09 mmol), sarcosine ( N-methyl glycine) (18 mg, 0.20 mmol),<br>
copper (I) iodide (26 mg, 0.14 mmol), and potassium phosphate (173 mg, 0.82 mmol)<br>
were combined and dissolved in N,N-dimethylformamide (4 mL). The flask was<br>
degassed and backfilled with nitrogen (3 Ã). The reaction was stirred at 100 Â°C for 4<br>
h. The mixture was allowed to cool to 25 Â°C, diluted with ethyl acetate (20 mL), and<br>
extracted with saturated aqueous sodium bicarbonate solution (2 Ã 20 mL). The<br>
combined organic layers were dried over magnesium sulfate, filtered and concentrated<br>
in vacuo. Purification by flash column chromatography (Teledyne Isco RediSep<br>
column; 0 to 8% methanol in dichloromethane) afforded the desired product,<br>
cyclopropane sulfonic acid {3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro- 1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide (76 mg, 0.13 mmol, 96%), as a white powder. 1H<br>
NMR (400 MHz, DMSO-d6)d: 0.85 -1.68 (8H, m), 2.50 - 2.62 (2H, m), 2.83 - 2.97<br>
(3H, m), 3.45 - 3.47 (1H, m), 4.56 (1H, bs), 5.17 - 5.20 (1H, m), 7.03 - 7.07 (2H, m),<br>
7.20 - 7.23 (2H, m), 7.63 - 7.69 (2H, m), 8.01 (1H, s). LC-MS (ESI) calcd for<br>
C27H27FN4O6S2 586.14, found 587.4 [M+H+].<br>
[00383] Example 3 6: (rac-di-exo)-N- {3 -[3 -(3,3 -Dimethyl-butyn-6-hydroxy-4-oxo-<br>
3-aza-tricyclor6.2.1.02,71undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-3 - {(3,3 -Dimethyl-butyl)- [2-(7-methanesulfonylamino-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,4]thiazin-3-yl)-acetyl]-amino}-bicyclo[2,2,1]hept-5-<br>
ene-2-carboxylic acid methyl ester<br><br>
[00384] To a stirred solution of (rac-di-exo)-3-(3,3-dimethyl-butylamino)-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (prepared as described in<br>
Example 32 a, 103 mg, 0.410 mmol) in anhydrous N,N-dimethylformamide (3 mL)<br>
under a nitrogen atmosphere, (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-3-yl)-acetic acid (prepared as described in Example 29a, 136 mg,<br>
0.410 mmol), N-methylmorpholine (87.1 mg, 0.861 mmol) and l-(3-<br>
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (82.3 mg, 0.431 mmol)<br>
were added sequentially. After stirring at 25 Â°C for 90 min, 1.0 M aqueous<br>
hydrochloric acid solution (10 mL) and saturated aqueous brine solution were added<br>
to the reaction mixture. The mixture was extracted with ethyl acetate (3Ã10 mL) and<br>
the combined organic layers were dried over sodium sulfate, filtered, and<br>
concentrated in vacuo. The crude product, (rac-di-exo)-3-{(3,3-dimethyl-butyl)-[2-<br>
(7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-benzo[1,4]thiazin-3-yl)-acetyl]-<br>
amino}-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester, was directly used in<br>
the next step without further purification. LC-MS calcd for C26H35N3O7S2 565.19,<br>
found 566.5 [M+H+].<br>
b) (rac-di-exo)-N- {3 -[3-(3,3 -Dimethyl-butyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo [ 1,4]thiazin-7-yl}-methanesulfonamide<br><br>
[00385] The crude (rac-di-exo)-3- {(3,3-dimethyl-butyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,4]thiazin-3 -yl)-acetyl]-<br>
amino}-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester was dissolved in<br>
ethanol (10 mL). To this solution was added a 21 wt. % solution of sodium ethoxide<br>
in ethanol (0.399 g, 1.23 mmol) and the reaction mixture was stirred at 25 Â°C for 2.5<br>
h. A 1.0 M aqueous hydrochloric acid solution (10 mL) was added and, after stirring<br>
for another 30 min, additional 1.0 M aqueous hydrochloric acid solution (5 mL) was<br>
added upon which the product precipitated. The solid was collected by vacuum<br>
filtration, washed with 1.0 M aqueous hydrochloric acid solution (5 mL), and then<br>
dried in vacuo, to afford the desired product, (rac-di-exo)-N-{3-[3-(3,3-dimethyl-<br>
butyl)-6-hydroxy-4-oxo-3 -aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1,4]thiazin-7-yl}-methanesulfonamide (59 mg, 0.111 mmol,<br>
27.1% over two steps), as a yellow-tan solid. 1H NMR (400 MHz, CDCl3)d: 1.00 -<br>
1.01 (9H, m), 1.26 - 1.29 (2H, m), 1.51 - 1.70 (4H, m), 2.57 - 2.63 (1H, m), 3.07 (3H,<br>
s), 3.10 - 3.17 (2H, m), 3.24 - 3.26 (1H, m), 3.35 - 3.39 (1H, m), 3.39 - 3.99 (1H, m),<br>
4.90 (0.7H, d, J= 16.7 Hz), 5.20 (0.3H, d, J= 16.2 Hz), 5.27 (0.7H, d, J= 16.9 Hz),<br>
5.73 (0.3H, d, J= 16.1 Hz), 6.17 - 6.22 (1H, m), 6.36 - 6.39 (1H, m), 7.17 (1H, s),<br>
7.22 - 7.25 (2H, m), 7.56 - 7.61 (1H, m), 7.67 - 7.69 (1H, m). LC-MS calcd for<br>
C25H31N3O6S2 533.17, found 534.4 [M+H+].<br>
[00386] Example 37: (rac-di-exo)-N-(3-[3-(4-Fluoro-benzvl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7lundeca-5.9-dien-5-yl1-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-3- {(4-Fluoro-benzyl)-[2-(7-methanesulfonylamino-1,1 -dioxo-<br>
1,4-dihydro-1?6-benzo[1,4]thiazin-3 -yl)-acetyl]-amino}-bicyclo[2,2,1 ]hept-5-ene-2-<br>
carboxylic acid methyl ester<br><br>
[00387] To a stirred solution of (rac-di-exo)-3-(4-fluoro-benzylamino)-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (prepared as described in<br>
Example 9b, 112.7 mg, 0.410 mmol) in anhydrous N,N-dimethylformamide (3 mL)<br>
under a nitrogen atmosphere, (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6 -<br>
benzo[1,4]thiazin-3-yl)-acetic acid (prepared as described in Example 29a, 136 mg,<br>
0.410 mmol), N-methylmorpholine (87.1 mg, 0.861 mmol) and l-(3-<br>
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (82.3 mg, 0.431 mmol)<br>
were added sequentially. After stirring at 25 Â°C for 90 min, 1.0 M aqueous<br>
hydrochloric acid solution (10 mL) and saturated aqueous brine solution (10 mL)<br>
were added to the reaction mixture. The mixture was extracted with ethyl acetate (3 Ã<br>
10 mL) and the combined organic layers were dried over sodium sulfate, filtered, and<br>
concentrated in vacuo. The crude product, (rac-di-exo)-3-{(4-fluoro-benzyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,4]thiazin-3 -yl)-acetyl]-<br>
amino}-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester, was used in the next<br>
step without any further purification. LC-MS calcd for C27H28FN3O7S2 589.14, found<br>
590.5 [M+H+].<br>
c) (rac-di-exo)-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[l ,4]thiazin-7-yl} -methanesulfonamide<br><br>
[00388] The crude (rac-di-exo)-3- {(4-fluoro-benzyl)-[2-(7-methanesulfonylamino-<br>
1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,4]thiazin-3 -yl)-acetyl]-amino} -bicyclo [2,2,1 ]hept-<br>
5-ene-2-carboxylic acid methyl ester was dissolved in ethanol. To this solution was<br>
added a 21 wt. % solution of sodium ethoxide in ethanol (0.399 g, 1.23 mmol) and the<br>
reaction mixture was stirred at 25 Â°C for 2.5 h. A 1.0 M aqueous hydrochloric acid<br>
solution (10 mL) was added and, after stirring for another 30 min, additional 1.0 M<br>
aqueous hydrochloric acid solution (5 mL) was added upon which the product<br>
precipitated. The solid was collected by vacuum filtration, washed with 1.0 M<br>
aqueous hydrochloric acid solution (5 mL), and then dried in vacuo, to afford the<br>
desired product, (rac-di-exo)-N- {3-[3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide (44 mg, 0.079 mmol, 19.3% over two<br>
steps), as a tan solid. 1H NMR (400 MHz, CDCl3)d: 0.83 - 0.93 (1H, m), 1.26 -1.29<br>
(2H, m), 1.51 (1H, d, J= 8.4 Hz), 1.69 (1H, d, J= 9.5 Hz), 2.59 (1H, d, J= 8.3 Hz),<br>
3.05 (3H, s), 3.09 (1H, s), 3.26 (1H, s), 3.35 (1H, d, J= 1.1 Hz), 4.36 (1H, d, J= 15.1<br>
Hz), 5.24 (1H, d, J= 15.6 Hz), 6.12 (1H, s), 6.33 (1H, s), 7.00 - 7.04 (2H, m), 7.19 -<br>
7.26 (3H, m), 7.56 (1H, d, J= 6.8 Hz), 7.68 (1H, s). LC-MS calcd for C26H24FN3O6S2<br>
557.11, found 558.1 [M+H+].<br>
[00389] Example 38: (rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yll-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide<br><br>
a) (rac-di-exo)-3-[[2-(7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid methyl ester<br><br>
[00390] To a stirred solution of (rac-di-exo)-3-(3-methyl-butylamino)-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (prepared as described in<br>
Example 3 lb, 97.2 mg, 0.410 mmol) in anhydrous N,N-dimethylformamide (3 mL)<br>
under a nitrogen atmosphere, (7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-3-yl)-acetic acid (prepared as described in Example 29a, 136 mg,<br>
0.410 mmol), N-methylmorpholine (87.1 mg, 0.861 mmol) and l-(3-<br>
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (82.3 mg, 0.431 mmol)<br>
were added sequentially. After stirring at 25 Â°C for 90 min, 1.0 M aqueous<br>
hydrochloric acid solution (10 mL) and saturated aqueous brine solution (10 mL)<br>
were added to the reaction mixture. The mixture was extracted with ethyl acetate (3 Ã<br>
10 mL) and the combined organic layers were dried over sodium sulfate, filtered, and<br>
concentrated in vacuo. The crude product, (rac-di-exo)-3-[[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,4]thiazin-3 -yl)-acetyl]-(3 -<br>
methyl-butyl)-amino]-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester, was<br>
used in the next step without further purification. LC-MS calcd for C25H33N3O7S2<br>
551.18, found 552.3 [M+H+].<br>
b) (rac-di-exo)-N- {3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro- 1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide<br><br>
[00391] The crude (rac-di-exo)-3-[[2-(7-methanesulfonylamino-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,4]thiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester was dissolved in ethanol (10<br>
mL). To this solution was added a 21 wt. % solution of sodium ethoxide in ethanol<br>
(0.399 g, 1.23 mmol) and the reaction mixture was stirred at 25 Â°C for 2.5 h. A 1.0 M<br>
aqueous hydrochloric acid solution (10 mL) was added and, after stirring for another<br>
30 min, additional 1.0 M aqueous hydrochloric acid solution (5 mL) was added upon<br>
which the product precipitated. The solid was collected by vacuum filtration, washed<br>
with 1.0 M aqueous hydrochloric acid solution (5 mL), and then dried in vacuo, to<br>
afford the desired product, (rac-di-exo)-N-{3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide (48.6 mg, 0.094 mmol, 22.8% over two<br>
steps), as a tan solid. 1H NMR (400 MHz, CDCl3)d: 0.96 - 1.01 (6H, m), 1.26-1.29<br>
(2H, m), 1,48 - 1.73 (5H, m), 2.58 - 2.63 (1H, m), 3.07 (3H, s), 3.08 - 3.17 (1H, m),<br>
3.25 (1H, s), 3.37 - 3.40 (1H, m), 3.89 - 3.97 (1H, m), 4.90 (0.7H, d, J= 17.3 Hz),<br>
5.21 (0.3H, d, J= 17.4 Hz), 5.28 (0.7H, d, J= 16.7 Hz), 5.72 (0.3H, d, J= 17.1 Hz),<br>
6.17 - 6.22 (1H, m), 6.35 - 6.39 (1H, m), 7.23 (1H, d, J= 8.5 Hz), 7.38 (1H, s), 7.56 -<br>
7.62 (1H, m), 7.68 - 7.69 (1H, m). LC-MS calcd for C24H29N3O6S2 519.15, found<br>
520.2 [M+H+].<br>
[00392] Example 39: (rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclor[6.2.1.02,71undeca-5.9-dien-S-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-N-methvl-methanesulfonamide<br><br>
a) (rac-di-exo)-3-(4-Fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-3 -aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-4-<br>
one<br><br>
[003931 To a stirred solution of (rac-di-exo)-3-(4-fluoro-benzylamino)-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (prepared as described in<br>
Example 9b, 400 mg, 1,454 mmol) in anhydrous N,N-dimethylformamide (14 mL)<br>
under a nitrogen atmosphere, (7-iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in US patent<br>
application US 2008/0031852, 532.1 mg, 1,454 mmol), N-methylmorpholine (309<br>
mg, 3.053 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride<br>
(292 mg, 1.527 mmol) were added sequentially. After stirring at 25 Â°C for 4 h,<br>
triethylamine (441 mg, 4.362 mmol) was added, and the mixture was stirred at 50 Â°C<br>
for 2 h. The reaction mixture was allowed to cool to 25 Â°C and continued to stir for<br>
16 h. Upon addition of a 1.0 M aqueous hydrochloric acid solution (10 mL), a white<br>
precipitate formed that was collected by vacuum filtration, washed with 1.0 M<br>
aqueous hydrochloric acid solution (5 mL), and dried in vacuo to afford the desired<br>
product, (rac-di-exo)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo [1,2,4 ]thiadiazin-3 -yl)-3 -aza-tricyclo [6.2.1.02, 7]undeca-5,9 -dien-4-<br>
one (280.2 mg, 0.474 mmol, 32.6%), as a white solid. 1H NMR (400 MHz, DMSO-<br>
d6)d: 1.16- 1.20 (2H,m), 1.38 (1H, d, 7= 9.4 Hz), 1.63 (1H, d,J= 9.3 Hz), 2.86 (1H,<br>
bs), 3.21 (1H, bs), 3.41 (1H, d, J= 9.2 Hz), 4.53 (1H, d, J= 15.6 Hz), 5.05 (1H, d, J=<br>
15.6 Hz), 6.13 - 6.16 (1H, m), 6.35 - 6.37 (1H, m), 7.15 (2H, t, J= 8.4 Hz), 7.33 -<br>
7.38 (3H, m), 7.99 - 8.01 (1H, m), 8.09 (1H, s). LC-MS calcd for C24H19FIN3O4S<br>
591.01, found 592.4 [M+H+].<br>
b) (rac-di-exo)-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide<br><br>
[00394] (rac-di-exo)-3 -(4-Fluoro-benzyl)-6-hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-4-<br>
one (0.100 g, 0.1692 mmol), potassium triphosphate (0.1075 g, 0.5076 mmol),<br>
sarcosine (TV-methyl glycine) (0.0094 g, 0.1015 mmol), and copper (I) iodide (0.00128<br>
g, 0.0677 mmol) were combined. Anhydrous N,N-dimethylformamide (3 mL) was<br>
added followed by N-methyl methanesulfonamide (0.09223 g, 0.8460 mmol). The<br>
solution was degassed and backfilled with nitrogen. The mixture was stirred at 100<br>
Â°C for 16 h. Upon cooling, the mixture was diluted with ethyl acetate (200 mL),<br>
washed with 1.0 M aqueous hydrochloric acid solution (2 Ã 100 mL), dried over<br>
magnesium sulfate, filtered, and concentrated in vacuo to a solid. Purification by<br>
flash column chromatography (Teledyne Isco RediSep column; 0 to 100% ethyl<br>
acetate in hexanes) afforded the desired product, (rac-di-ero)-N-{3-[3-(4-fluoro-<br>
benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide<br>
(0.00105 g, 0.0184 mmol, 10.8%), as a pale yellow solid. 1H NMR (400 MHz,<br>
CDCl3)d: 1.27 (3H, s), 1.56 (1H, d, J= 9.5 Hz), 1.66 (1H, d, J= 9.2 Hz), 2.19 (1H,<br>
s), 2.64 (1H, s), 2.75 (1H, d, J= 9.3 Hz), 3.19 (1H, bs), 3.39 (1H, d, J= 9.4 Hz), 3.44<br>
(1H, bs), 3.75 (1H, s), 4.32 (1H, d, J= 15.4 Hz), 5.22 (1H, d, J= 14.8 Hz), 6.11 - 6.13<br>
(1H, m), 6.36 - 6.38 (1H, m), 6.97 (1H, d, J= 8.6 Hz), 7.04 (2H, t, J= 8.6 Hz), 7.20 -<br>
7.24 (2H, m), 7.85 (1H, dd, J1 = 8.6 Hz, J2 = 2.2 Hz), 8.22 (1H, s). LC-MS calcd for<br>
C26H25FN4O6S2 572.12, found 573.3 [M+H+].<br>
[00395] Example 40: Cyclopropanesulfonic acid (3-(1R,2S,7R,8S)-[6-hydroxy-3-<br>
(3-methyl-butyl)-4-oxo-3-aza-tricvclo[6.2.1.02,7lundec-5-en-5-yl]-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]lthiadiazin-7-yl} -amide<br><br>
[00396] A reaction flask was charged with copper (I) iodide (20 mg, 0.11 mmol),<br>
sarcosine (N-methyl glycine) (14.7 mg, 0.17 mmol), cyclopropanesulfonamide (125<br>
mg, 1.04 mmol), (1R,2S,7R,8S)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyl)-3-aza-tricyclo[6.2.1.02,7]undec-5-en-<br>
4-one (prepared as described in Example 34, 115 mg, 0.21 mmol) and potassium<br>
phosphate (176 mg, 0.83 mmol). The flask was degassed and backfilled with<br>
nitrogen, and then anhydrous N,N-dimethylformamide (5 mL) was added. The<br>
resulting suspension was vigorously stirred at 100 Â°C for 3 h, and then allowed to cool<br>
to 25 Â°C. The mixture was passed through a plug of Celite and rinsed with 10%<br>
methanol/dichloromethane. The filtrate was concentrated in vacuo, and the residue<br>
was purified by prep-HPLC [Column Luna 5Âµ C18 (2) 100Ã AXIA 150 Ã 21.2 mm, 5<br>
micron, 30%-95% in 7 min @ 30 mL/min flow rate, 0.05% trifluoroacetic acid in<br>
acetonitrile/ 0.05% trifluoroacetic acid in water] to afford the desired product,<br>
cyclopropanesulfonic acid {3-(1R,2S,7R,8S)-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide (25 mg, 0.046 mmol, 22%), as a white solid. 1H<br>
NMR (400 MHz, DMSO-d6) d: 0.92 - 0.98 (10H, m), 1.20 - 1.64 (9H, m), 2.52 (1H,<br>
m), 2.62 (1H, s), 2.68 (1H, m), 3.00 (1H, d, J= 9.6 Hz), 3.07 (1H, m), 3.61 (1H, d, J=<br>
10.4 Hz), 3.66 (1H, m), 7.50 - 7.59 (3H, m), 10.17 (1H, s). LC-MS (ESI) calcd for<br>
C25H32N4O6S2 548.18, found 549.4 [M+H+].<br>
[00397] Example 41: N-{3-[(1R,2S,7R,8S)-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3 -aza-tricyclo [6.2.1.02,7]undec-5 -en-5-yl] -1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-benzenesulfonamide<br><br>
[00398] (1R,2S,7R,8S)-3 -(4-Fluoro-benzyl)-6-hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br>
(prepared as described in Example 19, 0.10 g, 0.17 mmol), cyclopropane sulfonic acid<br>
amide (0.21 mg, 1.36 mmol), sarcosine (N-methyl glycine) (0.02 g, 0.26 mmol),<br>
copper (I) iodide (0.03 g, 0.17 mmol), and potassium phosphate (0.22 g, 1.02 mmol)<br>
were combined and dissolved in N,N-dimethylformamide (10 mL). The flask was<br>
degassed and backfilled with nitrogen (3 Ã). The reaction was stirred at 100 Â°C for 4<br>
h. The mixture was allowed to cool to 25 Â°C, diluted with ethyl acetate (20 mL), and<br>
extracted with saturated aqueous sodium bicarbonate solution (2 Ã 20 mL). The<br>
combined organic layers were dried over magnesium sulfate, filtered and concentrated<br>
in vacuo. Purification by flash column chromatography (Teledyne Isco RediSep<br>
column; 0 to 8% methanol in dichloromethane) afforded the desired product, N- {3 -<br>
[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-<br>
5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-<br>
benzenesulfonamide (0.10 g, 0.16 mmol, 92%), as a white powder. 1H NMR (400<br>
MHz, DMSO-d6)d: 1.16 - 1.19 (3H, m), 1.38 - 1.57 (5H, m), 2.98 (1H, d, J= 8.4 Hz),<br>
3.51 (1H, d, J=9.2 Hz), 4.40 (1H,d, 7=15.6 Hz), 4.94 (1H,d,J= 15.6 Hz), 7.11 -<br>
7.15 (1H, m), 7.29 - 7.32 (2H, m), 7.39 - 7.47 (2H, m), 7.54 - 7.64 (4H, m), 7.74 -<br>
7.82 (3H, m), 10.74 (1H, s). LC-MS (ESI) calcd for C30H27FN4O6S2 622.69, found<br>
623.3 [M+H+].<br>
[00399] Example 42: (rac-di-exo)-Cyclopropanesulfonic acid {3-[6-hydroxy-3-(3-<br>
methyl-butyl)-4-oxo-11oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yll-1.1-dioxo-1,4-<br>
dihydro-1?6-benzo[l .2.4]thiadiazin-7-yl} -amide<br><br>
[00400] A reaction flask was charged with copper (I) iodide (20 mg, 0.11 mmol),<br>
sarcosine (TV-methyl glycine) (14.7 mg, 0.17 mmol), cyclopropanesulfonamide (125<br>
mg, 1.04 mmol), (rac-di-exo)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo [ 1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyl)-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (prepared as described in Example 33, 115 mg,<br>
0.21 mmol) and potassium phosphate (175 mg, 0.82 mmol). The flask was degassed<br>
and backfilled with nitrogen, and then anhydrous N,N-dimethylformamide (5 mL) was<br>
added. The resulting suspension was vigorously stirred at 100 Â°C for 5 h, and then<br>
allowed to cool to 25 Â°C. The mixture was passed through a plug of Celite and rinsed<br>
with 10% methanol/dichloromethane. The filtrate was concentrated in vacuo, and the<br>
residue was purified by prep-HPLC [Column Luna 5Âµ C18 (2) 100A AXIA 150 Ã<br>
21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min flow rate, 0.05% trifluoroacetic<br>
acid in acetonitrile/ 0.05% trifluoroacetic acid in water] to afford the desired product,<br>
(rac-di-exo)-cyclopropanesulfonic acid {3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-l 1-<br>
oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide (17 mg, 0.031 mmol, 15%), as a white solid. 1H<br>
NMR (400 MHz, DMSO-d6)d: 0.91 - 0.96 (10H, m), 1,40 - 1.76 (7H, m), 2.69 (1H,<br>
m), 3.00 (1H, bs), 3.29 (1H, m), 3.84 (2H, m), 4.74 (2H, m), 7.51 - 7.59 (3H, m),<br>
10.17 (1H, s). LC-MS (ESI) calcd for C24H30N4O7S2 550.16, found 551,4 [M+H+].<br>
[00401] Example 43: (rac-di-exo)-Cyclopropanesulfonic acid {3-[3-(3,3-dimethyl-<br>
butyl)-6-hydroxy-4-oxo-3 -aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-amide<br><br>
a)(rac-di-exo)-3-{(3,3-Dimethyl-butyl)-[2-(7-iodo-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-amino}-bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid methyl ester<br><br>
[00402] To a solution of (rac-di-exo)-3-(3,3-dimethyl-butylamino)-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester (prepared as described in<br>
Example 32a, 227.8 mg, 0.907 mmol) in N,N-dimethylformamide (3 mL) was added<br>
(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3-yl)-acetic acid (prepared<br>
as described in US patent application US 2008/0031852, 398.2 mg, 1.088 mmol) and<br>
the mixture was vortexed until all material had completely dissolved. A 1.0 M<br>
solution of N,N-dicyclohexylcarbodiimide in dichloromethane (1.179 mL, 1.179<br>
mmol) was added to the above solution and the mixture was stirred at 25 Â°C for 18 h<br>
under a nitrogen atmosphere. The precipitated N,N-dicyclohexylurea was removed by<br>
filtration over Celite, the filter cake was washed with dichloromethane (3 Ã 5 mL),<br>
and the solvent was removed in vacuo. The residue was dissolved in a 1:1 mixture of<br>
ethyl acetate and hexanes (20 mL), washed with saturated aqueous brine solution,<br>
saturated aqueous sodium bicarbonate solution and water. The layers were separated<br>
and the aqueous layers were back-extracted with a 1:1 mixture of ethyl acetate and<br>
hexanes (20 mL). The combined organic layers were dried over sodium sulfate,<br>
filtered, and concentrated in vacuo to afford the crude product, (rac-di-exo)-3- {(3,3-<br>
dimethyl-butyl)-[2-(7 -iodo-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester, as a yellow<br>
oil, which was used in the next step without any further purification. LC-MS calcd<br>
for C24H30IN3O5S 599.10, found 600.3 [M+H+].<br>
b)(rac-di-exo)-3-(3,3-Dimethyl-butyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-4-<br>
one<br><br>
[00403] The crude (rac-di-exo)-3-{(3,3-dimethyl-butyl)-[2-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-amino}-bicyclo[2,2,1]hept-5-ene-2-<br>
carboxylic acid methyl ester (877.2 mg, 0.907 mmol) was dissolved in ethanol (20<br>
mL). To this solution was added a 21 wt. % solution of sodium ethoxide in ethanol<br>
(1.176 g, 3.628 mmol) and the reaction mixture was stirred at 25 Â°C for 2 h. A 1.0 M<br>
aqueous hydrochloric acid solution (20 mL) was added upon which the product began<br>
to precipitate. The reaction mixture was stirred for another 30 min before the<br>
precipitate was collected by vacuum filtration. The solid was washed with 1.0 M<br>
aqueous hydrochloric acid solution followed by water and was then dried in vacuo.<br>
The resulting solid was then triturated with methanol, filtered and dried in vacuo.<br>
Further purification by flash column chromatography (Teledyne Isco RediSep<br>
column; 0 to 50% ethyl acetate in hexanes) afforded the desired product, (rac-di-exo)-<br>
3 -(3,3 -dimethyl-butyl)-6-hydroxy- 5-(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-4-one (154.1<br>
mg, 0.272 mmol, 30%), as a white solid. 1H NMR (400 MHz, CDCl3d: 1.01 (9H, s),<br>
1.32 - 2.00 (4H, m), 2.19 (1H, d, J= 2.2 Hz), 2.75 (1H, d, J= 9.5 Hz), 3.10 - 3.52<br>
(4H, m), 3.78 - 3.88 (1H, m), 6.17 - 6.20 (1H, m), 6.40 - 6.46 (1H, m), 7.01 (1H, d,J<br>
= 8.6 Hz), 7.84 (1H, dd, J1 = 8.5 Hz, J2 = 1.5 Hz), 8.22 (1H, s). LC-MS calcd for<br>
C23H26rN3O4S 567.07, found 568.3 [M+H+].<br>
c) (rac-di-exo)-Cyclopropanesulfonic acid {3-[3-(3,3-dimethyl-butyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-<br>
1?6-benzo[ 1,2,4]thiadiazin-7-yl} -amide<br><br>
[00404] (rac-di-exo)-3-(3,3-Dimethyl-butyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-4-<br>
one (0.155 g, 0.255 mmol), potassium triphosphate (0.271 g, 1.275 mmol), sarcosine<br>
(TV-methyl glycine) (0.027 g, 0.306 mmol), and copper (I) iodide (0.024 g, 0.128<br>
mmol) were combined. Anhydrous N,N-dimethylformamide (7 mL) was added<br>
followed by cyclopropanesulfonic acid amide (0.155 g, 1.275 mmol). The solution<br>
was degassed and backfilled with nitrogen. The mixture was stirred at 100 Â°C for 16<br>
h. Upon cooling, the mixture was diluted with ethyl acetate (200 mL), washed with<br>
1.0 M aqueous hydrochloric acid solution (2 Ã 100 mL), dried over magnesium<br>
sulfate, filtered, and concentrated in vacuo to a solid. Purification by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 100% ethyl acetate in hexanes)<br>
afforded the desired product, (rac-di-exo)-cyclopropanesulfonic acid {3-[3-(3,3-<br>
dimethyl-butyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-amide (0.089 g, 0.159 mmol,<br>
62.5%), as a pale yellow solid. 1H NMR (400 MHz, CDCl3) d: 1.00 (9H, s), 1.14 -<br>
1.21 (2H, m), 1.24- 1.37 (2H,m), 1.51 - 1.63 (2H, m), 2.49 - 2.61 (1H, m), 2.73 -<br>
2.76 (1H, m), 3.09 - 3.16 (1H, m), 3.19 - 3.25 (1H, m), 3.38-3.46 (2H, m), 3.79 -<br>
3.88 (1H, m), 6.17 - 6.19 (1H, m), 6.38 - 6.40 (1H, m), 7.18 - 7.25 (1H, m), 7.57 (1H,<br>
s), 7.63 - 7.66 (1H, m), 7.73 - 7.79 (1H, m). LC-MS (ESI) calcd for C26H32N4O6S2<br>
560.18, found 561.6 [M+H+].<br>
[00405] Example 44: N-[3-(1R,2S,7R,8S)-3-Cyclopentyl-6-hydroxy-4-oxo-3-aza-<br>
tricvclo[6.2.1.02,7]undec-5-en-5-yl)1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl]-methanesulfonamide<br><br>
a) (1S,2R,3S,4R)-3-Cyclopentylamino-bicyclo[2,2, 1]heptane-2-carboxylic acid<br>
ethyl ester<br><br>
[00406] Cyclopentanone (0.12 mL, 1.38 mmol) was added to a solution of<br>
(1S,2R,3S,4R)-3-amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (prepared<br>
as described in Example 6k, 230 mg, 1.26 mmol) in anhydrous methanol (10 mL) at<br>
25 Â°C under a nitrogen atmosphere. After stirring for 10 min, glacial acetic acid (0.5<br>
mL) and sodium cyanoborohydride (260 mg, 3.15 mmol) were added sequentially,<br>
and the resulting mixture was stirred at 50 Â°C for 30 min. The reaction mixture was<br>
poured into saturated aqueous sodium bicarbonate solution and extracted with ethyl<br>
acetate. The combined organic layers were washed with saturated aqueous brine<br>
solution, dried over sodium sulfate and filtered. The filtrate was concentrated in<br>
vacuo to afford the desired product, (1S,2R,3S,4R)-3-cyclopentylamino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (237 mg, 0.94 mmol, 75%), as a<br>
yellow oil. LC-MS (ESI) calcd for C15H25NO2 251.19, found 252.0 [M+H+].<br>
b)N-[3-(1R,2S,7R,8S)-3-Cyclopentyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide<br><br>
[00407] To a stirred solution of (1S,2R,3S,4R)-3-cyclopentylamino-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (150 mg, 0.60 mmol) and (7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetic<br>
acid (prepared as described in Example lg, 181 mg, 0.54 mmol) in anhydrous N,N-<br>
dimethylformamide (5 mL) under a nitrogen atmosphere, iV-methylmorpholine (0.12<br>
mL, 1.08 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride<br>
(104 mg, 0.54 mmol) were added sequentially. The mixture was stirred at 25 Â°C for<br>
45 min, triethylamine (0.25 mL, 1.76 mmol) was added and the resulting mixture was<br>
stirred at 50 Â°C for 60 h. The reaction mixture was allowed to cool to 25 Â°C, diluted<br>
with ethyl acetate, washed with 1.0 M aqueous hydrochloric acid solution and<br>
saturated aqueous brine solution, dried over magnesium sulfate and filtered. The<br>
filtrate was concentrated in vacuo and the residue was purified by prep-HPLC<br>
[Column Luna 5Âµ C18 (2) 100A AXIA 150 Ã 21.2 mm, 5 micron, 30%-95% in 7 min<br>
@ 30 mL/min flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05%<br>
trifluoroacetic acid in water] to afford the desired product, N-[3-(1R,2S,7R,8S)-3-<br>
cyclopentyl-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1 -dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide (80 mg, 0.15<br>
mmol, 26%), as a yellow solid. 1H NMR (400 MHz, DMSO-d6) d: 1.20 - 1.65 (8H,<br>
m), 1.75 - 1.95 (6H, m), 2.42 (1H, s), 2.60 (1H, s), 2.99 (1H, d, J= 9.2 Hz), 3.05 (3H,<br>
s), 3.60 (1H, d, J=9.2 Hz), 3.93 (1H, m), 7.48 - 7.58 (3H, m), 10.17 (1H, s). LC-MS<br>
(ESI) calcd for C23H28N4O6S2 520.15, found 521,4 [M+H+].<br>
[00408] Example 45: (rac-di-exo)-Cyclopropanesulfonic acid {3-[6-hydroxy-3-(3-<br>
methyl-butyl)-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5 -yl]-1.1 -dioxo-1,4-<br>
dihydro- 1?6-benzo[ 1,2,4]thiadiazin-7-yl} -amide<br><br>
a) (rac-di-exo)-3-[[2-(7-Iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-bicyclo[2,2,1]hept-5-<br>
ene-2-carboxylic acid methyl ester<br><br>
[00409] To a solution of (rac-di-exo)-3-(3-methyl-butylamino)-bicyclo[2,2, 1]hept-<br>
5-ene-2-carboxylic acid methyl ester (prepared as described in Example 3 lb, 214.8<br>
mg, 0.906 mmol) in N,N-dimethylformamide (3 mL) was added (7-iodo-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in US<br>
patent application US 2008/0031852, 397.7 mg, 1.087 mmol) and the mixture was<br>
vortexed until all material had completely dissolved. A 1.0 M solution of N,N-<br>
dicyclohexylcarbodiimide in dichloromethane (1.178 mL, 1.178 mmol) was added to<br>
the above solution and the mixture was stirred at 25 Â°C for 18 h under a nitrogen<br>
atmosphere. The precipitated N,N-dicyclohexylurea was removed by filtration over<br>
Celite, the filter cake was washed with dichloromethane (3 Ã 5 mL), and the solvent<br>
was removed in vacuo. The residue was dissolved in a 1:1 mixture of ethyl acetate<br>
and hexanes (20 mL), washed with saturated aqueous brine solution, saturated<br>
aqueous sodium bicarbonate solution and water. The layers were separated and the<br>
aqueous layers were back-extracted with a 1:1 mixture of ethyl acetate and hexanes<br>
(20 mL). The combined organic layers were dried over sodium sulfate, filtered, and<br>
concentrated in vacuo to afford the crude product, (rac-di-exo)-3-[[2-(7-iodo-l ,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-<br>
bicyclo[2,2,1]hept-5-ene-2-carboxylic acid methyl ester, as a yellow oil, which was<br>
used in the next step without any further purification. LC-MS calcd for C23H28IN3O5S<br>
585.08, found 586.3 [M+H+].<br>
b) (rac-di-exo)-6-Hydroxy-5-(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyl)-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-<br>
dien-4-one<br><br>
[00410] The crude (rac-di-exo)-3-[[2-(7-iodo-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-3-yl)-acetyl]-(3-methyl-butyl)-amino]-bicyclo[2,2,1 ]hept-5-<br>
ene-2-carboxylic acid methyl ester was dissolved in ethanol (20 mL). To this solution<br>
was added a 21 wt. % solution of sodium ethoxide in ethanol (1.174 g, 3.624 mmol)<br>
and the reaction mixture was stirred at 25 Â°C for 2 h. A 1.0 M aqueous hydrochloric<br>
acid solution (20 mL) was added upon which the product began to precipitate. The<br>
reaction mixture was stirred for another 30 min before the precipitate was collected by<br>
vacuum filtration. The solid was washed with 1.0 M aqueous hydrochloric acid<br>
solution followed by water and was then dried in vacuo. The resulting solid was then<br>
triturated with methanol, filtered and dried in vacuo. Further purification by flash<br>
column chromatography (Teledyne Isco RediSep column; 0 to 50% ethyl acetate in<br>
hexanes) afforded the desired product, (rac-di-exo)-6-hydroxy-5-(7-iodo-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3-yl)-3 -(3 -methyl-butyl)-3 -aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-4-one (28.7 mg, 0.0519 mmol, 5.7% over two<br>
steps), as an off-white solid. 1H NMR (400 MHz, CDCl3)d: 0.98 (3H, d, J= 3.3 Hz),<br>
0.99 (3H, d, J= 2.9 Hz), 1,47 - 1.68 (6H, m), 2.75 (1H, d, J= 9.3 Hz), 3.08 - 3.32<br>
(2H, m), 3.39 - 3.44 (2H, m), 3.82 - 3.89 (1H, m), 6.18 - 6.20 (1H, m), 6.39 - 6.41<br>
(1H, m), 6.99 (1H, d, J= 8.6 Hz), 7.84 (1H, d, J= 10.8 Hz), 8.21 (1H, s). LC-MS<br>
calcd for C22H24IN3O4S 553.05, found 554.1 [M+H+].<br>
c) (rac-di-exo)-Cyclopropanesulfonic acid {3-[6-hydroxy-3-(3-methyl-butyl)-<br>
4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -amide<br><br>
[00411] (rac-di-exo)-6-Hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-3 -yl)-3 -(3 -methyl-butyl)-3 -aza-tricyclo [6.2.1.02,7]undeca-5,9-<br>
dien-4-one (0.029 g, 0.052 mmol), potassium triphosphate (0.055 g, 0.259 mmol),<br>
sarcosine (N-methyl glycine) (0.006 g, 0.062 mmol), and copper (I) iodide (0.005 g,<br>
0.026 mmol) were combined. Anhydrous N,N-dimethylformamide (7 mL) was added<br>
followed by cyclopropanesulfonic acid amide (0.031 g, 0.259 mmol). The solution<br>
was degassed and backfilled with nitrogen. The mixture was stirred at 100 Â°C for 16<br>
h. Upon cooling, the mixture was diluted with ethyl acetate (200 mL), washed with<br>
1.0 M aqueous hydrochloric acid solution (2 Ã 100 mL), dried over magnesium<br>
sulfate, filtered, and concentrated in vacuo to a solid. Purification by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 100% ethyl acetate in hexanes)<br>
afforded the desired product, (rac-di-exo)-cyclopropanesulfonic acid {3-[6-hydroxy-<br>
3-(3-methyl-butyl)-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-amide (0.009 g, 0.016 mmol, 31.6%), as<br>
a pale yellow solid. 1H NMR (400 MHz, CDCl3)d: 0.98 - 1.08 (6H, m), 1.17 - 1.26<br>
(3H, m), 1.52 - 1.73 (4H, m), 2.48 - 2.62 (2H, m), 2.75 - 2.77 (1H, m), 3.08 - 3.15<br>
(1H, m), 3.39 - 3.44 (2H, m), 3.83 - 3.91 (1H, m), 6.19 (1H, dd, J1 = 5.5 Hz, J2 = 3.1<br>
Hz), 6.40 (1H, dd, J1 = 5.4 Hz, J2 = 4.0 Hz), 7.01 (1H, s), 7.24 (1H, t, J= 7.1 Hz),<br>
7.63 - 7.65 (1H, m), 7.70 - 7.73 (1H, m). LC-MS (ESI) calcd for C25H30N4O6S2<br>
546.16, found 547.4 [M+H+].<br>
[00412] Example 46: (rac-di-exo)Cyclopropanesulfonic acid (3-[3-(4-fluoro-<br>
benzyl)6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-<br>
1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-7-yl} -amide<br><br>
[00413] (rac-di-exo)-3 -(4-Fluoro-benzyl)-6-hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-4-<br>
one (prepared as described in Example 39a, 0.169 g, 0.285 mmol), potassium<br>
triphosphate (0.303 g, 1,426 mmol), sarcosine (N-methyl glycine) (0.031 g, 0.342<br>
mmol), and copper (I) iodide (0.027 g, 0.146 mmol) were combined. Anhydrous N,N-<br>
dimethylformamide (7 mL) was added followed by cyclopropanesulfonic acid amide<br>
(0.173 g, 1,426 mmol). The solution was degassed and backfilled with nitrogen. The<br>
mixture was stirred at 100 Â°C for 16 h. Upon cooling, the mixture was diluted with<br>
ethyl acetate (200 mL), washed with 1.0 M aqueous hydrochloric acid solution (2 *<br>
100 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to a solid.<br>
Purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
100% ethyl acetate in hexanes) afforded the desired product, (rac-di-exo)-<br>
cyclopropanesulfonic acid {3-[3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide (0.093 g, 0.159 mmol, 55.8%), as a pale yellow<br>
solid. 1H NMR (400 MHz, CDCl3)d: 0.97 - 1.04 (2H, m), 1.14-1.20 (2H, m), 1.53<br>
(1H, d, J= 9.4 Hz), 1.66 (1H, d, J= 9.5 Hz), 2.48 - 2.61 (2H, m), 2.74 (1H, d, J= 9.4<br>
Hz), 3.37 - 3.41 (2H, m), 4.32 (1H, d, J= 15.3 Hz), 5.19 (1H, d, J= 14.8 Hz), 6.09 -<br>
6.11 (1H, m), 6.33 - 6.36 (1H, m), 7.02 (2H, t, J= 8.6 Hz), 7.16 - 7.23 (3H, m), 7.63<br>
(1H, dd, J1 = 9.3 Hz, J2 = 2.3 Hz), 7.77 (1H, d, J= 2.3 Hz), 8.04 (1H, s). LC-MS<br>
(ESI) calcd for C27H25FN4O6S2 584.12, found 585.2 [M+H+].<br>
[00414] Example 47: N-[3-(1R,2S,7R,8S)-(3-Cyclopentyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclor6.2.1.02,7lundec-5-en-5-yl)1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl]-methanesulfonamide-N-isopropyl carbamate<br><br>
[00415] N-[3-(1R,2S,7R,8S)-3-cyclopentyl-e-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide (prepared as described in Example<br>
44, 48.5 mg, 0.093 mmol) was dissolved in anhydrous pyridine (2 mL) under a<br>
nitrogen atmosphere, a 1.0 M solution of isopropyl chloroformate in toluene (0.46<br>
mL, 0.46 mmol) was added slowly. The resulting mixture was stirred at 25 Â°C for 15<br>
min, LC-MS showed the completion of the reaction. The reaction was quenched with<br>
methanol (1 mL) and the resulting mixture was concentrated in vacuo. The residue<br>
was purified by prep-HPLC [Column Luna 5Âµ C18 (2) 100A AXIA 150 Ã 21.2 mm, 5<br>
micron, 30%-95% in 7 min @ 30 mL/min flow rate, 0.05% trifluoroacetic acid in<br>
acetonitrile/ 0.05% trifluoroacetic acid in water] to afford the desired product, N-[3-<br>
(1R,2S,7R,8S)-(3-cyclopentyl-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-<br>
5-yl)-1,1 -dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-7-yl]-methanesulfonamide-N-<br>
isopropyl carbamate (15 mg, 0.025 mmol, 27%), as a yellow solid. 1H NMR (400<br>
MHz, DMSO-d6) d: 1.19 (6H, d, J= 6.0 Hz), 1.30 - 1.65 (8H, m), 1.75 - 1.95 (6H, m),<br>
2.43 (1H, m), 2.61 (1H, m), 3.00 (1H, m), 3.55 (1H, m), 3.62 (3H, s), 3.95 (1H, m),<br>
4.94 (1H, m), 7.57 (1H, d, J= 9.2 Hz), 7.64 (1H, dd, J= 8.8, 1.6 Hz), 7.97 (1H, s).<br>
LC-MS (ESI) calcd for C27H34N4O8S2 606.16, found 607.3 [M+H+].<br>
[00416] Example 48: (rac-di-exo)-N-[3-(3-Cyclopentyl-6-hydroxy-4-oxo-11-oxa-<br>
3-aza-tricyclo[6.2.1.02,7lundec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide<br><br>
a) (rac-di-exo)-3-Cyclopentylamino-7-oxa-bicyclo[2,2,1 ]heptane-2-carboxylic<br>
acid methyl ester<br><br>
[00417] Cyclopentanone (0.56 mL, 6.37 mmol) was added to a solution of (rac-di-<br>
exo)-3-amino-7-oxa-bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (prepared<br>
as described in Example 8a, 1.10 g, 6.37 mmol) in anhydrous methanol (15 mL) at 25<br>
Â°C under a nitrogen atmosphere. After stirring for 20 min, glacial acetic acid (0.75<br>
mL) and sodium cyanoborohydride (1.0 g, 15.92 mmol) were added sequentially, and<br>
the resulting mixture was stirred at 50 Â°C for 1 h. The reaction mixture was poured<br>
into saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate.<br>
The combined organic layers were washed with saturated aqueous brine solution,<br>
dried over sodium sulfate and filtered. The filtrate was concentrated in vacuo to<br>
afford the desired product, (rac-di-exo)-3-cyclopentylamino-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (1.06 g, 4.43 mmol, 70%), as a<br>
yellow oil. LC-MS (ESI) calcd for C13H21NO3 239.15, found 240.2 [M+H+].<br>
b) (rac-di-exo)-N-[3-(3-Cyclopentyl-6-hydroxy-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl]-methanesulfonamide<br><br>
[00418] To a stirred solution of (rac-di-exo)-3-cyclopentylamino-7-oxa-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid methyl ester (170 mg, 0.71 mmol) and (7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetic<br>
acid (prepared as described in Example lg, 197 mg, 0.60 mmol) in anhydrous N,N-<br>
dimethylformamide (5 mL) under a nitrogen atmosphere, N-methylmorpholine (0.132<br>
mL, 1.20 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride<br>
(115 mg, 0.60 mmol) were added sequentially. The mixture was stirred at 25 Â°C for 1<br>
h, triethylamine (0.34 mL, 2.4 mmol) was added and the resulting mixture was stirred<br>
at 50 Â°C for 1 h. The reaction mixture was allowed to cool to 25 Â°C, diluted with ethyl<br>
acetate, washed with 1.0 M aqueous hydrochloric acid solution and saturated aqueous<br>
brine solution, dried over magnesium sulfate and filtered. The filtrate was<br>
concentrated in vacuo and the residue was purified by prep-HPLC [Column Luna 5Âµ<br>
C18 (2) 100Ã AXIA 150 x 21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min<br>
flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic acid in<br>
water] to afford the desired product, (rac-di-exo)-N-[3-(3-cyclopentyl-6-hydroxy-4-<br>
oxo-11 -oxa-3 -aza-tricyclo[6.2.1.02,7]undec-5 -en-5-yl)-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide (120 mg, 0.23 mmol, 38%), as an<br>
off-white solid. 1H NMR (400 MHz, DMSO-d6) d: 1,48 - 1.96 (12H, m), 3.05 (3H, s),<br>
3.30 (1H, d, J= 8.0 Hz), 3.89 (1H, d, J= 9.2 Hz), 4.13 (1H, m), 4.57 (1H, s), 4.74<br>
(1H, s), 7.49 - 7.58 (3H, m), 10.17 (1H, s). LC-MS (ESI) calcd for C22H26N4O7S2<br>
522.12, found 523.4 [M+H+].<br>
[00419] Example 49: N-(3-[(2S,7R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.2.02,7ldodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzon[1,2,4]thiadiazin-<br>
7-yl} -methanesulfonamide<br><br>
a)4-Oxa-tricyclo[5.2.2.02,6]undecane-3,5-dione<br><br>
[00420] 4-Oxa-tricyclo[5.2.2.02,6]undec-8-ene-3,5-dione (4.00 g, 22.45 mmol) was<br>
dissolved in ethyl acetate (100 mL). 10% Palladium on carbon (400 mg) was added.<br>
The flask was degassed and backfilled with hydrogen gas via balloon. The mixture<br>
was stirred at 25 Â°C for 16 h. The mixture was passed through a plug of Celite and the<br>
filtrate was concentrated in vacuo to afford a thick clear oil. Purification by flash<br>
column chromatography (Teledyne Isco RediSep column; 0 to 30% ethyl acetate in<br>
hexanes) afforded the desired product, 4-oxa-tricyclo[5.2.2.02,6]undecane-3,5-dione<br>
(2.92 g, 16.20 mmol, 72%), as a white powder. 1H NMR (400 MHz, DMSO-d6) d:<br>
1.55 - 1.64 (6H, m), 1.76 (2H, d, J=9.2 Hz), 2.25 (2H, s), 3.11 (2H, s). LC-MS (ESI)<br>
calcd for C10H12O3 180.20, found 181.0 [M+H+].<br>
b) (2S,3R)-Bicyclo[2.2.2]octane-2,3-dicarboxylic acid monomethyl ester<br><br>
[00421] 4-Oxa-tricyclo[5.2.2.02,6]undec-3,5-dione (0.90 g, 4.99 mmol) was<br>
dissolved in toluene (50 mL) and carbon tetrachloride (50 mL). Quinine (1.78 g, 5.49<br>
mmol) was added and the mixture was cooled to - 55 Â°C. Methanol (0.61 mL, 14.97<br>
mmol) was added dropwise to the above mixture. The reaction was stirred at - 55 Â°C<br>
for 18 h. The reaction was warmed to 25 Â°C and concentrated in vacuo. The crude<br>
material was dissolved in ethyl acetate (50 mL) and washed with 1.0 M aqueous<br>
hydrochloric acid solution (2 Ã 40 mL). The organic layer was further washed with<br>
saturated aqueous brine solution (20 mL), dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo to afford a clear oil. Purification by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 50% ethyl acetate in hexanes)<br>
afforded the desired product, (2S,3R)-bicyclo[2.2.2]octane-2,3-dicarboxylic acid<br>
monomethyl ester (1.10 g, 5.18 mmol, 92%), as a clear oil. 1H NMR (400 MHz,<br>
DMSO-d6)d: 1.31 (2H, dd, J1 = 20.0 Hz, J2 = 12.4 Hz), 1.52 - 1.54 (4H, m), 1.63<br>
(1H, t, J= 10.4 Hz), 1.75 (1H, t, J= 9.6 Hz), 1.87 (2H, bs), 2.84 (2H, dd, J1 = 29.6<br>
Hz, J2 = 10.8 Hz), 3.52 (3H, s), 12.01 (1H, s). LC-MS (ESI) calcd for C11H16O4<br>
212.24, found 213.1 [M+H+].<br>
c) (2R,3S)-3-Benzyloxycarbonylamino-bicyclo[2.2.2]octane-2-carboxylic acid<br>
methyl ester<br><br>
[00422] (2S,3R)-Bicyclo[2.2.2]octane-2,3-dicarboxylic acid monomethyl ester<br>
(1.01 g, 4.76 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL). The flask<br>
was degassed and backfilled with nitrogen and the mixture was cooled to 0 Â°C.<br>
Triethylamine (1.99 mL, 14.28 mmol) was added followed by the dropwise addition<br>
of ethyl chloroformate (0.91 mL, 9.52 mmol) with vigorous stirring. The mixture was<br>
stirred at 0 Â°C for 1 h. Sodium azide (0.93 g, 14.28 mmol) was dissolved in water (5<br>
mL) and added to the reaction mixture at 0 Â°C. The mixture was stirred at 0 Â°C for 5<br>
min. The ice bath was removed. The mixture was warmed to 25 Â°C and was stirred<br>
for 2 h. The mixture was poured into water (50 mL) and the product extracted into<br>
ethyl acetate (50 mL). The organic layer was further washed with half-saturated<br>
aqueous sodium bicarbonate solution (2 Ã 20 mL), saturated aqueous brine solution<br>
(20 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
clear oil. The oil was dissolved in anhydrous benzene (10 mL) and refluxed while<br>
stirring under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was concentrated<br>
in vacuo to afford a slightly yellow oil. The oil was dissolved in dichloromethane (10<br>
mL) and benzyl alcohol (0.54 mL, 5.24 mmol) was added followed by triethylamine<br>
(1.33 mL, 9.52 mmol). The mixture was refluxed under nitrogen for 16 h. Upon<br>
cooling to 25 Â°C the solution was concentrated in vacuo to afford a golden oil.<br>
Purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
20% ethyl acetate in hexanes) afforded the desired product, (2R,3S)-3-<br>
benzyloxycarbonylamino-bicyclo[2.2.2]octane-2-carboxylic acid methyl ester (0.58 g,<br>
1.83 mmol, 38%), as a clear oil. 1H NMR (400 MHz, CDCl3) d: 1.18 - 1.28 (2H, m),<br>
1,42 - 1.50 (5H, m), 1.73 - 1.96 (3H, m), 2.88 (1H, d, J1 = 5.6 Hz), 3.27 (1H, s), 3.42<br>
(3H, s), 4.00 - 4.04 (1H, m), 4.97 (2H, dd, J1 = 46.4 Hz, J2 = 12.8 Hz), 7.06 (1H, d, J<br>
= 9.6 Hz), 7.24 - 7.34 (4H, m). LC-MS (ESI) calcd for C18H23NO4 317.38, found<br>
317.9 [M+H+].<br>
d) (2R,3S)-3-Amino-bicyclo[2.2.2]octane-2-carboxylic acid methyl ester<br>
hydrochloride<br><br>
[00423J (2R,3S)-3-Benzyloxycarbonylamino-bicyclo[2.2.2]octane-2-carboxylic<br>
acid methyl ester (0.57 g, 1.79 mmol) was dissolved in ethyl acetate (20 mL). 10%<br>
Palladium on carbon (60 mg) was added. The flask was degassed and backfilled with<br>
hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The mixture<br>
was passed through a plug of Celite and the filtrate was concentrated in vacuo to<br>
afford a thick clear oil. The oil was dissolved in diethyl ether (6 mL) and added<br>
dropwise with vigorous stirring to a mixture of 4.0 M solution of hydrochloric acid in<br>
1,4-dioxane (1.02 mL) and diethyl ether (10 mL). The desired product began to<br>
precipitate as a white solid. The mixture was stirred for 20 min. The precipitate was<br>
collected by vacuum filtration, washed with additional diethyl ether (5 mL). The<br>
solid was further dried in vacuo for 1 h to afford the desired product, (2R,3S)-3-<br>
amino-bicyclo[2,2,2]octane-2-carboxylic acid methyl ester hydrochloride (0.33 g,<br>
1.50 mmol, 84%), as a white powder. 1HNMR (400 MHz, DMSO-d6)d: 1.38 (2H,<br>
dd, J1 = 21.2Hz, J2=13.6Hz), 1.55 -1.63 (5H, m), 1.76- 1.89 (3H, m), 3.02 (1H,<br>
dd, J1 = 10.0 Hz, J2 = 2.4 Hz), 3.47 (1H, bs), 3.65 (3H, s), 7.97 (3H, s). LC-MS (ESI)<br>
calcd for C10H17NO2 (free amine) 183.25, found 184.2 [M+H+].<br>
e) (2R,3S)3-(4-Fluoro-benzylamino)-bicyclo[2.2.2]octane-2-carboxylic acid<br>
methyl ester<br><br>
[00424] (2R,3S)-3-Amino-bicyclo[2,2,2]octane-2-carboxylic acid methyl ester<br>
hydrochloride (0.34 g, 1.54 mmol) was dissolved in methanol (10 mL). Sodium<br>
acetate (0.25 g, 3.08 mmol) was added followed by 4A powdered molecular sieves<br>
(0.34 g) and 4-fluoro-benzaldehyde (0.16 mL, 1.54 mmol). Sodium<br>
cyanoborohydride (0.19 g, 3.08 mmol) was added and the mixture was stirred at 25 Â°C<br>
for 16 h. The mixture was poured into a mixture of saturated aqueous sodium<br>
bicarbonate solution (20 mL) and ethyl acetate (30 mL). After shaking, both layers<br>
were passed through a plug of Celite. The organic layer was further washed with<br>
saturated aqueous sodium bicarbonate solution (10 mL), saturated aqueous brine<br>
solution (10 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to<br>
afford the crude product, (2R,3S)-3-(4-fluoro-benzylamino)-bicyclo[2,2,2]octane-2-<br>
carboxylic acid methyl ester (0.32 g, 1.11 mmol, 72%), as a clear oil. LC-MS (ESI)<br>
calcd for C17H22FNO2 291.36, found 292.2 [M+H+].<br>
f) N- {3-[(2S,7R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.2.02,7]dodec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro- 1?6-benzo [ 1,2,4]thiadiazin-<br>
7-yl} -methanesulfonamide<br><br>
[00425] (2R,3S)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,2]octane-2-carboxylic acid<br>
methyl ester (93 mg, 0.32 mmol) was dissolved in anhydrous N,N-dimethylformamide<br>
(4 mL). (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-<br>
3-yl)-acetic acid (prepared as described in Example lg, 107 mg, 0.32 mmol) was<br>
added followed by N-methylmorpholine (74 ÂµL, 0.67 mmol). The mixture was stirred<br>
until everything dissolved, approximately 5 min. l-(3-Dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (65 mg, 0.34 mmol) was added and the mixture was<br>
stirred at 25 Â°C for 16 h. The reaction was quenched via addition of saturated aqueous<br>
sodium bicarbonate solution (20 mL). The mixture was extracted with ethyl acetate<br>
(3 Ã30 mL). The combined organic layers were washed with saturated aqueous brine<br>
solution (20 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to<br>
afford a golden oil. The oil was dissolved in ethanol (5 mL). A 21 wt. % solution of<br>
sodium ethoxide in ethanol (0.36 mL, 0.96 mmol) was added. The reaction was<br>
refluxed for 16 h. The reaction was quenched via the addition of 1.0 M aqueous<br>
hydrochloric acid solution (10 mL). The mixture was extracted with ethyl acetate (3<br>
Ã 20 mL). The organic layer was further washed with saturated sodium bicarbonate<br>
solution (2 Ã 20 mL), saturated aqueous brine solution (20 mL), dried over<br>
magnesium sulfate, filtered, and concentrated in vacuo to afford a clear oil.<br>
Purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
20% ethyl acetate in dichloromethane) afforded the desired product, N-{3-[(2S,7R)-3-<br>
(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.11 g,<br>
0.19 mmol, 59%), as a white powder. 1HNMR (400 MHz, DMSO-d6)d: 1.39 (2H, d,<br>
J= 8.0 Hz), 1.54 - 1.59 (8H, m), 1.91 (1H, s), 2.14 (1H, s), 3.06 (3H, s), 3.75 (1H, d, J<br>
= 11.6 Hz), 4.28 (1H, d, J= 15.2 Hz), 5.03 (1H, d, J= 15.6 Hz), 7.13 - 7.17 (2H, m),<br>
7.34 - 7.37 (2H, m), 7.50 - 7.60 (3H, m), 10.18 (1H, s). LC-MS (ESI) calcd for<br>
C26H27FN4O6S2 574.64, found 575.1 [M+H+]. m.p.: 203.8 - 205.7 Â°C. ee = 94.4%<br>
[HPLC-analysis: Chiralpak AS-RH 4.6 Ã 250 mm, 5 micron, 0.8 mL/min, 310 nm].<br>
[00426] Example 50: cis-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricvclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a) cis-Bicyclo[2.2.2]octane-2,3-dicarboxylic acid monomethyl ester<br><br>
[00427] 4-Oxa-tricyclo[5.2.2.02,6]undec-8-ene-3,5-dione (1.00 g, 5.61 mmol) was<br>
dissolved in methanol (20 mL). 10% Palladium on carbon (100 mg) was added. The<br>
flask was degassed and backfilled with hydrogen gas via balloon. The mixture was<br>
stirred at 25 Â°C for 16 h. The mixture was passed through a plug of Celite and the<br>
filtrate was left to stand at 25 Â°C for 72 h. The solution was then concentrated in<br>
vacuo to afford a clear oil. Purification by flash column chromatography (Teledyne<br>
Isco RediSep column; 0 to 60% ethyl acetate in hexanes) afforded the desired product,<br>
cz's-bicyclo[2.2.2]octane-2,3-dicarboxylic acid monomethyl ester (1.10 g, 5.18 mmol,<br>
92%), as a clear oil. 1H NMR (400 MHz, DMSO-d6) d: 1.31 (2H, dd, J1 = 20.0 Hz, J2<br>
= 12.4 Hz), 1.52 - 1.54 (4H, m), 1.63 (1H, t, J= 10.4 Hz), 1.75 (1H, t, J= 9.6 Hz),<br>
1.87 (2H, bs), 2.84 (2H, dd, J1 = 29.6 Hz, J2 = 10.8 Hz), 3.52 (3H, s), 12.01 (1H, s).<br>
LC-MS (ESI) calcd for C11H16O4 212.24, found 213.2 [M+H+].<br>
b)cis-3-Benzyloxycarbonylamino-bicyclo[2.2.2]octane-2-carboxylic acid<br>
methyl ester<br><br>
[00428] cis-Bicyclo[2.2.2]octane-2,3-dicarboxylic acid monomethyl ester (1.09 g,<br>
5.14 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL). The flask was<br>
degassed and backfilled with nitrogen and the mixture was cooled to 0 Â°C.<br>
Triethylamine (2.15 mL, 15.42 mmol) was added followed by the dropwise addition<br>
of ethyl chloroformate (0.98 mL, 10.28 mmol) with vigorous stirring. The mixture<br>
was stirred at 0 Â°C for 1 h. Sodium azide (1.00 g, 15.42 mmol) was dissolved in water<br>
(7 mL) and added to the reaction mixture at 0 Â°C. The mixture was stirred at 0 Â°C for<br>
5 min. The ice bath was removed. The mixture was warmed to 25 Â°C and was stirred<br>
for 2 h. The mixture was poured into water (70 mL) and the product extracted into<br>
ethyl acetate (70 mL). The organic layer was further washed with half-saturated<br>
aqueous sodium bicarbonate solution (2 Ã 30 mL), saturated aqueous brine solution<br>
(30 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
clear oil. The oil was dissolved in anhydrous benzene (10 mL) and refluxed while<br>
stirring under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was concentrated<br>
in vacuo to afford a slightly yellow oil. The oil was dissolved in dichloromethane (7<br>
mL) and benzyl alcohol (0.58 mL, 5.65 mmol) was added followed by triethylamine<br>
(1,43 mL, 10.28 mmol). The mixture was refluxed under nitrogen for 16 h. Upon<br>
cooling to 25 Â°C the solution was concentrated in vacuo to afford a golden oil.<br>
Purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
20% ethyl acetate in hexanes) afforded the desired product, cis-3-<br>
benzyloxycarbonylamino-bicyclo[2.2.2]octane-2-carboxylic acid methyl ester (1.32 g,<br>
4.16 mmol, 81%), as a clear oil. 1H NMR (400 MHz, CDCl3d: 1.18 - 1.28 (2H, m),<br>
1,42 - 1.50 (5H, m), 1.73 - 1.96 (3H, m), 2.88 (1H, d, J, = 5.6 Hz), 3.27 (1H, s), 3.42<br>
(3H, s), 4.00 - 4.04 (1H, m), 4.97 (2H, dd, J1 = 46.4 Hz, J2 = 12.8 Hz), 7.06 (1H, d, J<br>
= 9.6 Hz), 7.24 - 7.34 (4H, m). LC-MS (ESI) calcd for C18H23NO4 317.38, found<br>
317.92 [M+H+].<br>
c) cis-3-Amino-bicyclo[2.2.2]octane-2-carboxylic acid methyl ester<br>
hydrochloride<br><br>
[00429] cis-3-Benzyloxycarbonylamino-bicyclo[2.2.2]octane-2-carboxylic acid<br>
methyl ester (0.67 g, 2.11 mmol) was dissolved in ethyl acetate (10 mL). 5%<br>
Palladium on carbon (97 mg) was added. The flask was degassed and backfilled with<br>
hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The mixture<br>
was passed through a plug of Celite and the filtrate was concentrated in vacuo to<br>
afford a thick clear oil. The oil was dissolved in diethyl ether (6.7 mL) and added<br>
dropwise, with vigorous stirring, to a mixture of 4.0 M solution of hydrochloric acid<br>
in 1,4-dioxane (1.2 mL) in diethyl ether (12 mL). The desired product began to<br>
precipitate as a white solid. The mixture was stirred for 20 min. The precipitate was<br>
collected by vacuum filtration, washed with additional diethyl ether (5 mL). The<br>
solid was further dried in vacuo for 1 h to afford the desired product, cis-3-amino-<br>
bicyclo[2,2,2]octane-2-carboxylic acid methyl ester hydrochloride (0.35 g, 1.59<br>
mmol, 75%), as a white powder. 1H NMR (400 MHz, DMSO-d6)d: 1.38 (2H, dd, J1<br>
= 21.2 Hz, J2 = 13.6 Hz), 1.55 - 1.63 (5H, m), 1.76 - 1.89 (3H, m), 3.02 (1H, dd, J1 =<br>
10.0 Hz, J2 = 2.4 Hz), 3.47 (1H, bs), 3.65 (3H, s), 7.97 (3H, s). LC-MS (ESI) calcd<br>
for C10H17NO2 (free amine) 183.25, found 184.05 [M+H+].<br>
d)cis-3-(4-Fluoro-benzylamino)-bicyclo[2.2.2]octane-2-carboxylic acid<br>
methyl ester<br><br>
[00430] cis-3-Amino-bicyclo[2,2,2]octane-2-carboxylic acid methyl ester<br>
hydrochloride (0.34 g, 1.55 mmol) was dissolved in methanol (10 mL). Sodium<br>
acetate (0.25 g, 3.10 mmol) was added followed by 4Ã powdered molecular sieves<br>
(0.34 g) and 4-fluoro-benzaldehyde (0.17 mL, 1.55 mmol). Sodium<br>
cyanoborohydride (0.20 g, 3.10 mmol) was added and the mixture was stirred at 25 Â°C<br>
for 16 h. The mixture was poured into a mixture of saturated aqueous sodium<br>
bicarbonate solution (20 mL) and ethyl acetate (30 mL). After shaking, both layers<br>
were passed through a plug of Celite. The organic layer was further washed with<br>
saturated aqueous sodium bicarbonate solution (10 mL), saturated aqueous brine<br>
solution (10 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to<br>
afford the crude product, cis-3-(4-fluoro-benzylamino)-bicyclo[2,2,2]octane-2-<br>
carboxylic acid methyl ester (0.34 g, 1.17 mmol, 75%), as a clear oil. LC-MS (ESI)<br>
calcd for C17H22FNO2 291.36, found 292.18 [M+H+].<br>
d) cis-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00431] cis-3-(4-Fluoro-benzylamino)-bicyclo[2,2,2]octane-2-carboxylic acid<br>
methyl ester (0.20 g, 0.69 mmol) was dissolved in anhydrous N,N-dimethylformamide<br>
(8 mL). (7-Methanesulfonylamino-1,1-dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-<br>
3-yl)-acetic acid (prepared as described in Example lg, 0.23 g, 0.69 mmol) was added<br>
followed by N-methylmorpholine (0.16 mL, 1,45 mmol). The mixture was stirred<br>
until everything dissolved, approximately 5 min. l-(3-Dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (0.14 g, 0.72 mmol) was added and the mixture was<br>
stirred at 25 Â°C for 4 h. Triethylamine (0.29 mL, 2.07 mmol) was added and the<br>
mixture was stirred at 50 Â°C for 16 h. Upon cooling to 25 Â°C, the solution was diluted<br>
with ethyl acetate (50 mL) and washed with 1.0 M aqueous hydrochloric acid solution<br>
(2 Ã 50 mL), saturated aqueous brine solution (20 mL), dried over magnesium sulfate,<br>
filtered, and concentrated in vacuo to afford a golden oil. Purification by flash<br>
column chromatography (Teledyne Isco RediSep column; 0 to 20% ethyl acetate in<br>
dichloromethane) afforded the desired product, cis-N-{3-[3-(4-fluoro-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.30 g, 0.52 mmol, 76%), as a<br>
white powder. 1H NMR (400 MHz, DMSO-d6) d: 1.39 (2H, d, J= 8.0 Hz), 1.54 -<br>
1.59 (8H, m), 1.91 (1H, s), 2.14 (1H, s), 3.06 (3H, s), 3.75 (1H, d, J= 11.6 Hz), 4.28<br>
(1H, d, J= 15.2 Hz), 5.03 (1H, d, J= 15.6 Hz), 7.13 - 7.17 (2H, m), 7.34 - 7.37 (2H,<br>
m), 7.50 - 7.60 (3H, m), 10.18 (1H, s). LC-MS (ESI) calcd for C26H27FN4O6S2<br>
574.64, found 575.4 [M+H+]. m.p.: 203.8 - 205.7 Â°C. Anal, calcd for C26H27FN4O6S2<br>
â¢ 0.4 PhMe: C, 56.57; H, 4.98; N, 9.16; found C, 57.09; H, 5.08; N, 9.38.<br>
[00432] Example 51: (2R.7S)-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02,7.09,111tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) exo-4,4a,5,5a,6,6a-Hexahydro-4,6-etheno-1H-cycloprop[f]isobenzofuran-<br>
l,3(3aH)-dione and endo-4,4a,5,5a,6,6a-Hexahydro-4,6-etheno-1H-<br>
cycloprop[f]isobenzofuran-l,3(3aH)-dione<br><br>
[00433] Furan-2,5-dione (5.32 g, 54.26 mmol) was partially dissolved in xylene<br>
(100 mL). Cyclohepta-l,3,5-triene (5 g, 54.26 mmol) was added. The reaction was<br>
stirred at 144 Â°C for 5 h. The mixture was allowed to cool to 25 Â°C and concentrated<br>
in vacuo. Purification by flash column chromatography (Teledyne Isco RediSep<br>
column; 0 to 20% ethyl acetate in hexanes) afforded the desired products, exo-<br>
4,4a,5,5a,6,6a-hexahydro-4,6-etheno-1H-cycloprop[f]isobenzofuran-1,3(3aH)-dione<br>
(7.46 g, 39.22 mmol, 72%) and endo-4,4a,5,5a,6,6a-hexahydro-4,6-etheno-1H-<br>
cycloprop[f]isobenzofuran-l,3(3aH)-dione (0.88 g, 4.63 mmol, 8%), as white solids.<br>
1HNMR(400 MHz, CDCl3)d: exo: 0.27 - 0.42 (2H, m), 1.11 -1.15 (2H, m), 3.25<br>
(2H, t, J= 1.6 Hz), 3.46 - 3.50 (2H, m), 5.89 (2H, dd, J1 = 4.8 Hz, J2 = 3.2 Hz); endo:<br>
0.14 - 0.26 (2H, m), 1.12 - 1.16 (2H, m), 3.09 (2H, s), 3.40 - 3.44 (2H, m), 5.94 (2H,<br>
dd, J1 = 4.8 Hz, J2 = 3.2 Hz). LC-MS (ESI) calcd for C11H10O3 190.20, found exo<br>
191.0; endo 191.3 [M+H+].<br>
b)(6R,7S)-7-(Methoxycarbonyl)tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic<br>
acid<br><br>
[00434] exo-4,4a,5,5a,6,6a-Hexahydro-4,6-etheno-1H-cycloprop[f]isobenzofuran-<br>
l,3(3aH)-dione (1.00 g, 5.26 mmol) was dissolved in methanol (20 mL). The reaction<br>
was stirred at 25 Â°C for 72 h. The mixture was concentrated in vacuo to afford a clear<br>
oil. Purification by flash column chromatography (Teledyne Isco RediSep column; 0<br>
to 60% ethyl acetate in hexanes) afforded the desired product, (6R,7S)-7-<br>
(methoxycarbonyl)tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic acid (1.11 g, 5.00 mmol,<br>
95%), as a white solid. 1HNMR (400 MHz, DMSO-d6) d: 0.01-0.10 (2H, m), 0.93 -<br>
1.02 (2H, m), 2.98 - 3.05 (4H, m), 3.45 (3H, s), 5.68 - 5.77 (2H, m), 11.94 (1H, s).<br>
LC-MS (ESI) calcd for C12H14O4 222.24, found 223.2 [M+H+].<br>
b) Methyl (6S,7R)-7- {[(benzyloxy)carbonyl]amino}tricyclo[3.2.2.02,4]non-8-<br>
ene-6-carboxylate<br><br>
[00435] (6R,7S)-7-(Methoxycarbonyl)tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic<br>
acid (0.78 g, 3.53 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL). The<br>
flask was degassed and backfilled with nitrogen and the mixture was cooled to 0 Â°C.<br>
Triethylamine (1,48 mL, 10.59 mmol) was added followed by the dropwise addition<br>
of ethyl chloroformate (0.67 mL, 7.06 mmol) with vigorous stirring. The mixture was<br>
stirred at 0 Â°C for 1 h. Sodium azide (0.69 g, 10.59 mmol) was dissolved in water (5<br>
mL) and added to the reaction mixture at 0 Â°C. The mixture was stirred at 0 Â°C for 5<br>
min. The ice bath was removed. The mixture was warmed to 25 Â°C and was stirred<br>
for 2 h. The mixture was poured into water (70 mL) and the product extracted into<br>
ethyl acetate (70 mL). The organic layer was further washed with half-saturated<br>
aqueous sodium bicarbonate solution (2 Ã 30 mL), saturated aqueous brine solution<br>
(30 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
clear oil. The oil was dissolved in anhydrous benzene (10 mL) and refluxed while<br>
stirring under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was concentrated<br>
in vacuo to afford a slightly yellow oil. The oil was dissolved in dichloromethane (10<br>
mL) and benzyl alcohol (0.40 mL, 3.88 mmol) was added followed by triethylamine<br>
(0.98 mL, 7.06 mmol). The mixture was refluxed under nitrogen for 16 h. Upon<br>
cooling to 25 Â°C the solution was concentrated in vacuo to afford a golden oil.<br>
Purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
20% ethyl acetate in hexanes) afforded the desired product, methyl (6S,7R)-7-<br>
{[(benzyloxy)carbonyl]amino}tricyclo[3.2.2.02,4]non-8-ene-6-carboxylate (0.62 g,<br>
1.89 mmol, 54%) as a clear oil. 1H NMR (400 MHz, CDCl3)d: 0.17 - 0.22 (2H, m),<br>
0.90 - 1.05 (2H, m), 2.98 - 3.14 (3H, m), 3.48 (3H, s), 4.38 - 4.43 (1H, m), 5.00 - 5.12<br>
(2H, m), 5.77 (1H, t, J= 7.2 Hz), 6.05 (1H, t, J= 7.2 Hz), 7.29 - 7.37 (5H, m). LC-<br>
MS (ESI) calcd for C19H21NO4 327.37, found 328.3 [M+H+].<br>
c) Methyl (6S,7R)-7-aminotricyclo[3.2.2.02,4]nonane-6-carboxylate<br>
hydrochloride<br><br>
[00436] Methyl (6S,7R)-7-{[(benzyloxy)carbonyl]amino}tricyclo[3.2.2.02,4]non-8-<br>
ene-6-carboxylate (0.61 g, 1.85 mmol) was dissolved in ethyl acetate (10 mL). 5%<br>
Palladium on carbon (0.10 g) was added. The flask was degassed and backfilled with<br>
hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The mixture<br>
was passed through a plug of Celite and the filtrate was concentrated in vacuo to<br>
afford a thick clear oil. The oil was dissolved in diethyl ether (6 mL) and added<br>
dropwise, with vigorous stirring, to a mixture of a 4.0 M solution of hydrochloric acid<br>
in 1,4-dioxane (0.93 mL) in diethyl ether (11 mL). The mixture was concentrated and<br>
dried in vacuo to afford the desired product, methyl (6S,7R)-7-<br>
aminotricyclo[3.2.2.02,4]nonane-6-carboxylate hydrochloride (0.43 g, 1.85 mmol,<br>
100%), as a sticky gum. LC-MS (ESI) calcd for C11H17NO2 (free amine) 195.26,<br>
found 196.5 [M+H+].<br>
d) Methyl (6S,7R)-7-[(4-fluorobenzyl)amino]tricyclo[3.2.2.02,4]nonane-6-<br>
carboxylate<br><br>
[00437] Methyl (6S,7R)-7-aminotricyclo[3.2.2.02,4]nonane-6-carboxylate<br>
hydrochloride (0.43 g, 1.85 mmol) was dissolved in methanol (10 mL). Sodium<br>
acetate (0.30 g, 3.70 mmol) was added followed by 4A powdered molecular sieves<br>
(0.40 g) and 4-fluoro-benzaldehyde (0.20 mL, 1.85 mmol). Sodium<br>
cyanoborohydride (0.23 g, 3.70 mmol) was added and the mixture was stirred at 25 Â°C<br>
for 16 h. The mixture was poured into a mixture of saturated aqueous sodium<br>
bicarbonate solution (20 mL) and ethyl acetate (30 mL). After shaking, both layers<br>
were passed through a plug of Celite. The organic layer was further washed with<br>
saturated aqueous sodium bicarbonate solution (10 mL), saturated aqueous brine<br>
solution (10 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to<br>
afford the crude product, methyl (6S,7R)-7-[(4-<br>
fluorobenzyl)amino]tricyclo[3.2.2.02,4]nonane-6-carboxylate as a clear oil. LC-MS<br>
(ESI) calcd for C17H22FNO2 291.36, found 292.2 [M+H+].<br>
d) (2R,7S)-N- {3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02,7.09.11]tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00438] Methyl (6S,7R)-7-[(4-fluorobenzyl)amino]tricyclo[3.2.2.02,4]nonane-6-<br>
carboxylate (0.15 g, 0.49 mmol) was dissolved in anhydrous N,N-dimethylformamide<br>
(8 mL). (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-<br>
3-yl)-acetic acid (prepared as described in Example lg, 0.16 g, 0.49 mmol) was added<br>
followed by N-methylmorpholine (0.11 mL, 1.03 mmol). The mixture was stirred<br>
until everything dissolved, approximately 5 min. l-(3-Dimethylaminopropyl)-3-<br>
ethylcarbodiimide hydrochloride (0.10 g, 0.51 mmol) was added and the mixture was<br>
stirred at 25 Â°C for 4 h. Triethylamine (0.20 mL, 1,47 mmol) was added and the<br>
mixture was stirred at 50 Â°C for 16 h. Upon cooling to 25 Â°C, the solution was diluted<br>
with ethyl acetate (50 mL) and washed with 1.0 M aqueous hydrochloric acid solution<br>
(2 Ã 50 mL), saturated aqueous brine solution (20 mL), dried over magnesium sulfate,<br>
filtered, and concentrated in vacuo to afford a golden oil. Purification by flash<br>
column chromatography (Teledyne Isco RediSep column; 0 to 20% ethyl acetate in<br>
dichloromethane) afforded the desired product, (2R,7S)-N-{3-[3-(4-fluoro-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tetracyclo[6.3.2.02,7.09,11]tridec-5-en-5-yl]-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.23 g, 0.40 mmol,<br>
82%), as a white powder. 1H NMR (400 MHz, DMSO-d6)d: 0.44 - 1.28 (10H, m),<br>
2.29 (1H, bs), 3.06 (3H, s), 3.82 (1H, d, J= 11.6 Hz), 4.40 (1H, d, J= 14.0 Hz), 4.98<br>
(1H, d, J= 15.6 Hz), 7.12 - 7.60 (7H, m), 10.19 (1H, s). LC-MS (ESI) calcd for<br>
C27H27FN4O6S2 586.65, found 587.5 [M+H+].<br>
[00439] Example 52: (2S,7R)-N- (3-[3-(4-Fluoro-benzyn-6-hydroxy-4-oxo-3-aza-<br>
tetracvclo[6.3.2.02,709,11]tridec-S-en-5-yl]-1,1-dioxo-1 ,4-dihydro- 1?6-<br>
benzo[1,2,4]thiadiazin-7-yll -methanesulfonamide<br><br>
a) (6S,7R)-7-(Methoxycarbonyl)tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic<br>
acid<br><br>
[00440] endo-4,4a,5,5a,6,6a-Hexahydro-4,6-etheno-1H-cycloprop[f]isobenzofuran-<br>
l,3(3aH)-dione (prepared as described in Example 51a, 0.86 g, 4.50 mmol) was<br>
dissolved in methanol (20 mL). The reaction was stirred at 25 Â°C for 72 h. The<br>
mixture was concentrated to afford a clear oil. Purification by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 60% ethyl acetate in hexanes)<br>
afforded the desired product, (6S,7R)-7-(methoxycarbonyl)tricyclo[3.2.2.02,4]non-8-<br>
ene-6-carboxylic acid (0.94 g, 4.23 mmol, 94%) as a white solid. 1H NMR (400<br>
MHz, CDCl3) d: 0.06 - 0.17 (2H, m), 1.26 - 1.38 (2H, m), 2.74 - 2.85 (2H, m), 3.15 -<br>
3.19 (2H, m), 3.67 (3H, s), 5.85 - 5.86 (2H, m). LC-MS (ESI) calcd for C12H14O4<br>
222.24, found 223.5 [M+H+].<br>
b) Methyl (6R,7S)-1-{[(benzyloxy)carbonyl]amino}tricyclo[3.2.2.02,4]non-8-<br>
ene-6-carboxylate<br><br>
[00441] (6S,7R)-7-(Methoxycarbonyl)tricyclo[3.2.2.02,4]non-8-ene-6-carboxylic<br>
acid (0.68 g, 3.07 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL). The<br>
flask was degassed and backfilled with nitrogen and the mixture was cooled to 0 Â°C.<br>
Triethylamine (1.28 mL, 9.21 mmol) was added followed by the dropwise addition of<br>
ethyl chloroformate (0.58 mL, 6.14 mmol) with vigorous stirring. The mixture was<br>
stirred at 0 Â°C for 1 h. Sodium azide (0.60 g, 9.21 mmol) was dissolved in water (5<br>
mL) and added to the reaction mixture at 0 Â°C. The mixture was stirred at 0 Â°C for 5<br>
min. The ice bath was removed. The mixture was warmed to 25 Â°C and was stirred<br>
for 2 h. The mixture was poured into water (70 mL) and the product extracted into<br>
ethyl acetate (70 mL). The organic layer was further washed with half-saturated<br>
aqueous sodium bicarbonate solution (2 Ã 30 mL), saturated aqueous brine solution<br>
(30 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to afford a<br>
clear oil. The oil was dissolved in anhydrous benzene (10 mL) and refluxed while<br>
stirring under nitrogen for 2 h. Upon cooling to 25 Â°C the solution was concentrated<br>
in vacuo to afford a slightly yellow oil. The oil was dissolved in dichloromethane (10<br>
mL) and benzyl alcohol (0.35 mL, 3.38 mmol) was added followed by triethylamine<br>
(0.86 mL, 6.14 mmol). The mixture was refluxed under nitrogen for 16 h. Upon<br>
cooling to 25 Â°C the solution was concentrated in vacuo to afford a golden oil.<br>
Purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
20% ethyl acetate in hexanes) afforded the desired product, methyl (6R,7S)-7-<br>
{[(benzyloxy)carbonyl]amino}tricyclo[3.2.2.02,4]non-8-ene-6-carboxylate (0.36 g,<br>
1.10 mmol, 36%) as a clear oil. 1H NMR (400 MHz, CDCl3)d: 0.11 - 0.19 (2H, m),<br>
0.13 - 1.34 (2H, m), 2.77 - 3.03 (3H, m), 3.62 (3H, s), 4.01 - 4.07 (1H, m), 5.07 - 5.14<br>
(2H, m), 5.79 - 5.85 (2H, m), 7.30 - 7.38 (5H, m). LC-MS (ESI) calcd for C19H21NO4<br>
327.37, found 328.3 [M+H+].<br>
c) Methyl (6R,7S)-7-aminotricyclo[3.2.2.02,4]nonane-6-carboxylate<br><br>
[00442] Methyl (6R,7S)-7-{[(benzyloxy)carbonyl]amino}tricyclo[3.2.2.02,4]non-8-<br>
ene-6-carboxylate (0.35 g, 1.07 mmol) was dissolved in ethyl acetate (10 mL). 5%<br>
Palladium on carbon (0.04 g) was added. The flask was degassed and backfilled with<br>
hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The mixture<br>
was passed through a plug of Celite and the filtrate was concentrated in vacuo to<br>
afford the crude product, methyl (6R,7S)-7-aminotricyclo[3.2.2.02,4]nonane-6-<br>
carboxylate, as a thick clear oil, which was used in the next step without further<br>
purification. LC-MS (ESI) calcd for C11H17NO2 (free amine) 195.26, found 196.3<br>
[M+H+].<br>
d) Methyl (6R,7S)-7-[(4-fluorobenzyl)amino]tricyclo[3.2.2.02,4]nonane-6-<br>
carboxylate<br><br>
[00443] The crude methyl (6R,7S)-7-aminotricyclo[3.2.2.02,4]nonane-6-carboxylate<br>
was dissolved in methanol (10 mL). Acetic acid (0.12 mL, 2.14 mmol) was added<br>
followed by 4-fluoro-benzaldehyde (0.12 mL, 1.07 mmol). Sodium<br>
cyanoborohydride (0.14 g, 2.14 mmol) was added and the mixture was stirred at 60 Â°C<br>
for 16 h. The mixture was cooled to 25 Â°C and poured into a mixture of saturated<br>
aqueous sodium bicarbonate solution (20 mL) and ethyl acetate (30 mL). After<br>
shaking, both layers were passed through a plug of Celite. The organic layer was<br>
further washed with saturated aqueous sodium bicarbonate solution (10 mL),<br>
saturated aqueous brine solution (10 mL), dried over magnesium sulfate, filtered, and<br>
concentrated in vacuo to afford the crude product, methyl (6R,7S)-7-[(4-<br>
fluorobenzyl)amino]tricyclo[3.2.2.02,4]nonane-6-carboxylate, as a clear oil, which was<br>
used in the next step without further purification. LC-MS (ESI) calcd for<br>
C17H22FNO2 291.36, found 292.0 [M+H+].<br>
e)(2S,7R)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02,7.09,11]tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00444] The crude methyl (6R,7S)-7-[(4-<br>
fluorobenzyl)amino]tricyclo[3.2.2.02,4]nonane-6-carboxylate was dissolved in<br>
anhydrous N,N-dimethylformamide (8 mL). (7-Methanesulfonylamino-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in<br>
Example lg, 0.22 g, 0.66 mmol) was added followed by N-methylmorpholine (0.15<br>
mL, 1.39 mmol). The mixture was stirred until everything dissolved, approximately 5<br>
min. 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.13 g, 0.69<br>
mmol) was added and the mixture was stirred at 25 Â°C for 4 h. Triethylamine (0.28<br>
mL, 1.98 mmol) was added and the mixture was stirred at 50 Â°C for 16 h. Upon<br>
cooling to 25 Â°C, the solution was diluted with ethyl acetate (50 mL) and washed with<br>
1.0 M aqueous hydrochloric acid solution (2 Ã 50 mL), saturated aqueous brine<br>
solution (20 mL), dried over magnesium sulfate, filtered, and concentrated in vacuo to<br>
afford a golden oil. Purification by flash column chromatography (Teledyne Isco<br>
RediSep column; 0 to 20% ethyl acetate in dichloromethane) afforded the desired<br>
product, (2S,7R)-N-{3-[3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02,7.09,11]tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.50 g, 0.86 mmol, 80% over three<br>
steps), as a white powder. 1HNMR (400 MHz, DMSO-d6)d: 0.33-1.34 (10H, m),<br>
2.30 (1H, bs), 3.06 (3H, s), 3.81 (1H, d,J= 11.2 Hz), 4.48 (1H, d, J= 15.6 Hz), 4.98<br>
(1H, d, J= 14.8 Hz), 7.13 - 7.60 (7H, m), 10.19 (1H, s). LC-MS (ESI) calcd for<br>
C27H27FN4O6S2 586.65, found 587.3 [M+H+].<br>
[00445] Example 53: (1R,2S,7R,8S)-5-(1. 1 -Dioxo-7-pyrrolidin- 1-yl-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-3-yl)-6-hydroxy-3-(3-methyl-butyl)-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00446] Pyrrolidine (15 ÂµL, 0.180 mmol), sarcosine (N-methyl glycine) (3.2 mg,<br>
0.018 mmol), copper (I) iodide (3.4 mg, 0.018 mmol), and potassium phosphate (57.3<br>
mg, 0.270 mmol) were placed in a flask under a nitrogen atmosphere. (1R,2S,7R,8S)-<br>
6-Hydroxy-5 -(7-iodo-1, 1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-3 -(3-<br>
methyl-butyl)-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one (prepared as described in<br>
Example 34, 50 mg, 0.090 mmol) was dissolved in N,N-dimethylformamide (1 mL)<br>
and added to the above mixture. The mixture was stirred at 80 Â°C for 26 h.<br>
Additional pyrrolidine (50 ÂµL, 0.60 mmol), sarcosine (N-methyl glycine) (10 mg,<br>
0.056 mmol), and copper (I) iodide (15 mg, 0.079 mmol) were added and the mixture<br>
was stirred at 80 Â°C for another 16 h until LC-MS analysis indicated completion of the<br>
reaction. The reaction was repeated at the same scale as described above and after<br>
stirring at 80 Â°C for 24 h, additional pyrrolidine (50 ÂµL, 0.60 mmol), sarcosine (N-<br>
methyl glycine) (10 mg, 0.056 mmol), and copper (I) iodide (15 mg, 0.079 mmol)<br>
were added and the mixture was stirred at 80 Â°C for another 18 h until LC-MS<br>
analysis indicated completion of the reaction. Both batches were combined and<br>
filtered through a plug of Celite. The filter cake was washed with 10% methanol in<br>
dichloromethane (2Ã2 mL) and N,N-dimethylformamide (2 mL). The filtrate was<br>
concentrated in vacuo and the residue was purified by prep-HPLC [Column Luna 5Âµ<br>
C18 (2) 100Ã AXIA 150 x 21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min<br>
flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic acid in<br>
water] to afford the desired product, (1R,2S,7R,8S)-5-(1,1-dioxo-7-pyrrolidin-l-yl-<br>
1,4 -dihydro-1?6-benzo [1,2,4]thiadiazin-3 -yl)-6-hydroxy-3 -(3 -methyl-butyl)-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (36.7 mg, 0.074 mmol, 40.9%), as a yellow solid.<br>
1HNMR (400 MHz, DMSO-d6)d: 0.92 (6H, d, J= 5.5 Hz), 1.21 - 1.60 (9H, m), 1.96<br>
- 1.99 (4H, m), 2.52 - 2.52 (1H, m), 2.62 - 2.65 (1H, m), 2.94 - 2.98 (1H, m), 3.03 -<br>
3.10 (1H, m), 3.27 - 3.30 (4H, m), 3.60 - 3.71 (2H, m), 6.71 (1H, d, J= 2.3 Hz), 6.90<br>
(1H, dd, J1 = 9.2 Hz, J2 = 2.7 Hz), 7.41 (1H, d, J= 9.5 Hz). LC-MS (ESI) calcd for<br>
C26H34N4O4S 498.23, found 499.4 [M+H+]. Anal, calcd for C26H34N4O4S. 0.5 H2O:<br>
C, 61.51; H, 6.95; N, 11.04; found: C, 61,45, H, 6.74, N, 10.91.<br>
[00447] Example 54: Pvridine-3-sulfonic acid {3-r(1R,2S,7R,8S)-3-(4-fluoro-<br>
benzyl)-6-hydroxy-4-oxo-3 -aza-tricyclo[6.2.1.02,7]undec-5 -en-5 -yl]-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1.2.4]thiadiazin-7-yl} -amide<br><br>
[00448] (1R,2S,7R,8S)-3 -(4-Fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4 ]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br>
(prepared as described in Example 19, 100 mg, 0.17 mmol), pyridine-3-sulfonic acid<br>
amide (81 mg, 0.51 mmol), sarcosine (N-methyl glycine) (23 mg, 0.26 mmol), copper<br>
(I) iodide (33 mg, 0.17 mmol), and potassium phosphate (216 mg, 1.02 mmol) were<br>
combined and dissolved in N,N-dimethylformamide (10 mL). The flask was degassed<br>
and backfilled with nitrogen (3 Ã). The reaction was stirred at 100 Â°C for 4 h. The<br>
mixture was cooled to 25 Â°C, diluted with ethyl acetate (20 mL), and extracted with<br>
saturated aqueous sodium bicarbonate solution (2 Ã 20 mL). The combined organic<br>
layers were dried over magnesium sulfate, filtered, and concentrated in vacuo.<br>
Purification by flash column chromatography (Teledyne Isco RediSep column; 0 to<br>
8% methanol in dichloromethane) afforded the desired product, pyridine-3-sulfonic<br>
acid {3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide (56 mg, 0.09 mmol, 54%), as a white powder. 1H<br>
NMR (400 MHz, DMSO-d6) d: 1.38 - 1.58 (6H, m), 2.61 (1H, s), 3.00 (1H, d, J= 7.6<br>
Hz), 3.52 (1H, d, J= 8.4 Hz), 4.40 (1H, d, J= 15.6 Hz), 4.94 (1H, d, J= 15.2 Hz),<br>
7.13 (2H, t, J= 8.4 Hz), 7.29 - 7.32 (2H, m), 7.42 - 7.50 (3H, m), 7.60 -7.63 (1H, m),<br>
8.11 (1H, d, J= 7.6 Hz), 8.79 (1H, d, J= 4.4 Hz), 8.87 (1H, s), 10.94 (1H, s), 13.99<br>
(1H, s). LC-MS (ESI) calcd for C29H26FN5O6S2 623.68, found 624.2 [M+H+].<br>
[00449] Example 55:(1R,2S,7R,8S)-N-{3-[3-(4-Fluoro-benzyn-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7lundec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamide<br><br>
a) Benzyl [N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamoyl]carbamate<br><br>
[00450] Benzyl alcohol (35 ÂµL, 0.338 mmol) was dissolved in dichloromethane (3<br>
mL) and cooled to 0 Â°C. Chlorosulfonyl isocyanate (29.4 ÂµL, 0.338 mmol) was added<br>
and the mixture was stirred at 0 Â°C for 2.5 h. Triethylamine (47 ÂµL, 0.34 mmol)<br>
followed by a solution of (1R,2S,7R,8S)-5-(7-amino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (prepared as described in Example 30, 81,4 mg,<br>
0.169 mmol) in dichloromethane (2 mL) were added at 0 Â°C and the mixture was<br>
stirred at 25 Â°C for 17 h. The mixture was extracted with water (2Ã2 mL) and<br>
saturated aqueous brine solution (2 mL). The organic layer was concentrated in vacuo<br>
and further dried for 16 h under high vacuum to afford the crude product, benzyl [N-<br>
{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamoyl]carbamate, which was used in the next step<br>
without any further purification. LC-MS (ESI) calcd for C32H30FN5O8S2 695.15,<br>
found 696.6 [M+H+].<br>
b)(1R,2S,7R,8S)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamide<br><br>
[00451] The crude benzyl [N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamoyl]carbamate was dissolved in methanol (5 mL)<br>
and the mixture was degassed and backfilled with nitrogen (3 Ã). Palladium on<br>
carbon (10% dry, 180 mg) was added and the mixture was degassed and backfilled<br>
with hydrogen gas via balloon. The mixture was stirred at 25 Â°C for 16 h. The<br>
mixture was passed through a plug of Celite and the filtrate was concentrated in vacuo<br>
to afford the crude product, which was further purified by prep-HPLC [Column Luna<br>
5Âµ C18 (2) 100Ã AXIA 150 Ã 21.2 mm, 5 micron, 30%-95% in 7 min @ 30 mL/min<br>
flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05% trifluoroacetic acid in<br>
water] to afford the desired product, (1R,2S,7R,8S)-N-{3-[3-(4-fluoro-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamide (55.7 mg, 0.099 mmol, 58.7% over two steps),<br>
as a white solid. 1HNMR(400 MHz, DMSO-d6)d: 1.19 - 1.24 (2H, m), 1,40 - 1.60<br>
(4H, m), 2.51 - 2.54 (1H, m), 2.64 - 2.65 (1H, m), 3.04 (1H, d, J= 9.3 Hz), 3.53 (1H,<br>
d, J= 9.3 Hz), 4.42 (1H, d, J= 15.7 Hz), 4.96 (1H, d, J= 15.6 Hz), 7.15 (2H, m), 7.31<br>
- 7.34 (H, m), 7.43 (1H, dd, J1 = 9.4 Hz, J2 = 2.3 Hz), 7.51 - 7.55 (2H, m), 9.96 (1H,<br>
s). LC-MS (ESI) calcd for C24H24FN5O6S 561.12, found 562.5 [M+H+]. Anal, calcd<br>
for C24H24FN5O6S â¢ 0.5 H2O: C, 50.51; H, 4.42; N, 12.27; found: C, 50.42, H, 4.35,<br>
N, 11.90.<br>
[00452] Example 56: (1R,2S,7R,8S)-N-[3-(3-Benzyl-6-hydroxy-4-oxo-3-aza-<br>
tricvclo[6.2.1.027]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yl]-methanesulfonamide<br><br>
a) (1S,2R,3S,4R)-Benzylamino-bicyclol[2.2. l]heptane-2-carboxylic acid<br>
ethyl ester<br><br>
[00453] Benzaldehyde (0.454 mL, 4.47 mmol) and 10 drops glacial acetic acid<br>
were added sequentially to a solution of (1S,2R,3S,4R)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (prepared as described in Example<br>
6k, 0.82 g, 4.47 mmol) in methanol (15 mL) at 25 Â°C. Sodium cyanoborohydride<br>
(0.703 g, 11.2 mmol) was added, and the reaction mixture was stirred at 25 Â°C for 2 h,<br>
and then was partitioned between half-saturated aqueous sodium bicarbonate solution<br>
(150 mL) and ethyl acetate (2 Ã 150 mL). The organic layers were dried over sodium<br>
sulfate, filtered and concentrated in vacuo. The residue was purified by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 35% ethyl acetate in hexanes)<br>
to afford the desired product, (1S,2R,3S,4R)-3-benzylamino-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (0.875 g, 3.22 mmol, 72%), as a clear oil. 1H NMR (400<br>
MHz, CDCl3)d: 1.06-1.16 (2H,m), 1.20- 1.23 (2H, m), 1.28 (3H, t, J = 7.0 Hz),<br>
1,46 - 1.61 (2H, m), 1.93 - 1.97 (1H, m), 2.33 - 2.34 (1H, m), 2.43 - 2.44 (1H, m),<br>
2.59 - 2.62 (1H, m), 2.98 - 3.00 (1H, m), 3.71 (1H, d, J= 14.0 Hz), 3.85 (1H, d, J=<br>
13.3 Hz), 4.14 (2H, q, J= 7.3 Hz), 7.20 - 7.24 (1H, m), 7.27 - 7.33 (4H, m).<br>
b) (1R,2S,7R,8S)-N-[3-(3-Benzyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl]-methanesulfonamide<br><br>
[00454] (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.200<br>
g, 0.600 mmol), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride<br>
(0.121 g, 0.631 mmol) and N-methylmorpholine (0.139 mL, 1.26 mmol) were added<br>
sequentially to a solution of (1S,2R,3S,4R)-3-benzylamino-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (0.164 g, 0.600 mmol) in N,N-dimethylformamide (5 mL)<br>
at 25 Â°C. The reaction mixture was stirred at 25 Â°C for 2 h, and then was partitioned<br>
between 1.0 M aqueous hydrochloric acid solution (100 mL) and ethyl acetate (2 Ã<br>
100 mL). The organic layers were dried over sodium sulfate, filtered and<br>
concentrated in vacuo. The residue was dissolved in ethanol (15 mL) at 25 Â°C. A 21<br>
wt. % solution of sodium ethoxide in ethanol (0.972 mL, 3.00 mmol) was added and<br>
the reaction mixture was heated at 60 Â°C for 1 h. After cooling to 25 Â°C, the reaction<br>
mixture was partitioned between a 1.0 M aqueous hydrochloric acid solution (100<br>
mL) and ethyl acetate (2 Ã 100 mL). The organic layers were dried over sodium<br>
sulfate, filtered and concentrated in vacuo. The residue was purified by flash column<br>
chromatography (Teledyne Isco RediSep column; 40 to 100% ethyl acetate in<br>
hexanes) to afford the desired product, (1R,2S,7R,8S)-N-[3-(3-benzyl-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide (0.120 g, 0.222 mmol, 37%), as a<br>
white solid. 1HNMR(400 MHz, DMSO-d6)d: 1.15 - 1.21 (2H, m), 1.39 - 1.61 (4H,<br>
m), 2.52 (1H, bs), 2.64 (1H, bs), 3.05 (3H, s), 3.30 (2H, bs), 3.54 (1H, d, J= 9.5 Hz),<br>
4.43 (1H, d, J= 16.4 Hz), 4.99 (1H, d, J= 15.5 Hz), 7.23 - 7.28 (2H, m), 7.33 (2H,<br>
m), 7.48 - 7.51 (2H, m), 7.55 - 7.57 (2H, m), 10.17 (1H, s). LC-MS (ESI) calcd for<br>
C25H26N4O6S2 542.13, found 543.2 [M+H+].<br>
[00455] Example 57: 1R,2S,7R,8S)-N-[3-(6-Hydroxy-3-isobutyl-4-oxo-3-aza-<br>
tricvclo[6.2.1.02,7lundec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yl]-methanesulfonamide<br><br>
a) (1S,2R,3S,4R)-3-Isobutylamino-bicyclo[2,2,1 ]heptane-2-carboxylic acid<br>
ethyl ester<br><br>
[00456] Isovaleraldehyde (0.374 mL, 4.10 mmol) and 10 drops glacial acetic acid<br>
were added sequentially to a solution of (1S,2R,3S,4R)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (prepared as described in Example<br>
6k, 0.750 g, 4.09 mmol) in methanol (12 mL) at 25 Â°C. Sodium cyanoborohydride<br>
(0.643 g, 10.2 mmol) was added, and the reaction mixture was stirred at 25 Â°C for 2 h,<br>
and then was partitioned between half-saturated aqueous sodium bicarbonate solution<br>
(150 mL) and ethyl acetate (2 Ã 150 mL). The organic layers were dried over sodium<br>
sulfate, filtered and concentrated in vacuo to afford the desired product,<br>
(1S,2R,3S,4R)-3-isobutylamino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester, as<br>
a clear oil, which was used in the next step without any further purification.<br>
b)(1R,2S,7R,8S)-N-[3-(6-Hydroxy-3-isobutyl-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide.<br><br>
[00457] (7-Methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1 -1?6-<br>
benzo[1 ,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.317<br>
g, 0.951 mmol), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride<br>
(0.192 g, 1.00 mmol) and N-methylmorpholine (0.220 mL, 2.00 mmol) were added<br>
sequentially to a solution of crude (1S,2R,3S,4R)-3-isobutylamino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (0.228 g, 0.952 mmol) in N,N-<br>
dimethylformamide (4 mL) at 25 Â°C. The reaction mixture was stirred at 25 Â°C for 2<br>
h, and then was partitioned between 1.0 M aqueous hydrochloric acid solution (100<br>
mL) and ethyl acetate (2 Ã 100 mL). The organic layers were dried over sodium<br>
sulfate, filtered and concentrated in vacuo. The residue was dissolved in ethanol (15<br>
mL) at 25 Â°C. A 21 wt. % solution of sodium ethoxide in ethanol (1.23 mL, 3.80<br>
mmol) was added and the reaction mixture was heated at 60 Â°C for 1.5 h. After<br>
cooling to 25 Â°C, the reaction mixture was partitioned between 1.0 M aqueous<br>
hydrochloric acid solution (150 mL) and ethyl acetate (2 Ã 150 mL). The organic<br>
layers were dried over sodium sulfate, filtered and concentrated in vacuo. The residue<br>
was purified by flash column chromatography (Teledyne Isco RediSep column; 40 to<br>
100% ethyl acetate in hexanes) to afford the desired product, (1R,2S,7R,8S)-N-[3-(6-<br>
hydroxy-3-isobutyl-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide (0.096 g, 0.190 mmol,<br>
20%), as a white solid. 1H NMR (400 MHz, DMSO-d6) d: 0.83 (3H, d, J= 7.2 Hz),<br>
0.93 (3H,d, J=7.1 Hz), 1.19-1.21 (1H, m), 1.28 - 1.32 (1H, m), 1,43- 1.63 (3H,m),<br>
2.09 - 2.15 (1H, m), 2.54 (1H, bs), 2.61 - 2.61 (1H, m), 2.74 - 2.79 (1H, m), 3.05 (3H,<br>
s), 3.30 (1H, bs), 3.60 (1H, d, J= 9.2 Hz), 3.73 - 3.79 (1H, m), 7.49 - 7.52 (1H, m),<br>
7.56 - 7.58 (2H, m), 10.17 (1H, s). LC-MS (ESI) calcd for C22H28N4O6S2 508.15,<br>
found 509.4 [M+H+].<br>
[00458] Example 58: 1R,2S,7R,8S)-N-{3[3-(3-Chloro-4-fluoro-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7lundec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yl}-methanesulfonamide<br><br>
a) (1S,2R,3S,4R)-3-(3-Chloro-4-fluoro-benzylamino)-bicyclo[2,2,1 ]heptane-2-<br>
carboxylic acid ethyl ester<br><br>
[00459] 3-Chloro-4-fluoro-benzaldehyde (0.710 mL, 4.48 mmol) and 10 drops<br>
glacial acetic acid were added sequentially to a solution of (1S,2R,3S,4R)-3-amino-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (prepared as described in Example<br>
6k, 0.82 g, 4.47 mmol) in methanol (15 mL) at 25 Â°C. Sodium cyanoborohydride<br>
(0.709 g, 11.3 mmol) was added, and the reaction mixture was stirred at 25 Â°C for 2 h,<br>
and then was partitioned between half-saturated aqueous sodium bicarbonate solution<br>
(150 mL) and ethyl acetate (2 Ã 150 mL). The organic layers were dried over sodium<br>
sulfate, filtered and concentrated in vacuo. The residue was purified by flash column<br>
chromatography (Teledyne Isco RediSep column; 0 to 35% ethyl acetate in hexanes)<br>
to afford the desired product, (1S,2R,3S,4R)-3-(3-chloro-4-fluoro-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (1.12 g, 3.44 mmol, 77%), as a<br>
clear oil. 1H NMR (400 MHz, CDCl3)d: 1.04 - 1.16 (2H, m), 1.18- 1.24 (2H,m),<br>
1.29 (3H, t, J=7.4 Hz), 1,44-1.61 (2H, m), 1.91 - 1.94 (1H, m), 2.27 - 2.28 (1H, m),<br>
2.42 - 2.43 (1H, m), 2.60 (1H, d, J= 7.7 Hz), 2.91 (1H, d, J= 8.8 Hz), 3.64 (1H, d, J<br>
= 13.9 Hz), 3.79 (1H, d, J= 14.2 Hz), 4.14 (2H, q, J= 7.0 Hz), 7.02 - 7.06 (1H, m),<br>
7.13 - 7.17 (1H, m), 7.36 - 7.38 (1H, m).<br>
b)(1R,2S,7R,8S)-N-{3-[3-(3-Chloro-4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00460] (7-Methanesulfonylamino-1,1-dioxo-l ,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 0.258<br>
g, 0.774 mmol), l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride<br>
(0.156 g, 0.814 mmol) and N-methylmorpholine (0.170 mL, 1.55 mmol) were added<br>
sequentially to a solution of (1S,2R,3S,4R)-3-(3-chloro-4-fluoro-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (0.252 g, 0.773 mmol) in N,N-<br>
dimethylformamide (4 mL) at 25 Â°C. The reaction mixture was stirred at 25 Â°C for 2<br>
h, and then was partitioned between 1.0 M aqueous hydrochloric acid solution (100<br>
mL) and ethyl acetate (2 Ã 100 mL). The organic layers were dried over sodium<br>
sulfate, filtered and concentrated in vacuo. The residue was dissolved in ethanol (20<br>
mL) at 25 Â°C. A 21 wt. % solution of sodium ethoxide in ethanol (1.00 mL, 3.09<br>
mmol) was added and the reaction mixture was heated at 60 Â°C for 1 h. After cooling<br>
to 25 Â°C, the reaction mixture was partitioned between 1.0 M aqueous hydrochloric<br>
acid solution (100 mL) and ethyl acetate (2 Ã 100 mL). The organic layers were dried<br>
over sodium sulfate, filtered and concentrated in vacuo. The residue was purified by<br>
flash column chromatography (Teledyne Isco RediSep column; 40 to 100% ethyl<br>
acetate in hexanes) to afford the desired product, (1R,2S,7R,8S)-N-{3-[3-(3-chloro-4-<br>
fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1, 1 -dioxo-<br>
1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.196 g, 0.332<br>
mmol, 43%), as a white solid. 1H NMR (400 MHz, DMSO-d6)d: 1.04 - 1.21 (4H, m),<br>
1,40 - 1.60 (3H, m), 2.54 - 2.63 (1H, m), 3.05 (3H, s), 3.31 - 3.40 (2H, m), 3.55 - 3.58<br>
(1H, m), 4.45 (1H, d, J= 16.1 Hz), 4.91 (1H, d, J= 14.7 Hz), 7.31 - 7.35 (2H, m),<br>
7.51 - 7.57 (4H, m), 10.17 (1H, s), 13.96 (1H, s). LC-MS (ESI) calcd for<br>
C25H24C1FN4O6S2 594.08, found 595.3 [M+H+].<br>
[00461] Example 59: (rac-di-exo)-N-{3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-11-<br>
oxa-3-aza-tricvclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo(1,2,4]thiadiazin-7-yl}-N-methyl-methanesulfonamide<br><br>
[00462] (rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-11-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
25, 67 mg, 0.128 mmol) was dissolved in N,N-dimethylformamide (2 mL). Potassium<br>
carbonate (35 mg, 0.25 mmol) and iodomethane (0.008 mL, 0.128 mmol) were added<br>
sequentially. The reaction was stirred at 25 Â°C for 2 h. The reaction was quenched via<br>
the addition of 1.0 M aqueous hydrochloric acid solution (20 mL). The mixture was<br>
extracted with ethyl acetate (2 Ã 100 mL). The combined organic layers were washed<br>
with saturated aqueous brine solution (50 mL), dried over sodium sulfate, filtered, and<br>
concentrated in vacuo to afford an oil. Purification by flash column chromatography<br>
(Teledyne Isco RediSep column; 0 to 100% ethyl acetate in hexanes) afforded the<br>
desired product, (rac-di-exo)-N-{3-[6-hydroxy-3-(3-methyl-butyl)-4-oxo-l l-oxa-3-<br>
aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-N-methyl-merhanesuIfonamide (36 mg, 0.067 mmol,<br>
52%), as a white solid. 1H NMR (400 MHz, DMSO-d6) d: 0.92 (6H, d, J= 6.2 Hz),<br>
1.16 - 1.65 (7H, m), 2.79 - 2.93 (2H, m), 2.96 (3H, s), 3.26 (3H, s), 3.62 - 3.69 (1H,<br>
m), 3.76 - 3.83 (1H, m), 4.60 (2H, d, J=21.8 Hz), 7.27 (1H, d, J= 7.3 Hz), 7.55 (1H,<br>
d, J= 8.5 Hz), 7.65 (1H, s). LC-MS (ESI) calcd for C23H30N4O7S2 538.16, found<br>
539.4 [M+H-].<br>
[00463] Example 60: N-{3-[((1R,2S,7R,8S)-3-(3-Fluoro-4-methyl-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
a)(1S,2R,3S,4R)-3-(3-Fluoro-4-methyl-benzylamino)-bicyclo[2,2,1]heptane-<br>
2-carboxylic acid ethyl ester<br><br>
[00464] (1S,2R,3S,4R)-3-Amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl<br>
ester (prepared as described in Example 6k, 300 mg, 1.637 mmol) was suspended in<br>
ethanol (5 mL). 3 -Fluoro-4-methyl-benzaldehyde (0.2 mL, 1.637 mmol) was added<br>
followed by glacial acetic acid (0.1 mL, 3.724 mmol) and 4Ã powdered molecular<br>
sieves (0.6 g). Sodium cyanoborohydride (0.593 g, 9.406 mmol) was added and the<br>
mixture was stirred under nitrogen at 50 Â°C for 18 h. Upon cooling, the mixture was<br>
filtered through Celite. The filtrate was diluted with half-saturated aqueous sodium<br>
bicarbonate solution (50 mL) and extracted with ethyl acetate (2 Ã 75 mL). The<br>
layers were separated and the organic layer was washed with saturated aqueous brine<br>
solution, dried over sodium sulfate, filtered, and concentrated in vacuo. Further<br>
purification by flash column chromatography (Teledyne Isco RediSep column; 1st<br>
column: 0 to 25% ethyl acetate in hexanes; 2nd column: 0 to 20% ethyl acetate in<br>
hexanes) afforded the desired product, (1S,2R,3S,4R)-3-(3-fluoro-4-methyl-<br>
benzylamino)-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (221 mg, 0.724<br>
mmol, 44%), as a clear thick oil. 1H NMR (400 MHz, CDCl3)d: 1.04 - 1.15 (2H, m),<br>
1.21 (1H,d, J=10.1 Hz), 1.29 (3H,t, J=7.1 Hz), 1,42- 1.63 (4H,m), 1.94(1H,dt,<br>
J1 = 10.2 Hz, J2 = 2.0 Hz), 2.25 (3H, s), 2.43 (1H, d, J= 3.5 Hz), 2.59 (1H, dd, J, =<br>
8.6 Hz, J2 = 1.6 Hz), 2.93 (1H, dd, J1 = 8.6 Hz, J2 = 1.6 Hz), 3.65 (1H, d, J= 13.4<br>
Hz), 3.79 (1H, d, J= 14.2 Hz), 4.15 (2H, q, J= 7.1 Hz), 6.94 (1H, d, J= 7.9 Hz), 6.98<br>
(1H, d, J= 10.9 Hz), 7.08 (1H, t, J= 7.8 Hz). LC-MS (ESI) calcd for C18H24FNO2<br>
305.18, found 305.9 [M+H+].<br>
b) (1S,2R,3S,4R)-3- {(3-Fluoro-4-methyl-benzyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br><br>
[00465] To a solution of (1R,2S,7R,8S)-3-(3-fluoro-4-methyl-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (92 mg, 0.30 mmol), (7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetic<br>
acid (prepared as described in Example lg, 100 mg, 0.30 mmol) and l-[3-<br>
(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (60 mg, 0.315 mmol) in<br>
N,N-dimethylformamide (4.0 mL) was added N-methylmorpholine (0.07 mL, 0.63<br>
mmol). After stirring at 25 Â°C for 3 h, the mixture was poured into a 1.0 M aqueous<br>
hydrochloric acid solution and extracted with ethyl acetate (2 Ã 100 mL). The<br>
combined organic layers were washed with saturated aqueous brine solution, dried<br>
over sodium sulfate, filtered, and concentrated in vacuo to afford the crude product,<br>
(1S,2R,3S,4R)-3-{(3-fluoro-4-methyl-benzyl)-[2-(7-methanesulfonylamino-1,1-dioxo-<br>
1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-acetyl]-amino} -bicyclo [2,2,1 ]heptane-2 -<br>
carboxylic acid ethyl ester, as an orange oil. The crude product was used in the next<br>
step without further purification. LC-MS (ESI) calcd for C28H33FN4O7S2 620.18,<br>
found 621,4 [M+H+].<br>
c)N-{3-[(1R,2S,7R,8S)-3-(3-Fluoro-4-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00466] The crude (1S,2R,3S,4R)-3-{(3-fluoro-4-methyl-benzyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester was dissolved in<br>
ethanol (5 mL) at 25 Â°C. A 21 wt. % solution of sodium ethoxide in ethanol (0.224<br>
mL, 0.60 mmol) was added and the reaction mixture was heated at 60 Â°C for 90 min.<br>
After cooling to 25 Â°C, the reaction mixture stirred for 18 h at 25 Â°C. The mixture was<br>
partitioned between a 1.0 M aqueous hydrochloric acid solution (100 mL) and ethyl<br>
acetate (2 Ã 100 mL). The organic layers were washed with saturated aqueous brine<br>
solution, dried over sodium sulfate, filtered and concentrated in vacuo. The residue<br>
was purified by flash column chromatography (Teledyne Isco RediSep column; 1st<br>
column: 0 to 10% ethyl acetate in hexanes; 2nd column: 30 to 80% ethyl acetate in<br>
hexanes) to afford the desired product, N-{3-[(1R,2S,7R,8S)-3-(3-fluoro-4-methyl-<br>
benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (53 mg, 0.092 mmol,<br>
31% over two steps), as a white solid. 1H NMR (400 MHz, DMSO-d6) d: 1.12 - 1.21<br>
(2H, m), 1.39 - 1.64 (4H, m), 2.20 (3H, s), 2.63 (1H, bs), 3.02 (1H, d, J= 9.9 Hz),<br>
3.06 (3H, s), 3.54 (1H, d, J= 9.3 Hz), 4.42 (1H, d, J= 15.5 Hz), 4.92 (1H, d, J= 15.5<br>
Hz), 7.01 - 7.07 (2H, m), 7.23 (1H, t, J= 8.1 Hz), 7.49 - 7.58 (3H, m), 10.17 (1H, s).<br>
LC-MS (ESI) calcd for C26H27FN4O6S2 574.14, found 575.4 [M+H+].<br>
[00467] Example 61: (1R,2S,7R,8S)-5-(7-Bromo-1,1-dioxo-1,4-dihydro-1?6-<br>
pyrido[2,3-e][1,2,4 ]thiadiazin-3-yl)-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
a) 2-Amino-5-bromo-pyridine-3 -sulfonic acid amide<br><br>
[00468] 5-Bromo-pyridin-2-ylamine (10 g, 57.8 mmol) was added to<br>
chlorosulfonic acid (40 mL, 602 mmol) while stirring at 25 Â°C. The mixture was<br>
heated at 160 Â°C while stirring for 3 h. Upon cooling to 25 Â°C, the brown solution<br>
was carefully poured over ice (~500 g). The resulting precipitate was collected by<br>
vacuum filtration and rinsed with water to afford the intermediate, 2-amino-5-bromo-<br>
pyridine-3-sulfonyl chloride, as a beige solid. The solid was suspended in a 15%<br>
aqueous ammonium hydroxide solution. The reaction mixture stirred for 45 min.<br>
Everything was completely dissolved at this point. The mixture was cooled to 0 Â°C<br>
and the pH was adjusted to ~8 by the careful addition of 12.0 M aqueous hydrochloric<br>
acid solution. A solid precipitated and was collected by vacuum filtration, rinsed with<br>
water (2 Ã 50 mL) and dried in vacuo to afford the desired product, 2-amino-5-bromo-<br>
pyridine-3-sulfonic acid amide (7.48 g, 29.7 mmol, 51%), as a light beige solid. 1H<br>
NMR (400 MHz, DMSO-d6) d: 6.69 (2H, bs), 7.54 (2H, bs), 7.91 (1H, d, J= 2.5 Hz),<br>
8.22 (1H,d, J=2.3 Hz).<br>
b) N-(5-Bromo-3-sulfamoyl-pyridin-2-yl)-malonamic acid ethyl ester<br><br>
[00469] 2-Amino-5-bromo-pyridine-3-sulfonic acid amide (2.5 g, 9.9 mmol) was<br>
dissolved in 1,4-dioxane (50 mL). Chlorocarbonyl-acetic acid ethyl ester (1.9 mL,<br>
14.85 mmol) was added and the mixture was heated at 90 Â°C while stirring for 2 h.<br>
Upon cooling to 25 Â°C, the mixture was poured into half-saturated aqueous sodium<br>
bicarbonate solution (250 mL). A solid precipitated and was collected by vacuum<br>
filtration, rinsed with water (50 mL) and dried in vacuo to afford the desired product,<br>
N-(5-bromo-3-sulfamoyl-pyridin-2-yl)-malonamic acid ethyl ester (2.5 g, 6.82 mmol,<br>
69%), as a light beige solid. 1H NMR (400 MHz, DMSO-d6)d: 1.19 (3H, t, J= 7.0<br>
Hz), 3.67 (2H, s), 4.10 (2H, q, J= 7.3 Hz), 7.78 (2H, bs), 8.33 (1H, d, J=2.3 Hz),<br>
8.70 (1H, d, J = 2.4 Hz), 9.85 (1H, bs).<br>
c)(7-Bromo-1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-e][1,2,4]thiadiazin-3-yl)-<br>
acetic acid ethyl ester<br><br>
[00470] In a sealed tube, N-(5-Bromo-3-sulfamoyl-pyridin-2-yl)-malonamic acid<br>
ethyl ester (2.2 g, 6.0 mmol) was suspended in toluene (44 mL) and triethylamine (11<br>
mL, 78.9 mmol) was added. The mixture was heated at 110 Â°C while stirring for 30<br>
min. The solid was completely dissolved, yet an immiscible, oily residue was<br>
observed along the bottom of the flask Upon cooling to 25 Â°C, ethyl acetate (-50<br>
mL) was added. Everything became miscible. The solution was concentrated in<br>
vacuo to afford a golden oil. The oil was dissolved in methanol (~50 mL) and<br>
concentrated in vacuo to afford the crude product, (7-bromo-1,1-dioxo-1,4-dihydro-<br>
1?6-pyrido[2,3-e][1,2,4]thiadiazin-3-yl)-acetic acid ethyl ester (2.18 g, &gt;6.0 mmol,<br>
100%, still contained some solvent), as a golden oil. LC-MS (ESI) calcd for<br>
C10H10BrN3O4S 346.96, found 348.1 (100%), 349.2 (10%), 350.2 (99%) [M+H+].<br>
d) Sodium-(7-bromo-1,1 -dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e][ 1,2,4]thiadiazin-3 -yl)-acetate<br><br>
[00471] The crude (7-bromo-1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e][1,2,4]thiadiazin-3-yl)-acetic acid ethyl ester (1.14 g, 3.27 mmol) was dissolved in<br>
methanol (20 mL). Solid sodium hydroxide (0.392 g, 9.8 mmol) was added followed<br>
by water (10 mL). Everything was completely dissolved within ~5 minutes. After<br>
~20 minutes, a solid began to precipitate. The mixture continued to stir for 10 min.<br>
The product was collected by vacuum filtration, rinsed with methanol (~5 mL) and<br>
dried under vacuum to afford the desired product, sodium-(7-bromo-1,1-dioxo-1,4-<br>
dihydro-1?6-pyrido[2,3-e][1,2,4]thiadiazin-3-yl)-acetate (0.48 g, 1.5 mmol, 46%), as a<br>
white solid. 1H NMR (400 MHz, D2O)d: 3.30 (2H, s), 8.31 (1H, d, J= 2.2 Hz), 8.57<br>
(1H, d, J= 1.6 Hz). Note: Successive NMR acquisitions of the product in DMSO-d6<br>
indicated decarboxylation over a period of~30 min to afford 7-bromo-3-methyl-4H-<br>
pyrido[2,3-e][1,2,4]thiadiazine 1,1-dioxide. However, the product appears to be<br>
stable as the solid sodium salt form.<br>
e) (1R,2S,7R,8S)-5-(7-Bromo-1,1 -dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e] [ 1,2,4]thiadiazin-3 -yl)-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00472] (1S,2R,3S,4R)-3-(4-Fluoro-benzylamino)-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester (prepared as described in Example 61, 0.213 g, 0.73 mmol),<br>
sodium-(7-bromo-1,1 -dioxo-1,4-dihydro-1?6-pyrido [2,3 -e][ 1,2,4]thiadiazin-3 -yl)-<br>
acetate (0.25 g, 0.73 mmol) and 0-(7-azabenzotriazol-l-yl)-1,1,3,3-<br>
tetramethyluronium hexafluorophosphate (0.305 g, 0.803 mmol) were combined and<br>
dissolved in N,N-dimethylformarnide (1.5 mL). The mixture was shaken vigorously<br>
for about 1 min until everything dissolved. The solution continued to stir for 1 h.<br>
Triethylamine (0.5 mL, 3.65 mmol) was added and the mixture was stirred at 50 Â°C<br>
for 16 h. The mixture was concentrated in vacuo to a volume of ~5 mL. Water (~20<br>
mL) was added and the product precipitated. The solid was collected by vacuum<br>
filtration and purified by flash column chromatography (Merck silical gel 60, 40-63<br>
Âµm; 35% ethyl acetate in hexanes) to afford the desired product, (0.24 g, 0.44 mmol,<br>
60%) as a white, brittle foam. A portion of the product (0.07 g, 0.128 mmol) was<br>
recrystallized from n-propanol (0.5 mL) to afford the pure desired product, 5-(7-<br>
bromo-1,1 -dioxo-1,4-dihydro-1?6-pyrido[2,3 -e][ 1,2,4]thiadiazin-3-yl)-3-(4-fluoro-<br>
benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one (0.044 g, 0.081 mmol,<br>
63%), as a yellow powder. 1H NMR (400 MHz, DMSO-d6)d: 1.13 - 1.23 (2H, m),<br>
1.38 - 1.60 (4H, m), 2.51 (1H, s), 2.63 (1H, s), 3.00 (1H, d, J= 8.4 Hz), 3.55 (1H, d, J<br>
= 9.4 Hz), 4.41 (1H, d, J= 14.7 Hz), 4.95 (1H, d, J= 15.4 Hz), 7.14 (2H, t, J =9.0<br>
Hz), 7.33 (2H, dd, J1 = 8.6 Hz, J2 = 5.5 Hz), 8.66 (1H, s), 8.82 (1H, s). LC-MS (ESI)<br>
calcd for C23H20BrFN4O4S 546.04, found 547.2 [M+H+].<br>
[00473] Example 62: N-{3-[{(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7lundec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-pyrido[2.3-<br>
e] [ 1,2,4]thiadiazin-7 - yl} -methanesulfonamide<br><br>
[00474] Methane sulfonamide (0.348 g, 3.66 mmol), potassium phosphate (0.078<br>
g, 0.366 mmol), L-proline (0.021 g, 0.183 mmol) and copper iodide (0.035 g, 0.183<br>
mmol) were combined and suspended in dimethylsulfoxide (0.5 mL). The flask was<br>
degassed and backfilled with argon. The mixture was heated, while stirring, at 110 Â°C<br>
for 5 min. 5-(7-Bromo-1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-e][1,2,4]thiadiazin-3-<br>
yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br>
(prepared as described in Example 62, 0.1 g, 0.183 mmol) was dissolved in<br>
dimethylsulfoxide (0.5 mL) and transferred to the reaction mixture. The mixture was<br>
stirred at 110 Â°C for 16 h. Upon cooling, the mixture was poured into ethyl acetate<br>
(150 mL) and saturated aqueous ammonium chloride solution (100 mL). The mixture<br>
was shaken and everything was passed through a plug of Celite. The organic layer<br>
was separated from the filtrate, washed with saturated aqueous ammonium chloride<br>
solution (50 mL), saturated aqueous brine solution (50 mL), dried over magnesium<br>
sulfate, filtered and concentrated in vacuo to a brown waxy solid. Flash column<br>
chromatography (Merck silica gel 60, 40-63 Âµm; 0 to 50% ethyl acetate in<br>
dichloromethane) afforded the desired product, N-{3-[(lR,2S,7R,SS}-3-(4-fluoro-<br>
benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-<br>
dihydro-1?6-pyrido[2,3-e][1,2,4]thiadiazin-7-yl}-methanesulfonamide (0.018 g, 0.032<br>
mmol, 17.5%), as a beige solid. 'HNMR (400 MHz, DMSO-d6)d: 1.04 - 1.52 (6H,<br>
m), 2.37 - 2.41 (1H, m), 2.53 - 2.56 (1H, m), 3.05 (3H, s), 3.25 - 3.34 (2H, m), 4.25<br>
(1H, d, J= 15.1 Hz), 4.93 (1H, d, J= 15.0 Hz), 7.11 (2H, t, J= 9.1 Hz), 7.27 (2H, dd,<br>
J1 = 8.7Hz,J2 = 5.4Hz), 7.81 (1H,s), 8.36 (1H,s), 10.01 (1H,bs). LC-MS (ESI)<br>
calcd for C24H24FN5O6S2 561.12, found 562.4 [M+H+].<br>
[00475] Example 63: ((1R,2S,7R,8S)-5-(1,1-Dioxo-1,4-dihydro-1?6-pyridor2.3-<br>
e][1,2,4]thiadiazin-3-yl)-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00476] 5-(7-Bromo-1,1 -dioxo-1,4-dihydro-1?6-pyrido[2,3-e][ 1,2,4]thiadiazin-3 -<br>
yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br>
(prepared as described in Example 62, 0.07 g, 0.128 mmol) was dissolved in methanol<br>
(8 mL). Ammonium formate (0.2 g, 3.17 mmol) followed by 10% palladium on<br>
carbon (wet, 0.1 g) were added. The mixture stirred at 50 Â°C for 3 h. The mixture<br>
was filtered through Celite and the filtrate was concentrated in vacuo. The residue<br>
was dissolved in water (5 mL) and ethyl acetate (50 mL). The mixture was shaken<br>
and the layers were separated. The organic layer was dried over magnesium sulfate,<br>
filtered and concentrated in vacuo to a clear oil. Flash column chromatography<br>
(Merck silica gel 60, 40-63 Âµm; 20 to 40% ethyl acetate in hexanes) afforded the<br>
desired product, (1R,2S,7R,8S)-5-(1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e][1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (0.0441 g, 0.094 mmol, 74%), as a white, brittle<br>
foam. 1H NMR (400MHz, DMSO-d6) d: 1.11 - 1.61 (6H, m), 2.51 (1H, s), 2.63 (1H,<br>
s), 2.99 (1H, d, J= 9.4 Hz), 3.54 (1H, d, J= 9.4 Hz), 4.41 (1H, d, J= 15.7 Hz), 4.95<br>
(1H, d, J= 15.4 Hz), 7.14 (2H, t, J= 8.6 Hz), 7.33 (2H, dd, Jj = 8.6 Hz, J2 = 5.4 Hz),<br>
7.51 (1H, dd, J1 = 7.8 Hz, J2 = 4.5 Hz), 8.34 (1H, d, J = 7.6 Hz), 8.68 (1H, dd, J1 = 4.6<br>
Hz, J2 = 1.7 Hz). LC-MS (ESI) calcd for C23H21FN4O4S 468.13, found 469.4<br>
[M+H+].<br>
[00477] Example 64: (1R,2S,7R,8S)-5-(1,1-Dioxo-1,4-dihydro-1?6-pyrido[4,3-<br>
e][1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricvclor6.2.1.02,7]undec-5-en-4-one<br><br>
a) 4-Azido-pyridine-3-sulfonic acid amide<br><br>
[00478] 4-Chloro-pyridine-3-sulfonic acid amide (4 g, 20.77 mmol) and sodium<br>
azide (13.7 g, 210 mmol) were combined. Anhydrous N,N-dimethylformamide (80<br>
mL) and water (30 mL) were added. The mixture was stirred at 90 Â°C for 2 h. Upon<br>
cooling, the mixture was diluted with saturated aqueous ammonium chloride solution<br>
(200 mL). The product was extracted into ethyl acetate (6 Ã 200 mL). The combined<br>
organic layers were dried over magnesium sulfate, filtered and concentrated in vacuo<br>
to afford the desired product, 4-azido-pyridine-3-sulfonic acid amide (3.75 g, 18.83<br>
mmol, 91%), as a pale yellow solid. 1H NMR (400 MHz, DMSO-d6) d: 7.54 (2H, bs),<br>
7.57 (1H, d, J= 5.4 Hz), 8.68 (1H, d, J= 5.5 Hz), 8.81 (1H, s).<br>
b) 4-Amino-pyridine-3-sulfonic acid amide<br><br>
[00479] 4-Azido-pyridine-3-sulfonic acid amide (3.75 g, 18.83 mmol) was<br>
dissolved in methanol (80 mL). Sodium borohydride (0.712 g, 18.83 mmol) was<br>
carefully added portionwise. Vigorous effervescence was observed. The mixture<br>
continued to stir at 25 Â°C for 25 min. The mixture was concentrated in vacuo to a<br>
thick yellow sludge. The residue was dissolved in a mixture of ethyl acetate (200 mL)<br>
and saturated aqueous ammonium chloride solution (200 mL). The aqueous layer was<br>
back extracted with ethyl acetate (6 Ã 200 mL). The combined organic layers were<br>
dried over magnesium sulfate, filtered and concentrated in vacuo to afford the desired<br>
product, 4-amino-pyridine-3-sulfonic acid amide (1.8 g, 10.4 mmol, 55%), as a pale<br>
yellow solid. 1H NMR (400 MHz, DMSO-d6)d: 6.63 (2H, bs), 6.68 (1H, d, J= 5.4<br>
Hz), 7.40 (2H, bs), 8.06 (1H, d, J= 5.5 Hz), 8.43 (1H, s).<br>
c) (1,1 -Dioxo-1,4-dihydro-1?6-pyrido[4,3-e][1,2,4]thiadiazin-3-yl)-acetic acid<br>
methyl ester<br><br>
[00480] 4-amino-pyridine-3-sulfonic acid amide (0.25 g, 1,44 mmol) was<br>
suspended in malonic acid dimethyl ester (5 mL, 43.75 mmol). The flask was purged<br>
with nitrogen and the mixture was stirred at 180 Â°C for 60 min. Upon cooling, the<br>
mixture was diluted with ethyl acetate (5 mL) causing immediate precipitation of an<br>
undesired side product. The solid was removed by vacuum filtration and rinsed with<br>
ethyl acetate (2 mL). The filtrate was passed through a plug of silica gel, eluting with<br>
ethyl acetate followed by 5% methanol in ethyl acetate. The fractions containing the<br>
5% methanol in ethyl acetate were combined and concentrated in vacuo to afford the<br>
desired product, (1,1-dioxo-1,4-dihydro-1?6-pyrido[4,3-e][1,2,4]thiadiazm-3-yl)-<br>
acetic acid methyl ester (0.135 g, 0.529 mmol, 37%) as a yellow oil. LC-MS (ESI)<br>
calculated for C9H9N3O4S 255.03, found 256.0 [M+H+].<br>
d) Sodium-( 1,1 -dioxo-1,4-dihydro-1?6-pyrido[4,3-e][1,2,4]thiadiazin-3-yl)-<br>
acetate<br><br>
[00481] (1,1 -Dioxo- 1,4-dihydro-1?6-pyrido [4,3-e][1,2,4]thiadiazin-3-yl)-acetic<br>
acid methyl ester (0.13 g, 0.51 mmol) was dissolved in methanol (3 mL). Sodium<br>
hydroxide (0.08 g, 2.0 mmol) was dissolved in water (1.5 mL). The solutions were<br>
combined and were stirred at 25 Â°C for 3 h. The mixture was concentrated in vacuo to<br>
afford the desired product, sodium-(1,1-dioxo-1,4-dihydro-1?6-pyrido[4,3-<br>
e][1,2,4]thiadiazin-3-yl)-acetate, as a yellow oil. LC-MS (ESI) calculated for<br>
C8H7N3O4S (free acid) 241.02, found 242.2 [M+H+].<br>
e)(1R,2S,7R,8S)-5-(1,1-Dioxo-1,4-dihydro-1?6-pyrido[4,3-e][1,2,4]thiadiazin-<br>
3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00482] The crude sodium-(1,1-dioxo-1,4-dihydro-1?6-pyrido[4,3-<br>
e][1,2,4]thiadiazin-3-yl)-acetate, (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (prepared as described in Example<br>
61, 0.149 g, 0.51 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium<br>
hexafluorophosphate (0.194 g, 0.51 mmol) were combined and dissolved in<br>
anhydrous N,N-dimethylformamide (1 mL). The mixture was stirred at 25 Â°C for 1 h.<br>
Triethylamine (0.35 mL, 2.6 mmol) was added and the mixture was stirred at 50 Â°C<br>
for 16 h. Upon cooling, the mixture was diluted with ethyl acetate (100 mL), washed<br>
with saturated aqueous ammonium chloride solution (2 Ã 25 mL) and saturated<br>
aqueous brine solution (25 mL). The organic layer was dried over magnesium sulfate,<br>
filtered and concentrated in vacuo. Purification by flash column chromatography<br>
(Merck silica gel 60, 40-63 Âµm, 75% to 100% ethyl acetate in hexanes) followed<br>
trituration of the resulting oil with a 1:1 mixture of hexanes and diethyl ether (2 mL)<br>
afforded the desired product, (1R,2S,7R,8S)-5-(1,1-dioxo-1,4-dihydro-1?6-pyrido[4,3-<br>
e][1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (0.0184 g, 0.039 mmol, 7.7% over two steps), as<br>
a pale yellow powder. LC-MS (ESI) calculated for C23H21FN4O4S 468.13, found<br>
469.2 [M+H+]. 1H NMR (400 MHz, DMSO-d6)d: 1.01 - 1.54 (6H, m), 2.35 (1H, d, J<br>
= 3.7 Hz), 2.46 (1H, s), 2.53 (1H, s), 3.26 (1H, d, J = 9.5 Hz), 4.23 (1H, d, J = 15.8<br>
Hz), 4.94 (1H, d, J = 15.0 Hz), 7.08 - 7.13 (3H, m), 7.24 - 7.28 (2H, m), 8.44 (1H, d, J<br>
= 4.8 Hz), 8.67(1 H, s).<br>
[00483] Example 65: (1R,2S,7R,8S)-5-(1,1 -Dioxo-1,4-dihydro-1?6-pyrido[3,2-<br>
e][1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricvclo[6.2.1.02,7]undec-5-en-4-one<br><br>
a) 2 -Benzylsulfanyl-3 -nitro-pyridine<br><br>
[00484] Ethanol (150 mL) was added to a mixture of 2-chloro-3-nitro-pyridine (5<br>
g, 31.54 mmol) and potassium carbonate (4.8 g, 34.7 mmol). Benzyl mercaptan (4.09<br>
mL, 34.7 mmol) was added followed by water (30 mL). The mixture stirred at 25 Â°C<br>
for 4 h. Water (350 mL) was added and the product precipitated. The solid was<br>
collected by vacuum filtration, rinsed with water (100 mL) and dried in vacuo for 4 h<br>
to afford the desired product, 2-benzylsulfanyl-3-nitro-pyridine (6.6 g, 26.8 mmol,<br>
85%), as a yellow powder. 1H NMR (400 MHz, DMSO-d6) d: 4.47 (2H, s), 7.21 -<br>
7.31 (3H, m), 7.40 - 7.45 (3H, m), 8.58 (1H, dd, J1 = 8.6 Hz, J2 = 1.7 Hz), 8.83 (1H,<br>
dd,J1 = 4.7Hz,J2=1.7Hz).<br>
b) 3-Nitro-pyridine-2-sulfonyl chloride<br><br>
[00485] 2-Benzylsulfanyl-3 -nitro-pyridine (6 g, 24.39 mmol) was dissolved in<br>
dichloromethane (84 mL). Acetic acid (12 mL) and water (24 mL) were added. The<br>
mixture was chilled to 0 Â°C. With vigorous stirring, l,3-dichloro-5,5-dimethyl-<br>
imidazolidine-2,4-dione (14.4 g, 73.17 mmol) was added portionwise as a suspension<br>
in dichloromethane (48 mL). The mixture was allowed to slowly warm to 25 Â°C and<br>
continued to stir for 16 h. The mixture was poured into 5% aqueous sodium<br>
metabisulfite solution (100 mL) and shaken well. Dichloromethane (200 mL) and<br>
20% aqueous dibasic potassium phosphate solution (100 mL) were added and the<br>
mixture was shaken well. The layers were separated. The crude desired product, 3 -<br>
nitro-pyridine-2-sulfonyl chloride, dissolved in the organic layer was used directly in<br>
the next step without further isolation or characterization.<br>
c) 3-Nitro-pyridine-2-sulfonic acid amide<br><br>
[00486] The organic layer was chilled to 0 Â°C and concentrated aqueous<br>
ammonium hydroxide solution (25 mL) was added. The mixture was stirred for 10<br>
min. The mixture was washed with 10% aqueous citric acid solution (added until pH<br>
concentrated in vacuo. The resulting solid was triturated with a 1:1 mixture of<br>
hexanes and ethyl acetate (~15 mL), collected by vacuum filtration and dried in vacuo<br>
for 16 h to afford the desired product, 3-nitro-pyridine-2-sulfonic acid amide (3.1 g,<br>
15.26 mmol, 63%), as abeige solid. 1HNMR(400 MHz, DMSO-d6) d: 7.89 (1H, d, J<br>
= 4.7 Hz), 7.95 (2H, s), 8.48 (1H, dd, J1 = 8.6 Hz, J2 = 1.6 Hz), 8.92 (1H, d, J = 4.7<br>
Hz).<br>
d) 3-Amino-pyridine-2-sulfonic acid amide<br><br>
[00487] 3-Nitro-pyridine-2-sulfonic acid amide (3 g, 14.77 mmol) and iron powder<br>
(5 g, 
ammonium chloride solution (60 mL) was added and the mixture stirred at 105 Â°C for<br>
1.5 h. Upon cooling to 25 Â°C, ethyl acetate (200 mL) was added and the mixture was<br>
shaken vigorously. The entire mixture was filtered through a plug of Celite. The<br>
resulting filtrate was diluted with ethyl acetate (100 mL) and the layers were<br>
separated. The aqueous layer was back-extracted with ethyl acetate (3 x 200 mL).<br>
The organic layers were combined, dried over magnesium sulfate, filtered and<br>
concentrated in vacuo to dryness. The resulting solid was triturated with a 3:1<br>
mixture of hexanes and ethyl acetate (~10 mL). The solid was collected by vacuum<br>
filtration and dried in vacuo for 16 h to afford the desired product, 3-amino-pyridine-<br>
2-sulfonic acid amide (1.95 g, 11.27 mmol, 76%), as an off-white powder. 1H NMR<br>
(400 MHz, DMSO-d6)d: 5.98 (2H, bs), 7.19 - 7.21 (1H, m), 7.32 (2H, bs), 7.79 - 7.80<br>
(1H, m), 7.90-7.91 (1H, m).<br>
e) (1,1-Dioxo-1,4-dihydro-1?6-thia-2,4,8-triaza-naphthalen-3-yl)-acetic acid<br>
ethyl ester<br><br>
[00488] 3-Amino-pyridine-2-sulfonic acid amide (1.8 g, 10.4 mmol) was dissolved<br>
in 1,4-dioxane (45 mL). Chlorocarbonyl-acetic acid ethyl ester (1.57 mL, 12.48<br>
mmol) was added. The mixture was stirred at 90 Â°C for 1.5 h. Upon cooling, the<br>
mixture was diluted with ethyl acetate (300 mL) and washed with half-saturated<br>
aqueous sodium bicarbonate solution (100 mL) followed by saturated aqueous brine<br>
solution (100 mL). The organic layer was dried over magnesium sulfate, filtered and<br>
concentrated in vacuo. The resulting oily residue was treated with toluene (36 mL)<br>
and triethylamine (9 mL). The mixture was stirred at 110 Â°C in a sealed tube for 1.5<br>
h. The residue never completely dissolved. Upon cooling, the mixture was<br>
concentrated in vacuo to afford a thick oil. Trituration with a minimal amount of<br>
ethyl acetate (~5 mL) solidified the product. The solids were collected by vacuum<br>
filtration and dried in vacuo for 16 h to afford the desired product, (1,1-dioxo-1,4-<br>
dihydro-1?6-thia-2,4,8-triaza-naphthalen-3-yl)-acetic acid ethyl ester (0.3 g, 1.11<br>
mmol, 11%), as a white solid. 1H NMR (400 MHz, DMSO-d6) d: 1.21 (3H, t, J= 7.0<br>
Hz), 3.71 (2H, s), 4.16 (2H, quartet, J= 7.1 Hz), 7.70 - 7.76 (2H, m), 8.62 (1H, dd, J1<br>
= 4.0 Hz, J2 = 1.5 Hz), 12.29 (1H, bs). LC-MS (ESI) calcd for C10H11N3O4S 269.05,<br>
found 270.1 [M+H+],<br>
f) (1,1 -Dioxo-1,4-dihydro-1?6-thia-2,4,8-triaza-naphthalen-3-yl)-acetic acid<br>
sodium salt<br><br>
[00489] (1,1 -Dioxo-1,4-dihydro-1?6-thia-2,4,8-triaza-naphthalen-3-yl)-acetic acid<br>
ethyl ester (0.25 g, 0.928 mmol) was dissolved in methanol (5 mL) at approximately<br>
60 Â°C. Sodium hydroxide (0.111 g, 2.79 mmol) was dissolved in water (2.5 mL).<br>
Upon cooling to 25 Â°C, the solutions were combined. The mixture was stirred at 25<br>
Â°C for 3 h. The mixture was stored at -40 Â°C for 16 h. The mixture was concentrated<br>
in vacuo to afford the crude product, (1,1-dioxo-1,4-dihydro-1?6-thia-2,4,8-triaza-<br>
naphthalen-3-yl)-acetic acid sodium salt (-0.928 mmol), as a yellow film, which was<br>
used in the next step without further purification.<br>
g)(lR,2S,7R,8S)-5-(1,1-Dioxo-1,4-dihydro-1?6-thia-2,4,8-triaza-naphthalen-<br>
3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one<br><br>
[00490] The crude (1,1-dioxo-1,4-dihydro-1?6-thia-2,4,8-triaza-naphthalen-3-yl)-<br>
acetic acid sodium salt (~0.928 mmol), (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (0.27 g, 0.928 mmol) and O-(7-<br>
azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.494 g, 1.3<br>
mmol) were combined and dissolved in anhydrous N,N-dimethylformamide (2 mL).<br>
The mixture was stirred at 25 Â°C for 1.5 h. Triethylamine (0.697 mL, 5 mmol) was<br>
added and the mixture was stirred at 50 Â°C for 16 h. Upon cooling, the mixture was<br>
diluted with ethyl acetate (100 mL), washed with saturated aqueous ammonium<br>
chloride solution (2 x 25 mL) and saturated aqueous brine solution (25 mL). The<br>
organic layer was dried over magnesium sulfate, filtered and concentrated in vacuo.<br>
The resulting solid was triturated with ethyl acetate (~15 mL) and the product<br>
solidified. The solid was collected by vacuum filtration and dried in vacuo for 16 h to<br>
afford the desired product, (1R,2S,7R,8S)-5-(1,1-dioxo-1,4-dihydro-1?6-thia-2,4,8-<br>
triaza-naphthalen-3 -yl)-3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one (0.03 g, 0.064 mmol, 6.9%), as a white powder.<br>
1H NMR (400 MHz, DMSO-d6)d: 0.92 - 1.05 (2H, m), 1.18 - 1,46 (4H, m), 2.26 (1H,<br>
d, J= 3.1 Hz), 2.36 (1H, d, J= 9.5 Hz), 2.45 (1H, d, J= 3.0 Hz), 3.15 (1H, d, J= 9.4<br>
Hz), 4.13 (1H, d, J= 15.6 Hz), 4.86 (1H, d, J= 15.6 Hz), 7.01 - 7.05 (2H, m), 7.16 -<br>
7.20 (2H, m), 7.39 - 7.42 (1H, m), 7.50 (1H, dd, J1 = 8.6 Hz, J2 = 1.6 Hz), 8.26 (1H,<br>
dd, J1 = 4.6 Hz, J2 = 1.5 Hz). LC-MS (ESI) calcd for C23H21FN4O4S 468.13, found<br>
469.2 [M+H+].<br>
[00491] Example 66: N-{3-[(1R,2S,7R,8S)-3-(2-Cycloproply-ethyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo- 1,4-dihydro-1?6-<br>
benzo [1.2.4]thiadiazin-7 -yl} -methanesulfonamide<br><br>
a)(1S,2R,3S,4R)-3-(2-Cyclopropyl-ethylamino)-bicyclo[2,2,1]heptane-2-<br>
carboxylic acid ethyl ester<br><br>
[00492] A 1,4 M solution of cyclopropylacetaldehyde in dichloromethane<br>
(prepared as described in Example 23a, 3.4 mL, 4.76 mmol) was added to a solution<br>
of (1S,2R,3S,4R)-3-amino-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br>
(prepared as described in Example 6k, 580 mg, 3.17 mmol) in anhydrous methanol<br>
(15 mL) at 25 Â°C under a nitrogen atmosphere. After stirring for 20 min, glacial<br>
acetic acid (0.6 mL) was added. The solution was cooled to 0 Â°C, sodium<br>
triacetoxyborohydride (1.7 g, 7.93 mmol) was added, and the resulting mixture was<br>
stirred at 25 Â°C for 20 h. The reaction mixture was quenched with saturated aqueous<br>
sodium bicarbonate solution (25 mL) and was extracted with ethyl acetate (3 x 60<br>
mL). The combined organic layers were washed with saturated aqueous brine<br>
solution, dried over sodium sulfate and filtered. The filtrate was concentrated in<br>
vacuo to afford the desired product, (1S,2R,3S,4R)-3-(2-cyclopropyl-ethylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (676.4 mg, 2.69 mmol, 84.9%), as<br>
a yellow oil. LC-MS (ESI) calcd for C15H25NO2 251.19, found 252.0 [M+H ].<br>
b) (1S,2R,3S,4R)-3- {(2-Cyclopropyl-ethyl)-[2-(7-methanesulfonylamino-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-amino}-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester<br><br>
[00493] To a stirred solution of (1S,2R,3S,4R)-3-(2-cyclopropyl-ethylamino)-<br>
bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester (338.2 mg, 1.35 mmol) in<br>
anhydrous N,N-dimethylformamide (10 mL) under a nitrogen atmosphere, (7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3 -yl)-acetic<br>
acid (prepared as described in Example lg, 493 mg, 1,48 mmol), N-methylmorpholine<br>
(0.33 mL, 2.96 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide<br>
hydrochloride (284 mg, 1,48 mmol) were added sequentially. After shaking at 25 Â°C<br>
for 21 h, additional (7-methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-acetic acid (prepared as described in Example lg, 150<br>
mg, 0.45 mmol) and l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride<br>
(85 mg, 0.44 mmol) were added. After another 26 h, a 1.0 M aqueous hydrochloric<br>
acid solution (12 mL) was added and the mixture was extracted with ethyl acetate (3 x<br>
60 mL). The combined organic layers were washed with saturated aqueous brine<br>
solution (15 mL), dried over sodium sulfate, filtered, and concentrated in vacuo to<br>
afford the crude product, (1S,2R,3S,4R)-3-{(2-cyclopropyl-ethyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester, as a red oil, which<br>
was used in the next step without any further purification. LC-MS (ESI) calcd for<br>
C25H34N4O7S2 566.19, found 567.4 [M+H+].<br>
c)N-{3-[(1R,2S,7R,8S)-3-(2-Cyclopropyl-ethyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide<br><br>
[00494] To a solution of the crude (1S,2R,3S,4R)-3- {(2-cyclopropyl-ethyl)-[2-(7-<br>
methanesulfonylamino-1,1 -dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-3 -yl)-<br>
acetyl]-amino}-bicyclo[2,2,1]heptane-2-carboxylic acid ethyl ester in absolute ethanol<br>
(11 mL) was added a 21 wt. % solution of sodium ethoxide in ethanol (2.4 mL, 7.41<br>
mmol). After shaking at 25 Â°C for 23 h, additional 21 wt. % solution of sodium<br>
ethoxide in ethanol (1.0 mL, 3.09 mmol) was added. After shaking at 25 Â°C for 6 h,<br>
additional 21 wt. % solution of sodium ethoxide in ethanol (1.0 mL, 3.09 mmol) was<br>
added and the mixture was shaken for another 24 h. The mixture was then acidified<br>
with 1.0 M aqueous hydrochloric acid solution (22 mL) and was extracted with ethyl<br>
acetate (3 x 60 mL). The combined organic layers were dried over sodium sulfate,<br>
filtered, and concentrated in vacuo. The crude mixture was purified by prep-HPLC<br>
[Column Luna 5Âµ C18 (2) 100A AXIA 150 x 21.2 mm, 5 micron, 30%-95% in 7 min<br>
@ 30 mL/min flow rate, 0.05% trifluoroacetic acid in acetonitrile/ 0.05%<br>
trifluoroacetic acid in water] to afford the desired product, N- {3-[(1R,2S,7R,8S)-3-(2-<br>
cyclopropyl-ethyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1-<br>
dioxo-1,4-dihydro-1?6-benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (160.7 mg,<br>
0.309 mmol, 22.9% over two steps), as a solid. 1H NMR (400 MHz, CDCl3d: 0.09 -<br>
0.15 (2H, m), 0.49 - 0.54 (2H, m), 0.64 - 0.73 (1H, m), 1.27-1.31 (2H, m), 1,48 -<br>
1.78 (6H, m), 2.55 - 2.56 (1H, m), 2.74 - 2.80 (1H, m), 2.85 (1H, d, J = 9.2 Hz), 3.06<br>
(3H, s), 3.10 - 3.17 (1H, m), 3.57 (1H, d, J = 9.2 Hz), 3.80 - 3.87 (1H, m), 6.99 (1H,<br>
s), 7.22 - 7.25 (1H, m), 7.62 - 7.68 (2H, m). LC-MS (ESI) calcd for C23H28N4O6S2<br>
520.15, found 521,4 [M+H+].<br>
[00495] Example 67: N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6,9-dihydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yl}-methanesulfonamide<br><br>
[00496] N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
6, 168 mg, 0.299 mmol) was dissolved in dimethyl sulfoxide (15 mL). Reaction<br>
buffer was prepared by combining anhydrous D-glucose (3.3 g), GDH-102 (375 mg),<br>
and NADP+ (570 mg) in a 100 mM aqueous potassium phosphate (pH 8.0) solution<br>
(700 mL). Lyophilized MCYP-P1C11 (1800 mg, 1500 nmol, 0.84 nmol P450/mg,<br>
Codexis, Inc.) was dissolved in a 50 mM aqueous potassium phosphate (pH 8.0)<br>
solution (29 mL). The following components were added in order to a 2.8 L baffled<br>
Fernbach flask: the reaction buffer, followed by the MCYP-P1C11 stock solution,<br>
then the N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide solution. The vial used to make the<br>
N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide stock solution was washed with 0.1<br>
M aqueous potassium phosphate (pH 8.0) solution (6 mL) and this solution was then<br>
added to the flask, bringing the total volume of the reaction to 750 mL. The mixture<br>
was then incubated for 24 h at 30 Â°C with gentle shaking, followed by freezing at -80<br>
Â°C. Methanol (1.5 L) was added to the thawed reaction mixture resulting in the<br>
formation of a precipitate. The solids were removed as a pellet by centrifugation for<br>
45 min at 10,000 rpm. The supernatant was concentrated in vacuo and the residue<br>
was purified by prep-HPLC to afford the desired product, N-{3-[(1R,2S,7R,8S)-3-(4-<br>
fluoro-benzyl)-6,9-dihydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-<br>
dioxo-1,4-dmydro-1?6-benzo[1,2,4]miadiazin-7-yl}-methanesulfonamide(49.5 mg,<br>
0.086 mmol, 29%), as a white solid. 1H NMR (500 MHz, DMSO-d6) d: 1.21 (1H, dd,<br>
J1 = 14.7 Hz, J2 = 4.8 Hz), 1,46 - 1.59 (3H, m), 2.44 (1H, s), 2.53 (1H, s), 2.87 (1H, d,<br>
J= 8.7 Hz), 3.07 (3H, s), 3.39 (1H, d, J= 8.5 Hz), 3.80 (1H, d, J= 6.0 Hz), 4.42 (1H,<br>
d, J= 15.5 Hz), 4.96 (1H, d, J= 15.7 Hz), 7.16 (2H, t, J= 8.7 Hz), 7.32 - 7.34 (2H,<br>
m), 7.52 (1H, dd, J1 = 9.0 Hz, J2 = 2.3 Hz), 7.59 - 7.60 (2H, m), 10.23 (1H, s), 14.08<br>
(1H, s), 15.03 (1H, bs). LC-MS (ESI) calcd for C25H25FN4O7S2 576.11, found 577.5<br>
[M+H+].<br>
[00497] Example 68: N- {3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyn-6-hydroxy-4-oxo-<br>
3 -aza-tricyclo [6.2.1.02,7]undec-5 -en-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yll-methanesulfonamide. L-arginine salt<br><br>
[00498] N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
6, 0.280 g, 0.499 mmol) was dissolved in acetonitrile (5.0 mL). A 0.1 M aqueous L-<br>
arginine solution (3.0 mL, 0.3 mmol) was added, which was followed by addition of a<br>
0.1 M solution of L-arginine in 1-propanol (2.0 mL, 0.2 mmol). After stirring for 6 h<br>
at 23 Â°C, the flask was opened to the atmosphere and the suspension was stirred for 16<br>
h. The solid was collected by filtration and further dried in vacuo at 23 Â°C to afford<br>
the desired product, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, L-arginine salt, monohydrate<br>
(0.257 g, 0.341 mmol, 68%), as a crystalline solid. 1H NMR (300 MHz, DMSO-d6d:<br>
0.96- 1.17 (2H,m), 1.28 (1H, app t, J = 10.0 Hz), 1.35 - 1.82 (7H, m), 2.33 (1H, app<br>
d, J = 3.0 Hz), 2.43 (1H, d, J= 9.3 Hz), 2.97 (3H, s), 3.00 - 3.17 (2H, m), 3.23 (1H, d,<br>
J = 9.3 Hz), 4.21 (1H, d, J= 15.3 Hz), 4.94 (1H, d, J= 15.3 Hz), 7.04 - 7.15 (3H, m),<br>
7.27 (2H, dd, J= 5.7, 8.7 Hz), 7.35 (1H, dd, J= 2.5, 8.9 Hz), 7.35 - 7.51 (4H, m),<br>
8.82 (1H, br s), 15.29 (1H, br s). Anal, calcd for C31H39FN8O8S2 â¢ H2O: C, 49.46; H,<br>
5.49; N, 14.88; O, 19.13; S, 8.52; F, 2.52; found: C, 49.49; H, 5.23; N, 14.96; O,<br>
18.69; S, 8.82; F, 2.81. m.p. = 216 Â°C (DSC).<br>
[00499] Example 69: N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yl}-methanesulfonamide. L-lysine salt<br><br>
[00500] N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
6, 0.090 g, 0.160 mmol) was dissolved in acetonitrile (2.5 mL). An aqueous solution<br>
of L-lysine (0.469 mL of a 50 mg/mL solution in water, 0.160 mmol) was added. The<br>
solvent was allowed to evaporate under a flow of nitrogen and ethanol (0.5 mL) was<br>
added. The mixture was stirred at 35 Â°C for 2 d, and was then immersed in an<br>
ultrasonic bath. Water (0.5 mL) was added, and the mixture was stirred at 23 Â°C for 3<br>
d. The solid was collected by filtration and further dried in vacuo at 23 Â°C to afford<br>
the desired product, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonarnide, L-lysine salt, monohydrate (0.070<br>
g, 0.096 mmol, 60%), as a crystalline solid. 1H NMR (300 MHz, DMSO-d6) d: 0.96 -<br>
1.15 (2H, m), 1.22 - 1.76 (10H, m), 2.34 (1H, app d, J= 2.7 Hz), 2.43 (1H, d, J= 9.3<br>
Hz), 2.74 - 2.78 (2H, m), 2.97 (3H, s), 3.18 - 3.29 (1H, m), 4.21 (1H, d, J = 15.3 Hz),<br>
4.95 (1H, d, J= 15.6 Hz), 7.07 - 7.18 (3H, m), 7.27 (2H, dd, J= 5.7, 8.7 Hz), 7.36<br>
(1H, dd, J= 2.4, 8.7 Hz), 7.44 (1H, d, J= 2.4 Hz), 15.31 (1H, br s). Anal, calcd for<br>
C31H39FN6O8S2 â¢ H2O: C, 51.37; H, 5.70; N, 11.59; O, 19.87; S, 8.85; F, 2.62; found:<br>
C, 51.13; H, 5.52; N, 11.63; O, 20.07; S, 9.20; F, 2.71. m.p. = 200 Â°C (DSC).<br>
[00501] Example 70: N-{3-[(1R,2S,7R,8S)-3-('4-Fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02'7]undec-5-en-5-yl]-1,1-dioxo-1 ,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yl]-methanesulfonamide. hemi magnesium salt<br><br>
[00502] N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5 -en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
6, 0.465 g, 0.829 mmol) was dissolved in acetone (9.0 mL). A 7-8 wt. % solution of<br>
magnesium methoxide in methanol (0.593 mL, 0.414 mmol) was added. The solvent<br>
was evaporated, and the residue was then diluted with water (0.9 mL) and acetone<br>
(1.8 mL). The resulting mixture was stirred at 23 Â°C for 16 h. The solid was<br>
collected by filtration and further dried in vacuo at 23 Â°C to afford the desired<br>
product, N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, hemi magnesium salt, tr1Hydrate<br>
(0.377 g, 0.602 mmol, 73%), as a crystalline solid. 1H NMR (300 MHz, DMSO-d6) d:<br>
0.96 - 1.17 (2H, m), 1.22 - 1.58 (4H, m), 2.33 (1H, br s), 2.44 (1H, d, J = 9.6 Hz),<br>
2.98 (3H, s), 3.23 (1H, d, J = 9.3 Hz), 4.21 (1H, d, J= 14.7 Hz), 4.94 (1H, d, J= 15.3<br>
Hz), 7.03-7.19 (3H,m), 7.21 - 7.48 (4H, m), 9.81 (1H, brs), 15.35 (1H, brs). Anal,<br>
calcd for C25H24N4O6FS2 â¢ 0.5 Mg â¢ 3 H2O: C, 47.98; H, 4.83; N, 8.95; O, 23.01; S,<br>
10.25; F, 3.04; Mg, 1.94; found: C, 47.66; H, 4.89; N, 8.98; O, 23.00; S, 11.36; F,<br>
3.09; Mg, 1.82. m.p. = 184 Â°C (DSC).<br>
[005031 Example 71: N- {3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1.2.4]thiadiazin-7-yl}-methanesulfonamide. sodium salt<br><br>
[00504] N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
6, 0.407 g, 0.726 mmol) was suspended in ethanol (11.0 mL). A 1.0 M aqueous<br>
sodium hydroxide solution (0.726 mL, 0.726 mmol) and water (1.0 mL) were added.<br>
The mixture was seeded with a crystal of N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, sodium salt (produced from a<br>
separate batch), and the mixture was then stirred at 23 Â°C for 1 d. The solid was<br>
collected by filtration and further dried in vacuo at 23 Â°C to afford the desired<br>
product, N-{3-[(1R,2S,7R,8S) -3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, sodium salt, hydrate (2.25 molar<br>
equiv. water) (0.235 g, 0.377 mmol, 52%), as a crystalline solid. 1H NMR (300 MHz,<br>
DMSO-d6)d: 0.99 - 1.11 (2H, m), 1.28 (1H, app t, J = 10.2 Hz), 1.36 - 1.53 (3H, m),<br>
2.33 (1H, app d, J = 2.7 Hz), 2.42 (1H, d, J = 9.3 Hz), 2.97 (3H, s), 3.22 (1H, d, J =<br>
9.3 Hz), 4.20 (1H, d, J = 15.3 Hz), 4.95 (1H, d, J = 15.3 Hz), 7.09 - 7.16 (3H, m),<br>
7.25 - 7.36 (3H, m), 7.42 (1H, d, J = 2.4 Hz), 9.79 (1H, s), 15.32 (1H, s). Anal, calcd<br>
for C25H24FN4NaO6S2 â¢ 2.25 H2O: C, 48.19; H, 4.61; N, 8.99; O, 21.18; S, 10.29; F,<br>
3.05; Na, 3.69; found: C, 48.14; H, 4.67; N, 8.97; O, 21.07; S, 10.25; F, 3.13; Na,<br>
3.87. m.p. = 182-188 Â°C (DSC).<br>
[00505] Example 72: N- {3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-<br>
3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide. potassium salt<br><br>
[00506] N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide (prepared as described in Example<br>
6, 0.281 g, 0.501 mmol) was dissolved in methyl ethyl ketone (8.0 mL). A 0.5 M<br>
aqueous potassium hydroxide solution (1.0 mL, 0.500 mmol) was added. The<br>
solution was seeded with crystalline N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, potassium salt (produced from a<br>
separate batch), and the resulting mixture was then stirred at 23 Â°C for 3 h. The solid<br>
was collected by filtration and further dried in vacuo at 23 Â°C to afford the desired<br>
product, N- {3-[(1R,2S,7R,8S)3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, potassium salt, hydrate (0.75<br>
molar equiv. water) (0.127 g, 0.207 mmol, 41%), as a crystalline solid. 1H NMR (300<br>
MHz, DMSO-d6) d: 0.99 - 1.11 (2H, m), 1.27 (1H, app t,J = 10.3 Hz), 1.36-1.54<br>
(3H, m), 2.33 (1H, br s), 2.42 (1H, d, J = 9.0 Hz), 2.95 (3H, s), 3.22 (1H, d, J = 9.3<br>
Hz), 4.20 (1H, d, J = 15.3 Hz), 4.96 (1H, d, J = 15.6 Hz), 7.09 - 7.15 (3H, m), 7.25 -<br>
7.34 (3H, m), 7.41 (1H, d, J = 2.7 Hz), 9.84 (1H, br s), 15.30 (1H, s). Anal, calcd for<br>
C25H24FKN4O6S2 â¢ 0.75 H2O: C, 49.05; H, 4.20; N, 9.15; O, 17.64; S, 10.48; F, 3.10;<br>
K, 6.39; found: C, 48.82; H, 4.11;N, 9.06; O, 17.35; S, 10.37; F, 3.18; K, 6.75. m.p.<br>
= 278 Â°C (DSC).<br>
BIOLOGICAL TESTING<br>
[00507] The ability of compounds of Formula I to inhibit HCV replication can be<br>
demonstrated in the following in vitro assays.<br>
[00508] Compounds were tested for HCV polymerase inhibition. Assays were<br>
performed in a 96-well streptavidin-coated FlashPlate using 20 nM enzyme, 0.5 ÂµCi<br>
of [a-33P]GTP, 0.6 ÂµM GTP, and 250 nM 5'biotinylated oligo (rG13)/poly rC in 20<br>
raM Tris-HCl, pH 7.5, 5 mM MgCl2, 5 mM dithiothreitol, 0.1 g/L bovine serum<br>
albumin, and 100 U/mL RNAse inhibitor. The reaction was stopped by aspiration<br>
after 75 min at 28Â°C and the plate was washed several times. After washing and<br>
drying the plate, incorporated radioactivity was counted using a Microbeta<br>
scintillation counter. IC50 values were calculated relative to the uninhibited control<br>
and inhibition data were fitted to a 4-parameter IC50 equation. For very potent<br>
inhibitors, the data were fitted to a tight binding quadratic equation to obtain IC50<br>
values.<br>
[00509] Test results (IC50 values) for compounds of Formula I are summarized in<br>
Table 1, wherein ++++ means NS5B polymerase inhibition with IC50 values less than<br>
0.02 uM, +-H- means IC50 values between 0.02 uM and 0.1 ÂµM, ++ means IC50 values<br>
between 0.1 ÂµM and 1 ÂµM, and + means IC50 values between 1 ÂµM and 100 ÂµM. Test<br>
results for Example numbers 64 and 65 in Table 1 are EC50 values, wherein ****<br>
means HCV replicon inhibition with EC50 values less than 0.02 ÂµM, *** means EC50<br>
values between 0.02 uM and 0.1 uM, ** means EC50 values between 0.1 ÂµM and 1<br>
ÂµM, and * means EC50 values between 1 ÂµM and 100 ÂµM<br><br><br>
HCV Replicon Assay (Replicon EC50 (ÂµM))<br>
[00510] The cell culture component of the assay is performed essentially as<br>
described by Bartenschlager et al., Hepatology 2002, 35, 694-703, wherein<br>
exponentially growing HCV Huh-7/C24 replicon cells are seeded at 4.5 * 103<br>
cells/well in 96 well plates and 24 hours later are treated with six point half-log<br>
concentration of compound. After 72 hours exposure the media is discarded from the<br>
compound assay plate and the cell monolayers are lysed by addition of 150 L lysis<br>
mixture (Genospectra) with incubation at 53 oC for 45 minutes. Following<br>
incubation, each lysate is thoroughly mixed and 5 1 (NS3 probe) or 10 L (GAPDH<br>
probe) of each lysate is then transferred to the capture plate and analyzed by bDNA<br>
assay.<br>
Branched DNA (bDNA) Assay<br>
[00511] Based on provided sequences for NS3 [AJ242652], Genospectra (Fremont,<br>
CA, USA) designed and synthesized probes to these analytes (together with GAPDH).<br>
Cellular bDNA analysis is carried out essentially as described in the Genospectra<br>
protocol (details in Shyamala, V. et al, Anal. Biochem. 1999, 266, 140-7), wherein<br>
target specific capture extenders, label extenders and blocking probes are added to the<br>
capture plate after the addition of 5 or 10 ÂµL cell lysate. After annealing overnight,<br>
during which the target RNA is captured to the plate via interaction with the capture<br>
extenders, the plate is washed, and then amplifier (which binds via the label<br>
extenders) and label probe are sequentially added.<br>
[00512] After subsequent addition of the chemilumigenic substrate (dioxetan), each<br>
plate is read by luminometer (Wallac 1420 Multilabel HTS Counter Victor 2). The<br>
luminescence signal is proportional to the amount of mRNA present in each lysate. In<br>
addition to the samples, cell lysate only (no probe) background controls are also<br>
included on each bDNA assay plate and the average signal from these control wells is<br>
subtracted from the sample reading prior to analysis. Percent of no drug control is<br>
determined for both the NS3 and GAPDH signals for each compound also. Percent<br>
inhibition is determined for each compound concentration in relation to the no drug<br>
control to calculate the EC50.<br>
Luciferase-based HCV Replicon Assay Protocol<br>
[00513] Exponentially growing HCV Huh-luc/neo-ET replicon cells were seeded at<br>
6 x 103 cells/well in 96 well assay plate. 24 hours later the cells were treated with<br>
various concentrations of compound in triplicate. After 72 hours exposure to the<br>
compound the luciferase activity in the wells was determined using Bright-Glo<br>
reagent (Promega, Madison, Wisconsin) with a luminometer (Wallac 1420 Multilabel<br>
HTS Counter Victor 2). The background control was replicon cells treated with 100<br>
nM BILN-2061, an inhibitor of the HCV protease. % Inhibition was determined for<br>
each compound concentration in relation to the negative (no compound) control to<br>
calculate the EC50.<br>
[00514] It is to be understood that the foregoing description is exemplary and<br>
explanatory in nature, and is intended to illustrate the invention and its preferred<br>
embodiments. Through routine experimentation, the artisan will recognize apparent<br>
modifications and variations that may be made without departing from the spirit of the<br>
invention.<br>
What is claimed is:<br>
1. A compound of Formula I<br><br>
wherein<br>
X is N or CR3,<br>
A is<br><br>
Ring B is 6-membered aryl or heterocyclyl, optionally substituted by 1 -3<br>
R1 moieties, wherein is R1 is H, halo, nitro, -CHR4-S(O)2R5, -C(S(O)2R5)=CHR4-,<br>
-NR5R6, -NR4S(O)2R5, or -NR4S(O)2NR5R6, wherein R4, R5, and R6 are<br>
independently H, C1-C6 alkyl, C3-C8 cycloalkyl, C(O)O-(C1-C6 alkyl), aryl, or<br>
heterocyclyl, or R4 and R5 or R5 and R6 combine with the atom(s) to which they are<br>
attached to form a 5- or 6-membered heterocyclyl ring,<br>
R2 is H, C1-C6 alkyl, C3-C8 cycloalkyl, -C1-C6 alkylene(C3-C8 cycloalkyl), -C1-C6<br>
alkylene(aryl), -C1-C6 alkylene(heterocyclyl), aryl, or heterocyclyl,<br>
R3 is H, halo, or C1-C6 alkyl,<br>
Z is -(CR13R14)â-, or O,<br>
n is 1 or 2,<br>
R7 and R8 are independently H or C1-C6 alkyl,<br>
R9, R10, R11, R12, R13, R14, R15, and R16 are independently H, C1-C6 alkyl, hydroxy,<br>
or halo,<br>
wherein the above alkyl, alkylene, aryl, cycloalkyl, or heterocyclyl moieties<br>
provided in R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, and R16 are<br>
each optionally and independently substituted by 1-3 substituents selected from<br>
alkylamine,<br>
amino,<br>
aryl, cycloalkyl, heterocyclyl,<br>
C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxyalkyl, C1-C6 alkoxy, C1-C6<br>
alkylamine, C1-C6 dialkylamine, C2-C6 alkenyl, or C2-C6 alkynyl, wherein<br>
each of which may be interrupted by one or more hetero atoms,<br>
carboxyl,<br>
cyano,<br>
halo,<br>
hydroxy,<br>
keto,<br>
nitro,<br>
-C(O)OH, -C(O)NH2, -C(O)(C1-C6 alkylamine), -C(O)(C1-C6 dialkylamine),<br>
-C(O)2-(C1-C6 alkyl), -C(O)2-(C3-C8 cycloalkyl), -C(O)2-(aryl), -C(O)2-<br>
(heterocyclyl), -C(O)2-(C1-C6 alkylene)aryl, -C(O)2-(C1-C6<br>
alkylene)heterocyclyl, -C(O)2-(C1-C6 alkylene)cycloalkyl, -C(O)(C1-C6<br>
alkyl), -C(O)(C3-C8cycloalkyl), -C(O)(aryl), -C(O)(heterocyclyl), -C(O)(C,-<br>
C6 alkylene)aryl, -C(O)(C1-C6 alkylene)heterocyclyl, and -C(O)(C1-C6<br>
alkylene)cycloalkyl,<br>
wherein each of the above optional substituents can be further optionally<br>
substituted by 1-5 substituents selected from amino, cyano, halo, hydroxy, nitro, C1-<br>
C6 alkylamine, C1-C6 dialkylamine, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkenyl, and<br>
C1-C6 hydroxyalkyl, wherein each alkyl is optionally substituted by one or more<br>
halo substituents,<br>
or a pharmaceutically acceptable salt or stereoisomer thereof.<br>
2. The compound according to claim 1 wherein Ring B is selected from<br><br>
3. The compound according to claim 2 wherein Ring B is<br><br>
R1 is H, halo, nitro, -CHR4-S(O)2R5, -C(S(O)2R5)=CHR4-, -NR5R6,<br>
-NR4S(O)2R5, or -NR4S(O)2NR5R6.<br>
4. The compound according to claim 3 wherein R1 is -NR4S(O)2R5, and R4 and<br>
R5 are independently H, C1-C6 alkyl, or C3-C8 cycloalkyl.<br>
5. The compound according to claim 4 wherein R1 is selected from<br><br>
6. The compound according to claim 1 wherein R2 is selected from<br><br>
7. The compound according to claim 6 wherein R2 is selected from<br><br>
8. The compound according to claim 7 wherein R2 is selected from<br><br>
9. The compound according to claim 1 wherein R3 is selected from hydrogen or<br>
C1-C6 alkyl.<br>
10. The compound according to claim 9 wherein R3 is selected from<br><br>
11. The compound according to claim 1 wherein R7 and R8 are H.<br>
12. The compound according to claim 1 wherein R9, R10, R11, R12, R13, R14, R15,<br>
and R16 are independently selected from<br><br>
13. The compound according to claim 12 wherein R9, R10, R11, R12, R13, R14, R15,<br>
and R16 are independently selected from<br><br>
14. The compound according to claim 13 wherein R9, R10, R11, R12, R13, R14, R15,<br>
and R16 are H or hydroxy.<br>
15. The compound according to claim 14 wherein R9, R10, R11, R12, R13, R14, R15,<br>
and R16 are H.<br>
16. The compound according to claim 1 wherein n is 1.<br>
17. A compound selected from<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-endo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo [6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-endo)-N{3-[3-(5-Fluoro-pyridin-2-ylmethyl)-6-hydroxy-4-oxo-3-<br>
aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N- {3 -[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo [6.2.1.02,7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-endo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo [6.2.1.02,7]undeca-5,9-dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N- {3 -[(1R,2S,7R,8S)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-11 -<br>
oxa-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N- {3 -[3 -(4-Fluoro-3 -methyl-benzyl)-6-hydroxy-4-oxo-11 -oxa-<br>
3 -aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N- {3 -[3 -(3,3 -Dimethyl-butyl)-6-hydroxy-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N-{3 -[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N- {3 -[(1R,2S,7R,8S)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
N-{3-[(1R,2S,7R,8S)-3-(3,4-Difluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo [1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N- {3-[(1R,2S,7R,8S)-3-(3,4-Difluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -Nmethyl-methanesulfonamide,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-3-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide,<br>
(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-<br>
dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl)-3 -aza-tricyclo [6.2.1.02,7]undec-5-en-4-one,<br>
(1R,2S,7R,8S)-5-[7-(1,1 -Dioxo-4,5-dihydro- 1H- R6-thiophen-2-yl)-1,1 -<br>
dioxo-1,4-dihydro-1?6-benzo[ 1,2,4]thiadiazin-3 -yl]-3 -(4-fluoro-benzyl)-6-hydroxy-<br>
3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(1R,2S,7R,8S)-5-[7-(1, 1-Dioxo-tetrahydro-1?6-thiophen-2-yl)-1,1 -dioxo-1,4-<br>
dihydro-1?6-benzo[1,2,4]thiadiazin-3-yl]-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(1R,2S,7R,8S)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N-{3-[3-(2-Cyclopropyl-ethyl)-6-hydroxy-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(1R,2S,7R,8S)-N- {3 -[6-Hydroxy-3 -(3 -methyl-butyl)-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide,<br>
(rac-di-exo)-N- {3 -[6-Hydroxy-3 -(3 -methyl-butyl)-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(1R,2S,7R,8S)-5-[7-(1,1 -Dioxo-1?6-isothiazolidin-2 -yl)-1,1 -dioxo-1,4-<br>
dihydro- 1?6-benzo[1,2,4]thiadiazin-3 -yl] -3 -(4-fluoro-benzyl)-6-hydroxy-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(1R,2S,7R,8S)-N-[3-(6-Hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-<br>
5-yl)-1,1 -dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(1R,2S,7R,8S)-5-( 1,1 -Dioxo-1,4-dihydro-1?6-benzo [ 1,2,4]thiadiazin-3 -yl)-3 -<br>
(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
N- {3 -[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-benzo[1,4]thiazin-7-<br>
yl} -methanesulfonamide,<br>
(1R,2S,7R,8S)-5 -(7-Amino-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(rac -di-exo)-N- {3 -[6-Hydroxy-3 -(3 -methyl-butyl)-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N- {3 -[3 -(3,3 -Dimethyl-butyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-6-Hydroxy-5 -(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyl)-l l-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(1R,2S,7R,8S)-6-Hydroxy-5-(7-iodo-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-3-yl)-3-(3-methyl-butyl)-3-aza-tricyclo[6.2.1.02'7]undec-5-<br>
en-4-one,<br>
Cyclopropanesulfonic acid {3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(rac-di-exo)-N- {3 -[3 -(3,3 -Dimethyl-butyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,4]thiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N-{3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,4]thiazin-7-yl} -methanesulfonamide,<br>
(rac-di-exo)-N3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-N-methyl-methanesulfonamide,<br>
Cyclopropanesulfonic acid {3-(1R,2S,7R,8S)-[6-hydroxy-3-(3-methyl-butyl)-<br>
4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -amide,<br>
(1R,2S,7R,8S)-N- {3 -[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -benzenesulfonamide,<br>
(rac-di-exo)-Cyclopropanesulfonic acid {3-[6-hydroxy-3-(3-methyl-butyl)-4-<br>
oxo-11 -oxa-3 -aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(rac-di-exo)-Cyclopropanesulfonic acid {3-[3-(3,3-dimethyl-butyl)-6-<br>
hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo-1,4-<br>
dihydro- 1 N-benzo[1,2,4]thiadiazin-7-yl} -amide,<br>
N-[3-(1R,2S,7R,8S)-3-Cyclopentyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(rac-di-exo)-Cyclopropanesulfonic acid {3-[6-hydroxy-3-(3-methyl-butyl)-4-<br>
oxo-3-aza-tricyclo [6.2.1.02,7]undeca-5,9 -dien-5 -yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(rac-di-exo)-Cyclopropanesulfonic acid {3 -[3 -(4-fluoro-benzyl)-6-hydroxy-<br>
4-oxo-3-aza-tricyclo[6.2.1.02,7]undeca-5,9-dien-5-yl]-1,1-dioxo- 1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -amide,<br>
N-[3-(1R,2S,7R,8S)-(3-Cyclopentyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide-N-isopropyl carbamate,<br>
(rac-di-exo)-N- [3-(3 -Cyclopentyl-6-hydroxy-4-oxo-11 -oxa-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
N-{3-[(2S,7R)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
cis-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(2R,7S)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02,7.09,11]tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4 ]thiadiazin-7-yl}-methanesulfonamide,<br>
(2S,7R)-N-{3-[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tetracyclo[6.3.2.02,7.09,11]tridec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(1R,2S,7R,8S)-5-(1,1-Dioxo-7-pyrrolidin-1-yl-1,4-dihydro-1?6-<br>
benzo [1,2,4]thiadiazin-3-yl)-6-hydroxy-3-(3-methyl-butyl)-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
Pyridine-3-sulfonic acid {3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-<br>
oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-amide,<br>
(1R,2S,7R,8S)-N-{3 -[3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-sulfamide,<br>
(1R,2S,7R,8S)-N-[3-(3-Benzyl-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(1R,2S,7R,8S)-N-[3-(6-Hydroxy-3-isobutyl-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl)-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl]-methanesulfonamide,<br>
(1R,2S,7R,8S)-N-{3-[3-(3-Chloro-4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(rac-di-exo)-N3-[6-Hydroxy-3-(3-methyl-butyl)-4-oxo-11-oxa-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -N-methyl-methanesulfonamide,<br>
N3-[(1R,2S,7R,8S)-3-(3-Fluoro-4-methyl-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro- R6-<br>
benzo[ 1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(1R,2S,7R,8S)-5-(7-Bromo-1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e][1,2,4]thiadiazin-3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-<br>
tricyclo[6.2.1.027]undec-5-en-4-one,<br>
N- {3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-pyrido[2,3-<br>
e][1,2,4]thiadiazin-7-yl}-methanesulfonamide,<br>
(1R,2S,7R,8S)-5-(1,1-Dioxo-1,4-dihydro-1?6-pyrido[2,3-e][1,2,4]thiadiazin-<br>
3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(1R,2S,7R,8S)-5-(1,1 -Dioxo-1,4-dihydro-1?6-pyrido[4,3 -e][1,2,4]thiadiazin-<br>
3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
(1R,2S,7R,8S)-5-(1,1-Dioxo-1,4-dihydro-1?6-pyrido[3,2-e][1,2,4]thiadiazin-<br>
3-yl)-3-(4-fluoro-benzyl)-6-hydroxy-3-aza-tricyclo[6.2.1.02,7]undec-5-en-4-one,<br>
N-{3-[(1R,2S,7R,8S)-3-(2-Cyclopropyl-ethyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6,9-dihydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[ 1,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, L-arginine salt,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo [1,2,4]thiadiazin-7-yl}-methanesulfonamide, L-lysine salt,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, hemi magnesium salt,<br>
N- {3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro- 1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, sodium salt, and<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-berizyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, potassium salt.<br>
18. The compound of claim 17 selected from<br>
N- {3 -[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, L-arginine salt,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, L-lysine salt,<br>
N- {3 -[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, hemi magnesium salt,<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, sodium salt, and<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1 -dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, potassium salt.<br>
19. The compound of claim 17 selected from<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclot6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1 ,2,4]thiadiazin-7-yl} -methanesulfonamide,<br>
N- {3 -[(2S,7R)-3 -(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3 -aza-<br>
tricyclo[6.2.2.02,7]dodec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, and<br>
N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-<br>
tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1?6-<br>
benzo[1,2,4]thiadiazin-7-yl}-methanesulfonamide, or a pharmaceutically acceptable<br>
salt thereof.<br>
20. The compound of claim 19 that is N-{3-[(1R,2S,7R,8S)-3-(4-Fluoro-benzyl)-<br>
6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-<br>
1?6-benzo[1,2,4]thiadiazin-7-yl} -methanesulfonamide.<br>
21. The compound of claim 20 in crystalline form.<br>
22. The compound of claim 21 wherein the crystalline form has:<br>
an X-ray diffraction (2-theta) with the strongest line observed at an angle of<br>
6.2Â°, 17.9Â°, 19.7Â°, 20.5Â°, 22.6Â°, and 24.8Â° Â± 0.3Â°, with lesser intensity lines at 12.4Â°,<br>
16.5Â°, 18.7Â°, 21.6Â°, 23.2Â°, 24.1Â°, 25.6Â°, 26.6Â°, 27.1Â°, 28.5Â°, and 29.3Â°; and<br>
IR-characteristic absorption bands at 1617, 1524, 1321, 1260, 1229, 1217,<br>
and 1163 cm+1, with minor bands at 1498, 1465, 1147, 836, 727, and 406 cm-1.<br>
23. A pharmaceutically acceptable composition comprising a compound of claim<br>
1 and a pharmaceutically acceptable carrier.<br>
24. A compound selected from<br><br><br>
25. A method of inhibiting hepatitis C virus replication comprising exposing<br>
hepatitis C virus to a therapeutically effective amount of a compound of claim 1.<br>
26. The method of claim 25 wherein the inhibition of replication occurs in the<br>
presence of an additional therapeutic agent selected from the group consisting of an<br>
antibiotic, an antiemetic agent, an antidepressant, an antifungal agent, an anti-<br>
inflammatory agent, an antiviral agent, an anticancer agent, an immunomodulatory<br>
agent, an a-interferon, a Ã-interferon, a ribavirin, an alkylating agent, a hormone, a<br>
cytokine and a toll-like receptor modulator.<br>
27. A method for treating or preventing hepatitis C virus infection in a mammal<br>
in need thereof, comprising administering to the mammal a therapeutically or<br>
prophylactically effective amount of a compound of claim 1.<br>
28. The method of claim 27 wherein the mammal is a human.<br>
29. The method of claim 27 further comprising administering an additional<br>
therapeutic agent to the mammal.<br>
30. The method of claim 29 wherein the additional therapeutic agent is selected<br>
from the group consisting of an antibiotic, an antiemetic agent, an antidepressant, an<br>
antifungal agent, an anti-inflammatory agent, an antiviral agent, an anticancer agent,<br>
an immunomodulatory agent, an a-interferon, a Ã-interferon, a ribavirin, an<br>
alkylating agent, a hormone, a cytokine and a toll receptor-like modulator.<br>
256 <br><br><br>
The invention is directed to 5,6-dihydro-1H-pyridin-2-one compounds and pharmaceutical compositions containing<br>
such compounds that are useful in treating infections by hepatitis C virus.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/viewdoc.aspx?id=e6M/DvYQiSmOnGhmIj3X/w==&amp;amp;loc=wDBSZCsAt7zoiVrqcFJsRw==" target="_blank" style="word-wrap:break-word;">http://ipindiaonline.gov.in/patentsearch/GrantedSearch/viewdoc.aspx?id=e6M/DvYQiSmOnGhmIj3X/w==&amp;amp;loc=wDBSZCsAt7zoiVrqcFJsRw==</a></p>
		<br>
		<div class="pull-left">
			<a href="271474-novel-substituted-benzocycloalkyl-azole-derivatives-as-antileishmanial-agents.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="271476-slide-type-constant-velocity-universal-joint.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>271475</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>3637/KOLNP/2009</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>09/2016</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>26-Feb-2016</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>23-Feb-2016</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>19-Oct-2009</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ANADYS PHARMACEUTICALS, INC.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>5871 OBERLIN DRIVE, SUITE 200, SAN DIEGO, CALIFORNIA 92121 UNITED STATES OF AMERICA</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>RUEBSAM, FRANK</td>
											<td>4517 COPELAND AVE., SAN DIEGO, CA 92116 UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>2</td>
											<td>TRAN, CHINH, VIET</td>
											<td>10790 DABNEY DR. #2, SAN DIEGO, CA 92126 UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>3</td>
											<td>MURPHY, DOUGLAS, ERIC</td>
											<td>14822 HEATHER GLEN WAY, SAN DIEGO, CA 92128 UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>4</td>
											<td>DRAGOVICH, PETER</td>
											<td>5504 SHANNON RIDGE LANE, SAN DIEGO, CA 92130 UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>5</td>
											<td>ZHOU, YUEFEN</td>
											<td>11425 HONEY RIDGE, SAN DIEGO, CA 92130 UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>6</td>
											<td>CHEN, LIJIAN</td>
											<td>1410 AVENIDA LA POSTA, ENCINITAS, CA 92024 UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>7</td>
											<td>KUCERA, DAVID</td>
											<td>14099 RECUERDO DRIVE, DEL MAR, CA 92014 UNITED STATES OF AMERICA</td>
										</tr>
										<tr>
											<td>8</td>
											<td>BLATTER, FRITZ</td>
											<td>OERINSTRASSE 67, CH-4153 REINCH SWITZERLAND</td>
										</tr>
										<tr>
											<td>9</td>
											<td>VIERTELHAUS, MARTIN</td>
											<td>ST-ROCHUS-SIEDLUNG 3, D-54516 WITTLICH GERMANY</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A01N43/66; A01N43/64</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/US2008/059164</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2008-04-02</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>60/907,478</td>
									<td>2007-04-03</td>
								    <td>U.S.A.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/271475-5-6-dihydro-1h-pyridin-2-one-compounds by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:20:27 GMT -->
</html>
